NZ290008A - Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle - Google Patents

Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle

Info

Publication number
NZ290008A
NZ290008A NZ290008A NZ29000895A NZ290008A NZ 290008 A NZ290008 A NZ 290008A NZ 290008 A NZ290008 A NZ 290008A NZ 29000895 A NZ29000895 A NZ 29000895A NZ 290008 A NZ290008 A NZ 290008A
Authority
NZ
New Zealand
Prior art keywords
methyl
oxo
benzodiazepine
tetrahydro
carbonyl
Prior art date
Application number
NZ290008A
Inventor
Fadia Ali
William Bondinell
William Francis Huffman
M Amparo Lago
Richard Mcculloch Keenan
Chet Kwon
William Henry Miller
Thomas Nguyen
Dennis T Takata
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NZ290008A publication Critical patent/NZ290008A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Description

New Zealand Paient Spedficaiion for Paient Number £90008 4- New Zealand No. 290008 International No. PCT/US95/08306 TO BE ENTERED AFTER ACCEPTANCE AND PUBLICATION Priority dates: 29.06.1994;25.04.1995; Complete Specification Filed: 29.06.1995 Classification:^) C07D519/00; C07D498/04; C07D497/04; C07D495/04; C07D491/04,044,048,052; C07D487/04; C07D473/04,16,18,22,28,32,40; C07D471/04; C07D417/06,12; C07D413/06.12; C07D409/06.12; C07D403/06,12,14; C07D401/02,06,12,14; C07D235/06.08,18,22; C07D233/56 Publication date: 26 August 1998 Journal No.: 1431 Title of Invention: Vitronectin receptor antagonists Name, address and nationality of applicant(s) as in international application form: SMITHKLINE BEECHAM CORPORATION, a Pennsylvania corporation of One Franklin Plaza, Philadelphia, Pennsylvania 19103, United States of America NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION WO 96/00730 PCTAJS95/08306 % 2900 TITLE Vitronectin Receptor Antagonists FIELD OF THE INVENTION This invention relates to pharmaceutically active compounds which inhibit the vitronectin receptor and are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporosis.
BACKGROUND OF THE INVENTION Integrins are a superfamily of cell adhesion receptors, which are transmembrane glycoproteins expressed on a variety of cells. These cell surface adhesion receptors include gpUb /Ilia, the fibrinogen receptor, and avB3, the 15 vitronectin receptor. The fibrinogen receptor gpUb /IHa is expressed on the platelet surface and it mediates platelet aggregation and the formation of a hemostatic clot at the site of a bleeding wound. Philips, et al, Blood., 1988, 71, 831. The vitronectin receptor avB3 is expressed on a number of cells, including endothelial, smooth muscle, osteoclast, and tumor cells, and, thus, it has a variety of functions. The avB3 20 receptor expressed on the membrane of osteoclast cells mediates the bone resportion process and contributes to the development of osteoporosis. Ross, et al., J. Biol. Chem., 1987,262, 7703. The avB3 receptor expressed on human aortic smooth muscle cells stimulates their migration into neointima, which leads to the formation of atherosclerosis and restenosis after angioplasty. Brown, et al., Cardiovascular 25 Res., 1994, 28, 1815. Additionally, a recent study has shown that a ocvB3 antagonist is able to promote tumor regression by inducing apoptosis of angiogenic blood vessels. Brooks, el al.. Cell, 1994, 79,1157. Thus, agents that would block the vitronectin receptor would be useful in treating diseases mediated by this receptor, such as osteoporosis, atherosclerosis, restenosis and cancer.
PCTAJS95/08306 The vitronectin receptor is known to bind to bone matrix proteins, such as osteopontin, bone sialoprotein and thrombospondin, which contain the tri-peptide Arg-Gly-Asp (or RGD) motif. Thus, Horton, et al., Exp. Cell Res. 1991,195, 368, disclose that RGD-containing peptides and an anti-vitronectin receptor antibody 5 (23C6) inhibit dentine resorption and cell spreading by osteoclasts. In addition, Sato, et al., J. Cell Biol. 1990, 111, 1713 disclose that echistatin, a snake venom peptide which contains the RGD sequence, is a potent inhibitor of bone resorption in tissue culture, and inhibits attachment of osteoclasts to bone. Fisher, et al., Endocrinology 1993,132,1411, has further shown that echistatin inhibits bone 10 resorption in vivo in the rat. Bertolini et al., J. Bone Min. Res., 6, Sup. 1, S146,252 have shown that cylco-S,S-Na-acetyl-cysteinyl-Na-methyl-argininyl-glycyl-aspartyl-penicillamine inhibits osteoclast attachment to bone. EP 528 587 and 528 586 report substituted phenyl derivatives which inhibit osteoclast mediated bone resorption.
Alig et al., EP 0 381 033, Hartman, et al., EP 0 540,334, Blackburn, et al., WO 93/08174, Bondinell, et al., WO 93/00095, Blackburn, et al. WO 95/04057, Egbertson, et al, EP 0 478 328, Sugihara, et al. EP 529,858, Porter, et al., EP 0 542 363, and Fisher, et al., EP 0 635 492 disclose certain compounds that are useful for inhibiting the fibrinogen receptor. It has now been discovered that certain 20 appropriately substituted compounds are potent inhibitors of the vitronectin receptor. In particular, it has been discovered that such compounds are more potent inhibitors of the vitronectin receptor than the fibrinogen receptor and such compounds contain a fibrinogen receptor antagonist template.
SUMMARY OF THE INVENTION This invention comprises compounds of the formula (I)-(V) as described hereinafter, which have pharmacological activity for the inhibition of the vitronectin receptor and are useful in the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases 30 wherein bone resorption is a factor, such as osteoporosis.
This invention is also a pharmaceutical composition comprising a compound according to formula (I)-(V) and a pharmaceutical^ carrier.
This invention is also a method of treating diseases which are mediated by the vitronectin receptor. In a particular aspect, the compounds of this invention are 5 useful for U-eating atherosclerosis, restenosis, inflammation, cancer and diseases wherein bone resorption is a factor, such as osteoporosis.
DETAILED DESCRIPTION This invention comprises novel compounds which are more potent inhibitors 10 of the vitronectin receptor than the fibrinogen receptor. The compounds of the instant invention comprise a fibrinogen receptor antagonist template that is linked to a nitrogen-containing five-membered ring, which is optionally fused to an aromatic six-membered ring. The fibrinogen receptor antagonist template is substituted by an aliphatic substituent which contains an acidic moiety. It is preferred that about 15 fourteen intervening covalent bonds via the shortest intramolecular path will exist between the acidic group of the fibrinogen receptor antagonist template and the nitrogen of the optionally fused five-membered ring.
As used herein, the term "fibrinogen receptor antagonist template" means the core structure of a fibrinogen receptor antagonist, said core being substituted by an 20 acidic group and said core being linked to an organic group substituted with a basic nitrogen moiety. A fibrinogen receptor antagonist is an agent that inhibits the binding of fibrinogen to the platelet-bound fibrinogen receptor GPIIb-IIIa. It is an object of this invention that a fibrinogen receptor antagonist is converted to a vitronectin receptor antagonist by replacing the organic group substituted with a 25 basic nitrogen moiety in a fibrinogen receptor antagonist with an optionally fused nitrogen-containing five-membered ring, preferably an imidazole ring and, most preferably, a benzimidazole ring.
This invention comprises compounds of formula (I)-(V): 0) or (ID or (I'D ""-f T W A It N Re (IV) wherein: W is CHRga-U- CHRSb-V- or or (CH2)0 (V) N "V- N—(CH)q X _J .
» A is a fibrinogen receptor antagonist template; U and V are absent or CO, CRl2, C(=CRI2), S(0)k, O, NR', CR'OR', cr'(ork)cr'2, cr'2cr'(ork), C(0)cr'2, cr^CCO), conr', nr'co, oc(O), C(0)0, C(S)0, oc(S), C(S)nr\ nr'C(S), S(0)2nr', nr'S(0)2 N=N, NR'NR', NR'CR'2, NR'CR^, CR'20, OCR'2, C=C or CR'=CR'; G is NRe, S or O; R' is H, Ci_6alkyl, Het-Co-6alkyl, C3-7cycloalkyl-C()-6alkyl or Ar- C()-6alkyl; 15 Rl is R', -C(0)R', or -C(0)0Rf; R' is is H, Ci-6alkyl, Het-Co-6alkyl, C3-7cycloalkyl-C()-6alkyl, Ar- Co-6alkyl, or Ci-6alkyl substituted by one to three groups chosed from halogen, CN, NR'3, OR', SR', CO,R\ and CON(R')2; R' is H, Chalky 1 or Ar-C^alkyl; Re is H, Ci-6alkyi, Ar-Ci-6aIkyl, Het-Ci-6alkyl, C3-7cycIoalkyl-Ci_6 (CEy^OjR1; k is 0,1 or 2; q is 1 or 2; a is 0,1 or 2; b is 0,1 or 2; Rb and Rc are independently selected from H, Cj-tfalkyl, Ar-C()-6alkyl, Het- Co-galkyl, or C3-6cycloalkyl-Co-6alkyl, halogen, CF3, OR, S(0)kR, COR, NO2, N(r')2, CO(NRf)2, CH2N(Rf)2, or R^ and Rc are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF3, Ci-4alkyl, ORf, S(0)kRf, CORf, COjRf OH, NO2, N(R )2, CO(NR )2, and CH2N(R )2; or methylenedioxyl 15 or a phannaceutically acceptable salt thereof, with the proviso that: (i) when A is 1,2,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-1H-1,4-benzodiazepine-2-acetic acid, then W is not -(CHj)2ONMC0- attached at the 1-position of an imidazole ring; and 20 (ii) when A is l,2,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-lH-l,4- benzodiazepine-2-acetic acid, then W is not -(CH,), NHCO- attached at the 4(5)-position of an imidazole ring.
The compounds of formula (I), (II) and (IV) wherein G in NRC are 22 claimed in the present patent specification. The compounds of formula (II) wherein G is S or O are claimed in New Zealand Patent Specification No. 329656 and the compounds of formula (III) are claimed in New Zealand Patent Specification No. 329822.
Also included in this invention are phannaceutically acceptable addition 30 salts, complexes or prodrugs of the compounds of this invention. Prodrugs are / l,n&U£7ir??. - ~ considered to be any covalently bonded earners which release the acuve parerit.drug / ' according to formula (I) in vivo. In cases wherein the compounds of this invention, _ / ^ may have one or more chiral centers, unless specified, this invention includes each unique nonracemic compound which may be synthesized and resolved"by conventional techniques. In cases in which compounds have unsaturated carbon-carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention. In cases wherein compounds may exist in tautomeric forms, such as contemplated as being included within this invention whether existing in equilibrium or locked in one form by appropriate substitution with R'.
The compounds of formula (I) - (V) inhibit the binding of vitronectin and other RGD-containing peptides to the vitronectin (avP3) receptor. Inhibition of the 10 vitronectin receptor on osteoclasts inhibits osteoclastic bone resorption and is useful in the treatment of diseases wherein bone resorption is associated with pathology, such as osteoporosis. Additionally, since the compounds of the instant invention inhibit vitronectin receptors on a number of different types of cells, said compounds would be useful in the treatment of inflammation and cardiovascular diseases, such 15 as atherosclerosis and restenosis, and would be useful as anti-metastatic and antitumor agents.
OR' keto-enol tautomers, such as ^— and , and each tautomeric form is In a particuar embodiment, the compounds of this invention are of the b C formula (II), wherein R and R are joined to form an aromatic ring containing up to h c two nitrogen atoms. In a preferred embodiment R andR are joined to form an optionally substituted phenyl ring according to formula (Da): Rx wherein G is N-Re, S or O.
Suitably W is -(CHRgJaNR'CO- or N-CO Preferably W is -CHRENR'CO-.
Suitably R' is H, Chalky!, C3-7cycloalkyl, Ar or Cugalkyl substituted by one to three groups chosen from halogen, CN, NR'2, OR', SR', C02R', and CON(R')2, Ar, Het or C3-7cycloalkyl. In particular, R' is H, methyl, butyl, 5 cyanomethyl, carboxymethyl, phenylethyl or benzimidazolylmethyl.
Suitably Rx, Ry and Rz are independently chosen from Ci.galkyl, methoxy, nitro, trifluoromethyl, fluoro, chloro, amino or Rx and Ry are adjacent to one another and are joined to form a methylenedioxy group.
Preferably G is NRC.
Suitably Re is H, Cj^alkyl, Ar, Het or Ci-4alkyl substituted by Ar or Het.
More suitably, Re is H, methyl or benzimidazolylmethyl.
In another specific embodiment, Rb and Rc form a six membered aromatic ring containing one or two nitrogen atoms according to formulas (Ilb-d): c£Vw-a G N a R (lib) (He) (Ed) wherein G, R" and Ry are as above for formula (Da).
In another aspect this invention is an intermediate compound of formula XXX: (CH^NR'-Pr1 (XXX) wherein Pr1 is a nitrogen protecting group, Rf is H, C^alkyl or ArCwalkyl, a' is 1-3, and R\ R' and R1 are independently chosen from H, halogen, SRf, ORf, CF3, N(R*)3, NO, and C^alkyl. Preferred nitrogen protecting groups are alkyl and aryl carboxylic WO 96/00730 PCI7US95/08306 acid groups, and alkyloxycarbonyl or arylmethyloxycarbonyl groups, such as the acetyl, BOC and Cbz group. Typically RS is H or methyl.
Specifically, the compounds of this invention are comprised of a nitrogen-5 containing optionally fused five-membered ring, a linking group W, and a fibrinogen receptor antagonist template A. In particular, the fibrinogen receptor antagonist template A is as defined in Bondinell, et al., WO 93/00095, published Januaiy 7, 1993, of the sub-formula (VI): (VI) A1 iv A5 form an accessible substituted seven-membered ring, which may be saturated or unsaturated, optionally containing up to two heteroatoms chosen from the group of O, S and N wherein S and N may be optionally oxidized; D1 to D4 form an accessible substituted six membered ring, optionally containing up to two nitrogen atoms; R is at least one substituent chosen from the group of R', or Q-Cj^alkyl, Q-C2-4alkenyl, Q-C2-4alkynyl, optionally substituted by one or more of =0, R11 or R7; R* is H, Q-Ci_6alkyl, Q-Ci_60xoalkyl, Q-C2-6alkenyl, Q-C3^oxoalkenyl, Q-C3-40X0alkynyl, Q-C2-4alkynyl, C3-6cycIoalkyl, Ar or Het, optionally substituted 20 by one or more of R11; Q is H, C3_6cycloalkyl, Het or Ar; R7 is -COR8, -COCR'2R9, -C(S)R8, -S(0)m0R\ -S(0)mNR'R", -PO(OR'), -PO(OR')2, -B(OR')2, -N02 and Tet; R8 is -OR", -NR'R", -NR,S02R', -NR'OR', -0CR'2C(0)0R', -0CR*20C(0)-25 R', -0CR'2C(0)NR'2, CF3 or AA1; R9 is -OR', -CN, -S(0)rR', S(0)mNR'2, -C(0)R' C(0)NR'2 or -C02R'; WO 96/00730 PCT/DS95/08306 R11 is H, halo, -OR12, -CN, -NR'R12, -N02, -CF3, CF3S(0)r, -C02R', -CONR'2, Q-Co-6alkyl-, Q-Ci-goxoalkyl-, Q-C2-6alkenyl-, Q-C2-6alkynyl-, Q-Co-6alkyloxy-, Q-Co-galkylamino- or Q-Co-6alkyl-S(0)r; R12 is R', -C(0)R\ -C(0)NR'2, -C(0)0Rl5, -S(0)mR' or S(0)mNR'2; 5 R15 is H, Q-galkyl or Ar-Co^alkyl; R' is H, Ci^alkyl, C3-7cycloalkyl-Co-4alkyl or Ar-Co_4alkyl; R" is R", -C(0)R' or -C(0)0R15; AA1 is an amino acid attached through its amino group and having its JO carboxyl group optionally protected; - ■ m is 1 or 2; and r is 0 or 2; or 0 phannaceutically acceptable salts thereof, with the proviso that: (i) when A is l,2,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-lH-l,4-benzodiazepine-2-acetic acid, then W is not -(CH2)J.,NHCO- attached at the 1-position of an imidazole ring; and (ii) when A is l,2,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-lH-l,4-benzodiazepine-2-acetic acid, then W is not -(CHj)2 NHCO- attached at the 4(5)-position of an imidazole ring.
With reference to formula (VI), suitably, A1 is CRiR1', CR1, NRl, N, O or S(0)x; A2 is CR2R'2', CR2, NR2; A3 is CR3R3', CR3, NR3, N, O or S(0)x; WO S6/00730 A4 is CR4R4', CR4, NR4, or N; A5 is CR5R5', CR5, NR5, N, O or S(0)x; 9000 D1-D4areCR11,CR6orN; • R1 and R1' are R* or R, or together are =0; R2 and R2' are R\ R or =0; R3 and R3' are R*, R or =0; R4 and R4' are R", R or.=0; R5 and R5' are R', R or =0; and x is 0 to 2.
More suitably, A1 is CRlR1', CR1, NR1, N, O or S; A2 is CR2R2', NR2 or CR2; A3 is CR3R3'; a4 is CR4R4', CR4, NR4, or N; A5 is CR5R5', CR5, NR5. Nj or 0; d1 and D4 are CH; "tie of D2 or D3 is CH and the other is CH or N; one of R2 or R4 are R and the other is H; R3,R3' and R5,R5' are =0 or R*,H; R1 and R1' are R* or R; and R2' and R4' are H.
Preferably, A1 is CHR1, CR1, NR", N or S; A2 is CR2 or CR2R2'; A3 is CR3R3'; A4 is CR4R4' or NR4; A5 is CR5R5' and D1- D4 are CH in which R1 is R* or R; R2 and R2' are R*, R or together are =0; R3 and R3' are R*, R or together are =0; R4 and R4' are R*, R or together are =0; R5 and R5' are R*, R or together are =0.
In one embodiment, A1 is CR1, A2 is CR2, A3 is C=0. Ad is NR4 and A5 are CHR5 in which R1 is R* or R; R2 is R* or R; R4 is R* or R; R- is R" or R.
In another embodiment, A1 is NR1, A2 is CHCR2. A3 is CR3R3', A4 is NR4, and A5 are C=0 in which R1 is R* or R; R2 is R*, R; R3 and R3' are R*, R or together are =0; R4 is R* or R.
In yet another embodiment, A1 and A4 are C=0, A2 is NR-, A3 is CHR3 and A5 is NR5 in which R2 is R* or R; R3 is R* or R; R5 is R or R or =0.
In a preferred embodiment. A1 is NR1, A2 is CHR2, A3 is C=0, A4 is NR' and A5 is CHR5 in which R1 is R* or R; R2 is R* or R; R5 is R* or R.
Representative sub-formulas of (VI) are given by each of formulas (Vla)-(Vli) below: 4 •XVO 96/00730 PCT/U S95/08306 (Vid) (Vie) (Vlf) (VIg) r2 or (Vlh) (Vli) Specific embodiments of this invention wherein the fibrinogen receptor antagonist template A is of the sub-formula (VI) are named in Examples 1-75.
Preferred compounds of this invention are: 10 (2S)-7-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; -7-[[[2-(4-aza-5-methylbenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3- oxo-2,3,4,5-tetrahydro-iH-l,4-benzodiazepine-2-acetic acid; (±)-7-[[[2-(4-Azabenzimidazolyl)methyl]methylamino]carbonyl]-4-(2-15 methoxyethyl)-3-oxo-2,3,4,5-tetrahydro- 1H-1,4-benzodiazepine-2-acetic acid; (±)-7-[[[2-(benzimidazolyl)methyl]methylamino]carbonyl]-4-(2-methoxyethyl)-3- oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; -7-[[[2-(4-azabenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-20 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; (2S)-7-[[[N-butyl-N-benzimidazol-2-yl)methyl]amino]carbonyl]-3-oxo-4-methyl- 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; -7-[[[(2-benzimidazolyI)methyl]methylamino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; -7-[[[N-(2-benzimidazolyl)methyl-N-(2-phenylethyl)]amino]carbonyl]-4-niethyl-3- oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; (±)-7-[[[2-(benzimidazolyl)methyl]amino]carbonyl-4-[2-(3,4- methylenedioxyphenyl)ethyl]-3-oxo-2,3,4,5-tetrahydro- 1H-1,4-benzodiazepine-2-acetic acid; and (±)-7-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyI]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro- 1H-1,4-benzodiazepine-2-acetic acid.
The most preferred fibrinogen receptor antagonist template is of the sub-10 formula (Via), wherein CR:Rr is CHCHpDjH, CR3R3 is C=0, and CR*Rr is CH,. Vitronectin fibrinogen receptor antagonism is particularly pronounced when the A-W- substituent is attached to the 7-position of the 3-oxo-2,3,4,5-tetrahydro-lH-1,4-benzodiazepinering system. (±)-8-[[[(2-Benzimidazolyl)methyl]amino]-carbony l]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid 15 has a Ki of greater than 50 micromolar in the in vitro vitronectin binding assay described hereinbelow. In the formula below the definitions for the substituents are as defined in formulas (I)-(IV), unless specified otherwise.
Another embodiment of a preferred fibrinogen receptor template A is 20 represented by the 1,4-benzodiazepine 2,5-dione of sub-formula (VII); ■Y Y L O (VII) wherein: Y is H, Ci_4alkyl, Cj^alkoxy, Cj^alkoxycarbonyl, F, CI, Br, I, CF3, OR*, S(0)kRf, CORf, N02, N(Rf)2, CO(NRf)2, CH2N(R*)2, methylenedioxy, CN, C02Rf, 0C(0)Rf, orNHC(0)Rf; Rh is (c^co^f; / M Re is H, C,.6alkyl, Ar-C^alkyl, Het-C,.6alkyl, C3.7cycloalky l/c,^allfyl, or,, (CH2)kC02RB; / R' is H, C^alkvl or Ar-C^alkyl; »-•^-^Cc /< k is 0, 1 or 2; and q is 1 or 2.
PCT/U S95/08306 The preparation and the use of this sub-structure in preparing fibrinogen receptor antagonists of this sub-formula is detailed in Bondinell, et al., WO 93/00095 published January 7, 1993 and Blackburn, et al., WO 93/08174, published 5 April 29, 1993.
Table I, below, summaries other preferred fibrinogen receptor templates that are included within the scope of the present invention. Such templates are: Table I one of A1 or pO- is -Z-C02Rf or Z-CON(R*)2; Zis -CH2-, -0(CH2)q-, -NRf(CH2)q-, -S(CH2)q, -CH2CH2-, -CH(CH3)CH2-, -(CH2)3-, -CH=CH-, -C(CH3)=CH-, CH2-CH=CH- or CH=CHCH2; and 20 Y is H, Ci-4alkyl, Ci^alkoxy, Ci-4alkoxycarbonyl, F, CI, Br, I, CF3, ORf, S(0)kR^, CORf, NO2, N(Rf)2, CO(NR^)2, CH2N(Rf)2, methylenedioxy or Z-CO- F'.*, in Alig, et al., EP 0 381 033, published August 8,1990.
The preferred fibrinogen receptor template A in formula (VIE) is rviii) or wherein: R^ 1 and R^2 independently are H or -Z-CO2R or Z-CON(R^)2 with the proviso that 2 Specific embodiments of this aspect of the invention are: 4-[2- [[[ 1 -[(Benziimdazol-2-yl)rnethyl]beazimidazol-2-yl]methyl]methylamino]acetyl] phenoxyacetic acid; (±)-4-[[2-[(Benzimida?.ol-2-yl)methyl]methylamino]-l-hydroxyethyI]-l,2- phenylene dioxydiacetic acid; 4-[2-[[(Benzimidazol-2-yl)methyl]methylamino]acetyl]-l,2-phenylenedioxydiacetic acid; or 3-[[4-[[[(Benzimidazol-2-yl)methy]amino]carbonyI]phenyl]amino.]propionic acid.
Ci_iQalkaryl, Ci_ioalkylthioalkyl, C^ioalkoxythioalkyl, Ci_ioalkylamino, C4. j Qaralkylamino, Ci_i0alkanoylaminc, C4_ioaralkanoylamino, C^igalkanoyl, C4_|Qaralkanoyl, or Ci_i0carboxyalkyl; Y is H, Ci_4alkyl, Cj^aikoxy, C^alkoxycarbonyl, F, CI, Br, I, CF3, ORf, S(0)kRf CORf N02, N(Rf)2, CO(NRf)2, CH2N(Rf)2, methylenedioxy, CN, C02Rf, 0C(0)Rf, or NHC(0)Rf Rr is H, C,.6alkyl or Ar-C,..-alkyl; and k is 0,1 or 2, in Egbertson, et al., EP 0 478 328, published April 1,1992.
OX) Y wherein: R6 is aryl, Ci_ioalkyl, C3_6cycloalkyl» C4_ioaralkyl, Ci.joalkoxyalkyl, The preferred compounds of formula (IX) are those wherein R^ is aryl, Cj.
IQalkyl, C3_6cycloalkyl, or C^ioaralkyl. A specific embodiment of this aspect of the invention is (S)-(2-butylsuIfonyl-amino)-3-[4-(3-benzimidazo-2-yl)propyloxy)]phenylpropionic.
M' is CHor N; M2 is CH or N, with the proviso that when M1 is CH, M2 is N; G' is N or N®R"; Rris H, C^alkyl or Ar-CU6alkyl; and R8 is H, C,.6alkyl, Het-C0.6alkyl, C3.7cycloalkyl-C0.6alkyl or Ar-Co.6alkyl; in Eldred, et al., EP 0542 363, published May 19, 1993.
Preferred embodiments of the vitronectin receptor antagonists containing the substructure of Sejraula (X) are those wherein G* is N an M1 is N. A compound containing this substructure, naraejy 4-[4-[l-(2-methylbenzimidazolyl)piperidmyl]]-piperidineacetic acid, has a Ki of greater than 50 micromolar in the in vitro vitronectin binding assay described hereinbelow.
DO. wherein: (XI) wherein: M1 is CH or N; and M2 is CH or.N. with the proviso that when M' is CH, M2 is N; and Rf is H, C|.6alkyl or Ar-C,.6alkyl; in Porter, et al., EP 0 537 980, published April 21, 1993. gsh Y 290 wherein: M' isCHor N; Y is H, Ci_4alkyl, C^alkoxy, Ci^alkoxycarbonyl, F, CI, Br, I, CF3, ORf, S(0)kRf, COR^ NO2, N(Rf)2, CO(NRf)2, CH2N(Rf)2, methylenedioxy, CN, C02Rf, 0C(0)Rf, orNHC(0)Rf; M3 is CHj or C=0; Rh is (CH2)qC02Rr; Rf is H, Q.galkyi or Ar-Ct.6alkyl; " k is 0, 1 or 2; and q is 1 or 2; in Klinnick, et al., EP 0 635,492, published January 25,1995.
Y is H, Cj^alkyl, C^alkoxy, C^alkoxycarbonyl, F, CI, Br, I, CF3, ORf, S(0)kRf, CORf, NO2, N(Rf)2, CO(NRf)2, CH2N(Rf)2, methylenedioxy, CN, C02Rf, 0C(0)Rf, or NHC(0)Rf; R" is (CH^CO.Rf; and reran wherein: Rf is H, C,.6alkyl or Ar-C,_6alkyl; k is 0, 1 or 2; and Oi nis0or3; j in Blackburn, et al., WO 95/04057, published February 9,1995. ' 96/00730 ssn -CC /} L-C02R3 wherein: L* is -QOJNRyCH,)-, -C(0)-(CH,)r, NR'-CCH,),-, -O-(CR),-, or scoHoy,-.
Rg is H, C,.6alkyl, Het-CMalkyl, C3.7cycloalkyl-C0_6alkyl or Ar-C^alkyl; k is 0,1 or 2; and q is 1 or 2; in Hartman, et al., EP 0 540 331, published May 5, 1993. 'sm -N wherein: \ / co?o N—CH—C02R9 Rs is H, C[.6alkyl, Het-Co.6alkyl, C3.7cycloalkyl-C0.6alkyl, or Ar-C^alkyl; in Sugihara, et al., EP 0 529,858, published March 3, 1993.
(XVD Y wherein: Y is H, C^alkyl, C^alkoxy, Cj^alkoxycarbonyl, F, CI, Br, I. CF3, ORf, S(0)kRf, CORfl, N02, N(Rf)2, CO(NRf)2, CH2N(Rf)2, methylenedioxy, CN, C02Rf, 0C(0)Rf, or NHC(0)Rf; Rg is H, C,.6alkyl, Het-C0.6alkyl, C3.7cycloalkyl-Co.6alkyl or Ar-C^alkyl; Rf is H, C,.6alkyl or Ar-C,.6alkyl; and k is 0, 1 or 2; in Hinuneisbach, et al., EP 0 483 667, published May 6, 1992.
(XVTD 7>— (CH^CO^0 Oh wherein: O RB is H, C,.6alkvl, Het-C0.6alkyl, C3.7cycloalkyl-Co.6alky| or ArfCo.6aLkyt; and I 1 U -v,7 - "-5 q is 1 or 2* in Linz, et al., EP 0 567 968, published November 3, 1993. L^R FCFM/.n ' " . J rxvnr z; z" COzRg Rd wherein: Rd is Het-C^alkyl; and Z", Z'" independently are hydrogen, CMalkyl, halo, ORf, CN, S(0)kRr, 5 C02Rf, or OH, in Bovy, et al., EP 0 539 343, published April 28, 1993.
The above descriptions of fibrinogen receptor templates for use in the present invention were taken from pending published patent applications. Reference should 10 be made to such patent applications for their full disclosures, including the methods of preparing said templates and specific compounds using said templates, the entire disclosure of such patent applications being incorporated herein by reference.
Table n, below, describes other fibrinogen receptor antagonists, whose core 15 structures would be useful in carrying out the instant invention. Reference should be made to the patent applications and other publications for their full disclosures, including the methods of preparing said templates and specific compounds using said templates, the entire disclosure of the noted patent applications and other publications being incorporated herein by reference. Since it is contemplated that 20 any fibrinogen receptor antagonist that is linked to an optionally fused nitrogen-containing five-membered ring will possess the novel utility described herein, the list below does not limit the scope of the present invention.
Table II Adir et Compagnie FR 928004, June 30,1992, Fauchere, J. L., et al.
EP 0578535, June 29, 1993, Fauchere, J-L, et al.: Describes X-RGDW-OH analogs, where X contains a cationic amine.
CA 2128560, Jan. 24,1995, Godfroid, J-J, et al., substituted piperazines.
Asahi Breweries, Ltd.
JP 05239030, Sep. 17, 1993, aminomethyltetrahydroisoquinolines.
Asahi Glass WO 90/02751, Ohba, M. et al.: Sept. 8, 1989: Describes cyclic RGD-containing 5 peptides.
WO 90/115950, Mar. 22, 1990, Ohba, M., et al.
EP 0406428, 1/9/91: Describes cyclic RGD-containing peptides WO 92/09627, Isoai, A. et al.: Nov. 29, 1991: Describes cyclic RGD-containing peptides. 0 Cassella AG DE 4207254, (Der 93-289298/37) Mar. 7, 1992, Zoller, G., et al.: Describes guanidinopropyl-4-oxo-2-thioimidazolidin-3-yl-Asp-X analogs EP 93904010, Feb. 24, 1993, Zoller, G., 4-oxo-2-Thioxoimidazolidine Derivatives. 5 EP 0565896, Mar. 18, 1993, Klinger, O, et al.: Describes guanidinoethylphenyloxyacetyl-Asp-X analogs.
EP 0566919, (Der 93-338002/43) Apr. 3,1993, Zoller, G., et al.: Describes guanidinopropyl-4-oxo-2-thioimidazolidin-3-yl-Asp-X analogs.
EP 580008, (Der 94-027663/04) July 6, 1993, Zoller, G., et al.: Describes 5-m-0 guanidinophenyl-2,4-dioxoimidazolidin-3yl)acetyl-Asp-Phg.
DE 224414, July 6, 1993, Zoller, G., et al.: Describes 5-m-guanidinophenyl-2,4-dioxoimidazolidin-3yl)acetyl-Asp-Phg.
EP 584694, (Der 94-067259/09) Apr. 2, 1994, Zoller, G., et al.: Describes 5-m-guanidinophenyl-2,4-dioxoimidazolidin-3yl)acetyl-Asp-Phg. 5 DE 4301747, (Der 94-235891/29) Jul. 28, 1994, Zoller, G., et al.: Describes 5-m-guanidinophenyl-2,4-dioxoimidazolidin-3yl)acetyl-Asp-Phg analogs.
DE 4308034, (Der 94-286666/36) Sept. 15, 1994, Klinger, O. et al.: Describes 5-m-guanidinophenyl-2,4-dioxoimidazolidin-3yl)acetyl-Asp-Phg analogs.
DE 4309867, Sept. 29, 1994, Klingler, O, et al.: Describes 5-m-guanidinophenyl-0 2,4-dioxoimidazolidin-3yl)acetyl-Asp-Phg.
Chiron WO 93/07169, (Der 93-134382/16), Mar. 15,1993, Devlin, J. J., et al.: Describes RGD peptides.
Ciba Geigy EP 0452210, (Der 91-305246/42) Apr, 5, 1990, describes aminoalkanoyl-GDF analogs.
EP 0452257, Mar. 26, 1991, Allen, M. C., et al.: Describes aminoalkanoylAsp-Phe analogs.
COR Therapeutics WO 90/15620, June 15,1990: Describes cyclic RGD-containing peptides. EP 0477295, Apr. 1,1992: Scarborough, R. M. et al.
WO 92/08472, May 29,1992, Scarborough, R. M. et al.
WO 93/223356, April 27,1993, Swift, R. L., et al.: Describes cyclic RGD-containing peptides.
EP 0557442, Sept. 1,1993, Scarborough, R. M., et al.
Scarborough, R. M.; Rose, J. W.; Hsu, M. A.; Phillips, D. R.; Fried, V. A.; Campbell, A. M.; Nunnizzi, L.; Charo, I. F., Barbourin, A GPHb-IIIa-20 Specific Integrin Antagonist from the Venom of Sistrurus M. Barbouri, J.
Biol. Chem., 266, 9359,1991.
Daiichi Pharm Co Ltd.
JP 05078344-A, (Der 93-140339/17) Mar. 30,1993: Describes Bis-25 amidinoheterocycles, eg. benzofurans.
DuPont Merck WO 93/07170, Apr. 15,1993: Describes cyclic-RGD-containing peptides. WO 94/11398, May 26, 1994: Wells, G. J. et al. Describes cyclic RGD containing 30 peptides.
IL 109237, Jul. 31, 1994.
WO 94/22909 , (Der 94-333113/41) Oct. 13,1994: DeGrado W. F., et al.
WO 94/22910 , (Der 94-333114/41 Oct. 13,1994: DeGrado W. F., et al. Prodrugs.
WO 94/22494 , (Der 94-332838/41) Oct. 13,1994: DeGrado W. F., et al. Cyclic peptides EP 625164, Nov. 23, 1994: Degrado, W. F., et al. Cyclic peptides.
Mousa, S. A.; Bozarth, J. M.; Forsythe, M. S.; Jackson, S. M.; Leamy, A.; Diemer, M. M.; Kapil, R. P.; Knabb, R. M.; Mayo, M. C.; Pierce, S. K.; al., e., Antiplatelet and Antithrombotic Efficacy of DMP 728, a Novel Platelet GPIIb/nia Receptor Antagonist, Circulation, 89,3,1994.
Jackson, S.; DeGrado, W.; Dwivedi, A.; Parthasarathy, A.; Higley, A.; Krywko, J.; Rockwell, A.; Markwalder, J.; Wells, G.; Wexler, R.; Mousa, S.; Harlow, R., Template-Constrained Cyclic Peptides: Design of High-Affinity Ligands for GPHb/IIIa, J. Amer. Chem. Soc. ,116, 3220, 1994.
Ellem Ind Farma Spa GB 2207922, Aug, 3, 1988, describes linear RGD analogs.
Farmitalia Erba SRL Carlo EP 611765 (Der 94-265375/33), Aug 24,1994: Cozzi, P., et al. Describes 5-(2-20 pyrazinylmethyl-2-imidazol-1 -yl)-1 -cyclohexylethylidene)aminoxypentanoic acid.
Fuji Photo Film JP 04208296-A (Der. 92-303598/38), Nov. 30,1990, Describes RGD peptides. 25 JP 04213311-A (Der. 92-305482/38), Nov. 27, 1990, Describes multimeric RGD peptides.
JP 04217693-A, (Der 92-312284/38), Oct. 23,1990, Descirbes multimeric RGD peptides.
JP 04221394-A (Der. 92-313678/38), Oct. 26, 1990, Describes multimeric RGD 30 peptides.
JP 04221395-A (Der. 92-313679/38), Oct. 26, 1990, Describes multimeric RGD peptides.
JP 04221396-A (Der. 92-313680/38), Oct. 26, 1990, Describes multimeric RGD peptides.
JP 04221397-A (Der. 92-313681/38), Dec. 20, 1990, Describes multimeric RGD peptides.
EP 0482649 A2, April 29,1992, Kojima, M. et al.: Describes RGD peptides.
EP 0488258A2, June 3,1992, Komazawa, H., et al: Describes RGD peptides.
EP 503301-A2, Feb. 14,1991, Kitaguchi, H. et al.: Describes RGD peptides. 10 JP 05222092, May 21, 1993, Nishikawa, N., et al.: DescribesLinear X-RGDS.
JP 06239885, (Der 94-313705/39), Aug 30, 1993, Nishikawa, N. et al.: Describes multimeric RGD peptides.
WO 9324448, (Der 93-405663/50), Dec. 9,1993, Nishikawa, N., et al.: Describes multimeric retro-inverseo RGD peptides.
JP 06228189, (Der 94-299801/37), Aug. 16, 1994. Describes RGD peptides.
EP 619118, (Der 94-311647/39), Oct. 12, 1994, Nishikawa, N. et al.: Describes linear RGD peptides.
Fujisawa EP 0513675, May 8,1992, N. Umekita, et al.: Describes amidinophenyloxyalkanoyl-Asp-Val-OH analogs.
WO 9409030-A1, Apr. 28,1994, Takasugi, H., et al.: Describes Amidinophenoycbutanoyl-Asp-Val-OH analogs.
EP 0513675, (Der 92-383589/47): Describes Amidinophenyloxybutyrl-Asp-Val 25 analogs.
WO 9500502, Jan, 5, 1995, Oku, T., et al.,: Describes "aminopiperazine derivatives." FR 144633: Thromb Haem. 69,706, 1993.
Cox, D.; Aoki, T.; Seki, J.; Motoyama, Y.; Yoshida, K., Pentamidine: A Specific 30 Nonpeptide GPIIb/IIIa Antagonist, Thromb. Haem., 69,707, 1993.
Genentech WO 90/15072 (Der 91007159): Describes RGD-containing peptides: WO 91/01331 (Der 91058116), July 5, 1990, P. L. Barker, et al.: Describes cyclic RGD-containing peptides 5 WO 91/04247, Sept. 24,1990, T. R. Webb: Describes (guanidinoalkyl)Pro-GD analogs.
WO 91/11458 (Der 91252610), Jan. 28, 1991, P. L. Barker, et al.: Describes cyclic RGD-containing peptides WO 92/07870, Oct. 24,1991 J. P. Burnier, et al.: Describes cyclic RGD-10 containing peptides.
WO 92/17492, Oct. 15, 1992, Burnier, J. P. et al.: Describes cyclic RGD-containing peptides.
CA 2106314, Oct. 6, 1992, Burnier, J. P. et al.
WO 93/08174, Oct. 15, 1991, B. K. Blackburn, et al.: Describes 2,5-dioxo-l,4-15 benzodiazepines.
CA 2106314, Oct. 6,1992, Burnier, J. P., et al.
EP 0555328, Aug. 18, 1993, J. P. Burnier, et al.
WO 95/04057, Feb. 9,1995, Blackburn, B. K., et al.: Describes 1,4-benzodiazepines containing a heterocyclic at positions 1,2.
Scarborough, R. M., Naughton, M. A., Teng, W., Rose, J. W., Phillips, D. R., Nannizzi, L, Arfsten, A., Campbell, A. M., and Charo, I. F., J. Biol. Chem. 268,1066,1993.
Dennis, M. S.; Henzel, W. J.; Pitti, R. M.; T., L. M.; Napier, M. A.; Deisher, T. A.; Bunting, S.; Lazarus, R., Platelet Glycoprotein Ilb-HIa Protein Antagonists 25 from Snake Venoms: Evidence for a Family of Platelet-Aggregation Inhibitors, Proc. Natl. Acad. Sci. USA , 87, 2471,1989.
Barker, P. L.; Bullens, S.; Bunting, S.; Burdick, D. J.; Chan, K. S.; Deisher, T.; Eigenbrot, C.; Gadek, T. R.; Gantzos, R.; Lipari, M. T.; Muir, C. D.; Napier, M. A.; Pitti, R. M.; Padua, A.; Quan, C.; Stanley, M.; Struble, M.; Tom, J. Y. 30 K.; Burnier, J., P., Cyclic RGD Peptide Analogues as Antiplatelet Antithrombotics, J. Med. Chem., 35, 2040, 1992.
McDowell, R. S.; Gadek, T. R., Structural Studies of Potent Constrained RGD Peptides, J. Amer. Chem. Soc., 114, 9245, 1992.
Glaxo EP 537980, Oct. 13, 1992, B. Porter, et al.: Describes six cis-4-[4-(4- amidinophenyl)-l-piperazinyl]-l-hydroxycyclohexaneacetic acid analogs.
EO 0542363, Nov. 10, 1992, Porter, B., et al.: Describes 4-[-4-amidinophenyl-piperazinyl]-piperidine-l-acetic acid analogs.
WO 93/2°303, Jan. 11,1993, Middlemiss, D., et al.: Describes amidinophenyl-10 aiylpiperazineacetic acid analogs.
WO 93/22303, Jan. 11,1993, Middlemiss, D., et al.: Describes amidinophenyl-arylpiperazineacetic acid analogs.
WO 93/14077, Jan. 15, 1993, B. Porter, et al.: Describes amidinophenyl-piperizinyl-piperidine-acetic acid analogs.
EP 609282 Al, Aug. 10,1994, Porter, B. et al.: Describes cyclohexane acetic acid derivatives.
EP 612313, Aug. 31, 1994, Porter, B., et al. Describes alpha-alkylpiperidineacetic acid derivatives.
EP 93911769, Apr. 20, 1994, Midlemiss, D., et al.
EP 637304 Al, Feb. 8,1995, Middlemiss, D., et al. Piperazine Acetic acid Derivatives.
Hann, M. M.; Carter, B.; Kitchin, J.; Ward, P.; Pipe, A.; Broomhead, J.; Hornby, E.; Forster, M.; Perry, C., An Investigation of the Bioactive Conformation of ARG-GLY-ASP Containing Cyclic Peptides and Snake Venom Peptides 25 Which Inhibit Human Platelet Aggregation, In Molecular Recognition: Chemical and Biochemical Problems II", S. M. Roberts, Ed., The Royal Society of Chemistry, Cambridge, 1992.
Ross, B. C. Nonpeptide Fibrinogen Receptor Antagonists", (SAR leading to the discovery of GR 144053), In Seventh RSC-SCI Medicinal Chemistry 30 Symposium, The Royal Society of Chemistry Fine Chemicals and Medicinals Group and SCI Fine Chemicals Group, Churchill College, Cambridge, 1993, L20.
Pike, N. B.; Foster, M. R.; Hornby, E. J.; Lumley, P., Effect of the Fibrinogen Receptor Antagonist GR144053 Upon Platelet Aggregation Ex Vivo 5 Following Intravenous and Oral Administration to the Marmoset and Cynomologous Monkey, Thromb. Haem., 69, 1071, 1993.
Hoechst DE 4009506, Mar. 24, 1990, Konig, W., et al.: Describes Hydantoin-(Arg-Gly)- Asp-X analogs.
Hoffmann-La Roche AU 9344935, (Der 94-118783/15), Mar. 10, 1994,: Describes Cyclic RGD analogs.
EP 0592791, Apr. 20,1994, Bannwarth. W. et al.: Describes Cyclic RGD analogs.
Kogyo Gijutsuin JP 06179696, June 28, 1994, Maruyama, S., et al.: Describes Gly-Pro-Arg-Pro-Pro and analogs.
Kyowa Hakko Kogyo KK JP 05078244-A, Mar. 30, 1993: Describes dibenzo(b,e)oxepine derivatives.
Laboratoire Chauvin WO 9401456, Jan. 20, 1994, Regnouf, D. V. J. et al.: Describes Ac-Arg-Gly-Asp-NHBn analogs.
La Jolla Cancer Res. Fndn WO 9500544, Jan. 5, 1994, Pierschbacher, M. D. et al.
US 079441, Jan 5,1994, Pierschbacher, M. D. et al.: Describes RGD Peptides.
P CT/U S95/08306 Lilly/COR EP 0635492, Jan. 25,1995, Fisher, M. J., Happ, A. M., Jakubowski, J. A., Kinnick, M. D., Kline, A. D., Morin, Jr., J. M., Sail, M. A., Vasileff, R. T.,: Describes 5 compounds with 6,6-templates.
Medical University of South Carolina EP 587770, Mar. 23,1994 Halushka, P. V., Spicer, K. M. 0 Merck EP 0368486 (Der 90-149427/20), Nov. 10,1988: Describes X-R-Tyr-D-Y analogs.
EP 0382451 (Der 90248531): Descirbes RGD-containing snake venom inhibitors.
EP 0382538 (Der 90248420): Descirbes RGD-containing snake venom inhibitors.
EP 0410537, July 23, 1990, R. F. Nutt, et al.: Describes cyclic RGD-containing 5 peptides.
EP 0410539, July 25,1990, R. F. Nutt, et al.: Describes cyclic RGD-containing peptides.
EP 0410540, July 25,1990, R. F. Nutt, et al.: Describes cyclic RGD-containing peptides. 0 EP 041054 ], July 25,1990, R. F. Nutt, et al.: Describes cyclic RGD-containing peptides.
EP 0410767, July 26,1990, R. F. Nutt, et al.: Describes linear RGD-containing peptides.
EP 0411833, July 26,1990, R. F. Nutt, et al.: Describes cyclic RGD-containing 5 peptides.
EP 0422937, Oct. 11,1990, R. F. Nutt, et al.: Describes cyclic RGD-containing peptides.
EP 0422938, Oct. 11, 1990, R. F. Nutt, et al.: Describes cyclic RGD-containing peptides. 0 EP 0487238, Octover 13, 1991, T. M. Connolly, et al.: Describes Linear RGD-containing.
EP 0437367 (Der 91209968), M. Sato et al.: Describes cyclic RGD-containing peptides, as inhibitors of osteoclast-mediated bone resorption.
EP 576898, Jan. 5, 1994, Jonczyk, A., et al.: Describes linear RGD peptide analogs for use in inhibition of cell adhesion.
WO 9409029, Apr. 28, 1994, Nutt, R. F. and Veber, D. F., describes piperidinylethylpyrrolidinylacetyl-Asp-Trp(tetrazoles).
EP 618225, (Der 94-304404/38) Oct. 5, 1994, Describes RGD peptide analogs as antimetastatic compounds.
DE 4310643, (Der 94-311172/39), Oct. 6, 1994, Jonczyk, A., et al.,: Describes 10 cyclic RGD analogs as antimetastatic agents.
NO 9404093, Oct. 27, 1994, Jonczyk, A., et al.
EP 0632053, Jan. 4, 1995, Jonczyk, A., et al.,: Describes cyclic RGD analogs as antimetastatic agents.
EP 0479481, Sept. 25, 1991, M. E. Duggan et al.: Describes X-GlyAsp-Y linear 15 semipeptides.
EP 0478328, Sept. 26, 1991, M. S. Egbertson, et al.: Describes tyrosine derivatives.
EP 0478362, Sept. 27, 1991 M. E. Duggan et al.: Describes X-Gly-(3-phenethyl)pAla analogs.
EP 0478363, Sept. 27, 1991, W. L. Laswell, et al.: Describes Tyrosine 20 sulfonamides.
EP 0512829, May, 7, 1992, Duggan, M. E., et al.: Describes chiral 3-hydroxy-6-(4-piperidinyl)heptanoyl-P-X-(3-Ala-OH analogs, with variations on X and the central alkanoyl chain.
EP 0512831, May, 7, 1992, Duggan, M, E., et al.: Describes chiral 2-oxo-3-25 (Piperidinylethyl)piperidinylacetyl-P-X-P-Ala-OH analogs, with variations on X and the central piperidinyl ring.
EP 0528586, August 5, 1992, M. S. Egbertson, et al.: Describes tyrosine sulfonamides as inhibitors of osteoclast-mediated bone resorption.
EP 0528587, August 5,1992, M. S. Egbertson, et al.: Describes tyrosine 30 sulfonamides as inhibitors of osteoclast-mediated bone resorption.
EP 0540334, October 29, 1992, G. D. Hartman, et al.: Describes benzimidazoles.
WO 96/00730 PCT/US95/08306 US 5227490, Feb. 21,1992, G. D. Hartman, et al.: Describes Tyrosine sulfonamides.
CA 2088518, Feb. 10,1993, Egbertson, M. S., et la. aminoalkyl-phenyl derivs. as bone resorption inhibts.
US 5206373-A, (Der 93-151790/18) Apr. 27,1993, Chung, J. Y. L., et al.: Describes MK-383-type compounds.
WO 9316994, (Der 93-288324/36), Sep. 2,1993, Chung, J. Y. L., et al.: Describes pyridinylbutyl-L-Tyrbutylsulfonamide.
US 5264420-A, Nov. 23, 1993, Describes piperidinylalkyl-Gly-betaAla analogs.
US 5272158, Dec. 21,1993, Hartman, G. D. et al.,: Describes piperidinylethylisoinole analogs.
US 5281585, Jan. 25, 1994, Ihle, N., et al.,: Describes 3-(piperidinylethyl)-piperidinone analogs.
GB 945317 A, Mar. 17, 1994 (Priority US 34042A , Mar. 22, 1993).
GB 2271567 A, Apr. 20, 1994, Hartman, G. D. et al.: Describes compounds replacing Tyr with beta-phenylsuccinate.
US 5294616, (Der 94-091561/11) Mar. 15,1994, Egbertson, M. S., et al.
US 5292756, (Der 94-082364) Apr. 8, 1994, Hartman, G. D. et al.
WO 9408577, Apr. 28,1994, Hartman, G. D., et al.
WO 9408962, Apr. 28, 1994, Hartman, G. D., et al.
WO 9409029, (Der 94-151241/18) Apr. 28, 1994, Hartman, G. D., et al. Describes piperidinylpyrrolinylacetyl-Asp-Trp-tetrazoles.
US 5312923, May 17, 1994, Chung, J. Y. L. et al.
HU 9400249, May 30, 1994, Gante, J. et al.,: Describes piperazine analogs.
WO 9412181, (Der 94-199942/24), Jun. 9, 1994, Egbertson, M. S. et al.,: Describes piperidinylethyloxyphenyl acetic acid analogs US 5321034, June 14,1994, Duggan, M. E., et al.: Describes Piperidinylalkyl-betaamino acids.
US 5334596, Aug. 2, 1994, Hartman, G. D. et al.
EP 0608759 A, Aug. 3, 1994, GAnte, J. P. et al.: Describes amidinopiperazinyl compounds.
PCTAJS95/08306 WO 9418981, (Der 94-293975/36) Sep. 1,1994, Claremon, D. A., et al.: Describes Many different amine surrogate.
GB 2276384, (Der 94-287743/36) Sep. 28,1994, Claremon, D. A.., Liverton, N.„: Describes piperidinylethylquinazoline analogs.
WO 9422825, Oct. 13, 1994, Claremon, D. A.. Liverton, N. J.,: Describes piperidinylethyl-retro-benzodiazepine analogs.
EP 0623615A, Nov. 9, 1994, Raddatz, P. et al: Describes amidinophenyloxazolidinylmethyl-piperidine-4-carboxylic acid and analogs.
WO 9504531, Feb. 16, 1995, Hartman, G D., et al.: Describes 0 piperidinylalkylheterocycles.
Nutt, R. F.; Brady, S. F.; Colton, C. D.; Sisko, J. T.; Ciccarone, T. M.; Levy, M. R.; Duggan, M. E.; Imagire, I. S.; Gould, R. J.; Anderson, P. S.; Veber, D. F., Development of Novel, Highly Selective Fibrinogen Receptor Antagonists as Potentially Useful Antithrombotic Agents, In Peptides, Chemistry and 5 Biology, Proc. 12th Amer. Peptide Symp., J. A. Smith and J. E. Rivier, Ed., ESCOM, Leiden, 1992; 914.
Hartman, G. D.; Egbertson, M. S.; Halszenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R. J.; Zhang, G.; Chang, C. T. C.; Gould, R. J., Non-peptide Fibrinogen Receptor Antagonists. 1. 0 Discovery and Design of Exosite Inhibitors, J. Med. Chem., 35,4640, 1992.
Gould, R. J.; Barrett, S.; Ellis, J. D.; Holahan, M. A.; Stranieri, M. T.; Theoharides, A. D.; Lynch, J. J.; Friedman, P. A.; Duggan, M. E.; Ihle, N. C.; Anderson, P. S.; Hartman, G. D., Characterization of L-703,014, A Novel Fibrinogen Receptor Antagonist, Following Oral Administration to Dogs, Thromb. 5 Haem., 69,539, 1993.
Merrell Dow WO 93/24520, May 14,1993, Harbeson, S. L., et al.: Describes cyclic RGD peptides.' 0 WO 9324520, Dec. 9, 1993, Harbeson, Bitonti,J., A.,: Describes cyclic RGD analogs as antimetastatic agents.
WO 9429349, Dec. 22,1994, Harbeson, Bitonti,J., A.,: Describes cyclic RGD analogs as antimetastatic agents.
Nippon Steel Corp WO 9405696, Mar. 17, 1993, Sato, Y„ et al,.
EP 628571, Dec. 14, 1994, Sato, Y. et al.
WO 9501371, Jan. 12, 1995, Sato, Y. et al.: Describes RWSRGDW analogs.
ONO Pharmaceuticals JP 05286922 (Der 93-383035/48), Describes guanidinophenol alkylbenzoic acid esters.
Roche EP 038,362, Feb. 19, 1990, M. Muller, et al.: Describes X-NHCHYCO-Gly-Asp- NHCHZC02H analogs.
EP 0372486, June, 13,1990, Allig, L., et al.
EP 0381033, July, 8, 1990, Allig, L., et al.
EP 0384362, August 29,1990, Allig, L. et al.: Describes amidinophenyl-linked Gly-Asp-X semipeptides.
EP 0445796, Sept. 11,1991, Allig, L. et al.: Describes amidinophenyl-linked Gly-Asp-X semipeptides.
EP 0505868, Sept. 30,1992, Allig, L. et al.: Describes N-acyl-alphaamino acid derivatives, ie. analogs from EP0381003 with variations in the phenyloxyacetic acid group.
US 5273982-A, (Der 94-006713/01) Dec. 28, 1993: Describes amidinophenyl-linked Gly-Asp-X semipeptides.
Alig, L.; Edenhofer, A.; Hadvary, P.; Hurzeler, M.; Knopp, D.; Muller, M.; Steiner, B.; Trzeciak, A.; Weller, T., Low Molecular Weight, Non-peptide Fibrinogen Receptor Antagonists, J. Med. Chem., 35,4393,1992.
PCTAJ S95/08306 Rhone-Poulenc Rorer US 4952562, Sept. 29, 1989, S. I. Klein et al.: Describes X-Gly-Asp-Val-OH analogs.
US 5064814, (Der 91-353169/48) Apr. 5, 1990: Describes Piperidinyl-azetidinyl-5 Asp-X analogs.
WO 9104746, Sept. 25,1990, S. I. Klein et al.: Describes X-Asp-Val-OH analogs WO 91/05562, Oct. 10,1989, S. I. Klein et al.: Describes X-Gly-Asp-V.al-OH analogs.
WO 91/07976, (Der 91-192965) Nov. 28,1990, S. 1. Klein et al.: Describes X-10 cycloAA-Asp-Val-OH analogs.
WO 91/04746, S. I. Klein et al.: Describes des-AminoArginine RGD analogs.
WO 92/18117, Apr. 11, 1991, S. I. Klein et al.: Describes X-Asp-Val-OH analogs.
US 5086069, (Der 92-064426/08) Ap*. 2, 1992,: Describes X-Gly-Asp-Val-OH analogs.
WO 92/17196, Mar. 30,1992, S. I. Klein et al.: Describes X-Gly-Asp-Val-OH analogs.
US 5328900, (Der 94-221950/27) Jul. 12, 1992,: Describes X-azetidinyl-Asp-Val-OH analogs.
US 5332726, (Der 94-241043/29) Jul. 26, 1994,: Describes guanidinoalkanoyl-(N-20 alkyl)Gly-Asp-Val-OH analogs.
WO 93/11759, Dec. 7, 1992, S. I. Klein et al.: Describes Bis-guanidinoaklanoic acid analogs.
EP 0577775, Jan 12,1994, Klein, S. I. et al.
CA 2107088, Sept. 29,1992, Klein, S.I. et al.
Sandoz EP 0560730, Mar. 8, 1993 G. Kottirisch and R. Mettemich: Describes amidinophenylalkanamid-S-a-acetic acid analogs.
G. Kottirisch, et al. Biorg. Med. Chem. Lett 3, 1675-1680, 1993, Describes 30 amidinophenylacetyl-(Gly-Asp-y-lactam mimetic)analogs.
Schering AG E 530937, Mar. 10,1993, Noeski-Jungblut, C., et a). "Collagen Induced Platelet Aggregation Inbitor." Searle / Monsanto EP 0319506, (Der 89-3195506) Dec. 2, 1988, S. P. Adams, et al.: Describes RGD-X analogs.
EP 0462,960, June, 19.1991, Tjoeng, F. S., et al.: Describes guanidinooctanoyl-Asp-Phe analogs. 0 US 4857508, S. P. Adams, et al.: Describes RGD analogs.
EP 0502536, (Der 92-301855) Mar. 3,1991, R. B. Garland, et al.: Describes amidinophenylalkanoyl-Asp-Phe analogs.
EP 0319506, Dec. 2, 1988, S. P. Adams et al.: Describes RGDX analogs.
US 4992463, Aug. 18, 1989: Describes guanidinoalkanoyl-Asp-X analogs.
US 5037808, Apr. 23,1990: Describes guanidinoalkanoyl-Asp-X analogs.
EP 0454651 A2, Oct. 30,1991, Tjoeng, F. S., et al.: Describes amidinoalkanoyl-Asp-X analogs.
US 4879313, July, 20, 1988: Describes guanidinoalkanoyl-Asp-X analogs.
WO 93/12074, Nov. 19,1991, N. Abood, et al.: Describes amidinophenylalkanoyl- 0 P-X-AlaOH analogs.
WO 93/12103, Dec. 11,1991, P. R. Bovy, et al.: Describes amidinophenylalkanoyl-P-X-lactone analogs.
US 5091396, Feb. 25,1992, Tjoeng, F. S., et al.: Describes amidinoalkanoyl-Asp-X analogs.
WO 92/15607, Mar. 5, 1992, Garland, R. B., et al.: Describes amidinophenylalkanoyl-Asp-X analogs.
WO 93/07867, Apr. 29,1993, P. R. Bovy, et al.: Describes amidinophenyl- amidopropionyl-P-X-AlaOH analogs.
US 888686, May 22, 1992, Bovy, P. R. et al. 0 CA 2099994, Sept. 7,1992, Garland, R. B., et al.
US 5254573, Oct. 6, 1992, Bovy, P. R., et al.: Describes amidinophenylamidopropionyl-P-X-P-Ala-OH.
(PF54C06), EP 0539343, Oct. 14, 1992, P.R. Bovy et al.: Describes amidinophenylamidopropionyl-P-X-p-Ala-OH.
WO 93/12074, Nov. 27, 1992, N. A. Abood, et al.: Describes amidinophenylalkylamido-(R)-Asp-(i.e. retro-Asp)-alkyl and aryl amides and sulfonamides.
WO 93/12103, Dec. 11, 1992, P. R. Bovy et al.: Describes amidinophenylalkanoyl-Asp-X lactones 0 EP 0 539343, Apr. 28, 1993, Bovy, P. R., et al.
EP 0542708, May, 19, 1993, Bovy. P. R., et al.
WO 94/00424, June 23,1993, Abood, N. A., et al.: Describes amidinophenylalkanoic acid lactones related to previous compounds.
WO 93/16038, Aug. 16, 1993, Miyano. M. et al.: Describes 5 amidinophenylpentanoyl-p-arylsulfonamidomethyl-P-Ala-OH analogs.
WO 93US7975, Aug. 17,1993, Zablocki, J. A., Tjoeng, F. S.
WO 93/18058, Sept. 16,1993, Bovy, P. R. et al.: Describes amidinophenylamidoproionoyl-Asp-X-OH analogs.
US 5254573, Oct. 19, 1993, Bovy, P. R., et al., Describes amidinophenylpropionyl-0 amino acid dervs.
US, 5272162, Dec. 21, 1993, Tjoeng, F. S., et al.: Describes amidinophenyl-X-NHCO-p-Y-p-Ala-OH analogs.
EP 0574545, Dec. 22,1993, Garland, R. B., et al.: AmidinophenylX-Asp Analogs.
WO 9401396, Ian. 20, 1994, Tjoeng, F. S., et al., Describes 5 amidinophenylalkylamido-amino acid derivatives.
WO 9405694, (Der 94-101119/12) Mar. 17, 1994, Zablocki, et al.: Describes amidinophenylalkylamido-amino acid derivatives.
US 5314902, May 24, 1994, Adams, S. P. et al.: Describes amidinophenylamidoalkanoyl derivatives. 0 WO 9418162, Aug, 18,1994, Adams, S. P., et al.: Describes amidinophenylalkanoyl-amino acid derivatives.
WO 9419341, Sept. 1, 1994, Tjoeng, F. S., et al.: Describes amidinophenylnipecotic acid derivatives.
US 5344837, (Der 94-285503/35), Sept. 6, 1994, Zablocki, J. A., et al.
EP 614360, Sept. 14,1994, Bovy, P. R., et al.
WO 9420457, (Der 94-302907/37) Sep. 15, 1994, Tjoeng, F. S. et al. Amindinophenyl compounds with central ring.
WO 9421602, (Der 94-316876/39), Sept. 29,1994, Tjoeng, F. S., et al. Describes guanidinoalkylaminocarbonylaminoacid derivatives.
WO 9422820, Oct. 13, 1994, Abood, N. A., et al.: Describes 0 amidinophenylpyrollidinonyl-P-Ala derivatives.
EP 630366, Dec. 28,1994, Bovy, P. R., et al.
US 5378727, Jar:. 3, 1995, Bovy, P. R. et al.
K. F. Fok, et al., Int. J. Peptide Prot. Res., 38, 124-130,1991, SAR of RGDY analogs.
J. A. Zablocki, et al. J. Med. Chem. 35,4914-4917,1992, SAR summary of guanidinoalkanoyl-Asp-Phe analogs.
Tjoeng, F. S.; Fok, K. F.; Zupec, M. E.; Garland, R. B.; Miyano, M.; Panzer-Knodle, S.; King, L. W.; Taite, B. B.; Nicholson, N. S.; Feigen, L. P.; Adams, S. P., Peptide Mimetics of the RGD Sequence, In Peptides, Chem. and Biol. Proc. 0 12th Amer. Peptide Symp., J. A. Smith and J. E. Rivier, Ed., ESCOM, Leiden, 1992; 752.
Nicholson, N.; Taite, B.; Panzer-Knodle, S.; Salyers, A.; Haas, N.; Szalony, J.; Zablocki, J.; Feigen, L.; Glenn, K.; Keller, B.; Broschat, K.; Herin, M.; Jacqmin, P.; lesne, M., An Orally Active Glycoprotein Ub/IIIa Antagonist - SC-54684, Thromb. Haem., 69, 975,1993.
Sumitomo Pharm. Co. Ltd.
WO 9501336, June 6, 1994, Ikeda, Y., et at., Describes piperidinyloxyacetyl-Tyr-piperidinyloxyacetic acid derivatives. 0 Sumitomo Seiyaku KK JP 06025290, (Der 94-077374/10) Feb. 1, 1994. Describes multimeric RGDT. Taisho Pharm. (Teijin, Ltd) JP 05230009, (Der 93-317431/40, Feb. 24,1992: Describes amidino-Cbz-meta-5 aminophenylpropionate.
JP 9235479, Feb. 24,1992: Describes Amidinophenylcarbamates.
(PFD4C06), WO 94/17804, Aug. 18,1994, Mizushima, Y. Pharm. Comp for Treating Cerebral Thrombosis.
(EP 634171), Jan. 18,1995, Nizushima, M. Pharm. Comp for Treating Cerebral 10 Thrombosis. Prostaglandins Takeda EP 0529858, Apr. 3, 1993, H. Sugihara, et al.: Describes amidinobenzoyl-Gly-Piperazinone analogs.
EP 606881, Jul. 20, 1994, Cyclic peptides with beta and gamma turns.
EP 614664, Sept. 14,1994, Miyake, A., et al: Quinolonecarboxylic Acids as cell adhesion inhibitors.
Tanabe WO 89/07609, T. J. Lobl, et al.: Describes RGD analogs.
WO 92/00995, July 9, 1991, T. J. Lobl, et al.: Describes cyclic RGD analogs. WO 93/08823, Nov. 6, 1991, T. C. McKenzie: Describes guanidinoalkanoyl-Gly-Asp-X analogs.
CA 2087021, Jan 10, 1991, Lobl, T. J., et al: Describes cyclic RGD analogs. 25 WO 92/08464, Nov. 15,1991, T. C. McKenzie, et al.: Describes.
Telios / La Jolla Cancer Research US. 4578079, Nov. 22, 1983, E. Ruoslahti, and M. Pierschbacher: Describes X-RGD-Y analogs.
US. 4614517, June 17, 1985, E. Ruoslahti, and M. Pierschbacher: Describes X-RGD-Y analogs.
US. 4792,525, June 17, 1985, E. Ruoslahti, and M. Pierschbacher: Describes X-RGD-Y analogs.
US 4879237, (Der 90-154405/20) May, 24, 1985, Describes X-RGD-Y analogs.
WO 91/15515, (Der 91-325173/44) Apr. 6, 1990, describes cyclic RGD analogs.
US. 5041380, 1991, E. Ruoslahti, and M. Pierschbacher: Describes RGD-X analogs.
WO 95/00544 Jan. 5,1995, Craig, W. S., et. al.
Cheng, S.; Craig, W. S.; Mullen, D.; Tschopp, J. F.; Dixon, D.; Pierschbacher, M. F., Design and Synthesis of Novel Cyclic RGD-Containing Peptides as Highly Potent and Selective Integrin Antagonists, J. Medicin. Chem., 0 37, 1, 1994.
Collen, D.; Lu, H. R.; Stassen, J.-M.; Vreys, 1.; Yasuda, T.; Bunting, S.; Gold, H. K., Antithrombotic Effects and Bleeding Time Prolongation with Synthetic Platelet GPHb/IIIa Inhibitors in Animal Models of Platelet-Mediated Thrombosis, Thrombosis and Haemostasis , 71,95, 1994.
Temple U.
WO 9409036, (Der 94-151248/18), Apr. 28,1994, Describes disintegrin peptides.
Terumo KK 0 JP 6279389, Oct. 4, 1994, Obama, H., et al.: Describes 3-(4- amidinophenyloxymethyl)phenylamidopropionic acid analogs (ala Roche I-35).
Karl Thomae / Boehringer Ingelheim EP 0483667, May 6, 1992, Himmelsbach, F., et al.: Describes amidinobiphenyl-oxymethyl-2-pyrrolidinone-acetic acid.
EP 0496378, Jan. 22, 1992, Himmelsbach, F., et al.: Describes amidinobiphenyl-aminocarbonylcyclohexylcarboxylic acid analogs.
EP 0503548, Sep. 16,1992, Himmelsbach, F., et al.: Describes amidinophenyl- 0 pyrrolidinone-phenylpropionic acid analogs.
AU A-86926/91, May 7, 1992, Himmelsbach, F. et al.: Describes amidinophenyl compounds.
EP 0528369, Feb. 24,1993, Austel, V., et al.: Describes amidinobiphenyl-oxymethyl-2-pyrrolidinone-acetic acid.
EP 0537696, Apr. 21,1993 Linz, G., et al.: Describes'amidinophenyl-pyridazine analogs.
DE 4124942, Jan. 28, 1993, Himmelsbach, F. et al.: Describes amidino-triarylproionic acid analogs.
DE 4129603, Mar. 11,1993, Pieper, H, et al.: Describes amidinobiphenyl-0 benzimidazole.
EP 0547517 Al, (Der 93-198544) June 23, 1993, Soyka, R., et al.: Describes pyridyl compounds.
EP 0567966, Nov. 3, 1993, Himmelsbach, F., et al.: Describes amidinobiphenyl-oxymethyl-2-pyrrolidinone-acetic acid.
EP 0567967, Nov. 3 1993, Weisenberger, J., et al.: Describes amidinobiphenyl-oxymethyl2-pyrrolidinone-acetic acid.
EP 0567968, Nov. 3, 1993, Linz, G., et al.: Describes amidinobiphenyl-lactam-acetic acid and amidinophenyllactamphenylpropionic acid analogs.
EP 0574808, June 11, 1993, Pieper, H., et al.: Describes amidinobiphenyl-X-acetic 0 acid ester analogs.
Der 93-406657/51, Austel, V.., et al.: Describes amidinobiphenyl analogs.
EP 587134, (Der 94-085077/11) Mar. 16, 1994, Himmerlsbach, F. D. D., et al., Describes amidinophenyltriazolone analogs.
EP 589874, Apr. 6, 1994, Grell, W„ et al.
(P534005), DE 4234295, Apr. 14, 1994, Pieper, H., et al., Describes heteroaryl-azacyclohexylcarboxylic acid analogs.
EP 0592949, Apr. 20,1994, Pieper, H. D., et al., Describes amidinophenyl-4piperidinamido-4-cyclohexylcarboxylic acid analogs.
EP 596326, May, 11, 1994, Maier, R. et al. 0 DE 4241632, June 15,1994, Himmelsbach, F., et al., Describes piperidinophenylamido-phenylpropiony] analogs.
EP 0604800 A, Jul. 6,1994, Himmelsbach, F. et al., Describes piperidinophenylamido-phenylalanine derivatives.
DE 4302051, (Der 94-235999/29) July, 28,1994, describes compounds containing a 2H-pyrazol-5-one.
EP 0608858 A, Aug, 3, 1994, Linz, G. D., et al., Describes amidino-biphenyl compounds.
DE 4304650, (Der 94-256165/32), Aug, 18,1994, Austel, V., et al., describes compounds with a 5,6 template.
EP 611660, Aug, 24,1994, Austel, V., et al., Describes tricyclic template. 10 DE 4305388, (Der 94-264904/33), Aug. 25,1994, Himmelsbach, F., et al., Describes 6,6 and 7,6 templates.
(P5D4005), EP 612741, (Der 94-265886/33), Aug. 31,1994, Himmelsbach, F., et al., Describes 6,6 and 7,6 templates.
EP 0639575 A, Feb. 22, 1995, Linz, G., et al.: Describes tetrahydrothiazolo-15 [5,4,c]pyridine cation replacements.
DE 4324580, Jan. 26, 1995, Linz, G. et al.
EP 0638553, Feb. 15, 1995, Himmelsbach, F., et al.
F. Hiummelsbach, V. Austel, G. Kruger, H. Pieper, H. Weisenberger, T: H. Muller, and W. G. Eisert, in Xllth Int. Symp. on Med. Chem. Basel, Book of 20 Abstracts, 47, 1992.
V. Austel, W. Eisert, F. Himmelsbach, G. Kruger, G. Linz, T. Muller, H. Pieper, and J. Weisenberger, Natl. Mtg. Amer. Chem. Soc. Book of Abstracts, Denver, Div. Med. Chem., 1993.
Muller, T. H.; Schurer, H.; Waldmann, L.; Bauer, E.; Himmelsbach, F.; Binder, K., 25 Orally Activity of BIB U 104, a Prodrug of the Non-peptide Fibrinogen Receptor Antagonist BIBU 52, in Mice and Monkeys, Thromb. Haem., 69, 975, 1993.
Univ. California WO 94/14848, July, 7, 1994, Zanetti, M. RGD peptides from CDR.
PCIYUS95/08306 Univ. New York WO 94/00144, June 29, 1993, Ojiiaa, I. et al.: Describes RGD peptide multimers.
Yeda Res. and Dev. Co.
WO 93/09795, (Der 93-182236/22), Lido, O. et al.: Describes Guanidinopentanoic acid analogs.
Zeneca WO 9422834, Oct. 13, 1994, Wayne, M. G., et al. Describes pyridinopiperazino-10 phenylcarbonyl-amino acids.
WO 9422835, Oct. 13, 1994, Wayne, M. G., et al. Describes pyridinopiperidino- amidophenylacetic acids.
EP 632016, Jan. 4, 1995, Brewster, A. G.., et al. Describes pyridinopropionylhydrazinylbenzoyl analogs.
EO 632019, Jan. 4, 1995, Brown, G., Shute, R. E.
EO 632020, Jan. 4, 1995, Brown, G., Shute, R. E.
In cases wherein the compounds of this invention may have one or more chiral centers, unless specified, this invention includes each unique nonracemic 20 compound which may be synthesized and resolved by conventional techniques. In cases in which compounds have unsaturated carbon-carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention. The meaning of any substituent at any one occurrence is independent of its meaning, or any other substituent's meaning, at any other occurrence.
Abbreviations and symbols commonly used in the peptide and chemical arts are used herein to describe the compounds of this invention. In general, the amino acid abbreviations follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature as described in Eur. J. Biochem., 158, 9 (1984).
Ci_4alkyl as applied herein means an optionally substituted alkyl group of 1 30 to 4 carbon atoms, and includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl. Ci_6alkyl additionally includes pentyl, n-pentyl, isopentyl, neopentyl and hexyl and the simple aliphatic isomers thereof. C()-4alkyl and C0-6alkyl additionally indicates that no alkyl group need be present (e.g., that a covalent bond is present).
Any Ci-4alkyl or Cj-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or Ci-6 oxoalkyl may be optionally substituted with the group Rx, which may be on any carbon atom that results in a stable structure and is available by conventional synthetic techniques. Suitable groups for Rx are Ci-4alkyl, OR1, SR1, C].4alkyl, Ci-4alkylsulfonyl, Ci-4alkylsulfoxyl, -CN, N(R*)2j CH2N(R1)2, -NO2, -CF3, -C02R'3 -CON(R1)2, -COR*, -NR^C^R1, OH, F, CI, Br, I, or 10 CF3S(0)r,wherein r is 0 to 2.
Ar, or aryl, as applied herein, means phenyl or naphthyl, or phenyl or naphthyl substituted by one to three substituents, such as those defined above for alkyl, especially Ci-4alkyl, Ci_4alkoxy, Ci_4alkthio, trifluoroalkyl, OH, F, CI, Br or I.
Het, or heterocycle, indicates an optionally substituted five or six membered monocyclic ring, or a nine or ten-membered bicyclic ring containing one to three heteroatoms chosen from the group of nitrogen, oxygen and sulfur which are stable and available by conventional chemical synthesis. Illustrative hetei«t;ycles are benzofuryl, benzimidazole, benzopyran, benzothiophene, furan, imidazole, indoline, 20 morpholine, piperidine, piperazine, pyrrole, pyrrolidine, tetrahydropyridine, pyridine, thiazole, thiophene, quinoline, isoquinoline, and tetra- and perhydro-quinoline and isoquinoline. Any accessible combination of up to three substituents on the Het ring, such as those defined above for alkyl that are available by chemical synthesis and are stable are within the scope of this invention. 25 C3-7cycloalkyl refers to an optionally substituted carbocyclic system of three to seven carbon atoms, which may contain up to two unsaturated carbon-carbon bonds. Typical of C3-7cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclo1, :xyl, cyclohexenyl and cycloheptyl. Any combination of up to three substituents, such as those defined above for alkyl, on the cycloalkyl ring that WO 96/00730 PCT/US95/08306 is available by conventional chemical synthesis and is stable, is within the scope of this invention.
When Rb and Rc are joined together to form a five- or six-membered aromatic or non-aromatic carbocyclic or heterocyclic ring fused to the ring to which 5 Rb and Rc are attached, the ring formed will generally be a five- or six-membered heterocycle selected from those listed above for Het, or will be a phenyl, cyclohexyl or cyclopentyl ring. Preferably Rb and Rc will be -D1=D2-D3=D4 wherein D1 - D4 are independently CH, N or C-Rx with the proviso that no more than two of D1 - D4 are N. Most preferably, when R*5 and Rc are joined together they form the group -10 CH=CH-CH=CH-.
Certain radical groups are abbreviated herein. t-Bu refers to the tertiary butyl radical, Boc refers to the t-butyloxycarbonyl radical, Fmoc refers to the fluorenylmethoxycarbonyl radical, Ph refers to the phenyl radical, Cbz refers to the benzyloxycarbonyl radical, BrZ refers to the o-bromobenzyloxycarbonyl radical, 15 C1Z refers to the o-chlorobenzyloxycarbonyl radical, Bzl refers to the benzyl radical, 4-MBzl refers to the 4-methyI benzyl radical, Me refers to methyl, Et refers to ethyl, Ac refers to acetyl, Alk refers to Cj_4alkyl, Nph refers to 1- or 2-naphthyl and cHex refers to cyclohexyl. Tet refers to 5-tetrazolyl.
Certain reagents are abbreviated herein. DCC refers to 20 dicyclohexylcarbodiimide, DMAP refers to dimethylaminopyridine, DIEA refers to diisopropylethyl amine, EDC refers to l-(3-dimethylaminopropyl)-3-ethylcarbodiimide, hydrochloride. HOBt refers to 1-hydroxybenzotriazole, THF refers to tetrahydrofuran, DIEA refers to diisopropylethylamine, DME refers to dimethoxyethane, DMF refers to dimethylformamide, NBS refers to N-25 bromosuccinimide, Pd/C refers to a palladium on carbon catalyst, PPA refers to 1-propanephosphonic acid cyclic anhydride, DPPA refers to diphenylphosphoryl azide, BOP refers to benzotriazol-l-yloxy-tris(dimethyI-amino)phosphonium hexafluorophosphate, HF refers to hydrofluoric acid, TEA refers to triethylamine, TFA refers to trifluoroacetic acid, PCC refers to pyridinium chlorochromate.
PCT/U S95/08306 Compounds of the formula (I)-(V) are prepared, for example, by reacting a compound of formula (XIX) with a compound of formula (XX), wherein L1 and L2 are groups which may react to form a covalent bond in the moiety W, by methods generally known in the art. r!^q ][ IT ^-W-A R' N + L'-A —> RC N (XII) (XX) a) Typical methods include coupling to form amide bonds, nucleophilic displacement reactions and palladium catalyzed couplings. For instance, when W contains an ether or amine linkage, the bond may be formed by a displacement reaction, and one of and L2 will contain an amino or hydroxy group and the other will contain a displaceable group, such as a chloro, bromo or iodo group. When W contains an amide bond, typically one of L^ and L2 will contain an amino group, and the other will contain a carboxylic acid group. In another approach, L* may be an aryl or heteroaiyl bromide, iodide or trifluoromethylsulfonyloxy derivative and L2 may contain an amino group and the amide linkage may be formed by palladium-catalyzed aminocarbonylation with carbon monoxide in a suitable solvent such as dimethylformamide or toluene.
It will be apparent that the precise identity of L1 and L2 will be dependent upon the site of the linkage being formed. General methods for preparing the 20 linkage -(CHR")r-U-(CHR")s-V- are described, for example, in EP-A 0 372 486 and EP-A 0 381 033 and EP-A 0 478 363, which are incorporated herein by reference.
For instance, if V is CONH, L1 may be -NH2, L2 may be OH (as in an acid) or CI (as in an acid chloride), and R6" may be W-(CR'2)q-Z-(CR'R10)r-U-(CR,2)s-C(O), with any functional groups optionally protected. For example, R6" may be 25 (benzyloxycarbonyl-amidino)benzoyl- or (Na-Boc,Nguan-Tos)arginyl-. When L2 is OH, a coupling agent is used.
Similarly, if V is NHCO, L1 may be -CO2H or CO-C1, L2 may be -NH2, and R5" may be W-(CR'2)q-Z-(CR'R10)r-U-(CR'2)s-- For example, R6" may be (benzyloxycarbonyl-amidino)phenyl, (benzyloxycarbonylamino)methylbenzyl- or 6-(benzyloxycarbonylamino)hexyl-.
Where V is NHSO2, L1 may be SO2CI, L2 may be -NH2 and R6" may be as above. Where V is SO2NH, L1 may be -NH2 and L2 may be SO2CI. Methods to prepare such sulfonyl chlorides are disclosed, for instance, in J. Org. Chem., 23, 1257 (1958).
If V is CH=CH, L1 may be -CHO, L2 may be CH=P-Ph3 and R6" may be W-10 (CR,2)q-Z-(CR,R10)r-U-(CR,2)s-. Alternately, L1 may be CH=P-Ph3, L2 may be CHO, e.g., R6" may be W-(CR,2)q-Z-(CR,R10)r-U-(CR,2)s.1-CHO.
Where V is CH2CH2 may be obtained by reduction of a suitably protected compound wherein V is CH=CH.
Where V is CH2O, CH2N or Cs C, L1 may be -OH, -NH or 15 - C= C H,respectively; L2 may be -Br; and R6" may be W-(CR'2)q-Z-(CR'R10)rU-(CR'2)s-- For example, R^" maybe (benzyloxycarbonylamino)-methylbenzyl- or 2-(N-benzyl-4-piperidinyl)-ethyl. Similarly where U or V is OCH2, NR'CH2 or C= C, L1 may be -CH2Br and L2 may be -OH, -NH or -0s C H, respectively. Alternately, when U or V is C, L1 may 20 be Br, I or CF3S03, L2 may be C^CH and the coupling may be catalyzed by palladium and a base.
Compounds wherein V is CHOHCH2 may be prepared from a suitably protected compound where V is CH=CH by the procedure disclosed in J. Org. Chem., 54, 1354(1989).
Compounds wherein V is CH2CHOH may be obtained from a suitably protected compound where V is CH=CH by hydroboration and basic oxidation as disclosed in Tel. Lett., 31,231 (1990).
Compounds of the formula (I)-(V), wherein the fibrinogen receptor antagonist template is of the formula (VI) are prepared by the general methods described in Schemes I-III. 3 a) EDC, HOBT, (i-Pr)2NEt, DMF, 2-aminomethylbenzimidazole; b) SOCI2, reflux; c) 2-aminobenzimidazole, pyridine, CH2CI2; d) 1.0 N LiOH, aqueous THF; e) 10 acidification.
Methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (1-1), prepared as described by Bondinell, et al. (WO 93/00095), is converted to an activated form of the carboxylic acid using, for 15 example, EDC and HOBT or SOCI2, and the activated form is subsequently reacted with an appropriate amine to afford the corresponding amide 1-2. Many additional methods for converting a carboxylic acid to an amide are known, and can be found in standard reference books, such as "Compendium of Organic Synthetic Methods", Vol. I - VI (published by Wiley-Interscience). The methyl ester of 1-2 is hydrolyzed using aqueous base, for example, aqueous LiOH in THF or aqueous NaOH in methanol, and the intermediate carboxylate salt is acidified with a suitable acid, for 5 instance TFA or HC1, to afford the carboxylic acid 1-3. Alternatively, the intermediate carboxylate salt can be isolated, if desired.
Scheme II HOzC N \ H x—C02CH3 b,c BOC \— C02CH3 CH, / 3 6 a) (BOC)20, DMAP, CH3CN; b) SOCl2, toluene, 70°C; c) H2, 10 % Pd/C, 2,6-lutidine, THF; d) 2-(aminomethyl)benzimldazole, NaBH3CN, MeOH; e) formaldehyde, NaBH3CN, AcOH, CH3CN; f) LiOH, THF, H2O; g) acidification.
Conversion of the carboxylic acid moiety of 1-Scheme II to an aldehyde can be accomplished by standard methodology, as described in "Compendium of Organic Synthetic Methods" (published by Wiley-Interscience). For example, after protection of the aniline nitrogen as its tert-butyl carbamate, the carboxylic acid is converted to the corresponding acid chloride with a suitable reagent, such as thionyl 10 chloride. The ferf-butyl carbamate is lost under these conditions. The resulting acid chloride is then reduced to aldehyde 3-Scheme II by hydrogenation over a suitable catalyst, for instance palladium on carbon in the presence of 2,6-lutidine. The aldehyde 3-Sc.heme II is then converted to the amine 4-Scheme II by reaction with 2-(aminomethyl)benzimidazole in the presence of a suitable reducing agent, such as 15 sodium cyanoborohydride. Alternative methods for converting an aldehyde to an amine are described in "Compendium of Organic Synthetic Methods" (published by Wiley-Interscience). The basic nitrogen atoms of 4-Scheme II are methylated under modified Eschweiler-Clarke conditions (Sondengam, B. L. et al., Tetrahedron Letters 1973, 261; Borsch, R. F.; Hassid, A. I. J. Org. Chem. 1972,37, 1673). Thus, 20 reaction of 4-Scheme II with formaldehyde in the presence of a suitable reducing agent, such as sodium cyanoborohydride, gives 5-Scheme II. Saponification of the methyl ester of 5-Scheme II by the methods described earlier gives 6-Scheme H. The methyl ester of 4-Scheme II can be cleaved similarly. c02ch3 co2h a) NCS, DMF, 80 °C; b) see Scheme 1.
Halogenation of the aromatic moiety of 1-Scheme III can be accomplished with an appropriate elctrophilic halogenating reagent, such as N-chlorosuccinimide. The resulting chlorinated derivative, 2-Scheme HI, is then conveted to 3-Scheme III by the methods described in Scheme I.
The core 6-7 fused ring system is prepared of formula (VI) by methods well known in the art, e.g., Hynes, et al., J. Het. Chem., 1988,25,1173; Muller, et al., Helv. Chim. Acta., 1982, 65, 2118; Mori, et al., Heterocycles, 1981, 16, 1491. Similarly, methods for preparing benzazepines, 1,4-benzothiazepines, 1,4-15 benzoxazepines and 1,4-benzodiazepines are known and are disclosed, for instance, in Bondinell, et al., International Patent Application WO 93/00095.
A representative method for preparing the benzodiazepine nucleus is given by Schemes IV and V. A representative method for preparing a benzazepine nucleus is given by Scheme VI. A representative method for preparing a benzothiazepine is 20 given by Scheme VII. An benzoxazepine nucleus may be prepared in the same manner as Scheme VII, except substituting a benzyl alcohol for a benzyl thiol.
Scheme IV 0,n CHO NaCNBH X R3NH, ho2C^ ^ R'N-Boc couple NH-t-Boc 1) acid ► 2) DMSO/9C) DIEA H, Pd/C Scheme V o2n.
.CN H2N CO ZCH 3 —02N N o» DMSO/TEA ,CN H R' H g, Pd/C CO ZCH 3 _____ (Boc) 2O Boc-HN H 2, Raney-Ni CO 2CH 3 — NaOCH 3 ^ no Boc-HN Scheme VI t-BuO 2O NO 2 t-BuO 2C B.C «£« II BOC ~<CC0 2CH 3)2 NH 2 49 Scheme VII 1) bh 3 2) CBr 4,Ph3P HF 02N NH-R SH HO 2C CO 2H h2n 1) (CH 30) 2SO 2 2) H 2, Pd/C The simple tri-substituted benzene starting materials are commercially available or prepared by routine methods well known in the art.
Schemes VIII-XI are illustrative of the methods for preparing certain 25 compounds of the instant invention. In schemes VIII - X, a covalent bond of the group W is prepared by a nucleophilic displacement reaction.
In Scheme VHI, 4-[2-(methylamino)acetyl]phenol hydrochloride (Reel. Trav. Chim. Pays-Bas 1949,68, 960) is N-protected with a suitable nitrogen protecting group, such as a rm-butoxycarbonyl (BOC) group, to provide the N-protected 30 derivative 2-Scheme VIII. -50 96/00730 Scheme VIII boc C02Bn C02Bn O COjBn o c02h a) (BOC)20, NaOH, 1,4-dioxane, H2O; b) BrCH2C02Bn, K2CO3, acetone; c) 4 M HC1 in 1,4-dioxane; d) 2-(chIoromethyI)benzimidazole, Et3N, CH3CN, CH2C12; e) H2, 5% Pd/C, MeOH.
WO 96/00730 PCT/US95/08306 Other standard nitrogen protecting groups, such as those described in Greene "Protective Groups in Organic Synthesis", may be chosen such that the protecting group employed is compatible with the subsequent chemistry and can be removed selectively under conditions which will not interfere with other functionality in the 5 molecule. Alkylation of the phenol moiety of compound 2-Scheme VIII to afford the aryloxyacetic acid derivative 3-Scheme VUI can be accomplished by reaction with a haloacetic acid ester, for instance benzyl bromoacetate, under basic conditions in a neutral solvent. Generally, K2CO3 in refluxing acetone or 2-butanone gives acceptable results, but other bases, such as U2CO3 or CS2CO3, and other solvents, 10 such as DMF, THF, or DME, might also be used. The nitrogen protecting group of 3-Scheme VIII is removed under conditions appropriate for selective deprotection of the specific protecting group employed. For example, the BOC group of 3-Scheme VIII can be removed under acidic conditions, such as 4 M HCl in 1,4-dioxane or TFA in CH2C12, to afford amine 4-Scheme VIII as the corresponding ammonium 15 salt. Conversion of compound 4-Scheme VUI to the bis-benzimidazole derivative 5-Scheme Vm can be accomplished by alkylation with 2- (chloromethyl)benzimidazole in a solvent mixture of CH3CN and CH2C12 in the presence of Et3N. Subsequent removal of the ester group of compound 5-Scheme Vin under appropriate conditions gives compound 6-Scheme VIH. The conditions 20 selected for ester removal must be appropriate for the specific ester present as well as compatible with the other functionality in the molecule. For instance, the benzyl ester of 5-Scheme VEI can be removed by hydrogenolysis in the presence of a suitable catalyst, such as Pu on carbon, in an inert solvent, generally MeOH, EtOH, or acetic acid, to afford 6-Scheme Vm.
In Scheme IX, commercially available andrenolone hydrochloride (1-Scheme 2) is N-protected as discussed in Scheme 1 to provide the Cbz derivative 2-Scheme 2. -52 Scheme IX CBz CBz V^C°2CH3 C co2ch3 h3c u 'Nv^S^y/°\/C02CH3 TX O' COjCHJ c02ch3 e co2ch3 * , , co2h a) CbzCl, NaOH, toluene, H2O; b) BrCH2C02CH3, K2C03, acetone; c) H2,10% Pd/C, EtOAc, MeOH; d) 2-(chloromethyl)benzimidazole, Et3N, CH3CN, CH2CI2; e) 1.0 N LiOH, THF, H2O.
Dialkylation of 2-Scheme IX by reaction with a haloacetic acid ester, for instance methyl bromoacetate, under basic conditions in a neutral solvent, provides the 1,2-phenylenedioxydiacetic acid derivative 3-Scheme IX. K2CO3 in refluxing acetone generally gives acceptable results, but other bases and solvents, such as -53 those discussed in Scheme VIII, might also be used. Removal of the nitrogen protecting group of 3-Scheme IX by hydrogenolysis over a Pd/C catalyst in a solvent mixture of EtOAc and MeOH is accompanied by concomitant reduction of the ketone to afford aminoalcohol 4-Scheme IX. N-alkylation of compound 4-Scheme 5 IX with 2-(chloromethyl)benzimidazole in a solvent mixture of CH3CN and CH2CI2 in the presence of Et3N gives the mono-benzimidazole derivative 5-Scheme IX, Subsequent removal of the ester group of 5-Scheme IX under appropriate conditions, as discussed in Scheme Vm, gives compound 6-Scheme IX. Generally, a methyl ester, such as that present in 5-Scheme IX, is removed by hydrolysis in the 10 presence of an alkali metal hydroxide, such as LiOH, NaOH, or KOH, in an aqueous solvent, typically MeOH, EtOH, or THF.
In Scheme X, commercially available andrenolone hydrochloride (1-Scheme X) is N-protected as described in Scheme VIII to provide the BOC derivative 2- Scheme X.
Scheme X 0 1 \ 2 boc o I II O o c02ch3 c02ch3 o co2ch3 3 4 -54 0 CO2CH3 ^ /-N CHa O W ^Scc°^ " 7 a) (B0C)20, NaOH, 1,4-dioxane, H20; b) BrCH2C02CH3, K2CO3, acetone; c) 4 M HCl in 1,4-dioxane; d) l-(BOC)-2-(bromomethyl)benzimidazole, EtjN, THF, CH2Cl2; e) TFA, CH2CI2; f) 1.0 N LiOH, THF, H20.
Dialkylation of 2-Scheme X as discussed in Scheme IX affords 3-Scheme X. The nitrogen protecting group of 3-Scheme X is removed as discussed in Scheme Vffl to afford amine 4-Scheme X as the corresponding ammonium salt. Alkylation of 4-Scheme X with l-BOC-2-(bromomethyl)benzimidazole in a solvent mixture of THF and CH2Cl2 in the presence of Et3N gives the mono-benzimidazole derivative 5-Scheme X. Subsequent removal of the BOC group of 5-Scheme X as discussed in Scheme VIE delivers 6-Scheme X. Removal of the ester group of 6-Scheme X as discussed in Schemes 1 and 2 gives 7-Scheme IX. Alternatively, the ester group of 5-Scheme X might be removed first, followed by removal of the BOC group.
In Scheme XI, the moiety W is prepared by an amide coupling reaction. -55 WO 96/00730 PCT/US95/08306 Scheme XI a) ethyl acrylate, HOAc; b) SOCI2; c) 2-(aminomethyl)benzimida2ole, DEEA, CH2CI2; d) NaOH, H2O, MeOH.
Initially, ethyl 3-[4-(carboxy)phenyl]amlno]propionic acid (2-Scheme XI) is prepared by Michael-type addition of 4-(carboxy)aniline (1-Scheme XI) to ethyl acrylate in acetic acid as described in Chem. Ber., 91, 2239, 1958. The carboxyl in compound 2-Scheme XI is converted to the acid chloride with thionyl chloride, and 25 the acid chloride is condensed with 2-(aminomethyl)benzimidazole dihydrochloride hydrate with diisopropylethylamine in dichloromethane to form compound 3-Scheme XI. The ethyl ester 3-Scheme XI is saponified with sodium hydroxide in aqueous methanol to give compound 4-Scheme XI; alternatively the ester can be converted to the carboxylic acid with other metal hydroxides or carbonates in a 30 suitable solvent. -56 96/00730 n-BuS02NH C02Me 1d 3) HOAc reflux Scheme XII 1) H^Pd/C MeOH 2) CIC02(iBu) Et3N CcNH! n'Bu ^02M£ LiOH, THF n-BuS02NH C02H ig The starting material for the formula lg-Scheme XII compounds are 5 prepared following the procedures in Egbertson et al., J. Med. Chem., 1994, 37, 2537-3551which discloses general methods to alkylate the phenol of an N-protected tyrosine derivative, remove the N-pro tec ting group, and sulfonylate the amine.
Using benzyl 4-bromobutyrate as the alkylating agent, intermediate Id-Scheme XII was prepared. Removal of the benzyl ester and reaction with ortho-10 phenylenediamine under standard conditions afforded the benzimidazole lf-Scheme XII. Finally, saponification of the methyl ester yielded the target compound lg-Scheme xn.
Intermediate compounds of formula (XXX) may be prepared from suitably protected amino acids and phenyl-1,2-diamines or 2-nitro-anilines which are 15 commercially available or prepared by methods available to those skilled in the an according to the Scheme (XIII) and (XIV). -57 PCT7US95/08306 Scheme XIII Pr1-NR'-(CH2)a-C02H Pr1-NR'-(CH2)a-C0-0 -CO-0 R RyJi Rx ^Y^NHg NH, R Ry-jT T ^ (cH2)aNR'-Pr1 Rx b NHCO(CH2)aNR'-Pr1 Ry- B 'V<^ NH2 a) isobutyl chloroformate, THF, NEt3; b) A, AcOH Scheme XIV Pr1-NR,-(CH2)a-C02H Pr1-NR'-(CH2)a-CO-CI Ry rx'-^N02 R, *£0 Rx H (CHgJaNR'-Pr1 y^/NHCO(CH2)aNR'-Pr1 Ry- Jl Rx NO, a) thionyl chloride; b) Fe, AcOH, A Amide coupling reagents as used herein denote reagents which may be used to form peptide bonds. Typical coupling methods employ carbodiimides, activated -5& PCT/TJS95/08306 anhydrides and esters and acyl halides. Reagents such as EDC, DCC, DPPA, PPA, BOP reagent, HOBt, N-hydroxysuccinimide and oxalyl chloride are typical.
Coupling methods to form peptide bonds are generally well known to the art. The methods of peptide synthesis generally set forth by Bodansky et alTHE 5 PRACTICE OF PEPTIDE SYNTHESIS, Springer-Verlag, Berlin, 1984, Ali et al. in J. Med. Chem., 29, 984 (1986) and J. Med. Chem., 30, 2291 (1987) are generally illustrative of the technique and are incorporated herein by reference.
Typically, the amine or aniline is coupled via its free amino group to an appropriate carboxylic acid substrate using a suitable carbodiimide coupling agent, 10 such as N,N' dicyclohexyl carbodiimide (DCC), optionally in the presence of catalysts such as 1-hydroxybenzotriazole (HOBt) and dimethylamino pyridine (DMAP). Other methods, such as the formation of activated esters, anhydrides or acid halides, of the free carboxyl of a suitably protected acid substrate, and subsequent reaction with the free amine of a suitably protected amine, optionally in 15 the presence of a base, are also suitable. For example, a protected Boc-amino acid or Cbz-amidino benzoic acid is treated in an anhydrous solvent, such as methylene chloride or tetrahydrofuran(THF), in the presence of a base, such as N-methyl morpholine, DMAP or a trialkylamine, with isobutyl chloroformate to form the "activated anhydride", which is subsequently reacted with the free amine of a second 20 protected amino acid or aniline.
The compounds of formula (XIX) and (XX) are commercially available or are prepared by methods known in the art such as illustrated herein disclosed in standard reference books, like the COMPENDIUM OF ORGANIC SYNTHETIC METHODS, 25 Vol. I-VI (Wiley-Interscience). A generally applicable route to benzimidazoles is disclosed in Nestor et al, J. Med. Chem. 1984,27,320. Representative methods for preparing compounds of formula (XX) are also common to the art and may be found, for instance, in EP-A 0 381 033.
Acid addition salts of the compounds are prepared in a standard manner in a 30 suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hydrobromic, hydrofluoric, sulfuric, phosphoric, acetic, trifluoroacetic, -59 maleic, succinic or methanesulfonic. Certain of the compounds form inner salts or zwitterions which may be acceptable. Cationic salts are prepared by treating the parent compound with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation; or with an appropriate organic amine. Cations such as Li+, Na+, K+, Ca++, Mg++ and NH4"4" are specific examples of cations present in phannaceutically acceptable salts.
This invention also provides a pharmaceutical composition which comprises r. compound according to formula (I)-(V) and a phannaceutically acceptable carrier. Accordingly, the compounds of formula (I)-(V) may be used in the manufacture of a 0 medicament. Pharmaceutical compositions of the compounds of formula (I)-(V) prepared as hereinbefore described may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other phannaceutically acceptable carrier prior to use. The liquid formulation may be a buffered, isotonic, aqueous solution. Examples of 5 suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, 0 polyethylene glycol, mannitol, sodium chloride or sodium citrate.
Alternately, these compounds may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Solid carriers include starch, lactose, calcium 5 sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. Liquid carriers include syrup, peanut oil, olive oil, saline and water. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage 0 unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, 60 PCTAJ S95/08306 when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
For rectal administration, the compounds of this invention may also be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
The compounds described herein are antagonists of the vitronectin receptor, and are useful for treating diseases wherein the underlying pathology is attributable 10 to ligand or cell which interacts with the vitronectin receptor. For instance, these compounds are useful for the treatment of diseases wherein loss of the bone matrix creates pathology. Thus, the instant compounds are useful for the treatment of ostoeporosis, hyperparathyroidism, Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastasis, bone loss due to immobilization or 15 sex hormone deficiency. The compounds of this invention are also believed to have utility as antitumor, anti-angiogenic. antiinflammatory and anti-metastatic agents, and be useful in the treatment of atherosclerosis and restenosis.
The compound is administered either orally or parenterally to the patient, in a manner such that the concentration of drug is sufficient to inhibit bone resorption, or 20 other such indication. The pharmaceutical composition containing the peptide is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient. Preferably the oral dose would be about 0.5 to about 20 mg/kg. For acute therapy, parenteral administration is preferred. An intravenous infusion of the peptide in 5% dextrose in water or normal saline, or a 25 similar formulation with suitable excipients, is most effective, although an intramuscular bolus injection is also useful. Typically, the parenteral dose will be about 0.01 to about 100 mg/kg; preferably between 0.1 and 20 mg/kg. The compounds are administered one to four times daily at a level to achieve a total daily dose of about 0.4 to about 400 mg/kg/day. The precise level and method by which 30 the compounds are administered is readily determined by one routinely skilled in the 61- PCTAJS95/08306 an by comparing the blood level of the agent to the concentration required to have a therapeutic effect.
The compounds may be tested in one of several biological assays to determine the concentration of compound which is required to have a given 5 pharmacological effect.
Inhibition of vitronectin binding Solid-Phase [3HJ-SK&F-107260 Binding to avPi.' Human placenta or human platelet avP3 (0.1-0.3 mg/mL) in buffer T (containing 2 mM CaCl2 and 1% 0 octylglucoside) was diluted with buffer T containing 1 mM CaCl2, 1 mM MnCl2, 1 mM MgCl2 (buffer A) and 0.05% NaN3, and then immediately added to 96-well ELISA plates (Corning, New York, NY) at 0.1 mL per well. 0.1 - 0.2 ng of avP3 was added per well. The plates were incubated overnight at 4°C. At the time of the experiment, the wells were washed once with buffer A and were incubated with 5 0.1 mL of 3.5% bovine serum albumin in the same buffer for 1 hr at room temperature. Following incubation the wells were aspirated completely and washed twice with 0.2 mL buffer A.
Compounds were dissolved in 100% DMSO to give a 2 mM stock solution, which was diluted with binding buffer (15 mM Tris-HCl (pH 7.4), 100 mM NaCl, 10 1 mM CaCl2, 1 mM MnCl2, 1 mM MgCl2) to a final compound concentration of 100 fiM. This solution is then diluted to the required final compound concentration. Various concentrations of unlabeled antagonists (0.001 -100 pM) were added to the wells in triplicates, followed by the addition of 5.0 nM of [^HJ-SK&F-107260 (65 -86 Ci/mmol). *5 The plates were incubated for 1 hr at room temperature. Following incubation the wells were aspirated completely and washed once with 0.2 mL of ice cold buffer A in a well-to-well fashion. The receptors were solubilized with 0.1 mL of 1% SDS and the bound [^H]-SK&.F-107260 was determined by liquid scintillation counting with the addition of 3 mL Ready Safe in a Beckman LS Liquid 50 Scintillation Counter, with 40% efficiency. Nonspecific binding of [^HJ-SK&F- 62 107260 was determined in the presence of 2 (iM SK&F-107260 and was consistently less than 1 % of total radioligand input. The IC50 (concentration of the antagonist to inhibit 50% binding of [3H]-SK&F-107260) was determined by a nonlinear, least squares curve-fitting routine, which was modified from the LUNDON-2 program.
The Kj (dissociation constant of the antagonist) was calculated according to the equation: Kj = IC50AI + L/Kd), where L and Kd were the concentration and the dissociation constant of [3H]-SK&F-107260, respectively.
Compounds of the present invention inhibit vitronectin binding to SK&F 107260 in the concentration range of about 0.001 to 50 micromolar. 10 Compounds of this invention are also tested for in vitro and in vivo bone resorption in assays standard in the art for evaluating inhibition of bone formation, such as the pit formation assay disclosed in EP 528 587, which may also be performed using human osteoclasts in place of rat osteoclasts, and the ovarectomized rat model, described by Wronski et al., Cells and Materials 1991, Sup. 1, 69-74.
Vascular smooth muscle cell migration assay Rat or human aortic smooth muscle cells were used. The cell migration was monitored in a Transwell cell culture chamber by using a polycarbonate membrane 20 with pores of 8 um (Costar). The lower surface of the filter was coated with vitronectin. Cells were suspended in DMEM supplemented with 0.2% bovine serum albumin at a concentration of 2.5 - 5.0 x 106 cells/mL, and were pretreated with test compound at various concentrations for 20 min at 20°C. The solvent alone was used as control. 0.2 mL of the cell suspension was placed in the upper compartment of 25 the chamber. The lower compartment contained 0.6 mL of DMEM supplemented with 0.2% bovine serum albumin. Incubation was carried out at 37°C in an atmosphere of 95% air/5% CO2 for 24 hr. After incubation, the non-migrated cells on the upper surface of the filter were removed by gentle scraping. The filter was then fixed in methanol and stained with 10% Giemsa stain. Migration was measured 30 either by a) counting the number of cells that had migrated to the lower surface of PCTAJS95/08306 the filter or by b) extracting the stained cells with 10% acetic acid followed by determining the absorbance at 600 nM.
PARATHYROIDECTOMIZED RAT MODEL Each experimental group consists of 5-6 male Sprague-Dawley rats. The rats are parathyroidectomized (by the vendor, Taconic Farms) 7 days prior to use. Twenty four hours prior to use, circulating ionized calcium levels are measured in whole blood immediately after it has been withdrawn by tail venipuncture into heparinized tubes. Rats 10 are included if ionized Ca level (measured with a Ciba-Coming model 634 calcium pH analyzer) is _1.2 mM/L, The rats are then put on a diet of calcium-free chow and deionized water. At the start of the experiment the rats weigh approximately lOOg. Baseline Ca levels are measured and the rats are administered control vehicle (saline) or compound (dissolved in saline) as a single intravenous (tail vein) bolus injection followed 15 immediately by a single subcutaneous injection of either human parathyroid hormone 1-34 peptide (hPTHl-34, dose 0.2mg/kg in saline/0.1 % bovine serum albumen, Bachem, Ca) or the PTH vehicle. The calcemic response to PTH (and any effect of compound on this response) is measured 2h after compound/PTH administration.
RAT ULNA DRIFT MODEL Each experimental group consists of 8-10 male Sprague-Dawley or Wistar rats of approximately 30-40g body weight at the start of the experiment. The agent being tested is administered by an appropriate route as single or multiple daily doses for a period of 25 seven days. Prior to administration of the first dose, the rats are given a single dose of a fluorescent marker (tetracycline 25mg/kg, or calcein lOmg/kg) that labels the position of bone forming surfaces at that point in time. After dosing of compound has been completed, the rats are killed and both forelimbs are removed at the elbow, the foot is removed at the ankle and the skin removed. The sample is frozen and mounted vertically 30 on a microtome chuck. Cross sections of the midshaft region of the ulna are cut in the cryostat. The rate of bone resorption is measured morphometrically in the medial-dorsal U portion of the cortical bone. The measurement is done as follows: the amount of bone resorbed at the periosteal surface is equal to the distance by which the periosteal surface has advanced towards the fluorescent label which had been incorporated at the endosteal bone formation surface on day zero; this distance is calculated by subtracting the width of 5 bone between the label and the periosteal surface on day 7 from the width on day zero; the resorption rate in microns per day is calculated by dividing the result by 7.
HUMAN OSTEOCLAST RESORPTION ASSAY ("PIT ASSAY") • Aliquots of osteoclastoma-derived cell suspensions are removed from liquid nitrogen strorage, warmed rapidly at 37°C and washed xl in RPMI-1640 medium by centrifugation (lOOOrpm, 5 mins at 4°C).
• Aspirate the medium and replace it with murine anti-HLA-DR antibody, diluted 15 1:3 in RPMI-1640 medium. Incubate for 30 mins on ice and mix the cell suspension frequently.
• The cells are washed x2 with cold RPMI-1640 by centrifugation (lOOOrpm, 5 mins at 4°C) and the cells are transferred to a sterile 15 ml centrifuge tube. The number of mononuclear cells are enumerated in an improved Neubauer counting chamber.
• Sufficient magnetic beads (5 / mononuclear cell), coated with goat anti-mouse IgG, are removed from their stock bottle and placed into 5 ml of fresh medium (this washes away the toxic azide preservative). The medium is removed by immobilizing the beads on a magnet and is replaced with fresh medium.
• The beads are mixed with the cells and the suspension is incubated for 30 mins on ice. The suspension is mixed frequently.
• The bead-coated cells are immobilized on a magnet and the remaining cells (osteoclast-rich fraction) are decanted into a sterile 50 ml centrifuge tube. 65 PCTAJS95/08306 • Fresh medium is added to the bead-coated cells to dislodge any trapped osteoclasts. This wash process is repeated xlO. The bead-coated cells are discarded.
• The osteoclasts are enumerated in a counting chamber, using a large-bore disposable plastic pasteur to charge the chamber with the sample.
• The cells are pelleted by centrifugation and the density of osteoclasts adjusted to 1.5x lC^/ml in EMEM medium, supplemented with 10% fetal calf serum and 0 1.7g/litre of sodium bicarbonate. • 3ml aliquots of the cell suspension (per treatment) are decanted into 15ml centrifuge tubes. The cells are pelleted by centrifugation.
• To each tube 3ml of the appropriate treatment are added (diluted to 50 uM in the EMEM medium). Also included are appropriate vehicle controls, a positive control (87MEM1 diluted to 100 ug/ml) and an isotype control (IgG2a diluted to 100 ug/ml). Incubate at 37°C for 30 mins. .0 • 0.5ml aliquots of the cells are seeded onto sterile dentine slices in a 48-well plate and incubated at 37°C for 2 hours. Each treatment is screened in quadruplicate.
• The slices are washed in six changes of warm PBS (10 ml / well in a 6-well plate) and then placed into fresh treatment or control. Incubate at 37°C for 48 hours. :5 Tartrate resistant acid phosphatase (TRAP) procedure (selective stain for cells of the osteoclast lineage).
• The slices are washed in phosphate buffered saline and fixed in 2% gluteraldehyde 10 (in 0.2M sodium cacodylate) for 5 mins. 66 PCT/U S95/08306 • They are washed in water and incubated in TRAP buffer for 5 mins at 37°C.
• Following a wash in cold water they are incubated in cold acetate buffer / fast red garnet for 5 mins at 4°C.
• Excess buffer is aspirated, and the slices are air dried following a wash in water.
• The TRAP positive osteoclasts are enumerated by bright-field microscopy and are then removed from the surface of the dentine by sonication.
• Pit volumes are determined using the Nikon/Lasertec ELM21W confocal microscope.
Inhibition of RGD-mediated GPITb-IIIa binding Purification of GPEb-HIa Ten units of outdated, washed human platelets (obtained from Red Cross) were lyzed by gentle stirring in 3% octylglucoside, 20 mM Tris-HCl, pH 7.4, 140 mM NaCl, 2 mM CaCh at 4°C for 2 h. The lysate was centrifuged at 100,000g for 1 h. The supernatant obtained was applied to a 5 mL lentil lectin sepharose 4B column (E.Y. Labs) preequilibrated with 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 2 mM CaCl2, 1% octylglucoside (buffer A). After 2 h incubation, the column was washed with 50 mL cold buffer A. The lectin-retained GPIIb-HIa was eluted with buffer A containing 10% dextrose. All procedures were performed at 4°C. The GPIIb-ma obtained was >95% pure as shown by SDS polyacrylamide gel electrophoresis.
Incorporation of GPIIb-IIIa in Liposomes.
A mixture of phosphatidylserine (70%) and phosphatidylcholine (30%) (Avanti Polar Lipids) were dried to the walls of a glass tube under a stream of nitrogen. Purified GPIIb-IIIa was diluted to a final concentration of 0.5 mg/mL and mixed with the phospholipids in a protein:phospholipid ratio of 1:3 (w:w). The mixture was resuspended and sonicated in a bath sonicator for 5 mm. The mixture was then dialyzed overnight using 12,000-14,000 molecular weight cutoff dialysis 67 tubing against a 1000-fold excess of 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 2 mM CaC12 (with 2 changes). The GPIIb-IIIa-containing liposomes wee centrifuged at 12,000g for 15 min and resuspended in the dialysis buffer at a final protein concentration of approximately 1 mg/mL. The liposomes were stored at -70C until 5 needed.
Competitive Binding to GPIIb-IIIa The binding to the fibrinogen receptor (GPIIb-IIIa) was assayed by an indirect competitive binding method using [3H]-SK&F-107260 as an RGD-type ligand. The binding assay was performed in a 96-well filtration plate assembly (Millipore Corporation, Bedford, MA) using 0.22 um hydrophilic durapore membranes. The wells were precoated with 0.2 mL of 10 pg/mL polylysine (Sigma Chemical Co., St. Louis, MO.) at room temperature for 1 h to block nonspecific binding. Various concentrations of unlabeled benzadiazapines were added to the wells in quadruplicate. [3H]-SK&F-107260 was applied to each well at a final concentration of 4.5 nM, followed by the addition of 1 |ig of the purified platelet GPIIb-IIIa-containing liposomes. The mixtures were incubated for 1 h at room temperature. The GPIIb-IIIa-bound [3H]-SK&F-107260 was seperated from the unbound by filtration using a Millipore filtration manifold, followed by washing with ice-cold buffer (2 times, each 0.2 mL). Bound radioactivity remaining on tnc filters was counted in 1.5 mL Ready Solve (Beckman Instruments, Fullerton, CA) in a Beckman Liquid Scintillation Counter (Model LS6800), with 40% efficiency.
Nonspecific binding was determined in the presence of 2 pM unlabeled SK&F- 107260 and was consistently less than 0.14% of the total radioactivity added to the samples. All data points are the mean of quadruplicate determinations.
Competition binding data were analyzed by a nonlinear least-squares curve fitting procedure. This method provides the IC50 of the antagonists (concentration of the antagonist which inhibits specific binding of [3H]-SK&F-107260 by 50% at equilibrium). The IC50 is related to the equilibrium dissociation 30 constant (Ki) of the antagonist based on the Cheng and Prusoff equation: Ki = IC50/(l+L/Kd), where L is the concentration of [3H]-SK&F-107260 used in the 68 competitive binding assay (4.5 nM), and Kd is the dissociation constant of [3H]-SK&F-107260 which is 4.5 nM as determined by Scatchard analysis Compounds of the present invention inhibit the vitronectin binding to SK&F 007260 with a Ki at the vitronectin receptor that is about ten-fold greater than that 5 for the fibrinogen receptor. Preferred compounds have a Ki at the vitronectin receptor that is thirty-fold greater than that at the fibrinogen receptor. The most preferred compounds have a Ki at the vitronectin receptor that is a hundred-fold greater than that at the fibrinogen receptor.
The examples which follow are intended to in no way limit the scope of this invention, but are provided to illustrate how to make and use the compounds of this invention. Many other embodiments will be readily apparent to those skilled in the art.
Examples General Nuclear magnetic resonance spectra were recorded at either 250 or 400 MHz using, respectively, a Bruker AM 250 or Bruker / .C 400 spectrometer. CDCI3 is deuteriochloroform, DMSO-dg is hexadeuteriodimethylsulfoxide, and CD3OD is 0 tetradeuteriomethanol. Chemical shifts are reported in parts per million (8) downfield from the internal standard tetramethylsilane. Abbreviations for NMR data are as follows: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, dd=doublet of doublets, dt=doublet of triplets, app=apparent, br=broad. J indicates the NMR coupling constant measured in Hertz. Continuous wave infrared (IR) spectra were 5 recorded on a Perkin-Elmer 683 infrared spectrometer, and Fourier transform infrared (FTIR) spectra were recorded on a Nicolet Impact 400 D infrared spectrometer. IR and FTIR spectra were recorded in transmission mode, and band positions are reported in inverse wavenumbers (cm*1). Mass spectra were taken on either VG 70 FE, PE Syx API HI, or VG ZAB HF instruments, using fast atom 0 bombardment (FAB) or electrospray (ES) ionization techniques. Elemental analyses were obtained using a Perkin-Elmer 240C elemental analyzer. Melting points were taken on a Thomas-Hoover melting point apparatus and are uncorrected. All temperatures are reported in degrees Celsius.
Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates 5 were used for thin layer chromatography. Both flash and gravity chromatography were carried out on E. Merck Kieselgel 60 (230-400 mesh) silica gel. Analytical and preparative HPLC were carried out on Rainin or Beckman chromatographs. ODS refers to an octadecylsilyl derivatized silica gel chromatographic support. 5 |i Apex-ODS indicates an octadecylsilyl derivatized silica gel chromatographic support 0 having a nominal particle size of 5 |i, made by Jones Chromatography, Littleton, Colorado. YMC ODS-AQ® is an ODS chromatographic support and is a registered trademark of YMC Co. Ltd., Kyoto, Japan. PRP-1® is a polymeric (styrene-divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nevada) Celite® is a filter aid composed of acid-washed diatomaceous 5 silica, and is a registered trademark of Manville Corp., Denver, Colorado. 70 Methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate, methyl (2S)-7-carboxy-4-methyl-3-oxo-2,3,4,5-letrahydro-1H-1,4-benzodiazepine-2-acetate, methyl (2R)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate, methyl (±)-7-carboxy-4-5 isopropyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate, methyl (±)-7-carboxy-3-oxo-2-(2-phenylethyl)-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate, and methyl (±)-8-carboxy-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate were prepared by the method of Bondinell, et al., WO 93/00095. 2-(Aminomethyl)imidazole was prepared according to the procedure in 10 Annalen 1968, 718, 249.
Preparation 1 Preparation of methyl (,±V7-carboxv-4-f2-methoxvethvP-3-oxo-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetate 15 a) tert-Butyl 3-[(2-methoxyethyl)amino]methyl-4-nitrobenzoate A mixture of tert-butyl 3-methyl-4-nitrobenzoate (WO 93/00095; 14.96 g, 63.05 mmol), NBS (16.83 g, 94.58 mmol), benzoyl peroxide (1.53 g, 6.31 mmol), and CCI4 (315 mL) was heated at reflux. After 18.5 h, the reaction was cooled thoroughly in ice and filtered to remove the precipitated succinimide. The filtrate 20 was concentrated to leave a yellow oil.
This yellow oil was dissolved in dry THF (315 mL), and 2-methoxyethylamine (16.4 mL, 189.2 mmol) was added all at once. The orangish-yellow solution was stirred at RT for 40 min, then was concentrated to remove the THF. The residue was diluted with Et20 (630 mL) and washed sequentially with 1.0 25 N NaOH (125 mL) and H2O (125 mL). The combined aqueous layers were back-extracted with Et20 (300 mL), and the combined organic layers were washed with brine (125 mL) and dried (MgSOz}). Concentration and silica gel chromatography (3:2 EtOAc/hexanes) gave the title compound (10.30 g, 53%) as a yellow oil: TLC Rf (1:1 EtOAc/hexanes) 0.43; 'H NMR (250 MHz, CDCI3) 8 8.22 (d, J=1.7 Hz, 30 1H), 7.99 (dd, J=8.4, 1.7 Hz, 1H), 7.92 (d, J=8.4 Hz, 1H), 4.08 (s, 2H), 3.51 (t, J=5.1 Hz, 1H), 3.36 (s, 3H), 2.82 (t, J=5.1 Hz, 2H), 1.61 (s, 9H); FTIR (CCI4) 1723,1530, 1369, 1302, 1162, 1116, 842 cm*1; MS (ES) m/e 311 (M+H)+, 255 (M+H - C4H8)+. 71 PCTAJS95/0S306 b) tert-Butyl 3-[[N-(2-methoxyethyl)-N-(tert-butoxycarbonyl)]amino]methyl-4-nitrobenzoate Di-tert-butyl dicarbonate (7.97 g, 36.51 mmol) was added all at once to a solution of tert-butyl 3-[(2-methoxyethyl)amino]methyl-4-nitrobenzoate (10.30 g, 5 33.19 mmol) in CHCI3 (165 mL) at RT. After 16 h, the reaction was concentrated and reconcentrated from hexanes (to remove CHCI3). Silica gel chromatography (20% EtOAc/hexanes) gave the title compound (13.21 g, 97%) as a yellow oil: TLC Rf (20% EtOAc/hexanes) 0.49; >H NMR (250 MHz, CDCI3) 5 7.85-8.15 (m, 3H), 4.75-4.95 (m, 2H), 3.35-3.65 (m, 4H), 3.25 (bs s, 3H), 1.60 (s, 9H), 1.15-1.80 (m, 10 9H); FTIR (CCI4) 1723, 1701, 1531, 1368, 1304, 1161,1119 cm'1; MS (ES) m/e 428.2 (M+NR0+, 411.2 (M+H)+, 355.2 (M+H - C4H8)+, 311.2 (M+H - C4H8 -C02)+. c) tert-Butyl 4-amino-3-[[N-(2-methoxyethyl)-N-(tert-15 butoxycarbonyl)]amino]methyl benzoate % Pd/C (3.42 g, 3.22 mmol) was added to a solution of tert-butyl 3-[[N-(2-methoxyethyl)-N-(tert-butoxycarbonyl)]amino]methyl-4-nitrobenzoate (13.21 g, 32.18 mmol) in EtOAc (320 mL), and the mixture was shaken on a Parr apparatus at RT under H2 (55 psi). After 4 h, the reaction was filtered through Celite®, and the 20 filtrate was concentrated to afford the title compound (12.16 g, 99%) as a colorless foam: TLC Rf (20% EtOAc/hexanes) 0.34; »H NMR (250 MHz, CDCI3) 8 7.68-7.77 (m, 2H), 6.56 (d, J=8.9 Hz, 1H), 5.00 (br s, 2H), 4.46 (s, 2H), 3.38-3.52 (m, 2H), 3.32 (s, 3H), 3.20-3.35 (m, 2H), 1.57 (s, 9H), 1.48 (s, 9H); FTIR (CCI4) 3490, 3340, 3230, 1703, 1673, 1642, 1367, 1284, 1149, 1170 cm->; MS (ES) m/e 403.2 25 (M+Na)+, 381.2 (M+H)+, 325.2 (M+H - C4H8)+, 281 (M+H - C4H8 - C02)+, 269.0 (M+H - 2 x C4H8)+, 225.0 (M+H - 2 x C4H8 - C02)+. d) t-Butyl (±)-4-[2-( 1,4-dimethoxy-1,4-dioxobutyl)amino]-3-[[N-(2-methoxyethyl)-N-(tert-butoxycarbonyl)]amino]methylbenzoate A solution of tert-butyl 4-amino-3-[[N-(2-methoxyethyl)-N-(tert- butoxycarbonyl)]amino]methylbenzoate (12.16 g, 31.96 mmol) and dimethylacetylene dicarboxylate (4.3 mL, 35.2 mmol) in MeOH (65 mL) was heated at reflux for 45 min, then was cooled to RT. The resulting solution was combined with MeOH (260 mL) and 10% Pd/C (6.80 g, 6.4 mmol), and the mixture was 35 shaken on a Parr apparatus at RT under H2 (50 psi). After 6.5 h, the reaction was filtered through Celite®, and the filtrate was concentrated on the rotavap. The 72 WO 96/00730 PCT/US95/08306 residue was reconcentrated from CHCI3 (to remove MeOH), then was chromatographed on silica gel (30% EtOAc/hexanes). The title compound (15.03 g, 90%) was obtained as a faintly yellow oil: TLC Rf (30% EtOAc/hexanes) 0.39; 'H NMR (250 MHz, CDCI3) 5 7.82 (dd. J=8.6, 2.0 Hz, IH), 7.72 (d, J=2.0 Hz, IH), 5 6.63 (d, J=8.6 Hz, IH), 6.35-6.55 (m, IH), 4.55-4.70 (m, IH), 4.52 (1/2 AB, J=15.1 Hz, IH), 4.40 (1/2 AB, J=15.1 Hz, IH), 3.71 (s, 3H), 3.69 (s, 3H), 3.35-3.50 (m, 2H), 3.31 (s, 3H), 3.20-3.30 (m, 2H), 2.98 (dd, J=16.2, 6.7 Hz, IH), 2.84 (dd, J=16.2, 6.8 Hz, IH), 1.56 (s, 9H), 1.48 (s, IH); FTIR (CC14) 3312,1748, 1704, 1670, 1610, 1367, 1297,1142, 1172 cm'1; Me (ES) mIt 547.2 (M+Na)+, 525.2 10 (M+H)+, 469.2 (M+H - C4H8)+, 425.2 (M+H - C4H8 - C02)+. e) Methyl (±)-7-carboxy-4-(2-methoxyethyl)-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid TFA (140 mL) was added all at once to a solution of t-butyl (±)-4-[2-(l,4-15 dimethoxy-l,4-dioxobutyl)amino]-3-[[N-(2-methoxyethyl)-N-(tert- butoxycarbonyl)]amino]methylbenzoate (15.03 g, 28.65 mmol) in anhydrous CH2CI2 (140 mL) at 0°C, and the faintly yellow solution was warmed to RT. After 2 h, the solution was concentrated on the rotavap, and the residue was reconcentrated from toluene (to remove residual TFA). The resulting oil was combined with 20 toluene (280 mL) and Et3N (20 mL, 143 mmol), and the mixture was heated to reflux. A light yellow, homogeneous solution was produced. After 23.5 h, the reaction was concentrated on the rotavap to leave a solid residue. This was dissolved in a minimum of MeOH (ca. 720 mL) at reflux, diluted with H2O (720 mL), and acidified with glacial AcOH (8 mL). The solution was cooled to RT, then 25 was cooled in the refrigerator. After several h, more glacial AcOH (24 mL) was added. The mixture was kept in the refrigerator overnight then was filtered. The solid was washed sequentially with MeOH and Et20, then was dried in high vacuum to afford the title compound (6.40 g, 66%) as a nearly colorless powder: mp 228-230°C; TLC Rf (10% MeOH/CHCl3) 0.51; *H NMR (250 MHz, DMSO-d6) 6 7.59 30 (d, J=1.9 Hz, IH), 7.54 (dd, J=8.5, 1.9 Hz, IH), 6.50-6.60 (m, 2H), 5.43 (d, J=16.6 Hz, IH), 5.12-5.22 (m, IH), 4.04 (d, J=16.6 Hz, IH), 3.60 (s, 3H), 3.20-3.70 (m, 4H), 3.08 (s, 3H), 2.83 (dd, J=16.7, 8.8 Hz, IH), 2.65 (dd, J=16.7,5.3 Hz, IH); MS (ES) mIt 359.0 (M+Na)+, 337.0 (M+H)+. The mother liquors were concentrated on the rotavap to ca. 500 mL, cooled, and filtered to afford additional title compound 35 (1.51 g, total=7.91 g, 82%) as a light yellow solid: mp 226-229.5°C. 73 PCTAJS95/08306 Preparation 2 Using the procedures of Preparation 1, except substituting 3,4-methylenedioxyphenethylamine for 2-methoxyethylamine, the following compound was prepared: a) Methyl (±)-7-carboxy-4-[2-(3,4-methylenedioxyphenyl)ethyl]-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetate. 1H NMR (DMSO-d6) 6 7.51 (dd, J=8.6, 2 Hz, IH), 7.45 (s, IH), 6.57 (m, 2H), 6.49 (m, 2H), 5.87 (s, 2H), 5.32 (d, J=16.5 Hz, IH), 5.07 (m, IH), 3.78 (d, J=16.5 Hz, IH), 3.62 (s, 3H), 3.56 (m, 2H), 2.88 (dd, J=16.7, 8.8 Hz, IH), 2.60 (m, 3H).
Preparation 3 Preparation of methyl (±)-7-carboxv-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetate a) tert-Butyl 3-[[bis-(t-butoxycarbonyl)]amino]methyl-4-nitrobenzoate Di-tert-butyliminodicarboxylate (4.35 g, 20.0 mmol) was added to a suspension of sodium hydride (0.48 g, 20.0 mmol) in anhydrous DMF (30 mL) at RT. After 30 minutes, a solution of t-butyl 3-bromomethyl-4-nitrobenzoate (6.3 g, 20 mmol) in DMF (15 mL) was added rapidly dropwise. After 16 h, the solvent was evaporated and the residue partitioned between EtOAc (200 mL) and water (40 mL). The organic layer was extracted with water (3 x 50 mL) and brine (40 mL) and dried finally over Na2SC>4. Removal of solvent gave the crude product which was purified on flash chromatography (15:85; EtOAc:Hexane) to give the title compound (81.5%): MS (ES) m/e 453 (M+H)+; IH NMR (400 MHz, CDCI3) 8 7.97-8.10 (m, 3H), 5.16 (s, 2H), 1.62 (s, 9H), 1.49 (s, 18H). b) tert-Butyl 4-amino-3-[[bis-(t-butoxycarbonyl)]amino]methylbenzoate A solution of tert-butyl 3-[[bis-(t-butoxycarbonyl)]amino]methyl-4-nitrobenzoate (4.2 g, 9.3 mmol) in ethanol (150 mL) was hydrogenated at 40 psi in the presence of 10% Pd on C (0.40 g). After 30 minutes, catalyst was filtered and solvent removed to give the title compound in essentially quantitative yield: MS (ES) m/e 423 (M+H)+; *H NMR (400 MHz, CDCI3) 8 7.82 (s, IH), 7.71 (d, J=8 4 Hz, IH), 6.56 (d, J=8.4 Hz, IH), 4.92 (br s, 2H), 4.68 (s, 2H), 1.62 (s, 9H), 1.49 (s, 18H). 74 c) (E/Z) tert-Butyl 4-[2-( 1,4-dimethoxy-1,4-dioxo-2-butenyl)amino]-3-[[bis-(t-butoxycarbonyl)]amino]methylbenzoate A solution of tert-butyl 4-amino-3-[[bis-(t-butoxycarbonyl)]amino]methyl benzoate (3.9 g, 9.2 mmol) and dimethylacetylene dicarboxylate (1.34 g, 9.4 mmol) 5 was refluxed 1 h and evaporated to dryness to give the title compound: MS (ES) m/e 565.2 (M+H)+; 'H NMR (400 MHz, CDCI3) 5 9.69 (s, IH), 7.91 (s, IH), 7.77 (m, IH), 6.75 (d, J=7.3 Hz, IH), 5.56 (s, IH), 4.92 (s, 2H), 3.77 (s, 3H), 3.59 (s, 3H), 1.62 (s, 9H), 1.49 (s, 18H). d) tert-Butyl (±)-4-[2-(l,4-dimethoxy-l,4-dioxobutyl)amino]-3-[[bis-(t-butoxycarbonyl)] amino] methylbenzoate A solution of (E/Z) tert-butyl 4-[2-(l,4-dimethoxy-l,4-dioxo-2-butenyl)amino]-3-[[bis-(t-butoxycarbonyl)]amino]methylbenzoate (5.2 g, 9.2 mmol) in methanol (150 mL) was hydrogenated at 40 psi in the presence of 10% Pd/C (0.75 15 g). After 2 h, the catalyst was removed by filtration, and the solvent was removed to provide the crude product. Purification by flash chromatography gave the title compound (80%). MS (ES) m/e 567.2 (M+H)+; !H NMR (400 MHz, CDCI3) 8 7.82 (s, IH), 6.66 (d, J=8.5 Hz, IH), 6.39 (d, J=8.5 Hz, IH), 4.70 (d, J=4.5 Hz, 2H), 4.61 (m, IH), 3.72 (s, 6H), 2.82-2.99 (m, 2H), 1.62 (s, 9H), 1.49 (s, 18H). e) (±)-4-[2-( 1,4-Dimethoxy-1,4-dioxobutyl)amino]-3-(aminomethyl)benzoic acid, bis-(trifluoroacetate) A solution of tert-butyl 4-[2-(l,4-dimethoxy-l,4-dioxobutyl)amino]-3-[[bis-(t-butoxycarbonyl)]amino]methylbenzoate (4.0 g, 7.1 mmol) in a mixture of 25 methylene chloride (100 mL) and trifluoroacetic acid (25 mL) was kept 16 h at RT. The solvents were evaporated and the residue was triturated with ether to give the title compound in essentially quantitative yield: MS (ES) m/e 310.2 (M+H)+; JH NMR (400 MHz, DMSO-d6) 8 8.25 (br s, 3H), 7.89 (s, IH), 7.79 (d, J=8.4 Hz, IH), 6.75 (d, J=8.4 Hz, IH), 6.25 (d, J=8.4 Hz, IH), 4.65 (m, IH), 4.05 (s, 2H), 3.69 (s, 30 3H), 3.65 (s, 3H), 2.89-3.07 (m, 2H). f) Methyl (±)-7-carboxy-3-oxo-2,3,4,5-tetrahydro-IH-1,4-benzodiazepine-2-acetate A solution of sodium methoxide in methanol (25 wt%, 6.7 mL, 30 mmol) was added to a solution of 4-[2-(l,4-dimethoxy-l,4-dioxobutyl)amino]-3-35 (aminomethyl)benzoic acid, bis-(trifluo.roacetate) (4.0 g, 7.0 mmol) at -10°C under argon. After 30 minutes, the cold solution was quenched with acetic acid (1.5 mL).
The reaction mixture was kept one h at -20°C and filtered. The filter cake was slurried in water (30 mL) and filtered to provide the title compound (65%); MS (ES) m/e 279.0 (M+H)+; »H NMR (400 MHz, DMSO-d6) 5 8.21 (t, J=5.4 Hz, IH), 7.55 (m, 2H), 6.55 (d, J=8.4 Hz, IH), 6.45 (s, IH), 5.05 (m, 2H), 3.76 (dd, J=15.8, 7.5 5 Hz, IH), 2.82 (dd, 16.8,9.8 Hz, IH), 2.65 (dd, J=16.8,4.5 Hz, IH).
Preparation 4 Preparation of 2-(methvlaminomethvl'ibenzimidazole dihvdrochloride a) 2-[(tert-Butoxycarbonyl)sarcosyl]aminoaniline A solution of phenylenediamine (100 g, 0.924 mole) and Boc-sarcosine (175 g, 0.924 mole) in DMF (1750 mL) was cooled to -10°C under argon, and a solution of DCC (190.8 g, 0.924 mole) in CH2CI2 (1750 mL) was added in a slow stream 15 over 1 hr. The temperature rose to 0°C during the addition. The reaction was stirred overnight while the temperature was allowed to rise to RT. The white precipitate was removed by filtration, and the filtrate was diluted with H2O (3.5 L) and saturated brine (1 L). The CH2CI2 layer was separated and the aqueous phase was extracted with EtOAc (2x1 L). The combined organic layers were washed with H2O (1 L) 20 and brine (0.5 L), then were concentrated to a yellow residue (341 g). This was triturated with EtOAc to afford the title compound (179.4 g, 70%): mp 134 - 136°C. b) 2-[(N-tert-Butoxycarbonyl-N-methyl)aminomethyl]benzimidazole A solution of 2-[(tert-butoxycarbonyl)sarcosyl]aminoaniline (178.4 g, 0.639 25 mole) in THF (900 mL) and AcOH (900 mL) was heated to reflux under argon for 1 hr, then a vacuum was carefully applied to the reaction, and most of the THF was removed by distillation. The residual solution was poured into stirred ice water, and conc. NH4OH (1150 mL) was added to adjust the pH to 10. An oil formed which crystallized on stirring overnight. The solid was filtered and dried at 50°C at 30 atmospheric pressure for two days to leave a yellow-white solid (167 g, 100%): mp 140 - 150°C. Further drying at RT and atmospheric pressure gave the crude title compound (162 g, 97%). 76 PCTAJS95/08306 c) 2-(Methylaminomethyl)benzimidazole dihydrochloride A solution of 4 M HCl/dioxane (616 mL, 2.46 mole) and anisole (134 mL, 1.23 mole) was cooled to 0°C under argon, and a solution of 2-[(N-tert-5 butoxycarbonyl-N-methyl)aminomethyl]benzimidazole (161 g, 0.616 mole) in CH2CI2 (800 mL) was added in a slow stream over 30 min. The temperature rose to 8°C during the addition, and a white precipitate began to form before the addition was complete. The reaction was stirred for 20 min, then the title compound (66.6 g, 46%) was collected by filtration: mp 250 - 255 °C (dec.). Anal. Calcd for C9H11N3 -10 2 HCl: C, 46.17; H, 5.60; N, 17.95. Found: C, 46.33; H, 5.68; N, 17.55. The filtrate was diluted with Et2<D, and the mixture was allowed to stand overnight. Filtration gave additional title compound (62 g; total yield 128.6 g, 89%) as a pink solid: mp 248 - 253°C (dec.).
Example 1 Preparation of (±)-7-nT(2-benzimidazolvI)methvnaminolcarbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-l .4-benzodiazepine-2-acetic acid a) Methyl (±)-7-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate 20 A mixture of methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH- l,4-benzodiazepine-2-acetate (0.57 g, 1.82 mmol) and thionyl chloride (15 mL) was refluxed for 1 h. The resulting orange solution was concentrated to dryness to leave a yellow-orange foam. This was dissolved in CH2CI2 (10 mL) and added dropwise to a solution containing 2-(aminomethyl)benzimidazole dihydrochloride (1.2 g, 5.46 25 mmol), pyridine (0.72 g, 9.1 mmol), and triethylamine (0.55 g, 5.46 mmol) in CH2CI2 (15 mL) at 0°C under argon. The reaction mixture was then stirred in RT under argon. After 25.5 h, CH2CI2 (200 mL) and 5% NaHC03 (50 mL) were added to the reaction mixture to give a light yellow precipitate which was filtered and air-dried to give the title compound (0.11 g, 14%). The filtrate was separated and the 30 organic layer was washed sequentially with 5% NaHC03 (50 mL) and H2O (50 mL), then was concentrated on the rotavap. After trituration with CH2CI2 and air-drying, a yellowish solid was collected to yield more of the title compound (0.35 g, 45%): lH NMR (250 MHz, CDCl3/DMSO-d6) 6 6.30-8.70 (m, 9H), 5.52 (d, J=16 Hz, IH), 5.14 (m, IH), 4.67 (d, J=5 Hz, 2H), 3.80 (d, J=17 Hz, IH), 3.63 (s, 3H). 77 WO 96/00730 PCT/US95/08306 2.97 (s, 3H), 2.85 (dd, J=16,9 Hz, IH), 2.64 (dd, J=17, 5 Hz, IH); MS (ES) m/e 422.2 (M+H)+. b) (±)-7-[[[(2-Benzimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-5 tetrahydro-lH-l,4-benzodiazepine-2-acetic acid 1.0 N LiOH (0.57 mL, 0.57 mmol) was added dropwise at RT to a mixture of methyl (±)-7-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (0.11 g, 0.26 mmol) in THF (4 mL) and H2O (5 mL). The resulting light brownish-yellow solution was stirred for 21.5 h, 10 then was concentrated on the rotavap. The resulting residue was lyophilized to give the crude product (0.11 g, 100%) as a yellowish powder. Preparative HPLC (PRP-1® column, step gradient, 10-20% CH3CN/H20-0.1% TFA) afforded the title compound: *H NMR (250 MHz, DMSO-d6) 6 6.45-9.06 (m, 9H), 5.53 (d, J=16 Hz, IH), 5.13 (m, IH), 4.86 (d, J=5 Hz, 2H), 3.87 (d, J=17 Hz, IH), 2.95 (s, 3H), 2.80 15 (dd, J=17, 9 Hz, IH), 2.57 (dd, J=17, 5 Hz, IH); MS (ES) m/e 408.2 (M+H)+. Anal. Calcd for C21H21N5O4 • 4/3 CF3CO2H • H20: C, 49.22; H, 4.25; N, 12.13. Found: C, 49.24; H, 4.22; N, 12.11.
Example 2 Preparation of (±l-7-rrr(2-benzimidazolvl)methvllaminolcarbonvll-3-oxo-4-(2-phenvlethvn-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid a) Methyl (±)-7-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetate EDC (230 mg, 1.2 mmol) was added to a stirred solution of methyl (±)-7-25 carboxy-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2- acetate (382.4 mg, 1.0 mmol), 2-(aminomethyl)benzimidazole dihydrochloride (264 mg, 1.2 mmol), H0BT-H20 (162 mg, 1.2 mmol), and diisopropylethylamine (0.70 mL, 4.0 mmol) in anhydrous DMF (5 mL) at RT. After 19 h, the reaction was concentrated on the rotavap (high vacuum), and the residue was partitioned between 30 H2O (5 mL) and EtOAc (20 mL). The layers were separated and the organic layer was washed with H2O (5 mL). Drying (MgS04), concentration, and silica gel chromatography (load with 5% MeOH/CHCl3; gradient: 5% MeOH in 1:1 EtOAc/CHCl3 (300 mL), then 10% MeOH/EtOAc (400 mL), then 10% MeOH/CHC^) gave the title compound (414.9 mg, 81%) as an off-white solid: 35 TLC (10% MeOH/EtOAc) Rf 0.62; »H NMR (250 MHz, DMSO-d6) 8 8.72 (br t, J=5.6 Hz, IH), 7.35-7.75 (m, 4H), 7.00-7.35 (m, 7H), 6.56 (d, J=8.4 Hz, IH), 6.37 78 WO 96/00730 PCTAJS95/08306 (br d, J=3.5 Hz, IH), 5.42 (d, J=16.6 Hz, IH), 5.08-5.20 (m, IH), 4.52-4.75 (m, 2H), 3.93 (d, J=16.6 Hz, IH), 3.45-3.72 (m, 2H), 3.61 (s, 3H), 2.83 (dd, J=16.7, 8.9 Hz, IH), 2.60-2.75 (m, 3H); MS (ES) 512.2 (M+H)+. b) (±)-7-[[[(2-Benzimidazolyl)methyI]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid A mixture of methyl (±)-7-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate (413.1 mg, 0.81 mmol), 1.0 N LiOH (0.97 mL, 0.97 mmol), THF (4 mL), and H2O (3 mL) 10 was stirred at 40-45°C for 20 min, and the resulting solution was stirred at RT for 17 h. Acidification with TFA (0.19 mL, 2.4 mmol) and concentration left an off-white solid. Recrystallization from CH3CN/H2O gave the title compound (343.2 mg, 69%) as a colorless powder: HPLC (PRP-1®, 30% CH3CN/H20-0.1 % TFA) K'= 1.5; »H NMR (400 MHz, CD3OD) 5 7.68-7.75 (m, 2H), 7.60 (dd, J=8.6, 2.2 Hz, 15 IH), 7.51-7.58 (m, 2H), 7.49 (d, J=2.2 Hz, IH), 7.07-7.22 (m, 5H), 6.61 (d, J=8.6 Hz, IH), 5.46 (d, J=16.8 Hz, IH), 5.18 (dd, J=9.0,5.1 Hz, IH), 4.95 (s, 2H), 3.81 (d, J=16.8 Hz, IH), 3.61-3.78 (m, 2H), 2.94 (dd, J=16.8, 9.0 Hz, IH), 2.71-2.83 (m, 2H), 2.65 (dd, J=16.8,5.1 Hz, IH); MS (ES) m/e 498.4 (M+H)+. Anal. Calcd for C28H27N5O4 • CF3CO2H • 0.25 H20: C, 58.49; H, 4.66; N, 11.37. Found: C, 20 58.52; H, 4.47; N, 11.04.
Example 3 Preparation of (,±)-4-isopropvl-7-frr(2-benzimidazolvl)methvIlaminolcarbonvll-3-oxo-2.3.4.5-tetrahvdro-lH-l.4-benzodiazepine-2-acetic acid 25 a) Methyl (±)-4-isopropyl-7-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetate EDC (173 mg, 0.90 mmol) was added to a stirred solution of methyl (±)-7-carboxy-4-isopropyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate (240.3 mg, 0.75 mmol), 2-(aminomethyl)benzimidazole dihydrochloride (198 mg, 30 0.90 mmol), H0BT-H20 (122 mg, 0.90 mmol), and diisopropylethylamine (0.52 mL, 3.0 mmol) in anhydrous DMF (4 mL) at RT. After 20 h, the reaction was concentrated on the rotavap (high vacuum), and the residue was diluted with H2O (5 mL) to afford a gummy precipitate. EtOAc (3 mL) was added and the mixture was stirred briskly. The precipitate remained gummy, but changed in form so that it was 35 suspended as a mass in the solvents. The solvents were drawn off with a pipet .and the residue was suspended in MeOH (3 mL) and EtOAc (6 mL). The mixture was 79 WO 96/00730 PCT/US95/08306 stirred briskly at RT for several min, then was cooled in ice and filtered. The filter pad was washed with EtOAc and dried in high vacuum to leave the title compound (275.1 mg, 82%) as an off-white powder: ]H NMR (250 MHz, 20% CD3OD/CDCI3) 57.45-7.70 (m, 4H), 7.15-7.35 (m, 2H), 6.56 (d, J=9.1 Hz, IH), 5 5.22 (d, J=16.9 Hz, IH), 5.13 (app t, IH), 4.72-4.92 (m, IH), 4.72 (s, 2H), 4.03 (d, J= 16.9 Hz, IH), 3.74 (s, 3H), 3.00 (d, J=16.4, 7.7 Hz, IH), 2.67 (dd, J=16.4, 6.0 Hz, IH), 1.21 (d, J=6.7 Hz, 3H), 1.03 (d, J=6.8 Hz, 3H); MS (ES) 450.2 (M+H)+. b) (±)-4-Isopropyl-7-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-3-oxo-2,3,4,5-10 tetrahydro-1H-1,4-benzodiazepine-2-acetic acid A mixture of methyl (±)-4-isopropyl-7-[[[(2-benzimidazolyl)methyl]amino] carbonyl] -3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate (275.1 mg, 0.61 mmol), 1.0 N LiOH (0.73 mL, 0.73 mmol), THF (3 mL), and H20 (2.3 mL) was stirred at 35°C for 45 min, and the resulting solution was stirred at RT. After 15 17.5 h, the solution was filtered, and the filtrate was neutralized with 1.0 N HCl (0.73 mL). Since the product did not precipitate, the solution was acidified with TFA (0.2 mL) and concentrated. The resulting solid was triturated with H20 to leave a nearly colorless solid, which was dissolved with warming in 1:1 CH3CN/H2O. The solution was cooled to RT and diluted with several volumes of 20 H20/0.1 % TFA. ODS chromatography (20% CH3CN/H20-0.1 % TFA), concentration, and lyophilization gave the title compound (293.4 mg, 80%) as a colorless powder: HPLC (PRP-1®, 20% CH3CN/H20-0.1% TFA) K'=2.5; JH NMR (400 MHz, CD3OD) 5 7.70-7.76 (m, 2H), 7.65 (d, J=2.2 Hz, IH), 7.61 (dd, J=8.5, 2.2 Hz, IH), 7.53-7.60 (m, 2H), 6.62 (d, J=8.5 Hz, IH), 5.33 (d, J=16.9 Hz, IH), 25 5.21 (dd, J=8.9, 5.2 Hz, IH), 4.97 (d, J=1.9 Hz, 2H), 4.72-4.85 (m, IH), 4.10 (d, J= 16.9 Hz, IH), 2.96 (dd, J=16.8, 8.9 Hz, IH), 2.65 (dd, J=16.8,5.2 Hz, IH), 1.21 (d, J=6.7 Hz, 3H), 1.03 (d, J=6.8 Hz, 3H); MS (ES) m/e 436.2 (M+H)+. Anal. Calcd for C23H25N504 • 1.25 CF3C02H • 1.25 H20: C, 51.00; H, 4.83; N, 11.66. Found: C, 51.12; H, 4.91; N, 11.37.
Example 4 Preparation of C±')-7-rrrN-(2-benzothiazolvl)methvl-N-methvllamino1carbonvl1-4-methvl-3-oxo-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid a) 2-Bromomethylbenzothiazole 35 A mixture of 2-methylbenzothiazole (2.0 g, 13.40 mmol), N- bromosuccinimide (2.39 g, 13.40 mmol), and AIBN (0.5 g, 3.04 mmol) in CCI4 (40 80 mL) was refluxed for 12h, then the mixture was cooled and filtered. The filtrate was concentrated and purified by silica gel chromatography (5% EtOAc/hexane) to give the title compound (2.19 g, 72%) as a yellow oil: lH NMR (250 MHz, DMSO-d5): 8 5.12 (s, 2H), 7.5 (m, 2H), 8.01 (dd, J=7.9,1.8 Hz, IH), 8.15 (dd, J=7.9,1.8 Hz, 5 IH). b) 2-[(Methylamino)methyl]benzothiazole To a stirred solution of 2-bromomethylbenzothiazole (0.4 g. 1.75 mmol) in THF (4 mL) was added 40% aqueous methylamine (0.30 g, 8.77 mmol). Stirring 10 was continued overnight, then the mixture was concentrated. The residue was taken up in H2O, neutralized with 2.5 N NaOH, and extracted with CH2CI2. The organic extracts were dried (MgS04) and concentrated to give the title compound (0.36 g, 80%) as a brown oil: lH NMR (250 MHz, DMSO-d6): 5 2.70 (s, 3H), 4.71 (s, 2H), 7.55 (m, 2H), 8.0 (d, J=7.9 Hz, IH), 8.17 (d, J=7.9 Hz, IH). c) Methyl (±)-7-[[[N-(2-benzothiazolyl)methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate A mixture of methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (0.25 g, 0.855 mmol), 2-20 [(methylamino)methyl]benzothiazole (0.228 g, 1.283 mmol), EDC (0.31 g, 1.0026 mmol), HOBT • H2O (0.14 g, 1.026 mmol), and diisopropylethylamine (0.30 mL, 1.711 mmol) in dry DMF (5 mL) was stirred at RT in 20 h. The reaction mixture was concentrated, and the residue was: taken up in H2O and extracted with CH2CI2. The combined organic extracts were dried (MgS04) and concentrated. Silica gel 25 chromatography (5% MeOH/CH2Cl2) gave the title compound (0.289g, 75%) as a yellow oil: NMR (400 MHz, DMSO-d6): 8 2.65 (dd, J=16.8, 5.0 Hz, IH), 2.82 (dd, J=16.8,8.9 Hz, IH), 2.90 (s, 3H), 3.15 (s, 3H), 3.62 (s, 3H), 3.90 (d, J=16.1 Hz, IH), 4.90 (s, 2H), 5.13 (m, IH), 5.45 (d, J=16.1 Hz, IH), 6.29 (d, J=3.6 Hz, IH), 6.57 (d, J=8.3 Hz, IH), 7.19 (d, J=8.3 Hz, IH), 7.21 (s, IH), 7.45 (t, J=7.4 Hz, IH), 30 7.52 (t, J=7.4 Hz, IH), 8.00 (d, J=7.9 Hz, IH), 8.10 (d, J=7.9 Hz, IH). d) (±)-7-[[[N-(2-Benzothiazolyl)methyl-N-methyl]amino]carbonyl]~4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l ,4-benzodiazepine-2-acetic acid 2.5 N NaOH (3.0 mL) was added to a stirred solution of methyl (±)-7-[[[N-35 (2-benzothiazolyl)methyl-N-methyl] amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- tetrahydro-lH-l,4-benzodiazepine-2-acetate (0.289 g, 0.639 mmol) in MeOH (3 mL) 81 WO 96/00730 PCT/US95/08306 at RT. After 3 h, the mixture was concentrated, and the residue was acidified to pH 4. The colorless solid was collected and triturated in Et20 to give the title compound (0.250 g, 89%) as a colorless solid: 'H NMR (400 MHz, DMSO-dg) 5 2.55 (dd, J= 16.8, 5.0 Hz, IH), 2.75 (dd, J=16.8, 8.9 Hz, IH), 2.91 (s, 3H), 3.1 (s, 5 3H), 3.9 (d, J=16.1 Hz, IH), 4.9 (d, 5=5.1 Hz, 2H), 5.10 (m, IH), 5.45 (d, J=16.1 Hz, IH), 6.29 (d, J=3.6 Hz, IH), 6.57 (d, J=8.3 Hz, IH), 7.19 (d, J=8.3 Hz, IH), 7.21 (s, IH), 7.45 (t, J=7.4 Hz, IH), 7.52 (t, J=7.4 Hz, IH), 8.00 (d, J=7.9 Hz, IH), 8.10 (d, J=7.9 Hz, IH); IR (KBr) 3500,3286,3100, 3000, 1735, 1719, 1662,1652, 1614, 1595, 1482, 1392, 827, 765 cm*1; MS (ES) m/e 439.2 (M+H)+. Anal. Calcd for 10 C22H22N4O4S 1.5 H20: C, 56.76; H, 5.41; N, 12.03. Found: C, 56.37; H, 5.23; N, 11.86.
Example 5 Preparation of (±)-7-nTN-(2-benzoxazolvl)methvl-N-methvnaminolcarbonvn-4-15 methvl-3-oxo-2.3.4.5-tetrahvdro-lH-l .4-benzodiazepine-2-acetic acid a) 2-Bromomethylbenzoxazole Following the procedure of Example 4(a), except using 2-methylbenzoxazole in place of 2-methylbenzothiazole, the title compound (2.22 g, 70%) was prepared as a yellow oil: >H NMR (250 MHz, DMSO-d6) 5 5.17 (s, 2H), 7.55 (m, 2H), 8.01 (d, 20 J=7.9, 1.8 Hz, IH), 8.20 (dd, J=7.9,1.8 Hz, IH). b) 2-[(Methylamino)methyl]benzoxazole Following the procedure of Example 4(b), except using 2-bromomethyl benzoxazole in place of 2-bromomethylbenzothiazole, the title compound (0.250 g, 25 71%) was prepared as a brown oil: *H NMR (400 MHz, DMSO-d6) 5 2.75 (s, 3H), 4.71 (s, 2H), 7.60 (m, 2H), 8.01 (d, J=7.9 Hz, IH), 8.17 (d, J=7.9 Hz, IH). c) Methyl-(±)-7-[[[N-(2-benzoxazolyl)methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Following the procedure of Example 4(c), except using 2-[(methylamino) methyljbenzoxazole in place of 2-[(methylamino)methyl]benzothiazole, the title compound (0.342 g, 91%) was prepared as a brown oil: 'H NMR (DMSO-d6) 8 2.65 (dd, J=16.8,5.0 Hz, IH), 2.82 (dd, J=16.8,8.9 Hz, IH), 2.91 (s, 3H), 3.15 (s, 3H), 3.61 (s, 3H), 3.90 (d, J=16.1 Hz, IH), 4.91 (s, 2H), 5.15 (m, IH), 5.47 (d, 35 J=16.1 Hz, IH), 6.30 (d, J=3.6 Hz, IH), 6.57 (d, J=8.3 Hz, IH), 7.20 (m, 2H), 7.40 (m, 2H), 7.72 (t, J=7.4 Hz, 2H), 7.95 (s, IH). 82 d) (±)-7-[[[N-(2-Benzoxazolyl)methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-IH-1,4-benzodiazepine-2-acetic acid Methyl-(±)-7-[[[N-(2-benzoxazolyl)methyl-N-methyl]amino]carbonyl]-4-5 methyl-3-oxo-2,3,4,5-telrahydro-lH-l,4-benzodiazepine-2-acetate was saponified following the procedure of Example 4(d). Purification by silica gel chromatography (2:8:1 MeOH/CH2Cl2/Et3N) gave the title compound (0.231 g, 70%) as an off-white solid: lH NMR (400 MHz, DMSO-d6) 8 2.45 (dd, J=16.8, 5.0 Hz, IH), 2.70 (dd, J= 16.8, 8.9 Hz, IH), 2.90 (s, 3H), 3.15 (s, 3H), 3.91 (d, J=16.1 Hz, IH), 4.90 (d, 10 J=5.7 Hz, 2H), 5.07 (m, IH), 5.45 (d, J=16.1 Hz, IH), 6.30 (d, J=3.6 Hz, IH), 6.58 (d, J=8.3 Hz, IH), 7.20 (m, 2H), 7.40 (m, 2H), 7.70 (m, 2H); IR (KBr) 3370, 3100, 3000, 1728, 1653, 1612, 1575, 1485, 1455, 1397, 831,765 cm'1; MS (ES) m/e 421 (M -H)\ Anal. Calcd for C22H22N4O5 1.25 H20: C, 59.39; H, 5.45; N, 12.50. Found: C, 59.43; H, 5.23; N, 12.14.
Example 6 Preparation of (±)-7-nTN-f2-(5(6)-chlorobenzimidazolvl)methvl1-N-methvnamino1 carbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid a) 2-[[(N-tert-butoxycarbonyl-N-methyl)amino]methyl]-5(6)-chlorobenzimidazole 20 To a stirred and cooled (0°C) mixture of Boc-sarcosine (2.0 g, 10.571 mmol) and Et3N (1.12 g, 11.01 mmol) in anhydrous THF (25 mL) was added isobutylchloroformate (1.51 g, 11.01 mmol). After 1 h, 4-chloro-l,2-phenylenediamine (1.43 g, 10.571 mmol) was added. Stirring was continued for 2 h, then acetic acid (10 mL) was added, and the reaction was heated to reflux. After 4 h, 25 the mixture was cooled, concentrated, neutralized with 2.5 N NaOH, and extracted with CH2CI2. Drying (MgS04), concentration, and silica gel chromatography (1% MeOH/CH2Cl2) gave the title compound (2.10 g, 67%) as a brown foam: ^H NMR (250 MHz, DMSO-d6): 8 1.45 (s, 9H), 2.95 (s, 3H), 4.60 (s, 2H), 7.10 (d, J=9.3 Hz, IH), 7.50 (d J=9.3 Hz, IH), 7.60 (s, IH). b) 5(6)-Chloro-2-[(methylamino)methyl]benzimidazole To a stirred solution of 2-[[(N-tert-butoxycarbonyl-N-methyl)amino]methyl]-5(6)-chlorobenzimidazole (2.10 g, 7.101 mmol) in anhydrous CH2CI2 (20 mL) was added TFA (2.2 mL, 28.404 mmol). After stirring overnight, the mixture was 35 concentrated, neutralized with 2.5 N NaOH, and extracted with CH2CI2. The combined organic extracts were washed with brine, dried (MgS04), and 83 concentrated to give the title compound (1.25 g, 90%) as a brown oil: *H NMR (250 MHz, DMSO-d6) 8 2.35 (s, 3H), 3.88 (s, 2H), 7.17 (d, J=9.3 Hz, IH), 7.50 (d, J=9.3 Hz, IH), 7.55 (s, IH). c) Methyl (±)-7-[[[N-[2-(5(6)-chlorobenzimidazolyl)methyl]-N-methyl]amino] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Following the procedure of Example 4(c), except substituting 5(6)-chloro-2-[(methylamino)methyljbenzimidazole for 2-[(methylamino)methyl]benzothiazole, the title compound (0.262 g, 59%) was obtained as an off-white solid after silica gel 10 chromatography (5% MeOH/CH2Cl2): JH NMR (250 MHz, DMSO-d6) 8 2.65 (dd, J=16.8, 5.0 Hz, IH), 2.82 (dd, J=16.8, 8.9 Hz, IH), 2.91 (s, 3H), 3.15 (s, 3H), 3.61 (s, 3H), 3.91 (d, J=16.1 Hz, IH), 4.80 (d, J=5.7 Hz, 2H), 5.15 (m, iH), 5.47 (d, J=16.1 Hz, IH), 6.25 (d, J=3.6 Hz, IH), 6.55 (d, J=8.3 Hz, IH), 7.20 (m, 2H), 7.60 (m, 2H). d) (±)-7-[[[N-[2-(5(6)-Chlorobenzimidazolyl)methyl]-N-methyl]amino] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid Methyl (±)-7-[[[N-[2-(5(6)-chlorobenzimidazolyl)methyl]-N-methyl]amino] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate was 20 saponified following the procedure of Example 4(d). Trituration with Et0H/Et20 gave the title compound (0.100 g, 69%) as a colorless solid: JH NMR (400 MHz, DMSO-d6) 8 2.55 (dd, J=16.8, 5.0 Hz, IH), 2.75 (dd, J=16.8, 8.9 Hz, IH), 2.91 (s, 3H), 3.10 (s, 3H), 3.90 (d, J=16.1 Hz, IH), 4.9 (s, 2H), 5.10 (m, IH), 5.45 (d, 16.1 Hz, IH), 6.25 (s, IH), 6.57 (d, J=8.3 Hz, IH), 7.20 (m, 3H), 7.50 (d, J=9.3 Hz, IH), 25 7.60 (s, IH), 12.3 (br s, IH), 12.5 (br s, IH); MS (ES) m/e 456.0 (M+H)+. Anal. Calcd for C22H22CIN5O4: C, 56.30; H, 5.05; N, 14.92. Found: C, 56.27; H, 5.30; N, 15.14.
Example 7 Preparation of (,±V7-rrr(2-indolvl)methvnaminolcarbonvl1-4-methvl-3-oxo-2.3.4.5-tetrahvdro-l H-1.4-benzodiazepine-2-acetic acid a) Indole-2-carboxamide A mixture of ethyl indole-2-carboxylate (5 g, 26.5 mmol) and ammonium hydroxide (30 mL) was heated at 80°C in a sealed glass vessel overnight. The 35 reaction was cooled and the title compound (3.06g, 73%) w<'is collected by filtration 84 PCT/TJS95/08306 as a colorless solid: NMR (400 MHz, DMSO-d6) 5 7.95 (br, IH), 7.61 (d, IH), 7.41 (d, IH), 7.36 (br, 1H),7.12, (t, 1H),7.01 (t, IH). b) 2-Cyanoindole A solution of indole-2-carboxamide (3.02 g, 18.8 mmol) in dichlorophenylphosphine oxide (20 mL) was heated at 80°C overnight. The cooled reaction mixture was then poured over 100 mL ice and the pH was adjusted to 11 with 50% aqueous sodium hydroxide. Extraction with ethyl acetate followed by concentration in vacuo gave an off-white solid which was purified by silica gel 10 chromatography (1% MeOH/CH2Cl2) to yield the title compound (2.41 g, 90%): !H NMR (400 MHz, DMSO-d6) 5 7.68 (d, IH), 7.46 (d, IH), 7.36 (s, IH), 7.34 (t, IH), 7.14 (t, IH). c) 2-Aminomethylindole LAH (42 mL, 1M solution in THF) was added dropwise through a syringe to a solution of 2-cyanoindole (2.0 g, 14.1 mmol) in anhydrous THF (20 mL) with cooling, and the resulting solution was stirred at RT under argon for 5 h. H2O was added dropwise with cooling to destroy excess LAH, and the colorless precipitate was removed by filtration and washed with THF. The filtrate was dried (K2CO3) 20 and concentrated to afford the title compound (2.11 g, quantitative) as a yellow solid: IH NMR (400 MHz, DMSO-d6) 5 7.41 (d, IH), 7.29 (d, IH), 6.97 (t, IH), 6.91 (t, IH), 6.20 (s, IH), 3.82 (s, 2H), 2. 18 (br, IH). d) Methyl (±)-7-[[[(2-indolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-25 tetrahydro-lH-1,4-benzodiazepine-2-acetate EDC (1.53 g, 7.99 mmol) was added to a solution of methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (2.13 g, 7.26 mmol), 2-aminomethylindole (1.06 g, 7.26 mmol), HOBT • H2O (1.08 g, 7.99 mmol) and diisopropylethylamine (1.53 mL, 8.71 mmol) in anhydrous DMF (10 mL) 30 at RT. After 20 h the reaction was concentrated on the rotavap (high vacuum). The residue was taken up in EtOAc and washed sequentially with H2O and 10% Na2C03 (2 x 30 mL). Drying (MgS04), concentration, and silica gel chromatography (2% MeOH/CH2Cl2) gave the title compound (1.8 g, 60%): !H NMR (400 MHz, DMSO-d6) 6 8.56 (t, IH), 7.95 (s, IH), 7.59 (s, IH), 7.56 (d, IH), 7.43 (d, IH), 7.33 35 (d, IH), 7.01 (t, IH), 6.93 (t, IH), 6.55 (d, IH), 6.33 (br, IH), 6.25 (s, IH), 5.49 (d, 85 PCTAJS95/08306 IH), 5.14 (t, IH), 4.56 (d, 2H), 3.82 (d, IH), 3.61 (s, 3H), 2.92 (s, 3H), 2.75 (dd, IH), 2.53 (d, IH); MS(ES) m/e 421.2 (M+H)+ e) (±)-7-[[[(2-Indolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-5 lH-l,4-benzodiazepine-2-acetic acid 1.0 N NaOH (1 mL, 1.0 mmol) was added dropwise to a solution of methyl (±)-7-[[[(2-indolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-1,4-benzodiazepine-2-acetate (0.35 g, 0.83 mmol) in THF (5 mL) and MeOH (2 mL) at RT. The resulting mixture was stirred for 20 h then was concentrated. The 10 residue was dissolved in H2O (20 mL) and acidified with TFA. ODS chromatography (27% CH3CN/H20-0.1% TFA), concentration and lyophilization gave the title compound (100 mg, 30%) as an off-white solid: HPLC (ODS, 5-60% CH3CN/H20-0.1% TFA gradient elution over 20 min) K'=10.2; ]H NMR (400 MHz, DMSO-d6) 8 8.55 (t, IH), 7.57 (s, IH), 7.56 (d, IH), 7.43 (d, IH), 7.33 (d, 15 IH), 7.01 (t, IH), 6.93 (t, IH), 6.55 (d, IH), 6.33 (br, IH), 6.25 (s, IH), 5.49 (d, IH), 5.08 (t, IH), 4.55 (d, 2H), 3.82 (d, IH), 2.92 (s, 3H), 2.75 (dd, IH), 2.53 (d, IH); MS (ES) m/e 407.2(M+H)+. Anal. Calcd for C22H22N4O4 ■ H20: C, 62.25; H, 5.70; N, 13.20. Found: C, 62.66; H, 5.64; N, 12.99.
Example 8 Preparation of (2S)-7-rrf(2-Benzimidazolvl)methvllaminolcarbonvll-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-l .4-benzodiazepine-2-acetic acid a) Methyl (2S)-7-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate 25 EDC (1.15 g, 6.02 mmol) was added to a solution of methyl (2S)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (2.11 g, 5.02 mmol), 2-aminomethylbenzimidazole dihydrochloride (1.15 g, 6.02 mmol), H0BT-H20 (811 mg, 6.02 mmol), and diisopropylethylamine (1.76 mL, 10 mmol) in anhydrous DMF (25 mL) at RT. After 21 h, the reaction was concentrated on the 30 rotavap (high vacuum), and the residue was taken up in CH2Cl2 (240 mL) and washed with H2O. The organic layer was dried (Na2S04), dissolved in xylenes, and reconcentrated to remove residual DMF. The crude product was chromatographed on silica gel (MeOH/CHCl3) to give the title compound (1.1 g, 52%). b) (2S)-7-[[[(2-Benzimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-telrahydro-1H-1,4-benzodiazepine-2-acetic acid 1 N NaOH (4.75 mL, 4.75 mmol) was added to a cold solution of methyl (2S)-7-[[[(2-benzimidazolyl) methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-5 lH-l,4-benzodiazepine-2-acetate (1.0 g, 2.38 mmol), MeOH (10 mL) and H2O (5 mL). The solution was stirred at room temperature for 18 hr and concentrated. ODS chromatography (CH3CN/H2O-0.1% TFA) gave the title compound (0.91 g, 94%): HPLC (5 Altex Ultrasphere ODS, 4.5 mm x 25 cm, 5%-60% CH3CN/H20-0.1% TFA gradient over 20 min) K'=5.7; >H NMR (400 MHz, DMSO-d6) 5 8.7-8.9 (t, 10 IH), 6.3-7.6 (m, 8H), 5.4-5.6 (d, IH), 5.0-5.1 (q, IH), 4.5-4.7 (d 2H), 3.8-3.9 (d, IH), 2.9-3.0 (s, 3H), 2.7-2.9 (dd, 2H); MS (ES) m/e 408.2 (M+H)+. Anal. Calcd for C21H21N5O4 • 3.5 H20: C, 53.61; H, 6.00; N, 14.89. Found: C, 53.38; H, 6.00; N, 14.55. [a]D -237° (c 0.1).
Example 9 Preparation of (2R)-7-nT(,2-Benzimidazolvl)methvnamino'lcarbonvP-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-l .4-benzodiazepine-2-acetic acid a) Methyl (2R)-7-[[[(2-benzimidazoIyl)methyl]amino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4-benzodiazepine--2-acetate Following the procedure of Example 8(a), substituting methyl (2R)-7- carboxy-4-methyl-3-oxo-2,3,4,5-lH-l,4-be;nzodiazepine-2-acetate for the (2S) isomer, the title compound (0.37 g, 86%) was prepared. b) (2R)-7-[[[(2-Benzimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-25 tetrahydro-1H-1,4-benzodiazepine-2-acetic acid Following the procedure of Example 8(b), the compound of Example 9(a) is saponified to yield the title compound (0.20 g, 57%): HPLC (5 Altex Ultrasphere ODS, 4.5 mm x 25 cm, 12% CH3CN/ H20-0.1% TFA) K'=4.7; »H NMR (400 MHz, DMSO-d6) 5 8.7-8.9 (t, IH), 6.3-7.6 (m, 8H), 5.4-5.6 (d, IH), 5.0-5.1 (q, IH), 4.5-30 4.7 (d 2H), 3.8-3.9 (d, IH), 2.9-3.0 (s, 3H), 2.7-2.9 (dd, 2H); MS (ES) m/e 408.2 (M+H)+. Anal. Calcd for C2iH2iN504- 3.75 H20: C, 53.10; H, 6.05; N, 14.74. Found: C, 52.86; H, 6.03; N, 14.39. [a]D= +205° (c 0.1).
Example 10 Preparation of (±)-7-rrr(2-benzimidazolvl)methvl1amino1carbonvn-9-chloro-4-methvl-3-oxo-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid 87 WO 96/00730 PCTAJS95/08306 a) Methyl (±)-7-carboxy-9-chloro-4-methyl-3-oxo-2,3,4,5 -tetrahydro-1H-1,4-benzodiazepine-2-acetate A solution of (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (1.0 g, 3.4 mmol), NCS (0.683 g, 4.0 mmol) in DMF (15 mL) was heated to 50°C for 18 h. Water (150 mL) was added and the heterogeneous system was filtered. The solid was triturated with CH2Cl2/MeOH (9:1; 20 mL) for 1 h. Filtration and drying in vacuo gave the title compound (0.61 g, 55%): 'H NMR (400 MHz, DMSO-d6) 5 7.6-7.8 (m, 2H), 4.0-5.8 (m, 4H), 3.6-3.7 (s, 3H), 2.8-3.0 (m, 5H); MS (ES) mIt 327.0 (M+H)+ b) Methyl (±)-7-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-9-chloro-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate Following the procedure of Example 8(a), substituting methyl (±)-7-carboxy-9-chloro-4-methyl-3-oxo-2,3,4,5 -tetrahydro-1H-1,4-benzodiazepine-2-acetate for 15 methyl (2S)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate, and substituting 2-aminomethylbenzimidazole dihydrochloride for 4-(l-piperidinyl)piperidine, the title compound (0.68 g, 81%) was prepared. c) (±)-7-[[[(2-Benzimidazolyl)methyl]amino]carbonyl]-9-chloro-4-methyl-3-oxo-20 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid Following the procedure of Example 8(b), methyl (±)-7-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-9-chloro-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate was saponified and purified to give the title compound (0.53 g, 84%): HPLC (5 Altex Ultrasphere ODS, 4.5 rnm x 25 cm, 25 5%-60% CH3CN/H20-0.1% TFA gradient over 20 min) K'=6.5; 'H NMR (400 MHz, DMSO-d6) 8 8.8-9.0 (t, IH), 7.0-8.0 (m, 8H), 3.9-5.7 (m, 6H), 2.9-3.0 (s, 3H), 2.7-2.9 (m, 2H); MS (ES) m/e 442.2 (M+H)+ Anal. Calcd for C2iH2oC1N504 • 1.25 H2O: C, 54.31; H, 4.88; N, 15.08. Found: C, 54.77; H, 4.73; N, 14.68.
Example 11 Preparation of f±)-8-rnY2-Benzimidazolvl)methvIlaminolcarbonvl]-2-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-2-benzazepine-4-acetic acid a) Methyl (±)-8-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-2-methyl-3-oxo-2,3,4,5-tetrahydro-1 H-2-benzazepine-4-acetate 35 To a solution stirred under argon at room temperature of methyl (±)-8- carboxy-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine^-acetate (0.30 g, 1 88 _ WO 96/00730 mmol), 2-aminomethylbenzimidazole dihydrochloride (0.27 g, 1.2 mmol), HOBT • H20 (0.17 g, 1.2 mmol), diisopropylethylamine (0.53 g, 4 mmol), and DMF (5 mL) was added EDC (0.24 g, 1.2 mmol). The resulting mixture was stirred for 18 h, then was concentrated to dryness, and the residue was partitioned between EtOAc and 5 H2O. The organic phase was washed twice with H2O and once with brine, dried (MgS04), and concentrated. The residue was recrystallized from boiling EtOAc to give the title compound (0.16 g, 37%) as a colorless solid: 'H NMR (CDCI3) 8 9.95 (m, IH), 7.86 (d, J=8 Hz, IH), 7.79 (s, IH), 7.52 (m, 2H), 7.28 (m, 2H), 7.07 (d, J=8.1 Hz, IH), 5.16 (d, J=16.4 Hz, 1H),4.82 (m, 2H), 3.78 (m, IH), 3.69 (s, 3H), 10 3.65 (d, J=16.6 Hz, IH), 3.10-2.90 (m 3H), 2.87 (s, 3H), 2.40 (dd, J=16.9, 5.4 Hz, IH). b) (±)-8-[[[(2-Benzimidazolyl)methyl]amino]carbonyl]-2-methyl-3-oxo-2,3,4,5-tetrahydro-1 H-2-benzazepine-4-acetic acid 15 A solution of methyl (±)-8-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-2- methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate (0.10 g, 0.24 mmol), LiOH • H2O (0.013 g, 0.31 mmol), THF (2 mL), and H2O (2 mL) was stirred at RT for 18 h, then was concentrated to dryness. The residue was dissolved in H2O, and the solution was brought to pH 4-5 with 3N HCl. The resulting precipitate was 20 collected by filtration and dried. Recrystallization from boiling isopropanol gave the title compound (0.035 g, 36%) as a colorless solid: *H NMR (DMSO-d6) 8 9.13 (t, J=5.7 Hz, IH), 7.79 (m, IH), 7.48 (m, 2H), 7.23 (d, 1=1.9 Hz, IH), 7.14 (m, 2H), 5.32 (d, J=16.9 Hz, IH), 4.69 (d, J=5.7 Hz, 2H), 4.03 (d, J=16.7 Hz, IH), 3.79 (m, IH), 3.14 (dd, J= 18, 2 Hz, IH), 2.90 (s, 3H), 2.70 (m, 2H), 2.38 (dd, J=11.4, 3 Hz, 25 IH); MS (ES) m/e 407 (M+H)+. Anal. Calcd for C22H22N404 • 1.5 H2O • 0.5 C3HgO: C, 60.90; H, 6.31; N, 12.09. Found: C, 60.68; H, 6.05; N, 12.05.
Example 12 Preparation of (±)-8-[TrN-(2-benzimidazoIvI)methvl-N-methvllamino"|carbonvn-2-30 methvl-3-oxo-2.3.4.5-tetrahvdro-lH-2-benzazepine-4-acetic acid a) Methyl (±)-8-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyl]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benza2epine-4-acetate Following the procedure of Example 11(a), methyl (±)-8-carboxy-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate was coupled with 2-35 (methylamino)methylbenzimidazole. Chromatography on silica gel (5% MeOH/CH2Cl2) gave the title compound (67%) as a colorless foam: 'H NMR 89 (CDCI3) 6 7.62 (m, 2H), 7.30 (m, 4H), 7.16 (d, J=8.3 Hz, IH), 5.31 (d, J=16.4 Hz, IH), 4.92 (d, J=14.5 Hz, IH), 4.87 (d, J=14.5 Hz, IH), 3.88 (m, 2H), 3.71 (s, 3H), 3.02 (s, 3H), 3.16 (s, 3H), 3.15-2.90 (m, 3H), 2.43 (dd, J=16.9, 5.3 Hz, IH). b) (±)-8-[[[N-(2-Benzimidazolyl)methyl-N-methyl]amino]carbonyl]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetic acid Following the procedure of Example 11(b), methyl (±)-8-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyl]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate was saponified. Extraction with CH2CI2, 10 concentration, and drying gave the title compound (52%) as a colorless solid: !H NMR (DMSO-d6) 5 7.59 (m, IH), 7.47 (d, J=8 Hz, IH), 7.35 (m, 2H), 7.15 (m, 3H), 5.25 (d. J=16 Hz, IH), 4.87 (d, J=14 Hz, IH), 4.08 (d, J=16 Hz, IH), 3.78 (m, IH), 3.10 (m, IH), 3.35 (s, 3H), 3.03 (s, 3H), 2.85-2.65 (m, 2H), 2.35 (dd, J=16,5 Hz, IH); MS (ES) m/e 421.2 (M+H)+. Anal. Calcd for C23H24N4O4 • HCl • 1.2 CH2C12 15 • H20: C, 50.82; H, 5.18; N, 9.79. Found: C, 50.96; H, 5.48; N, 9.55.
Example 13 Preparation of (±V7-ITfN-(2-benzimidazolvDmethvl-N-methvnaminolcarbonvn-3-oxo-4-(2-phenvlethvD-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid 20 a) Methyl (±)-7-[[[N-(2-benzimidazolyl)n.ethyl-N-methyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahy dro-1H-1,4-benzodiazepine-2-acetate Following the procedure of Example 11(a), methyl (±)-7-carboxy-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine acetate and 2-(methylamino)methylbenzimidazole were coupled. Chromatography on silica gel 25 (1 %-5% MeOH/CH2Cl2) gave the title compound (57%) as a colorless solid: !H NMR (CDCI3) 8 7.62 (m, 2H), 7.35-7.00 (m, 9H), 6.46 (d, 1=8 Hz, IH), 5.24, (d, J= 16.6 Hz, IH), 5.03 (m, IH), 4.95 (d,J= 14.6 Hz, IH), 4.82 (d,J=14.6Hz, IH), 4.51 (d, J=5 Hz, IH), 3.82 (m, IH), 3.74 (s, 3H), 3.58 (m, 2H), 3.17 (s, 3H), 2.99 (dd, J=16, 6.8 Hz, IH), 2.81 (m, 2H), 2.67 (dd, J=16, 6.3, IH). b) (±)-7-[[[N-(2-Benzimidazolyl)methyl-N-methyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid Methyl (±)-7-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate was 35 saponified according to the procedure of Example 11(b). Recrystallization from boiling isopropanol gave the title compound (57%) as a colorless solid: *H NMR WO 96/00730 PCT/US95/08306 (DMSO-d6) 5 7.58 (m, IH), 7.47 (m, IH), 7.35-7.10 (m. 8H), 6.55 (d, J=8 Hz, IH), 6.23 (m, IH), 5.37 (d, J=16 Hz, IH), 5.05 (m, IH), 4.77 (s, 2H), 3.95 (m, IH), 3.58 (m, 2H), 3.05 (s, 3H), 2.65 (m, 2H), 2.58 (m, IH); MS (ES) m/e 512.2 (M+H)+ Anal. Calcd for C29H29N5O4 • 2H20: C, 63.61; H, 6.07; N, 12.79. Found: C, 5 63.33; H, 6.18; N, 12.58.
Example 14 Preparation of (±V7-fffN-(2-benzimidazolvPmethvl-N-methvnamino1methvl'l-l.4-dimethvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid 10 a) Methyl (±)-l-(tert-butoxycarbonyl)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahy dro-1H-1,4-benzodiazepine-2-acetate A mixture of methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-1,4-benzodiazepine-2-acetate (1 g, 3.42 mmol), di-tert-butyl dicarbonate (1.48 g, 6.8 mmol) and 4-dimethylaminopyridine (42 mg, 0.3 mmol) in anhydrous CH3CN (30 15 mL) was stirred at RT for 3 h. More di-tert-butyl dicarbonate (0.65 g, 3 mmol) was then added to the clear yellow solution and the reaction was stirred at RT for an additional h. The reaction mixture was then quenched with water, the CH3CN was removed in vacuo, and the residue was extracted with EtOAc. The organic layers were washed sequentially with saturated NH4CI and H2O, then were dried (MgS04) 20 and concentrated in vacuo. Silica gel chromatography (7/3 hexane/EtOAc-1% AcOH) gave the title compound (1.05 g, 78%) as a white solid: *H NMR (CDC13, 400 MHz) 6 1.55 (s, 9H), 2.69 (dd, J=16,5 Hz, IH), 2.98 (dd, J=16,5 Hz, IH), 3.10 (s, 3H), 3.65-3.68 (m, IH), 3.72 (s, 3H), 5.16 (dd, J=5,5 Hz, IH), 5.45 (d, J=16.4 Hz, IH), 6.52 (d, J=8.4 Hz, IH), 7.59 (d, J=1.4 Hz, IH), 7.78 (dd, J=8.4, 1.4 25 Hz, IH). b) Methyl (±)-7-formyl-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate Methyl (±)-l-(tert-butoxycarbonyl)-7-carboxy-4-methyl-3-oxo-2,3,4,5-30 tetrahydro-lH-l,4-benzodiazepine-2-acetate (400 mg, 1.02 mmol) was suspended in toluene and SOCI2 (3 mL) was added. The reaction was heated at 80°C for 3 h. The resulting solution was concentrated to dryness to leave a pale yellow solid. The acid chloride thus obtained was then suspended in THF (2 mL), and 2,6-lutidine (109 mg, 1.02 mmol) was added, followed by 10% Pd/C (40 mg). The resulting 35 suspension was stirred under a H2 atmosphere overnight, then was filtered through a short pad of Celite®. The filtrate was diluted with EtOAc and the solution was 91 washed sequentially with 5% HCl and H2O. Drying (MgSC>4) and concentration gave the title compound (139 mg, 60%) as a pale yellow solid, which was used in the next step without further purification: NMR (CDCl3t 400 MHz) 8 2.70 (dd, J=15.6, 6.8 Hz. IH), 3.01 (dd, J=15.6, 6.4 Hz, IH), 3.08 (s, 3H), 3.75-3.82 (m, IH), 5 3.76 (s, 3H), 5.17 (dd, J=6.8,6.4 Hz, IH), 5.47 (d, J=16.4 Hz, IH), 6.59 (d, J=8.4 Hz, IH), 7.50 (s, IH), 7.58 (d, J=8.4 Hz, IH). c) Methyl (±)-7-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]methyl]-l,4-dimethyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate 10 Methyl (±)-7-formyl-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4- benzodiazepine-2-acetate (125 mg, 0.45 mmol) was suspended in anhydrous MeOH, then sodium acetate (111 mg, 1.35 mmol), 2-(aminomethyl)benzimidazole dihydrochloride (100 mg, 0.45 mmol) and 4 A molecular sieves were added. After 30 min., sodium cyanoborohydride (32 mg, 0.49 mmol) was added in 2 portions 15 over a period of 30 min. The reaction mixture was allowed to stir at RT overnight, then the MeOH was removed under vacuum. Formaldehyde (37 wt.% in H2O, 3 mL) was added, followed by CH3CN (3 mL), AcOH, and sodium cyanoborohydride (34 mg, 0.49 mmol). After 40 min. the reaction was concentrated under reduced pressure. The residue was diluted with CH2CI2, and the solution was washed with 20 saturated NaHC03. Drying (MgS04), concentration, and silica gel chromatography (55% CH2Cl2/20% EtOAc/20% hexane/5% MeOH) gave the title compound (55 mg, 29%): NMR (CDCI3,400 MHz) 8 2.33 (s, 3H), 2.63 (dd, J=16.0,5.0 Hz, IH), 2.74 (s, 3H), 3.03 (dd, J=16.0, 8.8 Hz, IH), 3.07 (s, 3H), 3.57 (br s, 2H), 3.68 (s, 3H), 3.87 (br s, 2H), 3.87 (d, J=16.4 Hz, IH), 4.71 (dd, J=8.8 Hz, 5.0, IH), 5.20 25 (d, J=16.4 Hz, IH), 6.94-6.97 (m, 2H), 7.20-7.26 (m, 5H), 7.57 (bs, IH); MS(ES) m/e 436 (M+H)+ d) (±)-7-[[[N-(2-Benzimidazolyl)methyl-N-methyl]amino]methyl]-l,4-dimethyl-3-oxo-2,3,4,5-tetrahydro-IH-1,4-benzodiazepine-2-acetic acid 30 LiOH (5.8 mg, 0.17 mmol) was added at RT to a solution of methyl (±)-7- [ [ [N-(2-benzimidazolyl)methyl-N-methyl]amino] methyl]-1,4-dimethyl-3-oxo-2,3,4,5-tetraliydro-lH-l,4-benzodiazepine-2-acetate (50 mg, 0.115 mmol) in THF (2 mL) and H20(3 mL). The reaction mixture was heated at 50°C for 30 min, then was concentrated in vacuo. The resulting residue was lyophilized to afford a pale yellow 35 solid which was purified by preparative HPLC (11% CH3CN/H2O-0.1 % TFA) to afford the title compound (30 mg, 31%): *H NMR (CD30Dt 400 MHz) 8 2.57 (m, 92 1H), 2.58 (s, 3H), 2.76 (s, 3H), 2.95 (dd, J=16, 8 Hz, IH), 3.04 (s, 3H), 3.93 (d, J= 16.3 Hz, IH), 4.07 (br s, 2H), 4.38 (br s, 2H), 4.67 (dd, J=8.4, 7.0 Hz, IH), 5.18 (d, J= 16.3 Hz, IH), 6.91 (d, J=8.4 Hz, IH), 7.12 (s, IH), 7.26 (d, J=8.4 Hz, IH), 7.42 (m, 2H), 7.64 (m, 2H); MS(ES) m/e 422 .
(M+H)+. Anal. Calcd. for C25H27N5O3 • 3.5 CF3C02H: C, 42.51; H, 3.98; N, 8.26. Found: C, 42.58; H, 4.27; N, 7.89.
Example 15 Preparation of f±)-7-rrrN-f2-benzimidazolvl)methvl-N-methvnaminolcarbonvn-4-10 methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid a) 2-(Methylaminomethyl)benzimidazole dihydrochloride Methylamine (5.0 g, 0.16 mole) was dissolved in a solution of Et20 (100 mL) and EtOH (5 mL) at 0°C, and 2-chloromethylbenzimidazole (13.4 g, 0.08 mole) was added in small portions. The reaction mixture was stirred at RT for 3 h, then 15 was allowed to stand at RT overnight. More Et20 (200 mL) was added, and the reaction was cooled in an ice bath for 3 h before filtering off the precipitate. The filtrate was saturated with HCl and filtered, and the filtrate was concentrated. Silica gel chromatography (step gradient, 10-25% MeOH/CH2Cl2) yielded the title compound (2.5 g, 13%): >H NMR (250 MHz, 5:1 DMSO-d6/CDCl3) 6 7.13-7.54 20 (m, 4H), 4.11 (s, 2H), 2.50 (s, 3H); MS (ES) m/e 162.0 (M+H)+. b) Methyl (±)-7-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyl}-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate Following the procedure of Example 1(a), except substituting 2-25 (methylamino methyl)benzimidazole dihydrochloride (1.2 g, 5.13 mmol) for the 2-(aminomethyl) benzimidazole dihydrochloride, the crude title compound was prepared. Silica gel chromatography (10% MeOH/CH2Cl2) yielded the title compound (0.29 g, 39%) as an off-white solid: ]H NMR (250 MHz, CDCI3) 8 6.44-7.62 (m, 9H), 5.41 (d, J=16.2 Hz, IH), 5.07 (m, IH), 4.81 (m, 2H), 4.52 (d, J=5.2 30 Hz, 2H), 3.73 (s, 3H), 3.68 (d, J=16.6 Hz, IH), 3.04 (s, 3H), 2.96 (s, 3H), 2.93 (dd, J=17.1, 6.5 Hz, IH), 2.67 (dd, J=17.1, 6.3 Hz, IH); MS (ES) m/e 436.2 (M+H)+. c) (±)-7-[[[N-(2-Benzimidazolyl)methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid Following the procedure of Example 1(b), the compound of Example 15(b) was saponified and purified to give the title compound (0.21 g, 80%): MS (ES) m/e PCTAJS95/08306 422.2 (M+H)+ Anal. Calcd for C22H23N5O4 • 4/3 CF3C02H • H20: C, 47.93; H, 4.22; N, 10.96. Found: C, 47.88; H, 4.35; N, 10.96.
Example 16 Preparation of (±)-7-rff2-(2-benzimidazolvl)ethv]laminolcarbonvn-4-methvl-3-oxo-2.3,4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid a) 2-Aminoethylbenzimidazole diacetate A mixture containing 2-cyanomethylbenzimidazole (2.0 g, 12.7 mmol), 10% Pd/C (1.0 g), and AcOH ( 40 mL) was hydrogenated at 42 psi for 6 h in a Parr 0 apparatus. The reaction mixture was filtered through a bed of Celite® and concentrated to give the title compound (3.4 g, 95%); *H NMR (250 MHz, CDCI3) 5 7.04-8.13 (m, 7H), 3.17-3.39 (m, 4H); MS (ES) m/e 162.0 (M+H)+ b) Methyl (±)-7-[[[2-(2-benzimidazolyl)ethyl]amino]carbonyl]-4-methyl-3-oxo-5 2,3,4,5-tetrahydro- 1H-1,4-benzodiazepine-2-acetate Following the procedure of Example 1(a), except substituting 2-aminoethyl benzimidazole diacetate (1.44 g, 5.13 mmol) for the 2-(aminomethyl)benzimidazole dihydrochloride, the crude title compound was prepared. Silica gel chromatography (9% MeOH/CH2Cl2) yielded the title compound (0.64 g, 86%) as an off-white solid: 0 lH NMR (250 MHz, CDCI3) 8 6.20-8.23 (m, 9H), 5.50 (d, J=16.2 Hz, IH), 5.11 (m, IH), 3.70-3.81 (m, 3H), 3.64 (s, 3H), 3.11 (t, J=7.2 Hz, 2H), 2.98 (s, 3H), 2.86 (dd, J=16.8, 8.0 Hz, IH), 2.63 (dd, J=16.8,5.0 Hz, IH); MS (ES) m/e 436.2 (M+H)+. c) (±)-7-[[[2-(2-Benzimidazolyl)ethyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-5 tetrahydro-lH-l,4-benzodiazepine-2-acetic acid Following the procedure of Example 1(b), the compound of Example 16(b) was saponified and purified to give the title compound (7.8 mg, 10%): MS (ES) m/e 422.0 (M+H)+ Anal. Calcd for C22H23N5O4 ■ 2 CF3CO2H • 2.5 H20: C, 44.96; H, 4.35; N, 10.08. Found: C, 44.79; H, 4.21; N, 10.08. 0 Example 17 Preparation of f±)-7-rf(2-benzimidazolvl)aminolcarbonvll-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid 94 WO 96/00730 PCT/US95/08306 a) Methyl (±)-7-[[(2-benzimidazolyl)amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Following the procedure of Example 1(a), except substituting 2-amino benzimidazole (0.68 g, 5.13 mmol) for the 2-(aminomethyl)benzimidazole 5 dihydrochloride, the crude title compound was prepared. Silica gel chromatography (7% MeOH/CH2Cl2) yielded the title compound (0.48 g, 69%) as an off-white solid: •H NMR (250 MHz, CDC13) 5 6.50-8.16 (m, 9H), 5.47 (d, J=16.3 Hz, IH), 5.24 (m, IH), 3.82 (d, J=4.5 Hz, IH), 3.65 (s, 3H), 2.60-3.01 (m, 6H); MS (ES) m/e 408.2 (M+H)+ b) (±)-7-[[(2-Benzimidazolyl)amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid Following the procedure of Example 1(b), the compound of Example 32(a) was saponified and purified to give the title compound (50 mg, 55%): MS (ES) m/e 15 394.2 (M+H)+ Anal. Calcd for C20H19N5O4 • 4/3 CF3C02H: C, 49.91; H, 3.76; N, 12.84. Found: C, 49.92; H, 3.83; N, 12.93.
Example 18 Preparation of (2S)-7-rf[N-(2-benzimidazolvl)methvl-N-methvl1amino1carbonvn-4-20 methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid a) Methyl (2S)-7-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyl]-4-methy 1 -3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Diisopropylethylamine (0.29 g, 2.25 mmol) was added in one portion to a stirred mixture of 2-(methylaminomethyl)benzimidazole bis(trifluoroacetate) (1.8 25 mmol), methyl (2S)-7-carboxy~4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (0.44 g, 1.50 mmol), EDC (0.34 g, 1.8 mmol) and HOBTH2O (0.24 g, 1.8 mmol) in DMF (8 mL) at RT under argon. After 24 h, the solution was poured into a mixture of ice-water (90 g) and 5% NaHC03 (10 mL). The resulting precipitate was filtered and air-dried. Flash chromatography (silica 30 gel, MeOH/CH2Cl2) yielded the title compound (79%): !H NMR (400 MHz, CDCI3) 8 6.51-7.60 (m, 9H), 5.41 (d, J=16.4 Hz, IH), 5.07 (m, IH), 4.82 (t, J=15.0 Hz, 2H), 4.50 (d, J=4.8 Hz, IH), 3.74 (s, 3H), 3.68 (d, J=16.6 Hz, IH), 3.15 (s, 3H), 2.96 (s, 3H), 2.93 (dd, J=17.1,6.5 Hz, IH), 2.67 (dd, J=16.1 6.5 Hz, IH.); MS (ES) m/e 436.2 (M+H)+. 95 b) (2S)-7-[[[N-(2-Benzimidazolyl)methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid Following the procedure of Example 1(b), the compound of Example 18(a) was saponified and purified to give the title compound (0.11 g, 91%): MS (ESMS) 5 m/e 422.2 (M+H)+. Anal. Calcd for C22H23N5O4 • 3 H2O: C, 55.57; H, 6.15; N, 14.73. Found: C, 55.30; H, 6.13; N, 14.39.
Example 19 Preparation of (±V4-Methvl-7-lTrN-f2-n-methvl)benzimidazolvl)methvl-N-10 methvllaminol carbonvn-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid a) 2-^N-(tert-Butoxycarbonyl)-N-methyl]aminomethyl]benzimidazole Di-tert-butyl dicarbonate (1.12 g, 5.13 mmol) was added dropwise at 0°C to a mixture containing 2-(methylaminomethyl)benzimidazole dihydrochoride (1.0 g, 15 4.27 mmol), dioxane (25 mL), H2O (25 mL), and 1 N NaOH (12.8 mL, 12.8 mmol). After 2 h, the reaction was warmed to RT and stirred for 21 h. The solvent was evaporated on the rotavap, and the pH was adjusted to 5 using 1 M NaHS04. The mixture was extracted with CH2CI2 (2x80 mL), and the combined organic layers were washed with brine (30 mL) and dried (MgS04). Concentration gave the title 20 product (0.7 g, 64%): *H NMR (400 MHz, CDCI3) 6 7.59 (b, 2H), 7.26 (m, 3H), 4.57 (s, 2H), 2.98 (s, 3H), 1.50 (s, 9H); MS (ES) m/e 262.0 (M+H)+. b) l-Methyl-2-[[N-(tert-butoxycarbonyl)-N-meihyl]aminomethyl]benzimidazole A mixture of 2-[[N-(tert-butoxycarbonyl)-N-25 methyl]aminomethyl]benzimidazole (0.51 g, 1.95 mmol), NaH (0.12 g, 5.0 mmol), DMF (5 mL), and THF (20 mL) was stirred at RT under argon for 5 min, then methyl iodide (0.83 g, 5.86 mmol) was added. The reaction mixture was stirred at RT for 170 min, then was concentrated on the rotavap. The residue was diluted with CH2CI2 (100 mL), and the mixture was washed sequentially with H2O (30 mL), 5% 30 NaHC03 (30 mL), and brine (30 mL). Drying (Na2S04) and concentration gave the title compound (0.51,94%): *H NMR (250 MHz, CDCI3) 8 7.23-7.77 (m, 4H), 4.79 (s, 2H), 3.82 (s, 3H), 2.86 (s, 3H), 1.50 (s, 9H); MS (ES) m/e 276.2 (M+H)+. c) l-Methyl-2-(methylaminomethyl)benzimidazole bis(trifluoroacetate) A mixture of l-methyl-2-[[N-(tert-butoxycarbonyl)-N-methyl]aminomethyl] benzimidazole (0.51 g, 1.85 mmol) in 25% TFA/CH2CI2 (20 mL) was stirred at RT 96 WO 96/00730 PCTYUS95/08306 under argon for 20 min. The solvent was removed on the rotavap and the residue was recrystallized from Et20/CH2Cl2 to give title compound (0.69 g, 92%): 'H NMR (250 MHz, 5:1 CDCl3:DMSO-d6) 8 7.24-7.68 (m, 4H), 4.56 (s, 2H), 3.84 (s, 3H), 2.84 (s, 3H); MS (ES) m/e 176.0 (M+H)+ d) Methyl (±)-4-methyl-7-[[[N-(2-( 1 -methyl)benzimidazolyl)methyl-N-methyl]amino] carbonyl]-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate Following the procedure of Example 18(a), except substituting l-Methyl-2-(methylaminomethyl)benzimidazole bis(trifluoroacetate) for 2,6-diaminopyridine, 10 the title compound (0.53 g, 777o) was prepared: JH NMR (250 MHz, CDCI3) 8 6.50-7.80 (m, 9H), 5.43 (d, J=16.4 Hz, IH), 5.03-5.10 (m, 3H), 4.42 (d, J=4.7 Hz, IH), 3.88 (s, 3H), 3.74 (s, 3H), 3.68 (d, J=16.6 Hz, IH), 3.13 (s, 3H), 3.06 (s, 3H), 2.99 (dd, J=16.2, 6.7 Hz, IH), 2.66 (dd, J=16.2, 6.5 Hz, IH); MS (ES) m/e 450.2 (M+H)+ e) (±)-4-Methyl-7-[[[N-(2-(l-methyl)benzimidazolyl)methyl-N-methyl]amino] carbonyl]-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid Following the procedure of Example 1(b), the compound of Example 19(d) was saponified and purified to give the title compound (0.13 g, 60%): MS (ES) m/e 20 436.2 (M+H)+ Anal. Calcd for C23H25N5O4 • 1.5 H20: C, 59.73; H, 6.10; N, 15.14. Found: C, 59.39; H, 6.05; N, 14.96.
Example 20 Preparation of (±)-7-nT(2-(5(6)-methoxv)benzimidazolvl)methvnamino1carbonvn-4-25 methvl -3-oxo-2.3.4,5-letrahvdro-1H-1.4-benzodiazepine-2-acetic acid a) N-[N-(Benzyloxycarbonyl)glycyl]-4-methoxy-2-nitroaniline N-(Benzyloxycarbonyl)glycine (2.72 g, 13.13 mmol) was dissolved in CH2CI2 and an excess of thionyl chloride at room temperature. After 2 h, the reaction was evaporated under vacuum and the residue was stripped with toluene 30 twice and dried under vacuum. The white solid was taken into CH2CI2 and 4-methoxy-2-nitroaniline (2.1819 g, 12.98 mmol) was added as a solid, followed by triethylamine (2.0 mL, 1.455 g, 14.38 mmol). The reaction was stirred at RT for 24 h, then was evaporated under vacuum. The residue was dissolved in EtOAc and washed with aqueous IN NaHC03. The EtOAc layer was dried (MgS04) and 35 concentrated under vacuum. Thin layer.chromatography analysis (1:1:1 hexanes/Et20/CH2Cl2) showed good conversion to the acylated material. The crude 97 WO 96/00730 PCT/US95/08306 material was dissolved in 2:1:1 hexanes/Et20/CH2Cl2 initially, with the addition of enough Et20/CH2C12 and sonication/heating to dissolve all the solid material. Silica gel chromatography (2:1:1 hexanes/Et20/CH2Cl2 (2 L), then 1:1:1 hexanes/Et20/CH2Cl2 (1.5 L), then Et20/CH2C12) gave the title compound (3.3387 5 g, 72%): "H NMR (250 MHz, CDC13) 5 3.85 (s, 3H), 4.06 (d, 2H), 5.18 (s, 2H), 5.61 (t, IH), 7.2-7.4 (m, 6H),7.65 (d, IH), 8.63 (d, IH). b) 2-[N-[(Benzyloxycarbonyl)amino]methyl]-5(6)-methoxybenzimidazole N-[N-(Benzyloxycarbonyl)glycyl]-4-methoxy-2-nitroaniline (1.0 g, 2.87 10 mmol) was dissolved in glacial acetic acid, and iron powder was added. The mixture was heated in an oil bath at about 65 °C with stirring. After 24 h, the reaction was evaporated under vacuum. The residue was evaporated with toluene, dried under vacuum, and adsorbed onto silica gel. Chromatography on a dry silica gel column (1:1 Et20/CH2C12 (1.5 L) followed by 5% MeOH/CH2Cl2) gave the title 15 compound (1.0063 g, 94% ): »H NMR (250 MHz, CDC13) 5 3.78 (s, 3H), 4.57 (s, 2H), 5.05 (s, 2H), 6.8-7.5 (m, 8H), 10.85 (br. s., IH); MS (ES) m/e 312.0 (M+H)+. c) 2-(Aminomethyl)-5(6)-methoxybenzimidazole 2-[N-[(Benzyloxycarbonyl)amino]methyl]-5(6)-methoxybenzimidazole 20 (1.0063 g, 3.23 mmol) was dissolved in MeOH, and 10% Pd/C was added. The reaction was stirred at RT under H2 (balloon pressure) for 17 h, then was filtered through a bed of Celite®. The filtrate was evaporated under vacuum to yield the title compound (411.7 mg, 72%) as an oil: 'H NMR (250 MHz, CDCI3) 8 3.75 (s, 3H), 4.05 (s, 2H), 5.59 (br s, 2H), 6.82 (dd, IH), 6.97 (d, IH), 7.40 (d, IH). d) Methyl (±)-7-[[[(2-(5(6)-methoxy)benzimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate Methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l ,4-benzodiazepine-2-acetate (245.4 mg, 0.84 mmol) was dissolved in DMF. A solution 30 of EDC (169.3 mg, 0.88 mmol) in DMF was added, followed by HOBT • H2O (112.1 mg, 0.83 mmol). A solution of 2-(Aminomethyl)-5(6)-methoxybenzimidazole (1.434 mg, 0.81 mmol) in DMF was then added, followed by diisopropylethylamine (0.2 mL, 1.44 mmol). The reaction was stirred at RT for 5 d, then was concentrated under vacuum. The residue was evaporated once with 35 toluene. The crude material was partitioned between H2O and EtOAc. The aqueous phase was back-extracted with EtOAc, and the combined organic layers were dried 98 WO 96/00730 PCT/US95/08306 (MgS04) and concentrated. TLC (10% MeOH/CHCl3) showed two major products. Silica gel chromatography (CHCI3 (0.25 L), then 3% MeOH/CHCl3) gave three fractions; fraction 3 gave the title compound (112.9 mg, 31%): 'H NMR (250 MHz, CD3OD) 5 3.06 (s, 3H), 3.70 (s, 3H), 3.80 (s, 3H), 4.74 (s, 2H), 5.28 (t, IH), 5.51 (d, 5 IH), 6.58 (d, IH), 6.85 (d, IH), 7.00 (s, IH), 7.48 (d, IH), 7.5-7.65 (m, 2H); MS (ES) m/e 452.2 (M+H)+. e) (±)-7-[[[(2-(5(6)-Methoxy)benzimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid 10 Methyl (±)-7-[[[(2-(5(6)-methoxy)benzimidazolyl)methyl]amino]carbonyl]- 4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (112.9 mg, 0.25 mmol) was dissolved in MeOH, and aqueous IN sodium hydroxide (0.5 mL, 0.5 mmol) was added. The reaction was stirred at RT for two d, then was warmed in an oil bath at about 65 °C. The solution was concentrated and the residue was 15 redissolved in aqueous MeOH. The solution was neutralized with aqueous IN hydrochloric acid (0.5 mL, 0.5 mmol) and the mixture was evaporated under vacuum to remove most of the MeOH. The precipitate which formed was collected on a sintered glass funnel and dried under high vacuum to afford the title compound (103.1 mg, 94%): TLC (3:1:1 n-BuOH/AcOH/H20) Rf* 0.62; MS (ES) m/e 438.2 20 (M+H)+ Anal Calcd for C22H23N505 • 2 H20: C, 55.81; H, 5.75; N, 14.70.
Found: C, 55.69; H, 5.59; N, 14.41.
Example 21 Preparation of (±)-7-ITfN-r2-(4-azabenzimidazolvinmethvl-N-25 methvllaminolcarbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid a) 2-Amino-3-[[N-(benzyloxycarbonyl)sarcosyl]amino]pyridine N-(Benzyloxycarbonyl)sarcosine (4.1 g, 18.5 mmol) was dissolved in dry THF, and triethylamine (3 mL, 21.6 mmol) was added, followed by 30 isobutylchloroformate (2.5 mL, 19.27 mmol). The solution was cooled to about -20°C for 15 minutes, then a solution of 2,3-diaminopyridine (2.0767 g, 19.03 mmol) in dry THF was added slowly. The reaction was kept stirring between -10°C to -20°C for 15 minutes, then was allowed to warm to RT. After 3 d, the reaction was evaporated under vacuum, and the residue was partitioned between EtOAc and IN 35 NaHC03. The EtOAc phase was dried .(MgS04) and evaporated under vacuum. The residue was dissolved in glacial AcOH and was stirred in a oil bath at 70 °C. 99 WO 96/00730 PCT/US95/08306 After 24 h, the reaction was removed from the oil bath, allowed to cool to RT, and concentrated under vacuum. The residue was evaporated with toluene, then was chromatographed on silica gel (CHCI3, then 3% MeOH/CHCl3 , then 5% MeOH/CHCl3) 10 afford the title compound (1.13 g, 19%): 'H NMR (250 MHz, 5 CDCI3) 6 3.05 (s, 3H), 3.99 (s, 2H), 4.82 (br s, IH), 6.5-6.65 (m, IH), 7.32 (s, 5H), 7.87 (d, IH), 8.84 (brs, IH); MS (ES) m/e 315.4 (M+H)+. b) 2-[[N-(Benzyloxycarbonyl)-N-methylamino]methyl]-4-azabenzimidazole 2-Amino-3-[[N-(benzyloxycarbonyl)sarcosyl]amino]pyridine (513 mg, 1.63 10 mmol) was taken up in glacial AcOH (25 mL) and the reaction was heated in an oil bath set at 100-105°C. After 24 h, the reaction was evaporated under vacuum and the residue was concentrated from toluene. Silica gel chromatography (CHCI3, then 2% MeOH/CHCl3 , then 4% MeOH/CHCl3) gave the title compound (385 mg, 80%): >H NMR (250 MHz, CDC13) 5 3.07 (s. 3H), 4.83 (s, 2H), 5.17 (s, 2H), 7.1-15 7.4 (m, 6H), 8.03 (d, IH), 8.46 (d, IH); MS (ES) m/e 297.2 (M+H)+ c) 2-(Methylamino)methyl-4-azabenzimidazole 2-[[N-(Benzyloxycarbonyl)-N-methylamino]methyl]-4-azabenzimidazole (385.5 mg, 1.30 mmol) was dissolved in MeOH, and 10% Pd/C was added. The 20 mixture was stirred at RT under H2 (balloon pressure) for 4 h, then the catalyst was removed by filtration through a bed of Celite®. The clear, colorless filtrate was evaporated under vacuum to afford the title compound (237.0 mg, 100%): 'H NMR (250 MHz, CDCI3/CD3OD) 8 2.48 (s, 3H), 4.06 (s, 2H), 5.38 (br s, IH), 7.15-8.35 (m, 4H). d) Methyl (±)-7-[[[N-[2-(4-azabenzimidazolyl)]methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate EDC (263.1 mg, 1.37 mmol) was added to a suspension of methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (392.2 30 mg, 1.34 mmol) and HOBT • H20 (195.5 mg, 1.45 mmol) in DMF in a dried 100 mL round-bottomed flask. The white suspension slowly dissolved to afford a clear, colorless solution. A solution of 2-(methylamino)methyl-4-azabenzimidazole (237.0 mg, 1.3 mmol) in DMF and added, followed by diisopropylethylamine (0.3 mL, 1.72 mmol). The reaction was stirred at RT for 4 d, then was evaporated under high 35 vacuum. The residue was concentrated from toluene and was chromatographed on silica gel (CHCI3, then 5% MeOH/CHCl3, then 10% MeOH/CHCl3) to afford the 100 PCTAJS95/08306 title compound (183.3 mg, 32%): 'H NMR (250 MHz, CDCI3/CD3OD) 8 3.04 (s, 3H), 3.17 (s, 3H), 3.72 (s, 3H),4.13 (s, 2H), 5.13 (dd, IH), 5.49 (d, IH), 6.54 (d, IH), 7.2-7.5 (m, 5H), 8.37 (br s, IH); MS(ES) m/e 437.2 (M+H)+. e) (±)-7-[[[N-[2-(4-azabenzimidazolyl)]methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid Methyl (±)-7-[[[N-[2-(4-azabenzimidazolyl)]methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (183 mg, 0.42 mmol) was dissolved in MeOH, and IN sodium hydroxide 10 (1.5 mL, 1.5 mmol) was added. The reaction was stirred at RT until complete by TLC, then was neutralized with IN HCl (1.5 mL, 1.5 mmol). The reaction was evaporated under vacuum, and the residue was partially dissolved in MeOH and precipitated with H2O. The mixture was evaporated under vacuum to remove most of the MeOH, and the resulting aqueous suspension was allowed to stand at RT for 15 about 1 h before being filtered on a sintered glass funnel. The isolated material was dried in a vacuum dessicator under high vacuum to afford the title compound (154.5 mg): MS(ES) m/e 423.2 (M+H)+. Anal. Calcd for C2|H22N604 • 2.75 H20: C, 53.44; H, 5.87; N, 17.81. Found: C, 53.52; H, 5.62; N, 17.23.
Example 22 Preparation of (±)-7-nTN-r2-f5(6)-Azabenzimidazolvl)1methvl-N-methvnamino1 carbonvll-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid a) 2-[[N-(Benzyloxycarbonyl)-N-methylamino]methyl]-5(6)-azabenzimidazole N-(Benzyloxycarbonyl)sarcosine (4.07 g, 18.24 mmol) was dissolved in diy 25 THF, and triethylamine (3.0 mL, 21.57 mmol) was added, followed by isobutylchloroformate (2.5 mL, 19.27 mmol). The white mixture was cooled in an acetone/dry ice bath to about -20 °C. After 20 minutes, a solution of 3,4-diaminopyridine (2.0319 g, 18.62 mmol) in THF was added. The yellow solution was kept stirring at -10 to -20°C for 15 min, then was allowed to warm slowly to 30 RT. After 3 d, the reaction was evaporated under vacuum, and the residue was partitioned between EtOAc and 1.0 N NaHC03- The combined EtOAc layers were dried (MgS04) and concentrated. The clear, slightly tan colored residue was dissolved in glacial AcOH, and the solution was stirred in an oil bath at 70°C. After 24 h, the reaction was allowed to cool to RT and was concentrated. The residue was 35 concentrated from toluene, then was chromatographed on silica gel (CHCI3, then 2% MeOH/CHCl3, then 4% MeOH/CHCb). Two fractions were collected. Fraction 1 101 WO 96/00730 PCT7US95/08306 (530 mg, 5.5%) appeared to be the diacylated material (MS(ES) m/e 520.2 (M+H)+). Fraction 2 contained the title compound (761 mg, 14%): 'H NMR (250 MHz, CDC13) 5 3.07 (s, 3H), 4.77 (s. 2H), 5.07 (s, 2H), 7.2-7.3 (m, 5H), 7.44 (d, IH), 8.34 (d, IH). 8.95 (s, IH); MS (ES) m/e 297.2 (M+H)+. b) 2-(Methylamino)methyl-5(6)-azabenzimidazole 2-[[N-(BenzyloxycarbonyI)-N-methylamino]methyl]-5(6)-azabenzimidazole (685.5 mg, 2.31 mmol) was dissolved in MeOH, and 10% Pd/C was added. The mixture was stirred briskly at RT under H2 (balloon pressure) for 4 h, then was 10 filtered through Celite® to remove the catalyst. A clear, colorless filtrate was evaporated under vacuum to leave the title product (381 mg, 100%). c) Methyl (±)-7-[[[N-[2-(5(6)-azabenzimidazolyl)]methyl-N-methyl]amino] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate EDC (263.1 mg, 1.37 mmol) was added to a suspension of methyl (±)-7- carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-1,4-benzodiazepine-2-acetate (697.3 mg, 2.39 mmol) and HOBT • H20 (345.5 mg, 2.56 mmol) in DMF in a dried }00 mL round-bottomed flask. The white suspension began to dissolve. Afte jut 15 minutes, a solution of 2-(methyIamino)methyl-5(6)-azabenzimidazole (3oo.fj mg, 20 2.35 mmol) in DMF was added. The reaction was stirred at RT for 20 h, then was concentrated under vacuum. Silica gel chromatography (CHCI3, then 5% MeOH/CHCl3, then 10% MeOH/CHCl3) gave the title compound (679 mg, 66%): 'H NMR (250 MHz, CDCI3) 8 3.00 (s, 3H), 3.12 (s, 3H), 3.48 (s, 3H), 3.66 (s, 3H), 5.07 (m, IH), 5.40 (d, IH), 6.35 (br s , IH), 7.05 (br s , IH), 7.12 (s, IH), 7.47 (d, 25 IH), 8.36 (d, IH), 8.94 (s, IH). d) (±)-7-[[[N-[2-(5(6)-Azabenzimidazolyl)]methyl-N-methyl]amino] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid Methyl (±)-7-[[[N-[2-(5(6)-azabenzimidazolyl)]methyl-N-methyl]amino] 30 carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (679.0 mg, 1.56 mmol) was dissolved in MeOH, and IN NaOH (3.0 mL, 3.0 mmol) was added. A clear, yellow solution formed almost immediately. The reaction was stirred at RT for 24 h, then was neutralized with IN aqueous HCl (3.0 mL, 3.0 mmol). The reaction was concentrated and the residue was suspended in H20. The 35 mixture was sonicated, and the colorless precipitate was collected and dried in a vacuum dessicator to leave the title compound (471 mg, 71%): MS (ES) m/e 423.2 102 (M+H)+. Anal. Calcd for C21H22N6O4 • 2.25 H20: C, 54.48; H, 5.77; N, 18.15. Found: C, 54.67; H, 5.58; N, 17.64.
Example 23 Preparation of (±V7-rrf(2-imidazolvDmethvl1aminolcarbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetate a) Methyl (±)-7-[[[(2-imidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate A mixture of methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-10 1,4-benzodiazepine-2-acetate (584 mg, 2.0 mmol), 2-(aminomethyl)imidazole (2.2 mmol, prepared according to Annaleti 1968, 718,249), H0BT-H20 (270 mg, 2 mmol), triethylamine (1.0 mL, 7.2 mmol), and EDC (383 mg, 2 mmol) in anhydrous DMF (40 mL) was stirred at RT overnight. The reaction was concentrated in vacuum, and the resulting residue was diluted with 5% K2CO3. CH2CI2 extraction, 15 drying (MgS04), and concentration gave Ihe title compound (0.76 g, 86%); MS (ES) m/e 372 (M+H)+ b) (±)-7-[[[(2-Imidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid 20 The compound of Example 23(a) (0.7 g, 1.6 mmol) was suspended in MeOH (10 mL) and THF (5 mL), and 1.0 N NaOH (6 mL) was added. The reaction was stirred at RT for 2 d, then was concentrated in vacuum. The residue was diluted with H2O, and the pH was adjusted to 5 to 6 with 1.5 N HCl. Lyophilization gave the title compound: MS (ES) m/e 358 (M+H)+. Anal. Calcd for C17H19N5O4 • 1.75 25 CF3C02H: C, 44.21; H, 3.75; N, 12.57. Found: C, 44.21; H, 3.96; N, 12.54.
Example 24 Preparation of (±)-7-rrr2-(benzimidazolvl)methvllmethvlaminolcarbonvll-4-(2-methoxvethvD-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid 30 a) Methyl (±)-7-[[[2-(benzimidazolyl)methyI]methylamino]carbonyl]-4-(2-methoxyethyl)-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate EDC (138 mg, 0.72 mmol) was added to a solution of methyl (±)-7-carboxy-4-(2-methoxyethyl)-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetate (202 mg, 0.6 mmol), 2-(methylaminomethyl)benzimidazole dihydrochloride (0.72 mmol), 35 HOBt • H2O (97 mg, 0.72 mmol), and diisopropylethylamine (0.42 mL, 2.4 mmol) in anhydrous DMF (3 mL) at RT. The reaction was stirred at RT for 22.5 h, then was concentrated on the rotavap. The residue was reconcentrated from xylenes (to remove DMF), then was diluted with H20 (2 mL). CHCI3 extraction, drying (MgS04), concentration, and chromatography on silica gel (5% MeOH/CHCl3) gave the title compound (265.7 mg, 92%) as an off-white solid: TLC Rf (5% 5 MeOH/CHCl3) 0.39; >H NMR (400 MHz, CDCI3) 5 7.68-7.82 (m, IH), 7.37-7.51 (m, IH), 7.15-7.35 (m, 4H), 6.45-6.57 (m, 1H),5.38 (d, J=16.5 Hz, IH), 5.04-5.14 (m, IH), 4.82 (1/2 AB, J=14.6 Hz, IH), 4.74 (1/2 AB, J=14.6 Hz, IH), 4.53 (d, J=5.0 Hz, IH), 3.99 (d, J=16.5 Hz, IH), 3.74 (s, 3H), 3.65-3.83 (m, IH), 3.37-3.61 (m, 3H), 3.22 (s, 3H), 3.15 (s, 3H), 2.98 (dd, J=16.0,6.2 Hz, IH), 2.68 (dd, J=16.0, 10 6.7 Hz, IH); MS (ES) m/e 480.2 (M+H)+, 319.0 (M+H - 161)+ b) (±)-7-[[[2-(Benzimidazolyl)methyl]methylamino]carbonyl]-4-(2-methoxyethyl)-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid 1.0 N LiOH (0.66 mL, 0.66 mmol) was added to a solution of methyl (±)-7-15 [[ [2-(benzimidazolyl)methyl]methylamino]carbonyl]-4-(2-methoxyethyl)-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (265.7 mg, 0.55 mmol) in THF (2.8 mL) and H2O (2.1 mL) at RT. The light yellow solution was stirred at RT for 17 h, then was concentrated to dryness on the rotavap. The residue was dissolved in H2O (2 mL), and the solution was neutralized with 1.0 N HCl (0.66 mL). The solid 20 precipitate was collected by suction filtration and recrystallized from H2O/CH3CN to afford the title compound (147.0 mg, 55%): HPLC (PRP-1®, 15% CH3CN/H20-0.1% TFA) K'=4.3; lH NMR (400 MHz, DMSO-d6) 6 7.59 (d, J=7.6 Hz, IH), 7.47 (d, J=7.1 Hz, IH), 7.08-7.25 (m, 4H), 6.53 (d, J=8.2 Hz, IH), 6.13-6.26 (m, IH), 5.42 (d, J=16.3 Hz, IH), 5.00-5.12 (m, IH), 4.70-4.86 (m, 2H), 3.88-4.03 (m, IH), 25 3.44-3.60 (m, 2H), 3.22-3.40 (m, 2H), 3.33 (s, 3H), 3.08 (s, 3H), 2.76 (dd, J=16.7, 8.8 Hz, IH), 2.53 (dd, J= 16.7, 5.1 Hz, 1 H, partially obscured by residual solvent signal); MS (ES) 466.2 (M+H)+, 305.0 (M+H - 161)+. Anal. Calcd for C24H27N5O5 • H?0: C, 59.62; H, 6.04; N, 14.48. Found: C, 59.62; H, 6.18; N, 14.46.
Example 25 Preparation of (±)-7-ITr2-(4-AzabenzimidazolvOmethvnmethvlamino'lcarbonvn-4-(2-methoxvethvl)-3-oxo-2.3,4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid 104 "WO 96/00730 a) Methyl (±)-7-[[[2-(4-azabenzimidazolyl)methyl]methylamino]carbonyl]-4-(2-methoxyethyl)-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate EDC (115 mg, 0.60 mmol) was added to a solution of methyl (±)-7-carboxy-4-(2-methoxyethyl)-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate 5 (168.2 mg, 0.50 mmol), 4-aza-2-(methylaminomethyl)benzimiuazole (0.62 mmol), HOBt • H20 (81 mg, 0.60 mmol), and diisopropylethylamine (0.17 mL, 1.0 mmol) in anhydrous DMF (2.5 mL) at RT. The reaction was stirred at RT for 20 h, then was concentrated on the rotavap, and the residue was diluted with H20 (2 mL). CHCI3 extraction (3x5 mL), drying (MgS04), concentration, and reconcentration 10 from xylenes (to remove DMF) left a light yellow oil. Chromatography on silica gel (10% MeOH/CHCl3) gave the title compound (225.4 mg, 94%) as a colorless foam: TLC Rf (10% MeOH/CHCl3) 0.39; JH NMR (400 MHz, CDCI3) two components; data for the major component only. 6 8.37-8.47 (m, IH), 7.98-8.06 (m, IH), 7.17-7.37 (m, 3H), 6.43-6.57 (m, IH), 5.38 (d, J=16.6 Hz, IH), 5.04-5.13 (m, IH), 4.85 15 (1/2 AB, J=14.7 Hz, IH), 4.78 (1/2 AB, J=14.7 Hz, IH), 4.53 (d, J=4.9 Hz, IH), 4.00 (d, J=16.6 Hz, IH), 3.74 (s, 3H), 3.65-3.81 (m, IH), 3.35-3.61 (m, 3H), 3.23 (s, 3H), 3.16 (s, 3H), 2.98 (dd, J=15.9, 6.2 Hz, IH), 2.68 (dd, J=15.9, 6.7 Hz, IH); MS (ES) m/e 503.2 (M+Na)+, 481.2 (M+H)+, 319.0 (M+H - 162)+ b) (±)-7-[[[2-(4-Azabenzimidazolyl)methyl]methylamino]carbonyl]-4-(2-methoxyethyl)-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid 1.0 N LiOH (0.56 mL, 0.56 mmol) was added to a solution of methyl (±)-7-[[[2-(4-azabenzimidazolyl)methyl]methylamino]carbonyl]-4-(2-methoxyethyl)-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (225.4 mg, 0.47 mmol) in 25 THF (2.4 mL) and H20 (1.8 mL) at RT. The solution was stirred at RT for 16.5 h, then was acidified with TFA (0.11 mL) and concentrated to dryness on the rotavap. ODS chromatography (step gradient: 12% CH3CN/H20-0.1% TFA, then 20% CH3CN/H20-0.1% TFA), concentration to a small volume, and lyophilization gave the title compound (167.2 mg, 55%) as a light yellow powder: HPLC (PRP-1®, 30 12% CH3CN/H2O-0.1 % TFA) K'=2.7; >H NMR (400 MHz, DMSO-d6) 8 8.48 (d, J=4.9 Hz, IH), 8.22 (d, J=8.0 Hz, IH), 7.38-7.50 (m, IH), 7.15-7.30 (m, 2H), 6.54 (d, J=8.1 Hz, IH), 6.10-6.45 (m, IH), 5.43 (d, J=16.5 Hz, IH), 5.02-5.14 (m, IH), 4.82-4.99 (m, 2H), 3.95 (br d, J=16.5 Hz, IH), 3.44-3.63 (m, 2H), 3.23-3.40 (m, 2H), 3.13 (br s, 3H), 3.08 (s, 3H), 2.76 (dd, J=16.7, 8.8 Hz, IH), 2.53 (dd, J=16.7, 35 5.0 Hz, 1 H, partially obscured by residual solvent signal); MS (ES) m/e 467.2 105 WO 96/00730 PCTAJS95/08306 (M+H)+, 305.0 (M+H-162)+. Anal. Calcd for C23H26N6O5 • 1.5 CF3C02H • 0.5 H20: C, 48.30; H, 4.44; N, 13.00. Found: C, 48.09; H, 4.38; N, 12.95.
Example 26 Preparation of (,±V7-fff2-(l-methvlindolvnmethvllmethvlamino1carbonvl1-4-methvl-3-0X0-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid a) Ethyl l-methylindole-2-carboxylate Iodomethane (4.98 mL, 80 mmol) was added dropwise to a mixture containing ethyl indole-2-carboxylate (1.89 g, 10 mmol) and sodium hydride (1.2 g, 10 60% dispersion, prewashed by hexane) in anhydrous THF (60 mL) in a flame dried flask under argon at 0°C. After 4 h at RT the reaction was concentrated on the rotavap. The residue was taken into EtOAc and washed sequentially with H20 and saturated NaCl. Drying (MgS04) and concentration gave the title compound (1.01 g, 50%) as a pale yellow solid. b) 1 -Methyl-2-(methylaminocarbonyl)indole A mixture of ethyl l-methylindole-2-carboxylate (4.06 g, 20 mmol) and methylamine (50 mL) was heated at 80°C in a sealed glass vessel overnight The reaction was cooled and the title compound (2.4 g, 64%) was collected by filtration 20 as a colorless solid. MS (ES) m/e 189.0 (M+H)+. c) 1 -Methyl-2-(methylamino)methylindole LAH (50 mL, 1M solution in THF) was added dropwise through a syringe to a solution of l-methyl-2-(methylaminocarbonyI)indole (2.33 g, 12.4 mmol) in 25 anhydrous THF (10 mL) with cooling, and the resulting solution was stirred at RT under argon overnight. H2O was added dropwise with cooling to destroy excess LAH, and the colorless precipitate was removed by filtration and washed with THF. The filtrate was dried (K2CO3), concentrated, and purified by silica gel flash chromatography to afford the title compound (430 mg, 20% yield) as a yellow solid. 30 MS (ES) mIt 175 (M+H)+. d) Methyl (±)-7-[[[2-(l-methylindolyl)methyl]methylaminojcarbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate EDC (508 mg, 2.65 mmol) was added to a solution of methyl (±)-7-carboxy-35 4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzc"*iazepine-2-acetate (774 mg, 2.65 mmol), l-methyl-2-(methylamino)methylindole (420 mg, 2.41 mmol), HOBT • H2O 106 (358 mg, 2.65 mmol) and diisopropylethylamine (0.54 mL, 2.89 mmol) in anhydrous DMF (10 mL) at RT. After 20 h the reaction was concentrated on the rotavap (high vacuum). The residue was taken up in EtOAc and washed sequentially with H2O (3 x 30 mL) and 10% Na2C03 (2 x 30 mL). Drying (MgS04), concentration, and silica 5 gel chromatography (1% Me0H/CH2Cl2) gave the title compound (809 mg, 75%) as a white solid. MS(ES) m/e 449.2 (M+H)+. e) {±)-7-[[[2-(l-Methylindolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid 1.0 N NaOH (2 mL, 2 mmol) was added dropwise to a solution of methyl (±)-7-[[[2-(i-methylindolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (600 mg, 1.34 mmol) in MeOH (10 mL) at RT. The resulting mixture was stirred for 20 h then was concentrated. The residue was dissolved in H2O (10 mL) and acidified with 1.0 N HCl with cooling.
The precipitated solid was collected by filtration to give the title compound (400 mg, 69%) as a white solid. MS (ES) m/e 435.2 (M+H)+. Anal. Calcd for C24H26N4O4 • 0.75 H20: C, 64.34; H, 6.19; N, 12.51. Found: C, 64.16; H, 6.13; N, 12.50.
Example 27 Preparation of (±)-7-nT2-(l-methvlindolvl)methvnamino'lcarbonvl~l-4-methvl-3-oxo-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid a) l-Methylindole-2-carboxamide A mixture of ethyl l-methylindole-2-carboxylate (5.9 g, 29 mmol) and ammonium hydroxide (50 mL) was heated at 80°C in a sealed glass vessel overnight.
The reaction was cooled and the title compound (2.2 g, 44%) was collected by filtration as a colorless solid. MS (ES) m/e 175.0 (M+H)+. b) 1-Methyl- 2-(aminomethyl)indole Following the procedure of Example 26(c), except substituting 1-30 methylindole-2-carboxamide for l-methyl-2-(methylaminocarbonyl)indole, the title compound (86%) was obtained as a yellow brownish solid. MS (ES) m/e 161.0 (M+H)+. 107 c) Methyl (±)-7-[[[2-( 1 -methylindolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Following the procedure of Example 26(d), except substituting l-methyl-2-(aminomethyl)indole for the l-methyl-2-(methylamino)methylindole, the title 5 compound (50%) was prepared: MS (ES) m/e 435.2 (M+H)+. d) (±)-7-[[[2-(l-Methylindolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid Following the procedure of Example 26(e), methyl (±)-7-[[[2-(l-10 methylindolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate was saponified to give the title compound as a colorless solid: MS (ES) m/e 358 (M+H)+. Anal. Calcd for C23H24N4O4 • 3 HCl • 0.875 H20: C, 50.63; H, 5.31; N, 10.26. Found: C, 51.00; H, 5.02; N, 9.89.
Example 28 Preparation of 7-nT(2RS-indolinvl)methvnaminolcarbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2S-acetic acid a) Methyl (±)-indoline-2-carboxylate Thionyl chloride (2.86 mL, 39 mmol) was added to a solution of (±)-indo!ine-2-20 carboxylic acid (4.26 g, 26 mmol) in methanol (30 mL) at 0°C. The resulting mixture was stirred at RT for 18 h. The solvent was removed in vacuo and the residue was taken into CH2CI2 and washed sequentially with HoO and saturated NaCl. Drying (MgSC>4) and concentration gave the title compound (4.31 g, 94%) as a pale yellow oil. b) (±)-Indoline-2-carboxamide Gaseous NH3 was bubbled into a solution of methyl (±)-indoline-2-carboxylate (4.3 g, 24.2 mmol) in methanol (50 mL) at RT for 30 min. The reaction was stirred for 18 h, then was filtered to afford the title compound (3.35 g 85%) as a 30 colorless solid: MS (ES) m/e 163.0 (M+H)+. c) (±)-2-(Aminomethyl)indoline LAH (20 mL, 1M solution in THF) was added dropwise through a syringe to a solution of (±)-indoline-2-carboxamide (2.2 g, 13.6 mmol) in anhydrous THF (20 35 mL) with cooling, and the resulting solution was refluxed under argon for 5 h. More LAH (20 mL) was added, and reflux was continued for another 6 h. 10% aqueous 108 PCI7US95/08306 THF was added dropwise with cooling to destroy excess LAH, and then Et20 was added. After stirring for 10 min, the colorless precipitate was removed by filtration and washed with THF. The filtrate was dried (K2CO3), concentrated, and purified by silica gel flash chromatography (90:10:0.2 CH2Cl2/MeOH/Et3N). The title 5 compound (1.02 g, 51%) was obtained as an amber oil: MS (ES) m/e 149.0 (M+H)+. d) Methyl 7-[[[(2RS-indolinyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2S-acetate Following the procedure of Example 26(d), except substituting (±)-2- (aminomethyl)indoline for the l-methyl-2-(methylamino)methylindole, the title compound (44%) was prepared: MS (ES) m/e 423.0 (M+H)+. e) 7-[[[(2RS-Indolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-15 1h-1,4-benzodiazepine-2S-acetic acid Following the procedure of Example 26(e), methyl 7-[[[(2RS-indolinyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2S-acetate was saponified to give the title compound as a colorless solid. MS (ES) m/e 409.2 (M+H)+. Anal. Calcd for C22H24N4O4 1 HCl • 0.5 H20: 20 C, 58.21; H, 5.77; N, 12.34. Found: C, 58.36; H, 5.56; N, 12.26.
Example 29 Preparation of (±)-7-nT(2-imidazolvl)methvnamino1carbonvn-3-oxo-4-f2-phenvlethvI)-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid 25 a) Methyl (±)-7-[[[(2-imidazolyl)methyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate Methyl (±)-7-carboxy-3-oxo-2-(2-phenylethyl)-2,3,4,5-tetrahydro- 1H-1,4-benzodiazepine-2-acetate (400 mg, 1.04 mmol) was suspended in anhydrous toluene (5 mL), then thionyl chloride (3 mL) was added and the reaction mixture was heated 30 to reflux for 1.5 h. The solvent was then eliminated and more toluene was added (2 x 5 mL) and then distilled off. The acid chloride thus obtained was dissolved in diy DMF (8 mL) and diisopropylethylamine (506 mg, 3.9 mmol), DMAP (12.2, 0.1 mmol) and 2-(aminomethyl)imidazole dihydrochloride (222 mg, 1.3 mmol) were added. The reaction mixture was allowed to stir at RT overnight, then the solvent 35 was removed under vacuum. The residue was purified by silica gel flash column chromatography (95% CH2Cl2/5% methanol) to produce the title compound (120 109 PCTAJS95/08306 mg, 26%). !H NMR (CDCI3,400 MHz) 5 2.62 (dd, J=16.2, 6.2 Hz, IH), 2.76 (m, 2H), 2.94 (dd, J=16.2, 7.4 Hz, IH), 3.6-3.71 (m. 3H), 3.70 (s, 3H), 4.45 (s, 2H), 5.02 (dd, J=7.2,6.4 Hz, IH), 5.27 (d, J=16.6 Hz, IH), 6.47 (d, J=8.5. IH), 6.89 (s, 2H), 7.06-7.16 (m, 5H), 7.31 (br s, IH), 7.49 (d, J=8.5 Hz, IH). b) (±)-7-[[[(2-Imidazolyl)methyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid LiOH (16 mg, 0.38 mmol) was added at RT to a solution of methyl (±)-7-[[[(2-imidazolyl)methyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-10 tetrahydro-lH-l,4-benzodiazepine-2-acetate (98 mg, 0.21 mmol) in dioxane (3 mL) and H2O (3 mL). The reaction mixture was heated at fi5°C for 3 h then the organic solvent was removed in vacuo. The aqueous residue was acidified with 1M HCl solution (0.38 mL) to obtain a white solid which was filtered, dissolved in hot methanol, and precipitated with ether. The thus obtained white solid was collected 15 to yield the tide compound (72 mg, 78%). *H NMR (DMSO-d6,400 MHz) 8 2.59 (dd, J=16.2,5.0 Hz, IH), 2.77 (dd, J=7.7,6.8 Hz, 2H), 2.92 (dd, J=16.5, 8.8 Hz, IH), 3.63-3.75 (m, 2H), 3.79 (d, J =16.5 Hz, IH), 4.61 (s, 2H), 5.13 (dd, J=8.8, 5.0 Hz, IH), 5.45 (d, J=16.5 Hz, IH), 6.57 (d, J=8.6 Hz, IH), 7.07 (s, 2H), 7.10-7.19 (m, 5H), 7.41 (s, IH), 7.54 (d, J=8.4 Hz, IH). MS (ES) m/e 448 (M+H)+ Anal. 20 Calcd. for C24H25N5O4. H2O: C, 61.92; H, 5.85; N, 15.04. Found: C, 61.69; H, 5.60; N, 14.86.
Example 30 Preparation of (±)-7-nT(2-benzimidazolvl)methvnaminolmethvn-4-methvl-3-oxo-25 2.3.4.5-tetrahvdro-1H-1,4-benzodiazepine-2-acetic acid a) Methyl (±)-7-[[[(2-benzimidazolyl)methyl]amino]methyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetate Methyl (±)-7-formyl-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-1,4-benzodiazepine-2-acetate (180 mg. 0.65 mmol) (prepared as in Example 14(b)) was 30 suspended in anhydrous methanol, then sodium acetate (160 mg, 1.95 mmol), 2-(amino methyl)benzimidazole dihydrochloride (143 mg, 0.65 mmol) and 4 A molecular sieves were added. After 30 min., sodium cyanoborohydride (45 mg, 0.71 mmol) was added in 2 portions over a period of 30 min. The reaction mixture was allowed to stir at RT overnight, then the methanol was removed under vacuum. 35 The residue was diluted with CH2CI2, and the solution was washed with saturated NaHCC>3. Drying (MgSC>4), concentration, and silica gel chromatography (90% 110 CH2Cl2/9% methanol/1% NEt3) gave the title compound (133 mg, 49%): NMR (CDC13,400 MHz) 5 2.67 (dd, J=16.1, 6.1 Hz, IH), 2.96 (dd, J=16.1, 6.8 Hz, IH), 3.05 (s, 3H), 3.68 (d, J=16.4 Hz), 3.72 (br s, 2H), 3.75 (s, 3H), 4.11 (br s, 2H), 4.97 (dd, J=6.8 Hz, 6.1, IH), 5.35 (d, J=16.4 Hz, IH), 6.54 (d, J=8.1 Hz, IH), 6.87 (s, 5 1H), 7.05 (d, J=8.2 Hz, IH), 7.20-7.26 (m, 2H), 7.57 (m, 2H); MS(ES) m/e 408 (M+H)+. b) (±)-7-[[[(2-Benzimidazolyl)methyl]amino]methyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid 10 LiOH (14.6 mg, 0.34 mmol) was added at RT to a solution of methyl (±)-7- [[[(2-benzimidazolyl)methyl]amino]methyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-1,4-benzodiazepine-2-acetate (133 mg, 0.31 mmol) in dioxane (3 mL) and H2OO mL). The reaction mixture was stirred at RT overnight then the organic solvent was removed in vacuo. The aqueous residue was acidified with 1M HCl solution (0.38 15 mL) to obtain a white solid which was purified by ODS chromatography (10% acetonitrile/H20-0.1% TFA) to afford the title compound (65 mg, 51%): *H NMR (DMSO-dg, 400 MHz) 5 2.51 (m, IH), 2.73 (m, IH), 2.91 (s, 3H), 3.69 (bs, 2H), 3.76 (d, J=16.6 Hz, IH), 3.97 (br s, 2H), 4.97 (m, IH), 4.45 (d, J=16.6 Hz, IH), .77 (m, IH), 6.52 (d, J=8.1 Hz, IH), 6.97 (s, IH), 7.02 (d, J=8.1 Hz, IH), 7.20 (m, 20 2H), 7.52 (m, 2H); MS (ES) m/e 394 (M+H)+. Anal. Calcd. for C21H23N5O3 • 2 CF3C02H • H2O: C, 46.95; H, 4.26; N, 10.95. Found: C, 46.81; H, 4.00; N, .84.
Example 31 Preparation of (±)-7-[Tf(2-benzimidazolvI)methvnamino?carbonyn-1.4-dimethvl-3-oxo-2.3.4.5-tetrahvdro-lH-l ,4-benzodiazepine-2-acetic acid a) Methyl (±)-7-[[[(2-Benzimidazolyl)methyl]amino]carbonyl]-l ,4-dimethyl-3-oxo-2,3,4,5-tetrahydro-l H-1,4-benzodiazepine-2-acetate Following the procedure of Example 2(a), except substituting methyl (±)-7-30 carboxy-l,4-dimethyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate for the methyl (±)-7-carboxy-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate, the title compound was prepared (60%): MS (ES) m/e 435 (M+H)+; »H NMR (250 MHz, CDCI3) 5 9.82 (m, IH), 7.81 (d, J=7.9 Hz, IH), 7.62 (s, IH), 7.5 (m, 2H), 7.22 (m, 2H), 6.79 (d, J=7.9 Hz, IH), 5.09 (d, J=16.6 Hz, 35 IH), 4.76-5.01 (m, 3H), 3.61 (s, 3H), 3,59 (d, J=16.6 Hz, IH), 3.1 (m, IH), 2.90 (s, 3H), 2.81 (s, 3H), 2.65 IH).
Ill PCTAJS95/08306 b) (±)-7-[[[(2-Benzimidazolyl)methyl]amino]carbonyl]-l,4-dimethyl-3-oxo-2,3,4,5-tetrahydro-lH-1,4-benzodiazepine-2-acetic acid A solution of methyl (±)-7-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-l,4-5 dimethyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate (0.080 g, 0.18 mmol) in a mixture of methanol (10 mL), water (1.0 mL) and 1.0 M NaOH (0.75 mL) was heated at 50°C for 2 h, cooled to RT, and evaporated to dryness. The residue was dissolved in water (5.0 mL) and the solution acidified to pH 5 with 0.25 N HCl to precipitate the title compound (55%): MS (ES) m/e 422 (M+H)+; Anal. 10 Calcd for C22H23N5O4 • 2.3 H20: C, 57.09; H, 6.01; N, 15.13. Found: C, 57.29; H, 5.79; N, 14.82. >H NMR (400 MHz, DMSO-d6) 5 P.93 (br t, J=5.6 Hz, IH), 7.78 (d, J=8.4 Hz, IH), 7.73 (s, IH), 7.49 (m, 2H), 7.12 (m, 2H), 6.98 (d, J=8.4 Hz, IH), 5.30 (d, J=16.6 Hz, IH), 4.85 (m, IH), 4.68 (d, J=5.4 Hz, 2H), 4.10 (d, J=16.6 Hz, IH), 2.98 (s, 3H), 2.92 (m, IH), 2.80 (s, 3H), 2.60 (dd, J=16.7, 8.9 Hz, IH).
Example 32 Preparation of (±V7-rrf(2-benzimidazolvl)methvl'lmethvlamino'lcarbonvH-3-oxo-2.34.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid a) Methyl (±)-7-[[[(2-benzimidazolyl)methyl]methylamino]carbonyl]-3-oxo-20 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Following the procedure of Example 15(b), except substituting methyl 7-carboxy-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate for the methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate, the crude title compound was prepared. Chromatography (silica gel, 7% 25 MeOH/CH2Cl2) yielded the title compound (35%): MS (ES) m/e 422.2 (M+H)+. lU NMR (400 MHz, CDCI3) 8 7.45 (m, IH), 7.38 (m, 4H), 7.15 (d, J=8.4 Hz, IH), 6.90 (s, IH), 6.50 (d, 1=8.4 Hz, IH), 5.35 (s, 3H), 4.95 (m, IH), 4.65 (m, IH), 3.71 (s, 3H), 3.65 (m, IH), 3.48 (s, 3H), 3.07 (m, IH), 2.75 (dd, J=16.4, 8.4 Hz, IH). b) (±)-7-[[[(2-Benzimidazolyl)methyl]methylamino]carbonyl]-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid A solution of methyl (±)-7-[[[(2-benzimidazolyl)methyl)methylamino]carbonyl]-3-oxo-2,3,4,5-tetrahydro-lH-l,4-35 benzodiazepine-2-acetate (0.040 g, 0.09 mmol) in a mixture of methanol (7.0 mL), water (0.7 mL), and 1.0 M NaOH (0.7 mL) was kept 16 h at RT. Trifluoroacetic ; 112 acid (0.5 mL) was added and the solvents were removed to give the crude product. Purification by semi-preparative HPLC (YMC ODS-AQ, 15:85; acetonitrile:water, 0.1% TFA) gave the title compound: MS (ES) m/e 408.2 (M+H)+; 'H NMR (250 MHz, DMSO-d6) 8 8.19 (br t, J=4.5 Hz, IH), 7.72 (m, 2H). 7.38 (m, 2H), 7.28 (d, 5 J=8.4 Hz, IH), 7.15 (s, IH), 6.62 (d, J=8.4 Hz, IH), 6.22 (br s, IH), 5.05 (m, IH), 4.95 (s, 2H), 3.74 (dd, 15.8, 7.4 Hz, IH), 3.15 (s, 3H), 2.75 (dd, J=16.4, 8.5 Hz, IH), 2.50 (m, IH).
Example 33 Preparation of (2SV7-nTN-butvl-N-benzimidazol-2-vl)roethvnamino1carbonvn-3-oxo^i-methvl-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid a) N-BOC-2-methylbenzimidazole To a stirred mixture of 2-methylbenzimidazole (15 g, 113.5 mmol), triethylamine (12 g, 119.2 mmol), and DMAP (cat.) in dry CH2CI2 (150 mL) was 15 added (Boc)20. After 24 h, the mixture was concentrated. The residue was taken up in H2O, stirred and filtered to give a white solid (26.3 g, 100%): mp 71-72°C; ]H NMR (250 MHz, CDCI3) 6 1.71 (s, 9H), 2.83 (s, 3H), 7.29 (m, 2H), 7.65 (m, IH), 7.91 (m, IH). b) 1 -BOC-2-bromomethylbenzimidazole Following the procedure in Example 4(a), except substituting N-BOC-2-methylbenzimidazole for 2-methylbenzothiazole, the title compound was prepared 2:-a yellow oil (12.88 g, 77%): JH NMR (250 MHz, CDC13): 5 1.79 (s, 9H), 4.95 (s, 2H), 7.40 (m, 2H), 7.75 (m, IH), 8.01 (m, IH). c) 2-( 1 -Butylamino)methylbenzimidazole To a stirred solution of l-BOC-2-bromomethylbenzimidazole (2.00 g, 6.4 mmol) in dry THF (20 mL) was added n-butylamine (1.2 g, 15.4 mmol). After stirring at RT overnight, the mixture was concentrated. The residue was taken up in 30 H2O and extracted with CH2CI2. The organic extracts were dried over MgSC>4 and concentrated to give a brown residue, which was dissolved in CH2CI2 (15 mL) and treated with TFA (5 mL). The resulting mixture was stirred at RT overnight then was concentrated. The residue was taken up in H2O, and the solution was neutralized with 2.5 N NaOH. CH2CI2 extraction, drying (MgS04), concentration, 35 and silica gel chromatography (2% MeOH/CH2Cl2) gave the title compound as a yellow oil (0.91 g, 70%): >H NMR (250 MHz, CDCI3) 5 0.79 (t, J=7.2 Hz, 3H), 113 PCT/TJS95/08306 1.23 (m, 2H), 1.54 (m, 2H), 3.35 (t, J=7.2 Hz, 2H), 4.55 (s, 2H), 7.25 (m, 2H), 7.48 (m, IH), 7.75 (m, IH). d) Methyl-(S)-7-[[[N-(2-benzimidazolyl)methyl-N-(n-butyl)]amino]carbonyl]-4-5 methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate To a stirred mixture of 2-(l-butylamino)methylbenzimidazole (0.14 g, 0.6671 mmol), methyl (S)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (0.15 g, 0.5132 mmol), HOBT • H2O (0.083 g, 0.6158 mmol), and (i-Pr)2NEt (0.133 g, 1.0263 mmol) in dry MeCN (5 mL) was added 10 EDC (0.183 g, 0.6158 mmol). After stirring at RT overnight, the mixture was concentrated. The residue was taken up in H2O and extracted with CH2CI2. The combined organic layers were washed sequentially with saturated NaHC03 and brine, then were dried (MgS04) and concentrated to give the title compound as a yellow foam (0.232 g, 95%): >H NMR (250 MHz, CDCI3) 5 0.79 (t, J=7.2 Hz, 3H), 15 1.23 (m, 2H), 1.54 (m, 2H), 2.54 (dd, J=16.8 Hz, 5.0 Hz, IH), 2.75 (dd, J =16.8 Hz, 8.9 Hz, IH), 2.86 (s, 3H), 3.32 (t, J=7.2 Hz, 2H), 3.60 (s, 3H), 3.72 (d, J=16.1 Hz, IH), 4.75 (s, 2H), 5.05 (m, IH), 5.48 (d, J= 16.1 Hz, IH), 6.20 (d, J =3.6 Hz, IH), 6.55 (d, J=8.9 Hz, IH), 7.16 (m, 4H), 7.53 (m, 2H). e) (S)-7-[[[N-(2-Benzimidazolyl)methyl-N-(n-butyl)]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l ,4-benzodiazepine-2-acetic acid Following the procedure in Example 31(b), methyl-(S)-7-[[[N-(2-benzimidazolyl)methyl-N-(n-butyl)]amino]carbonyl]-4-methyl-3-oxo-2,3i4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate was saponified to give an off white 25 solid. Trituration in hot EtOH gave the title compound as a white solid (0.15 g, 60%): mp 160-162°C (dec); »H NMR (400 MHz, DMSO-d6) 5 0.79 (t, J=7.2 Hz, 3H), 1.23 (m, 2H), 1.54 (m, 2H), 2.54 (dd, J=16.8 Hz, 5.0 Hz, IH), 2.75 (dd, J =16.8 Hz, 8.9 Hz, IH), 2.86 (s, 3H), 3.32 (t, J=7.2 Hz, 2H), 3.72 (d, J=16.1 Hz, IH), 4.75 (s, 2H), 5.05 (m, IH), 5.48 (d. J= 16.1 Hz, IH), 6.20 (d, J =3.6 Hz, IH), 6.55 (d, 30 J=8.9 Hz, IH), 7.16 (m, 4H), 7.53 (m, 2H); MS (ES) m/e 464 (M+H)+; IR (KBr) 3400,3000-3100, 2800-'M00, 1712,1671, 1655,1630, 1611, 1271, 828 cm*'. Anal. Calcd for C25H29N5O4 • 0.75 H2O: C, 62.95; H, 6.44; N, 14.68. Found: C, 62.75; H, 6.40; N, 14.41. 114 Example 34 Preparation of (S)-7-ITfN-(2-benzimidazolvOmethvl-N-(2-phenvlethvl11amino1carbonvll-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid 5 a) 2-(2-Phenylethylamino)methylbenzimidazole Following the procedure of Example 33(c), except substituting 2-phenylethylamine for n-butylamine, the title compound (0.100 g, 31%) was prepared as a brown oil following silica gel flash chromatography (5% MeOH/CH2Cl2): NMR (250 MHz, CDCI3) 8 2.82 (t, J=7.5 Hz, 2H), 2.97 (t, J=7.5 Hz, 2H), 4.10 (s, 10 2H), 7.21 (m, 5H), 7.35 (m, 2H), 7.52 (m, 2H). b) Methyl {S)-7-[[[N-(2-benzimidazolyl)methyl-N-(2- phenylethyl)]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4- benzodiazepine-2-acetate Following the procedure of Example 33(d), except substituting 2-(2- phenylethylamino)methylbenzimidazole for 2-( 1 -butylamino)methylbenzimidazole, the title compound (0.195 g, 97%) was prepared as an off-white foam following silica gel flash chromatography (2-5% MeOH/CH2Cl2): 'H NMR(250 MHz, DMSO-d6) 8 2.54 (dd, J= 16.5,5.0 Hz, IH), 2.75 (dd, J=16.5, 8.9 Hz, IH), 2.85 (s. 3H), 2.90 (t, J=7.5 Hz, 2H), 3.60 (t, J=7.5 Hz, 2H), 3.65 (s, 3H), 3.78 (d, J=16.3 Hz, IH), 4.78 (s, 2H), 5.05 (m, IH), 5.42 (d, J=16.3 Hz, IH), 6.18 (d, J=3.5 Hz, IH), 6.54 (d, J=8.9 Hz, IH), 7.10 (m, 7H), 7.26( m, 2H), 7.48 (m, IH), 7.60 (m, IH), 12.30 (s, IH). c) (S)-7-[[[N-(2-Benzimidazolyl)methyl-N-(2-phenylethyl)]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-IH-1,4-benzodiazepine-2-acetic acid Following the procedure of Example 11(b), methyl (S)-7-[[[N-(2-benzimidazolyl)methyl-N-(2-phenylethyl)]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate was saponified. Recrystallization from 30 EtOH gave the tide compound (0.070 g, 40%) as an off white solid: MS (ES) m/e 512 (M+H)+; IR (KBr) 3300-3500, 3000-3100, 2800-300, 1631, 1647, 1652, 1618, 1405,698 cm-1. Anal. Calcd for C29H29N504-2.5 H2O: C, 62.58; H, 6.16; N, 12.58. Found: C, 62.92, H, 6.02, N, 12.28. 115 PCT7US95/08306 Example 35 Preparation of (S1-7-ITrN-(2-benzimidazolvl)methvl-N-carboxvmethvllaminolcarbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid a) N-[(2-Benzimizazolyl)methyl]glycine benzyl ester Following the procedure in Example 33(c), except substituting glycine benzyl ester HCl for n-butylamine, the title compound (1.00 g, 60%) was prepared as an off white solid: 'H NMR (250 MHz, CDCI3) 5 3.86 (s, 2H), 4.31 (s, 2H), 5.23 (s, 2H), 7.23 (m, 5H), 7.35 (m, 2H), 7.55 (m, 2H). b) Methyl-(S)-7-[[[N-(2-benzimidazolyl)methyl-N- (benzyloxycarbonyl)methyl]amino] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Following the procedure in Example 33(d), except substituting N-[(2-benziniizazolyl)methyl]glycine benzyl ester for 2-(l- butylamino)methylbenzimidazole, the title compound (0.95 g, 81%) was prepared as a yellow foam: {H NMR (250 MHz, CDCI3) 5 2.54 (dd, J=16.5, 3.5 Hz, IH), 2.75 (dd, J=16.5, 8.9 Hz, IH), 2.87 (s, 3H), 3.65 (s, 3H), 3.78 (d, J=16.3 Hz, IH), 4.30 (s, 2H), 4.86 (s, 2H), 5.05 (m, IH), 5.23 (s, 2H), 5.45 (d, J=16.3 Hz, IH), 6.55 (d, J=8.9 Hz, IH), 7.10 (m, 2H), 7.23 (m, 5H), 7.55 (m, 2H), 7.81 ( m, 2H). c) Methyl-(S)-7-[[[N-(2-benzimidazolyl)methyl-N-carboxymethyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4~ benzodiazepine-2-acetate A solution of methyl-(S)-7-[[[N (2-benzimidazolyl)methyl-N-(benzyloxycarbonyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (0.185 g, 0.333 mmol) in methanol (5 mL) was hydrogenated over 10% Pd/C at RT overnight. The catalyst was removed by filtration through Celite®, and the filtrate was concentrated to give a yellow foam. Trituration with acetone gave the title compound (0.140 g, 90%) as an off white solid. 'H NMR (250 MHz, CDCI3) 5 2.54 (dd, J=16.5, 3.5 Hz, IH), 2.75 (dd, J=16.5, 8.9 Hz, IH), 2.87 (s, 3H), 3.65 (s, 3H), 3.78 (d, J=16.3 Hz, IH), 4.86 (s, 2H), 5.05 (m, IH), 5.23 (s, 2H), 5.45 (d, J=16.3 Hz, IH), 6.55 (d, J=8.9 Hz, IH), 7.10 (m, 2H), 7.55 (m, 2H), 7.81 (m, 2H). 116 PCTAJS95/08306 d) (S)-7-[[[N-(2-Benzimidazolyl)methyl-N-carboxymethyl]amiiio]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid A solution of Example 35(b) in methanol (5 mL) was hydrogenated at RT in 10% Pd/C overnight. The catalyst was filtered through Celite. The filtrate was 5 concentrated to give a yellow foam which was triturated in acetone to give the title compound as an off white solid (0.140 g, 90%): MS (ES) m/e 465 (M+H)+: Anal. Calcd for C23H23N506-1.2 H2O: C, 56.92; H, 5.26; N, 14.38. Found: C, 57.09; H, 5.33; N, 14.00.
Example 36 Preparation of (S)-7-f[fN-(2-benzimidazolvl)methvl-N-cvclohexvnaminolcarbonvll-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid a) 2-(Cyclohexylamino)methylbenzimidazole Following the procedure of Example 33(c), except substituting 15 cyclohexylamine for n-butylamine, the title compound (0.191 g, 52%) was prepared as a brown oil: 'H NMR (250 MHz, CDCI3) 5 1.35 (m, 4H), 1.75 (m, 4H), 2.21 (m, 2H), 2.78 (m, IH), 4.31 (s, 2H), 7.21 (m, 2H), 7.51 (m, 2H). b) Methyl-(S)-7-[[[N-(2-benzimidazolyl)methyl-N-cyclohexyl)amino]carbonyl]-4-20 methy 1-3-0x0-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Following the procedure of Example 33(d), except substituting 2-(Cyclohexylamino)methylbenzimidazole for 2-( 1 -butylamino)methylbenzimidazole, the title compound (0.174 g, 50%) was prepared as a yellow foam: *H NMR (250 MHz, CDCI3) 5 1.15 (m, 4H), 1.60 (m, 4H), 1.85 (m, 2H), 2.65 (dd, J=16.5,3.5 Hz, 25 IH), 2.98 (dd, J=16.5, 8.9 Hz, IH), 3.07 (s, 3H), 3.71 (d, J=16.3 Hz, IH), 4.48 (d, J=3.5 Hz, IH), 4.67 (s, 2H\ 5.10 (m, IH), 5.47 (d, J=16.3 Hz, IH), 6.51 (d, J=8.9 Hz, IH), 7.15 (m, 3H), 7.22 (m, 2H), 7.31 (m, IH), 7.65 (m, IH). c) (S)-7-[[[N-(2-Benzimidazolyl)methyl-N-cyclohexyl]airino]carbonyl]-4-methyl-30 3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid Following the procedure of Example 4(d), methyl-(S)-7-[[[N-(2-benzimidazolyl)methyl-N-cyclohexyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro H-1. » '; •; iazepine-2-acetate was saponified. The title compound (0. iOO g, 60%) v«. s/tuained as an off white solid: 'H NMR (400 MHz, DMSO-d6) 35 5 1 15 (m, 4H), 1.55 (m, 4H), 1.9? (m, 2H), 2.54 (dd, J=16.5, 3.5 H.i, IH), 2.78 (dd, 7 -16.5, 8.9 Hi, 1H),2.91 (s, 3H),:!-.P3 (d,J=16.3 Hz, IH). 3.85 (m, 1H),4.97 (s, 117 2H), 5.07 (m, IH), 5.48 (d, J=16.3 Hz, IH), 6.56 (d, J=8.9 Hz, IH), 7.20 (s, IH), 7.25 (d, J=8.9 Hz, IH), 7.50 (m. 2H), 7.82 (m, 2H); MS (ES) m/e 489 (M+H)+.
Anal. Calcd for C27H31N5O4 • H2O: C, 63.90; H, 6.55; N, 13.80. Found: C, 63.91; H, 6.27; N, 13.60.
Example 37 Preparation of (±)-7-rff2-(5-nitrobenzimidazolvl)methvllmethvlamino1carbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid a) 2-[[N-(tert-Butoxycarbonyl)-N-methyl]aminomethyl]-5-nitrobenzimidazole 10 BOC sarcosine (2.555 g, 13.51 mmol) was weighed into a dry 250 mL roundbottom flask, purged with argon. The material was dissolved in dry THF (20 mL). Et3N (3 mL, 21.6 mmol) was added, followed by isobutylchloroformate (1.8 mL, 13.88 mmol). The reaction was stirred at RT under argon for 30 minutes, then was cooled to -20°C, and 4-nitrophenylenediamine (2.0423 g, 13.34 mmol) was 15 added as a solid. After the addition was complete, the cooling bath was removed and the reaction was allowed to warm to RT. After 20 h, the reaction was concentrated under vacuum. The material was dissolved in EtOAc and extracted with 1.0 N NaHC03. The organic phase was dried (MgS04), filtered and concentrated under vacuum. The residue was dissolved in glacial AcOH and heated 20 to 75 °C in an oil bath. After 24 h, the reaction was concentrated under vacuum. The residue was reconcentrated from toluene. The material was flash chromatographed (silica gel, 1:2 CH2Cl2/Et20,1:1 CH2Cl2/Et20,5% MeOH/CH2Cl2) to give the title compound (2.05 g, 51 %). Both fractions had identical mass spectral data: MS(ES) m/e 307.0 (M+H)+; 'H NMR (250 MHz, 25 CDCI3) 8 8.61-7.46 (m, 5H), 4.65 (s, 2H), 3.04 (s, 3H), 1.50 (S, 9H). b) 2-(Methylamino)methyl-5-nitrobenzimidazole 2-[N-(tert-Butoxycarbonyl)-N-methyllaminomethyl-5-nitrobenzimidazole (904.8 mg, 2.96 mmol) was treated with 4 N HCl in dioxane. The reaction was 30 stirred at RT for 1 h, then was concentrated under vacuum. The yellow slurry was reconcentrated from toluene. The residue was dried under high vacuum, leaving tne title compound (830.5 mg) as a light yellow solid. This material was used without further purification. 118 PCTAJ S95/08306 c) Methyl (±)-7-[[[2-(5-nitrobenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l ,4-benzodiazepine-2-acetate (511.8 mg, 1.75 mmol) was weighed into a dry 200 mL roundbottom flask. Dry DMF was added, followed by HOBt • H2O (258.1 mg, 1.91 mmol) and EDC (351.5 mg, 1.83 mmol). The mixture was stirred at RT until all solids had dissolved, then a solution of 2-(methylamino)methyl-5-nitrobenzimidazole (492.5 mg, 1.76 mmol) and diisopropylethylamine (1.0 mL, 5.74 mmol) in DMF was added at RT. The reaction was stirred at RT for 24 h then was 10 concentrated under vacuum. The residue was reconcentrated from toluene, then was chromatographed on silica gel (CHCI3 (0.25 L), then 3% MeOH/CHCl3 (1L), then 5% MeOH/CHCl3 (1L)) to afford the title compound (847.5 mg, quantitative): MS (ES) m/e 481.0 (M+H)+ d) (±)-7-[[[2-(5-Nitrobenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid Methyl (±)-7-[[[2-(5-nitrobenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (386.3 mg, 0.080 mmol) was suspended in MeOH, and 1.0 N NaOH (2.5 mL, 2.5 mmol) was added. 20 The reaction was stirred at RT for 18 h, then was warmed in an oil bath set at 70°C. After 4 h, the reaction was cooled to RT and neutralized with 1.0 N HCl (2.5 mL). The solution was concentrated under vacuum. After most of the MeOH had evaporated, a yellow precipitate formed. The precipitate was collected on a sintered glass funnel and dried in a desiccator under vacuum to afford the title compound 25 (317.3 mg, 85%). >H NMR (250 MHz, CDCI3) 8 8.55-6.60 (m, 6H), 5.50 (d, IH), 5.15 (dd, IH), 4.91 (s, 2H), 3.20 (s, 3H), 3.09 (s, 3H); MS (ES) m/e 467.2 (M+H)+. Anal. Calcd for C22H22N6O6 • HCl: C, 52.54; H, 4.61; N, 16.71. Found: C, 52.63; H, 4.83; N, 16.53.
Example 38 Preparation of (±)-7-rrr2-(5-aminobenzimidazolvl)rnethvl1methvlamino'lcarbonvll-4-methvl-3-oxo-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid a) (±)-7-[[[2-(5-Aminobenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid 35 Methyl (±)-7-[[[2-(5-nitrobenzimidazolyl)methyl]methylamino]carbonyl]-4- methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepirie-2-acetate (367.4 mg, 0.76 119 PCTAJS95/08306 mmol) was suspended in MeOH, and 10% Pd/C catalyst was added. The mixture was stirred briskly at RT under H2 (balloon). After 4.5 h, the catalyst was removed by filtration through Celite®. The filtrate was concentrated under vacuum, and the residue was dissolved in MeOH. 1.0 N NaOH (2.5 mL, 2.5 mmol) and H2O (10 5 mL) were added. The reaction was stirred at RT for 24 h, then was neutralized with 1.0 N HCl (2.5 mL). Concentration in vacuum left a dark residue, which was dissolved in MeOH. Activated carbon (Norit®) was added, and the mixture was heated at reflux on the steam bath. The activated carbon was removed by filtration through Celite®, and the filtrate was concentrated to about 50 mL. The precipitate 10 was collected on a sintered glass funnel and dried in a vacuum desiccator to give the title compound (158.0 mg) as a red powder: HPLC (PRP-1®, 10% CH3CN/H2O-0.1% TFA) tR=4.64; MS (ES) m/e 437.2 (M+H)+; >H NMR (250 MHz, CD3OD) 5 7.42-6.56 (m, 6H), 5.54 (d, IH), 5.15 (dd, IH), 4.80 (s, 2H), 3.13 (s, 3H), 3.05 (s, 3H). Anal. Calcd for C22H24N6O4 • 0.75 HCl • 1.75 H20: C, 53.35; H, 5.75; N, 15 16.97. Found: C, 53.91; H, 6.00; N, 16.36.
Example 39 Preparation of (±)-7-f2-(1.2.3.4-tetrzihvdro-9H-pvridor3.4-b1indolvl')carbonvn-4-methvl-3-oxo-2.3,4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid 20 a) Methyl (±)-7-[2-( 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indolyl)carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (308.5 mg, 1.06 mmol) was weighed into a 250 mL roundbottom flask. Dry DMF was added, followed by HOBt • H2O (159.1 mg, 1.18 25 mmol) and EDC (248.3 mg, 1.30 mmol). Diisopropylethylamine (0.20 mL, 1.15 mmol) was added, followed by a solution of l,2,3,4-tetrahydro-9H-pyrido[3,4b]indole (187.6 mg, 1.09 mmol) in DMF. The reaction was stirred at RT for 24 h, then was concentrated under vacuum. Chromatography (silica gel, step gradient, 2% MeOH/CHCl3, 3% MeOH/CHCl3) gave the title compound as a clear, 30 colorless oil (484.7 mg): >H NMR (250 MHz, CDC13) 5 9.09 (br s, IH), 7.47-7.04 (m, 7H), 6.49 (d, IH), 5.37 (d, IH), 5.05 (dd, IH), 4.77 (s, 2H), 3.69 (s, 3H), 2.99 (s, 3H); MS (ES) m/e 447.2 (M+H)+ 120 b) (±)-7-[2-(l,2,3,4-tetrahydro-9H-pyrido[3,4-b]indolyl)carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid Methyl (±)-7-[2-( 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indolyl)carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (484.7 mg, 1.09 5 mmol) was dissolved in MeOH, and 1.0 N NaOH (2.0 mL, 2.0 mmol) was added. The reaction was stirred at RT for 24 h, then was heated in an oil bath set at 75°C. After 4 h, the reaction was neutralized with 1.0 N HCl and concentrated under vacuum. The resultant precipitate was collected and reprecipitated from methanol/water to afford the title compound (380 mg., 80%) as a colorless powder: 10 MS (ES) m/e 433.2 (M+H)+ Anal. Calcd for C24H24N4O4 • 1.5 H20: C, 62.73; H, 5.92; N, 12.19. Found: C, 62.56; H, 5.55; N, 11.91.
Example 40 Preparation of (S)-7-rrr2-('5.6-methvlendioxvbenzimidazolvl)methvllmethvlamino1 15 carbonvll-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid a) 2-[[N-(Benzyloxycarbonyl)-N-methyl]aminomethyl]-5,6-methylenedioxybenzimidazole Cbz-sarcosine (310.0 mg, 1.39 mmol) was dissolved in dry THF (10 mL) in a 250 mL roundbottom flask under argon. Isobutylchloroformate (0.2 mL, 1.54 mmol) 20 was added, followed by Et3N (0.25 mL, 1.80 mmol). The reaction was stirred at RT under argon for 30 min, then was cooled to -10°C to -20°C. A solution of 1,2-diamino-4,5-methylenedioxybenzene (0.2 g, 1.314 mmol) in dry THF was added, and the reaction was allowed to warm to RT. After 18 h, the reaction was concentrated under vacuum. The white solid residue was dissolved in EtOAc, and 25 the solution was washed with 1.0 N NaHC03. The organic layer was dried (MgS04), filtered, and concentrated under vacuum. The residue was dissolved in glacial AcOH and heated an oil bath set at 70 °C. After 24 h, the reaction was concentrated under vacuum. The residue was reconcentrated from toluene, then was chromatographed on silica gel (1:1 CH2Cl2/Et20). The material obtained in this 30 way (two components co-eluted) was redissolved in glacial AcOH and heated to 100 °C. TLC of the reaction after 24 h still showed two products. Concentration and chromatography (silica gel, 1:1 CHCl3/Et20) gave the title compound (145.0 mg, 32.7%): MS (ES) m/e 340.0 (M+H)+; »H NMR (250 MHz, CDCI3) 5 7.32 (s, 5H), 7.27 (s, IH), 7.11 (s, IH), 5.94 (s, 2H), 5.13 (s, 2H), 4.58 (s, 2H), 3.03 (s, 3H). 121 PCTAJS95/08306 b) 2- (Methylamino)methyl-5,6-methylenedioxybenzimidazole 2-[[N-(Benzyloxycarbonyl)-N-methyl]aminomethyl]-5,6-me thy lenedioxy benzimidazole (145.0 mg, 0.43 mmol) was dissolved in MeOH, and 10% Pd/C was added. The mixture was stirred briskly at RT under H2 (balloon).
After 4 h, the reaction was filtered through Celite®, and the filtrate was concentrated under vacuum to afford the title compound (70.8 mg, 80.2%). c) Methyl (S)-7-[[[2-(5,6-methylendioxybenzimidazolyl)methyl]methylamino] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate EDC (76.2 mg, 0.40 mmol) was added to a solution of methyl (2S)-7- carboxy-4-methy l-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate (0.35 mmol) and HOBt • H2O (57.9 mg, 0.43 mmol) in dry DMF, and the reaction was stirred at RT. Diisopropylethylamine (0.150 mL, 0.86 mmol) was added, followed by a solution of 2-(methylamino)methyl- 5,6-methylenedioxybenzimidazole (70.8 15 mg, 0.35 mmol) in dry DMF. The reaction was stirred at RT for 24 h, then was concentrated under vacuum. Chromatography (silica gel, step gradient, CHCI3,1:1 MeOH/CHCl3) and rechromatography (2% MeOH/CHCl3,10% MeOH/CHCl3) gave the title compound (102.5 mg, 61.1%); 'H NMR (250 MHz, CDCI3) 8 7.18-7.13 (m, 3H), 6.82 (s, IH), 6.49 (s, IH), 5.97 (s, 2H), 5.40 (d, IH), 5.05 (dd, IH), 20 4.74-4.56 (m, 2H), 3.73 (s, 3H), 3.13 (s, 3H), 3.01 (s, 3H). d) (S)-7-[[[2-(5,6-Methylendioxybenzimidazolyl)methyl]methylamino] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid Methyl (S)-7-[[[2-(5,6-methylendioxybenzimidazolyl)methyl]methylamino] 25 carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (102.5 mg, 0.21 mmol) was dissolved in MeOH, and 1.0 N NaOH (0.5 mL, 0.5 mmol) was added. The reaction was stirred at RT for 48 h, then was neutralized with 1.0 N HCl. Concentration under vacuum left a residue which was diluted with water and allowed to stand at RT overnight. The resultant precipitate was collected 30 by filtration and dried under high vacuum to yield the title compound (29.0 mg, 30%): HPLC tR=l 1.67;(PRP-1@, gradient elution over 20 min, 5-50% CH3CN/H2O-O.I % TFA) MS (ES) m/e 466.2 (M+H)+.
Example 41 Preparation of (S)-7-nT2-(4.6-diazabenzimidazoIvI)methvl1methvlamino"lcarbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid 122 a) 2-[[N-(tert-Butoxycarbonyl)-N-methyl]aminomethyl]-4,6-diazabenzimidazole Boc-sarcosine (3.6 g, 19.1 mmol) was dissolved in dry THF in a flame-dried 250 mL roundbottom flask, and Et3N (6 mL, 43.14 mmol) was added. The solution was cooled to 0°C to -5°C, and isobutylchloroformate (2.5 mL, 1.93 mmol) was 5 added. The white mixture was stirred at - 5 °C for 15 min, then was cooled to -20 °C to -30 °C, and 4,5-diaminopyrimidine (2.1 g, 19.15 mmol.) was added as a solid. The cooling bath was removed and the reaction was allowed to warm to RT. After 24 h, tne reaction was concentrated under vacuum. The residue was dissolved in EtOAc and washed with 1.0 NaHC03. The organic layer was dried (MgS04), 10 filtered, and concentrated under vacuum. The residue was redissolved in glacial AcOH and heated in an oil bath set at 70°C. After 24 h, the reaction was cooled to RT, concentrated under vacuum, and reconcentrated from toluene. Flash chromatography column (silica gel, step gradient, 5% MeOH/CHCl3, 10% MeOH/CHCl3) gave the title compound (1.66 g, 33%); 'H NMR (250 MHz, 15 CDC13) 5 9.11 (s, IH), 9.09 (s, IH), 3.92 (s, 2H), 2.90-2.95 (m, 3H), 1.40-1.45 (m, 9H); MS (ES) m/e 264 (M+H)+. b) 2-(Methylamino)methyl-4,6-diazabenzimidazole 2-[[N-(tert-Butoxycarbonyl)-N-methyl]aminomethyl]-4,6-20 diazabenzimidazole (1.13 g, 4.29 mmol) was treated with 4 N HCl in dioxane. A suspension formed, and more 4 N HCl in dioxane was added. The heterogeneous mixture was stirred at RT for 2 h, then was concentrated under vacuum. The re; . was dissolved in MeOH and the product was precipitated with Et20. The precipitate was collected on a sintered glass funnel and dried in a vacuum desiccator to yield the 25 title compound (328.5 mg, 46.9%) as a white powder. TLC RfO.36 (3:1:1 n- Bu0H/H0Ac/H20); >H NMR (250 MHz, CD3OD) 8 9.56 (s, IH), 9.33 (s, IH), 4.81 (s, 2H), 2.99 (s, 3H); MS (ES) m/e 164.0 (M+H)+. c) Methyl (S)-7-[[[2-(4,6-diazabenzimidazolyl)methyl]methylamino]carbonyl]-4-30 methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Methyl (S)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-1,4-benzodiazepine-2-acetate (262.6 mg, 0.55 mmol) was suspended in CH3CN (10 mL), and HOBt • H2O (86.7 mg, 0.64 mmol) was added, followed by EDC (115.5 mg, 0.60 mmol). Diisopropylethylamine (150 mL, 0.86 mmol) was added, affording 35 a homogeneous solution. A solution of.2-(methylamino)methyl-4,6- diazabenzimidazole (99.0 mg, 0.61 mmol) and diisopropylethylamine (150 mL, 0.86 123 mmol) was added, and the reaction was stirred at RT. After 3 d, the solvents were evaporated under vacuum, and the residue was reconcentrated from toluene. Chromatography (silica gel, step gradient, 5% MeOH/CHCl3, 10% MeOH/CHCl3) yielded the title compound (190 mg, 79.%): MS (ES) m/e 438.2 (M+H)+; 'H NMR 5 (250 MHz, CDC13) 5 9.06 (s, IH), 9.03 (s, IH), 7.90-7.15 (m, 3H), 6.45 (d, IH), 5.40 (d, IH), 4.93 (dd, IH), 3.71 (s, 3H), 3.16 (s, 3H), 2.98 (s, 3H). d) (S)-7-[[[2-(4,6-Diazabenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid 10 1.0 N NaOH (1.5 mL, 1.5 mmol) was added to a solution of methyl (S)-7- [[[2-(4,6-diazabenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (190.3 mg, 0.44 mmol) in MeOH (5 mL) and H2O (5 mL). The reaction was stirred at RT for 24 h, then was neutralized with 1.0 N HCl (1.5 mL). The reaction was concentrated to dryness 15 under vacuum, and the residue was purified by chromatography ( ODS, step gradient, 5% CH3CN/H2O-0.1 % TFA, 10% CH3CN/H20-0.1% TFA, 20% CH3CN/H20-0.1% TFA). One fraction was collected and concentrated under vacuum. The residue was reconcentrated from toluene and dried under vacuum, then was dissolved in MeOH and precipitated with F.t3N. The white precipitate was 20 collected on a sintered glass funnel and dried in a vacuum desiccator to afford the title compound as a white powder (126.5 mg, 67.9%): HPLC tR 0.41; (ODS, gradient elution over 20 min, 5-50% CH3CN/H20-0.1% TFA); MS (ES) m/e 424.2 (M+H)+. Anal. Calcd for C20H21N7O4 • 0.5 CF3C02H: C, 52.50; H, 4.51; N, 20.41. Found: C, 52.62; H, 4.88; N, 20.01.
Example 42 Preparation of (S)-7-rfr2-(4-azabenzimidazolvI)methvllmethvlaminolcarbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid a) 2-[[N-(Benzyloxycarbonyl)-N-methyl]aminomethyl]-4-azabenzimidazole 30 A solution of Cbz-sarcosine (5 g, 22.4 mmol) and Et3N (4 mL, 28.76 mmol) in dry THF was cooled to 0°C in an ice bath, and isobutylchloroformate (3.0 mL, 23.13 mmol) was added. The reaction was stirred at RT for 15 min, then was added to a solution of 2,3-diaminopyridine (2.5 g, 22.7 mmol) in dry THF at -25°C. The reaction was stirred at -20°C for 30 min, then was allowed to warm to RT. After 24 35 h, the reaction was concentrated under vacuum. The residue was taken up in EtOAc and washed with 1.0 N NaHC03. The organic layer was dried (MgS04), filtered and 124 concentrated under vacuum. The residue was dissolved in glacial AcOH (200 mL) and heated in an oil bath set at 109 CC. After 20 h, the reaction was concentrated under vacuum, and the residue was reconcentrated from toluene. Chromatography (Silica gel, step gradient, CHCI3,3% MeOH/CHCl3,5% MeOH/CHCl3) gave the 5 title compound (2.2 g, 33%), which was recrystallized fromEt20: MS (ES) m/e 296.2 (M+H)+. b) 2-(Methylamino)methyl-4-azabenzimidazole 2-[[N-(Benzyloxycarbonyl)-N-methyl]aminomethyl]-4-azabenzimidazole 10 (551.3 mg, 1.86 mmol) was dissolved in MeOH, and 10% Pd/C was added. The mixture was stirred briskly at RT under H2 (balloon). After 4 h, the reaction was filtered through Celite®, and the filtrate was concentrated under vacuum to afford the title compound (420.1 mg, quantitative): *H NMR (250 MHz, CDCI3) 5 8.34-8.32 (m, IH), 7.98-7.14 (m, 4H), 5.18-5.12 (m, IH), 4.87 (s, 2H), 3.32 (s, 3H). c) Methyl (S)-7-[[[2-(4-azabenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate EDC (309.1 mg, 1.61 mmol) was added to a solution of methyl (S)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate (504.6 20 mg, 1.54 mmol), diisopropylethylamine (0.30 mL, 1.78 mmol), and HOBt • H2O (228.2 mg, 1.69 mmol) in dry DMF at RT. After 10 minutes. 2-(methylamino)methyl-4-azabenzimidazole (3.08 mmol) neutralized with diisopropylethylamine (0.600 mL) was added, and the reaction was stirred at RT. After 20 h, the solvents were evaporated under vacuum, and the residue was 25 reconcentrated from toluene. Chromatography (silica gel, step gradient, CHCI3, 5% MeOH/CHCls, 10% MeOH/CHCl3) gave the title compound (326.8 mg, 48.6%): MS (ES) m/e 437.2 (M+H)+; >H NMR (250 MHz, CDCI3) 5 8.39 (d, IH), 8.00-7.20 fm, 5H), 5.50 (d, IH), 5.15-4.80 (m, 3H), 3.70 (s, 3H), 3.10 (s, 3H), 2.93 (s, 3H). d) (S )-7-[[[2-(4-Azabenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-IH-1,4-benzodiazepine-2-acetate 1.0 N NaOH (2.0 mL, 2.0 mmol) was added to a solution of methyl (S)-7-[[[2-(4-azabenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- 1H-1,4-benzodiazepine-2-acetate (326.8 mg, 0.75 mmol) in MeOH (10 35 mL) and H2O (10 mL) at RT. After 26 h, the reaction was neutralized with 1.0 N HCl (2.0 mL, 2.0 mmol) and concentrated under vacuum. The residue was taken up 125 in H2O and the resultant white precipitate was collected on a sintered glass funnel, washed with H2O and dried under vacuum to afford the title compound (218.1 mg, 69%) as a white powder: MS (ES) m/e 423.4 (M+H)+. Anal. Calcd for C21H22N604 • 2 H20: C, 55.02; H, 5.72; N, 18.33. Found: C, 55.07; H, 5.55; N, 5 17.81.
Example 43 Preparation of 7-ri-f2R-(2-benzimidazolvnpvrrolidinvllcarbonvll-4-methvl-3-oxo-2,3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2S-acetic acid 10 a) l-tert-Butoxycarbonyl-2R-(2-benzimidazolyl)pyrrolidine A solution of BOC-D-proline (3.0 g, 14 mmol.) and Et3N (2.5 mL, 18 mmol) in dry THF was cooled to 0 °C in an ice bath, and isobutylchloroformate (2.0 mL, 15 mmol) was added. The reaction was stirred at 0°C for 20 min, then was removed from the cooling bath and allowed to warm to RT for 10 minutes. The white slurry 15 was added to a solution of o-phenylenediamine (1.55 g, 4.3 mmol) in THF at -20 to -30°C. After the addition was complete, the reaction was removed from the cooling bath and allowed to proceed at RT. After 20 h, the reaction was concentrated under vacuum. The residue was taken up in EtOAc and washed with 1.0 N NaHC03. The organic layer was dried (MgS04), filtered and concentrated under vacuum. The 20 residue was dissolved in glacial AcOH and heated in an oil bath set at 70-75°C.
After 24 h, the AcOH was evaporated under vacuum, and the residue was reconcentrated from toluene. Recrystallizadon from EtOAc gave the title compound (1.1 g). The mother liquors were concentrated and the residue taken into Et20 to afford additional title compound (1.47 g). b) 2R-(2-benzimidazolyl)pyrrolidine l-tert-Butoxycarbonyl-2R-(2-benzimidazolyl)pyrrolidine (1.0702 g, 3.72 mmol) was treated with 4 N HCl/dioxane. After 2 h at RT, the reaction was concentrated under vacuum, and the residue was treated with Et20. The white 30 precipitate was collected and dried under vacuum to afford the title compound ( 958.1 mg, 99.1%): lH NMR (250 MHz, CDC13) 8 7.89-7.85 (m, 2H), 7.68-7.65 (m, 2H), 5.38-5.31 (m, IH), 3.67-3.61 (m, 2H), 3.33-3.31 (m, IH), 2.88-2.21 (m, 4H); [a]D -4.9_ (cl.0, H20). 126 c) Methyl 7-[l-[2R-(2-benzimidazolyl)pyrrolidinyl]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2S-acetate EDC (74.4 mg, 0.39 mmol) was added to a solution of methyl (S)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (104.2 mg, 0.32 5 mmol.), diisopropylethylamine (0.06 mL, 0.34 mmol), and HOBt • H2O (56.6 mg, 0.42 mmol) in dry DMF at RT. The reaction was stirred at RT, and a solution of 2R-(2-benzimidazolyl)pyrrolidine (89.7 mg, 0.35 mmol) and diisopropylethylamine (0.120 mL, 0.69 mmol) in DMF was added. After 20 h, the reaction was concentrated under vacuum, and the residue was reconcentrated from toluene. 10 Chromatography (silica gel, step gradient, CHCI3, 3% MeOH/CHCl3, 5% MeOH/CHCl3) gave the title compound (136.9 mg, 92.5%): !H NMR (250 MHz, CDCI3) 8 7.77 (d. IH), 7.63 (d, IH), 7.34-7.22 (m, 4H), 7.06-7.05 (m, IH), 6.37 (d, IH), 5.55-5.49 (a, IH), 5.30 (d, IH), 5.08-5.00 (m, IH), 3.68 (s, 3H), 2.92 (s, 3H),' 2.55-1.70 (m, 4H), 1.22 (t, 3H); MS (ES) m/e 462.2 (M+H)+ d) 7-[ 1 -[2R-(2-Benzimidazolyl)pyrTolidinyl]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahy dro-1H-1,4-benzodiazepine-2S-acetic acid 1.0 N NaOH (0.75 mL, 0.75 mmol) was added to a solution of methyl 7-[l-[2R-(2-benzimidazolyl)pyrrolidinyl]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-20 lH-l,4-benzodiazepine-2S-acetate (136.9 mg, 0.30 mmol) in MeOH (5 mL) and H2O (5 mL) at RT. After 24 h, 1.0 N HCl (0.75 mL, 0.75 mmol) was added and the reaction mixture was concentrated under vacuum. Chromatography (ODS, step gradient, 0.1% TFA/H20,20% CH3CN/H2O-0.1 % TFA), concentration, and reconcentration from toluene left a residue, which was redissolved in H2O. 25 Lyophilization gave the title compound (92 mg): HPLC tR=10.68 (ODS, gradient elution over 20 min, 5-50% CH3CN/H20-0.1% TFA); MS (ES) m/e 448.2 (M+H)+.
Example 44 Preparation of 7-f 1 -r2S-(2-benzimidazolvl)pvirolidinvPcarbonvn-4-methvl-3-oxo-30 2,3.4.5-tetrahvdro-lH-l .4-benzodiazepine-2S-acetic acid a) 1 -tert-Butoxycarbonyl-2S-(2-benzimidazolyl)pyrrolidine Following the procedure of Example 43(a), except substituting BOC-L-proline for the BOC-D-proline, the title compound (3.2 g, 74%) was prepared. 'H NMR (250 MHz, CDCI3) 8 7.53 (br s, IH), 7.19-7.16 (m, 4H), 5.14 (d, IH), 3.50 (s, 35 2H), 2.87 (br s, IH), 2.19-1.97 (m, 3H)„ 1.49 (s, 9H), 1.25 (br s, 2H); MS (ES) m/e 288.2 (M+H)+. 127 PCT/U S95/08306 b) 2S-(2-benzimidazolyl)pyrrolidine Following the procedure of Example 43(b), except substituting 1-tert-butoxycarbonyl-2S-(2-benzimidazolyl)pyrrolidine for the l-tert-butoxycarbonyl-2R-5 (2-benzimidazolyl)pyrrolidine, the title compound was prepared( 1.7988 g, 98.4%): 'H NMR (250 MHz, CDC13) 8 7.89-7.86 (m, 2H), 7.69-7.65 (m, 2H), 5.30-5.40 (m, IH), 3.68-3.63 (m, 2H), 3.33-3.32 (m, IH), 2.20-2.89 (m, 4H), [a]D +3.9- (c 1.0, H20). c) Methyl 7-[l-[2S-(2-benzimidazolyl)pyrrolidinyl]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2S-acetate Following the procedure of Example 43(c), except substituting 2S-(2-benzimidazolyl)pyrrolidine for the 2R-(2-benzimidazolyl)pyrrolidine, the title compound (90.4 mg, 61%) was prepared: MS (ES) m/e 462.4 (M+H)+. d) 7-[ 1 -[2S-(2-Benzimidazolyl)pyrrolidinyI]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-1,4-benzodiazepine-2S-acetic acid Following the procedure of Example 43(d), except substituting methyl 7-[l-[2S-(2-benzimidazolyl)pyrrolidinyl]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-20 1H-1,4-benzodiazepine-2S-acetate for the methyl 7-[ 1 -[2R-(2- benzimidazolyl)pyrrolidinyl] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2S-acetate, the title compound (65.8 mg, 75%) was prepared; HPLC tR=10.63 (ODS, gradient elution over 20 min, 5-50% CH3CN/H20-0.1% TFA); MS (ES) m/e 448.2 (M+H)+.
Example 45 Preparation of (±)-7-nT2-(4-azabenzimidazolvI)methvnmethvlamino'lcarbonvn-4-isopropvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid a) Methyl (±)-7-[[[2-(4-azabenzimidazolyl)methyl]methylamino]carbonyl]-4-30 isopropyl-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetate Following the procedure of Example 42(c), except substituting methyl (±)-7-carboxy-4-isopropyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate for the methyl (S)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate, the title compound (226 mg, 96%) was prepared: TLC Rf 35 (5% MeOH/CHCl3) 0.28; *H NMR (250 MHz, CDC13) 8 8.45 (d, IH), 7.96-7.10 (m, 128 5H), 6.40 (br s, IH), 5.09-4.77 (m, 5H), 3.70 (s, 3H), 3.47 (s, 3H), 3.09 (s, 3H), 1.23 (t, IH), 1.09 (d, IH), 0.86 (brs, IH). b) (±)-7-[[[2-(4-Azabenzimidazolyl)methyl]methylamino]carbonyl]-4-isopropyl-3' 5 oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid 1.0 N NaOH (1.5 mL, 1.5 mmol) was added to a solution of methyl (±)-7-[[[2-(4-azabenzimidazolyl)methyl]methylamino]carbonyl]-4-isopropyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (226.2 mg, 0.49 mmol) in MeOH (5 mL) and H20 (5 mL) at RT. After 24 h, the reaction was neutralized with 10 1.0 N HCl and the solvents were evaporated under vacuum. ODS chomatography (0.1 % TFA/H2O, followed by 20% CH3CN/H20-0.1% TFA), concentration, and reconcentration from toluene left a residue, which was redissolved in H20. Lyophilization gave impure title compound (181.9 mg) as a white powder, which was repurified by ODS chromatography (10% CH3CN/H20-0.1% TFA, followed by 15 20% CH3CN/H20-0.1 % TFA). Concentration and reconcentration from toluene left a residue, which was dissolved .in MeOH and precipitated with Et20. The precipitate was collected on a sintered, glass funnel and dried in a vacuum desiccator to afford the title compound (65.5 mg): HPLC (ODS, gradient elution over 20 min, 5-50% CH3CN/H20-0.1% TFA) tR=12.32; MS (ES) m/e 451.2 (M+H)+. Anal. 20 Calcd for C23H26N6O4 • 0.5 CF3C02H • 0.75 H20: C, 55.33; H, 5.42; N, 16.13. Found: C, 55.43; H, 5.60; N, 16.01.
Example 46 Preparation of (S)-7-riT2-(4-aza-5-25 methvlbenzimidazolvl')methvl1methvlaminolcarbonvn-4-methvl-3-oxo-2.3.4.5-tetrahydro-1H-1.4-benzodiazepine-2-acetic acid a) 2-Amino-6-methyl-3-nitropyridine 2-Amino-6-picoline (5.1 g,47.1 mmol) was weighed into a 500 mL round bottom flask, and the flask was cooled to -30°C. Concentrated H2S04 (20 mL) was 30 added, which caused some fuming to occur. Concentrated HNO3 (10 mL, 160 mmol) was then added dropwise slowly. The reaction was allowed to warm to RT over 30 min, then was heated in an oil bath set at 80°C. After 90 min, the reaction was removed from the heating bath, and ice was added. 6.25 N NaOH (150 mL, 937.5 mmol) was added slowly, and the resulting yellow precipitate was collected on 35 a sintered glass funnel. Drying in a vacuum desiccator gave the title compound (1.7 129 g, 24%): TLC Rf (5% MeOH/CHCl3) 0.77; «H NMR (250 MHz, CDC13) 8 8.31 (d, IH), 6.32 (d, IH), 2.46 (s, 3H); MS (ES) m/e 154.0 (M+H)+ b) 2,3-Diamino-6-methylpyridine 2-Amino-6-methyl-3-nitropyridine (754 mg, 4.92 mmol) was suspended in MeOH, and 10% Pd/C was added. The mixture was stirred briskly at RT under H2 (balloon). After 4 h, the reaction was filtered through Celite®, and the filtrate was concentrated under vacuum to afford the title compound (677. mg, quantitative): 'H NMR (250 MHz, CD3OD) 5 6.82 (d, lH), 6.36 (d, IH), 2.25 (s, 3H). c) 2-[[N-(Benzyloxycarbonyl)-N-methyl]aminomethyl]-5-methyl-4-azabenzimidazole A solution of Cbz-sarcosine (1.8 g, 7.85 mmol) in dry THF at RT was treated with isobutylchloroformate (1.25 mL, 9.64 mmol), followed by Et3N (3.0 mL, 21.57 15 mmol). After 30 min, a solution of 2,3-diamino-6-methylpyridine (882 mg, 7.16 mmol) in dry THF was added, and the reaction was stirred at RT. After 3 d, the reaction was concentrated under vacuum. The residue was taken up in EtOAc and washed with 1.0 N NaHC03. The organic layer was dried (MgS04), filtered, concentrated under vacuum, and reconcentrated from toluene. The residue was 20 dissolved in glacial AcOH (100 mL) and heated in an oil bath set at 110°C. After 24 h, the reaction was concentrated under vacuum, and the residue was reconcentrated from toluene. Chromatography (silica gel, step gradient, CHC13, 2% MeOH/CHCl3, 3% MeOH/CHCb) gave the title compound (1.0 g, 46.6%): 'H NMR (250 MHz, CDCI3) 8 7.29 (s, 5H), 7.17 (s, IH), 7.03 (d, IH), 5.09 (s, 2H), 4.74 (s, 2H), 3.05 (s, 25 3H), 2.61 (s, 3H); MS (ES) m/e 311.0 (M+H)+ d) 2-(Methylamino)methyl-5-methyl-4-azabenzimidazole 2-[[N-(Benzyloxycarbonyl)-N-methyl]aminomethyl]-5-methyl-4~ azabenzimidazole (1.0347 g, .33 mmol) was dissolved in MeOH, and 10% Pd/C was 30 added. The mixture was stirred briskly at RT under H2 (balloon). After 20 h, the reaction was filtered through Celite®, and the light yellow filtrate was concentrated under vacuum to afford the title compound (678.9 mg, quantitative) as a reddish colored material. 130 WO 96'00730 e) Methyl (S)-7-[[[2-(4-aza-5- methylbenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1 H-l ,4-benzodiazepine-2-acetate EDC (212.7 mg, 1.11 mmol) was added to a solution of methyl (S)-7-5 carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodi'azepine-2-acetate (293.5 mg, 0.93 mmol), diisopropylethylamine (0.30 mL, 1.72 mmol), and HOBt • H20 (143.5 mg, 1.06 mmol) in dry DMF at RT. After 30 minutes, a solution of 2-(methylamino)methyl-5-methyl-4-azabenzimidazole (190.7 mg, 1.08 mmol) in diy DMF was added. The reaction was stirred at RT for 24 h, then was concentrated 10 under vacuum, and the residue was reconcentrated from toluene. Chromatography (silica gel, step gradient, CHCI3, 3% MeOH/CHCl3, 5% MeOH/CHCl3) gave the title compound (265 mg, 63%): !H NMR (250 MHz, CDCI3) 8 8.51 (br s. IH), 7.86-7.05 (m, 5H), 5.34 (d, IH), 5.06 (t, IH), 3.69 (s, 3H), 3.08 (s, 3H), 2.62 (s, 3H); MS (ES) mIt 451.2 (M+H)+ f) (S)-7-[[[2-(4-Aza-5-methylbenzimidazolyl)methyl]methylammo]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid 1.0 N NaOH (2.0 mL, 2.0 mmol) was added to a solution of methyl (S)-7-[[[2-(4-aza-5-methylbenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-20 oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (264.7 mg, 0.59 mmol) in MeOH (10 mL) and H20 (10 mL) at RT. After 20 h, the reaction was neutralized with 1.0 N HCl (2.0 mL) and the solvents were evaporated under vacuum. The crude material was precipitated from water to give the title compound (49.8 mg): TLC Rf0.51 (3:1:1 n-Bu0H/H0Ac/H20); HPLC tR=8.35 min (PRP-1®, gradient 25 elution over 20 min, 5-50% CH3CN/H20-0.1 % TFA); MS (ES) m/e 437.2 (M+H)+. Anal. Calcd for C22H24N6O4 • 0.75 H20 • 1.2 HCl: C, 42.56; H, 3.53; N, 11.03. Found: C, 42.20; H, 3.02; N, 11.36.
Example 47 Preparation of fS)-7-rrf2-(5.6- dimethoxvbenzimidazolvl)methvllmethvlamino1carbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid a) 2-[[N-(Benzyloxycarbonyl)-N-methyl]aminomethyl]-5,6-d imethoxybenzimidazole 35 Cbz-sarcosine (1.4 g, 6.1 mmol) was dissolved in dry THF in a 100 mL roundbottom flask, and Et3N (1.5 mL, 10.8 mmol) was added, followed by 131 isobutylchloroformate (0.80 mL, 6.17 mmol). The reaction was stirred at RT, then was added to a solution of 4,5-dimethoxyphenylenediamine (6.06 mmol) in dry THF at -25°C. The Cbz-sarcosine, mixed-anhydride solution was added to the cooled phenylenediamine solution. The reaction was stirred at -25°C for 10 min, then was 5 allowed to warm to RT. After 20 h, the reaction was concentrated under vacuum. The residue was taken up in EtOAc and washed with 1.0 N NaHC03. The organic layer was dried (MgSO/}), filtered, concentrated under vacuum, and reconcentrated from toluene. The residue was dissolved in glacial AcOH (100 mL) and heated in an oil bath heated set at 110 °C. After 24 h, the reaction was concentrated under 10 vacuum. Flash chromatography (silica gel, step gradient, 2% MeOH/CHCl3, 5% MeOH/CHCl3) gave the title compound (1.7 g, 81%): >H NMR (250 MHz, CDC13) 8 7.33 (s, 5H), 7.05 (s, 2H), 5.15 (s, 2H), 4.64 (s, 2H), 3.88 (s, 6H), 3.04 (s, 3H); MS (ES) m/e 356.2 (M+H)4 . b) 2-(Methylamino)methyl-5,6-dimethoxybenzimidazole 2-[[N-(Benzyloxycarbonyl)-N-methyl]aminomethyl]-5,6-dimethoxybenzimidazole (1.7454 g, 4.91 mmol) was dissolved in MeOH, and 10% Pd/C was added. The mixture was stirred briskly at RT under H2 (balloon). After 4 h, the reaction was filtered through Celite®, and the filtrate was concentrated under 20 vacuum to afford the title compound. c) Methyl (S)-7-[[[2-(5,6- dimethoxybenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahy dro-1H-1,4-benzodiazepine-2-acetate 25 EDC (139.9 mg, 0.73 mmol) was added to a suspension of methyl (S)-7- carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate (198.5 mg, 0.68 mmol), and HOBt • H20.(98.8 mg, 0.73 mmol) in CH3CN at RT. After 15 minutes, diisopropylethylamine (0.200 mL, 1.15 mmol) was added, followed by a solution of 2-(methylamino)methyl-5,6-dimethoxybenzimidazole (147.3 mg, 0.67 30 mmol) in CH3CN. The reaction was stirred at RT for 24 h, then the solvents were evaporated under vacuum. The residue was reconcentrated from toluene, then was chromatographed (silica gel, step gradient, CHCI3, 3% MeOH/CHCl3,5% MeOH/CHCl3) to afford the title compound (227 mg, 68%): 'H NMR (250 MHz, CDCI3) 5 7.29-7.16 (m, 5H), 5.37 (d, IH), 5.09 -5.03 (m, IH), 4.86-4.72 (m, 3H), 35 3.90 (s, 6H), 3.71 (s, 3H), 3.12 (s, 3H); MS (ES) m/e 496 (M+H)+. 132 d) (S)-7-[[[2-(5,6-dimethoxybenzimidazolyl)methyl]methylamino'icarbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid 1.0 N NaOH (1.5 mL, 1.5 mmol) was added to a solution of methyl (S)-7-[[[2-(5,6-dimethoxybenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-5 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (227.1 mg, 0.46 mmol) in MeOH (10 mL) and H2O (10 mL) at RT. After 24 h, the reaction was neutralized with 1.0 N HCl (1.5 mL, 1.5 mmol). After 30 min, a white precipitate had formed, which was collected on a sintered glass funnel and washed with water. The material was dried in a vacuum desiccator to afford the title compound (144.3 mg, 65%): MS 10 (ES) m/e 482.2 (M+H)+. Anal. Calcd for C24H27N506 • 1.75 H20 • 0.4 HCl: C, 54.64; H, 5.90; N, 13.27. Found: C, 54.69; H, 5.92; N, 12.67.
Example 48 Preparation of (±')-8-lT2-(2-benzimidazolvl)acetv]1amino'l-2-methvl-3-oxo-2.3.4.5-15 tetrahydro- lH-2-benzazepine-4-acetic acid a) Methyl (±)-8-[[2-(2-benzimidazolyl)acetyl]amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-1 H-2-benzazepine-4-acetate Methyl (±)-8-amino-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate was coupled with 2-benzimidazloylacetic acid according to the procedure of 20 example 11(a). Purification by chromatography (silica gel, 2%-5% CH3OH/CH2CI2) gave the title compound as a colorless foam (31%): JH NMR (CDCI3) 7.55 (m, IH), 7.44 (d, J=2 Hz, IH), 7.38 (dd, J=8.3 Hz, 3=2 Hz, IH), 7.30 (m, 2H), 5.18 (d, J=16.3 Hz, IH), 4.24 (s, 2H), 3.71 (m, IH), 3.68 (s, 3H), 3.65 (d, J=16.3 Hz, IH), 3.03 (m, IH), 2.95 (s, 3H), 2.85 (m, IH), 2.40 (dd, J=16.9,6.3 Hz, 25 IH). b) (±)-8-[[2-(2-Benzimidazolyl)acetyl]amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetic acid Methyl (±)-8-[[2-(2-benzimidazolyl)acetyl]amino]-2-methyl-3-oxo-2,3,4,5-30 tetrahydro-lH-2-benzazepine-4-acetate was saponified according to the procedure of Example 24(b) to give the tide compound as a white solid (47%): JH NMR (DMSO-d6) 6 10.38 (s, IH), 7.49 (m, 3H), 7.42 (d, J=8.4 Hz, IH), 7.15 (m, 2H), 7.06 (d, J=8.4 Hz, IH), 5.24 (d, J=16.5 Hz, IH), 3.96 (s, 2H), 2.35 (m, IH); MS (ES) m/e 407.2 (M+H)+. Anal. Calcd for C22H22N4O4 -1.75 H2O: C, 60.33; H, 5.87; N, 35 12.79. Found: C, 60.57; H, 5.49; N, 12,41.
PCTAJS95/08306 Example 49 Preparation of ('±)-8-rrff2-benzimidazolvl')methvllmethvlamino1carbonvll-4-methvl-3-0X0-2.3.4.5-tetrahvdro-lH-2-benzazepine-4-acetic acid a) Methyl (±)-8-[[[(2-benzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3- oxo-2,3.4,5-tetrahydro-lH-2-benzazepine-4-acetate Methyl (±)-8-carboxy-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate was coupled with 2-(methylamino)methylben7imidazole according to the procedure of Example 2(a). Purification by chromatography (silica gel, l%-6% CH3OH/CH2CI2) gave the title compound as a white foam (76%): 'H NMR 10 (CDCI3) 8 7.62 (m, 2H), 7.43 (m, IH), 7.30 (m, 2H), 7.13 (m, 2tf), 5.06 (d, J=14.6 Hz, IH),.4.86 (d, J=14.6 Hz, IH), 4.77 (dd, J=16.6 Hz, J=4 Hz), 3.91 (dd, J=16.6,6 Hz, IH), 3.72 (s, 3H), 3.08 (s, 3H), 3.05 (m, 2H), 2.52 (dd, J=16.9, 5.7 Hz, IH). b) (±)-8-[[[(2-Benzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-15 2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetic acid Methyl (±)-8-[[[(2-benzimidazolyl)methyI]methylamino]carbonyl]-4-methyl-3-0X0-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate was saponified according to the procedure of Example 11 (b) 10 give the title compound as a white solid (90%): *H NMR (DMSO-d6) 8 7.88 (m, IH), 7.54 (m, 2H), 7.34 (d, J=7.9 Hz, IH), 7.30 (s, 20 IH), 7.16 (m, 2H), 6.98 (m, IH), 4.87 (m, IH), 4.67 (m, 2H), 4.00 (m, IH), 3.87 (m, IH), 3.10 (m, IH), 3.02 (s, 3H), 2.76 (m, IH), 2.43 (m, IH), 1.97 (m, IH); MS (ES) m/e 407 (M+H)+. Anal. Calcd for C22H2lN4C>4Li • 2.375 H2O: C, 58.05; H, 5.70: N, 12.31. Found: C, 57.85; H, 5.41; N, 12.66.
Example 50 Preparation of fS)-7-nT(2-benzimidazolvl)methvnmethvlamino'lcarbonvl1-3-oxo-4-(2-phenvlethvl')-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid a) Methyl (S)-7-carboxy-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate 30 To a solution stirred under argon at RT of methyl (±)-7-carboxy-3-oxo-4-(2- phenylethyl)-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (9.0 g, 23 mmol) in CH3CN (100 mL) was added diazabicycloundecene (4.6 g, 30 mmol), followed by benzyl bromide (20 g, 116 mmol). The resulting solution was stirred for 1 h, then was concentrated. The residue was partitioned between 1.0 N HCl and EtOAc, and 35 the layers were separated. The organic layer was washed with brine, dried (MgS04), and concentrated. The residue was purified by chromatography (silica gel, CH2CI2) 134 PCTAJS95/08306 to give a pale yellow oil (7 g). Preparative HPLC (Whelk 0-1, 50:50:1 hexanc:CHCl3:CH30H) gave an oil which was 97% of the desired (S)-enantiomer. Removal of racemate by crystallization (EtOAc) gave a colorless oil (3.2 g, 98% ee). This material was placed in a 500 mL Parr hydrogenation vessel with CH3OH (30 5 mL) and 10% Pd/C (0.45 g), and the mixture was shaken under H2 (50 psi) for 6 h. The reaction mixture was then filtered and the filtrate was concentrated to give the title compound as a colorless foam (2.1 g, 47%): 'H NMR (CDCI3) 8 7.78 (dd, J=8.5, 1.9 Hz, IH), 7.55 (d, J=1.9 Hz, IH), 7.30-7.10 (m, 5H), 6.51 (d,J=8.5 Hz, IH), 5.30 (d, J= 16.6 Hz, IH), 5.10 (t, J=6.5 Hz, IH), 3.77 (s, 3H), 3.74 (m, 3H), 10 3.67 (d, J=16.6 Hz, IH), 3.02 (dd, J=16, 6.8 Hz, IH), 2.83 (t, J=7.1 Hz, 2H) 2.69 (dd, J=16, 6.5 Hz, IH). b) Methyl (S)-7-[[[(2-benzimidazolyl)methyl]methylamino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate 15 Methyl (S )-7-carboxy-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,4- benzodiazepine-2-acetate was coupled with 2-(methylamino)methylbenzimidazole according to the procedure of Example 2(a). Purification by chromatography on silica gel (l%-5% CH3OH/CH2CI2) gave the title compound (2.85 g, 99%) as a colorless foam: iH NMR (CDCI3) 8 7.63 (m, 2H), 7.33 (m, 2H), 7.25-7.10 (m, 7H), 20 6.59 (d, J=8.3 Hz, IH), 5.24 (d, J=16.7 Hz, IH), 5.03 (m, IH), 4.94 (d, J=14.6 Hz, IH), 4.85 (d, J=14.6 Hz, IH), 4.50 (d, J=4.7 Hz, IH), 3.77 (m, IH), 3.76 (s, 3H), 3.59 (d, J=16.7 Hz, IH), 3.57 (m, IH), 3.19 S, 3H), 2.99 (dd, J=16, 6.5 Hz, IH), 2.81 (m, 2H), 2.67 (dd, J=16, 6.4 Hz, IH). c) (S)-7-[[[(2-Benzimidazolyl)methyl]methylamino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid Methyl (S)-7-[[[(2-benzimidazolyl)methyI]methylamino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate was saponified according to the procedure of Example 11(b) to give the title compound (1.8 g, 66%) 30 as a white solid: *H NMR (DMSO-d6) 8 7.54 (m, 2H), 7.30-7.10 (m, 9H), 6.54 (d, J=8.3 Hz, IH), 6.30 (br s, IH), 5.37 (d, J=16.2 Hz, IH), 5.05 (m, IH), 4.77 (s, 2H), 3.97 (br s, IH), 3.51 (m, 3H), 3.05 (s, 3H), 2.65 (m, 3H), 2.49 (m, IH). Anal. Calcd for C29H29N5O4 • H2O: C, 65.77; H, 5.90; N, 13.22. Found: C, 65.51; H, 5.84; N, 13.19.
Example 51 Preparation of (±)-7-i IT2-(benzimidaz0lvnmethvnamir)0lcarb0nvl-4-f2-(3.4-methvlenedioxvphenvl')ethvll-3-oxo-2.3.4.5-tetrahvd'ro-1H-1.4-benzodiazepine-2-acetic acid a) Methyl (±)-7-[[[2-(benzimidazolyl)methyl]ainino]carbonyl-4-[2-(3,4- methylenedioxyphenyl)ethyl]-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Methyl (±)-7-carboxy-4-[2-(3,4-methylencdioxyphenyl)ethyl]-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate was coupled with 2-10 (aminomethyl)benzimidazole dihydrochloride hydrate according to the procedure of Example 2(a). Purification by chromatography (silica gel, l%-5% CH3OH/CH2CI2) followed by recrystallization (CH30H/Et0Ac) gave the title compound as a tan solid (59%): !H NMR (DMSO-d6) 5 8.72 (t, J=5 Hz, IH), 7.61 (s, IH), 7.56 (m, 2H), 7.43 (m, IH), 7.13 (m, 2H), 6.76 (m, 2H), 6.57 (m, 2H), 6.37 (d, J=3.6 Hz, IH), 15 5.95 (s, 2H), 5.42 (d, J=16.5 Hz, IH), 5.13 (m, IH), 4.64 (m, 2H), 3.92 (d, J=16.5 Hz, IH), 3.61 (s, 3H), 3.58 (m, 2H), 2.83 (dd, J=16.6, 7.6 Hz, IH), 2.65 (m, 3H). b) (±)-7-[[[2-(Benzimidazolyl)methyl]ammo]carbonyl-4-[2-(3,4-methylenedioxyphenyl)ethyl]-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-20 acetic acid Methyl (±)-7-[[[2-(benzimidazolyl)methyl]amino]carbonyl-4-[2-(3,4-methylenedioxyphenyl)ethyl]-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate was saponified according to the procedure of Example 11(b) to give the title 25 compound (84%) as a white solid: 'H NMR (DMSO-d6) 8 8.76 (t, J=5 Hz, IH), 7.58 (m, 2H), 7.48 (m, 2H), 7.13 (m, 2H), 6.76 (m, 2H), 6.58 (m, 2H), 5.94 (s, 2H), 5.40 (d, J=16.5 Hz, IH), 5.06 (m, IH), 4.64 (m, 2H), 3.91 (d, J=16.5 Hz, IH), 3.54 (m, 2H), 2.72 (m, IH), 2.60 (t, J=8 Hz, 2H), 2.50 (m, 1); MS (ES) m/e 542 (M+H)+. Anal. Calcd for C29H27N5O6 • 1.5 H2O: C, 61.26; H, 5.32; N, 12.32. Found: C, 30 61.42; H, 5.22; N, 12.25.
Example 52 Preparation of (±)-7-nT(4(5)-imidazolvl)methvllaminolcarbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid 136 a) Methyl (±)-7-[[[(4(5)-imidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate Following the procedure of Example 23(a), except substituting 4(5)-(aminomethyl)imidazole (prepared according to J. Pharm. Sci. 1973, 403) for the 2-5 (aminomethyl)imidazole, and healing the reaction at 90-100°C for 24 h, the title compound (21%) was prepared: MS (ES) m/e 372 (M+H)+. b) (±)-7-[[[(4(5)-Imidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid Following the procedure of Example 23(b), methyl (±)-7-[[[(4(5)- imidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate was saponified to give the title compound: MS (ES) m/e 358 (M+H)+. Anal. Calcd for C17H19N5O4 • 1.15 CF3C02H • 0.05 H20: C, 47.37; H, 4.17; N, 14.31. Found: C, 47.70; H, 3.91; N, 13.92.
Example 53 Preparation of (±)-r[T4-(2-phenvlimidazolvl)methvnaminolcarbonvn-4-methvl-3-oxo-2.3.4.5-tetrahydro-1H-1.4-benzodiazeDine-2-acetic acid a) 4-Aminomethyl-2-phenylimidazole dihydrochloride 20 Hydroxylamine hydrochloride (229 mg, 3.3 mmol) was added to a suspension of 2-phenylimidazolc-4-carboxaldehyde (516 mg, 3 mmol; prepared according toJ. Chem. Soc. Perkin Trans. 11974, 1527) and sodium acetate (541 mg, 6.6 mmol) in absolute EtOH (5 mL) and H2O (5 mL) at RT. A yellow, homogeneous solution was produced. After 15 min, the reaction was concentrated 25 on the rotavap to remove the EtOH, and the oily, aqueous mixture was extracted with 20% MeOH/CHCl3 (10 mL) then with CHCI3 (10 mL). The combined organic layers were dried (MgS04) and concentrated to leave a yellow foam.
The yellow foam was dissolved in absolute EtOH (9 mL), and 1.0 N HCl (6 mL, 6 rnmol) and 10% Pd/C (0.32 g, 0.3 mmol) were added. The mixture was 30 shaken on a Parr apparatus at RT under H2 (50 psi) for 4 h, then was filtered through Celite®. The filtrate was concentrated on the rotavap to leave a light yellow solid. Recrystallization fron absolute EtOH/H20 gave the title compound as a light pink solid (465 mg, 63%): mp 273-275°C (dec.); >H NMR (250 MHz, CD3OD) 6 7.93-8.12 (m, 2H), 7.80 (s, IH), 7.50-7.76 (m, 3H), 4.40 (s, 2H); MS (ES) m/e 347.2 (2M 35 +H)\ 174.0 (M+H)+, 157.0 (M+H-NH3)+. 137 PCTAJS95/08306 b) Methyl (±)-[[[4-(2-phenylimidazolyl)methyl]ainino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate EDC (138 mg, 0.72 mmol) was added to a solution of methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (175.4 mg, 0.6 5 mmol), 4-aminomethyl-2-phenylimidazole dihydrochloride (177.2 mg, 0.72 mmol), HOBTH2O (97.3 mg, 0.72 mmol), and diisopropylethylamine (0.52 mL, 3.0 mmol) in anhydrous DMF (3 mL) at RT. After 22 h, the reaction was concentrated on the rotavap (high vacuum), and the residue was partitioned between H2O and EtOAc. The layers were separated, and the aqueous was extracted with CHCI3. The organic 10 layers were combined, which caused an oil to separate. This was dissolved by addition of MeOH. Drying (MgS04), concentration, and reconcentration from xylenes (to remove DMF) left a yellow semisolid residue. Chromatography (silica gel, 10% MeOH/CHCl3) gave the title compound (230 mg, 86%) as an oily foam which solidified to an off-white solid on treatment with EtOAc: TLC Rf 0.42 (10% 15 MeOH/CHCl3); *H NMR (400 MHz, 10% CD3OD/CDCI3) 6 7.82 (d, J=7.3 Hz, 2H), 7.28-7.57 (m, 5H), 7.03 (s, IH), 6.54 (d, J=8.5 Hz, IH), 5.48 (d, J=16.6 Hz, IH), 5.12 (t, J=6.8 Hz, IH), 4.52 (s, 2H), 3.79 (d, J=16.6 Hz, IH), 3.73 (s, 3H), 3.06 (s, 3H), 2.98 (dd, J=16.2, 7.6 Hz, IH), 2.66 (dd, J=16.2, 6.0 Hz, IH); MS (ES) m/e 470.2 (M+Na)+, 448.2 (M+H)+. c) (±)-[[[4-(2-Phenylimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahy dro-1H-1,4-benzodiazepine-2-acetic acid A suspension of methyl (±)-[[[4-(2-pheny limidazolyl )methy 1] amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-25 l,4-benzodiazepine-2-acetate (229.6 mg, 0.51 mmol), 1.0 N LiOH (0.61 mL, 0.61 mmol), THF (2.6 mL), and H20 (2 mL) was stirred at RT. A homogeneous solution had formed within 15 min. After 2.5 h, the reaction was concentrated to about 1 mL and filtered. An extra portion of H2O (2 mL) was used in the filtration. The filtrate was neutralized with 1.0 N HCl (0.61 mL), and the solid was collected and washed 30 with H20. The resulting solid was triturated with hot 1:1 CH3CN/H2O, filtrered, and washed sequentially with CH3CN and H2O. Drying in high vacuum gave the title compound (187.4 mg, 82%) as a colorless powder: HPLC k' 1.6 (PRP-1®, 20% CH3CN/H20-0.1% TFA); *H NMR (400 MHz, DMSO-d6) 8 8.32-8.47 (m, IH), 7.90 (d, 5=1.5 Hz, 2H), 7.51-7.61 (m, 2H), 7.38-7.48 (m, 2H), 7.26-7.36 (m, IH), 35 7.01 (br s, IH), 6.54 (d, J=8.3 Hz, 1H),.6.30 (s, IH), 5.48 (d, J=16.5 Hz, IH), 5.02-5.12 (m, IH), 4.38 (br s, 2H), 3.81 (d, J=16.5 Hz, 1H),2.91 (s, 3H),2.76(dd, 138 J=16.7, 9.1 Hz, IH), 2.54 (dd, J=16.7, 4.9 Hz, 1 H, partially obscured by residual solvent signal); MS (ES) m/e 434.2 (M+H)+. Anal. Calcd for C23H23N5O4 • 0.75 H20: C, 61.81; H, 5.52; N, 15.67. Found: C, 62.05; H, 5.44; N, 15.59.
Example 54 Preparation of (±y7-nT2-(3-indolvPethvnaminolcarbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acctic acid a) Methyl (±)-7-[[[2-(3-Indolyl)ethyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate Following the procedure of Example 26(d), except substituting 3-(2- aminoethyl)indole for the l-methyl-2-(methylamino)metliylindole, the title compound was prepared (50%): MS (ES) m/e 435.2 (M+H)+. b) (±)-7-[[[2-(3-Indolyl)ethyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-15 tetrahydro-1H-1,4-benzodiazepine-2-acetic acid Following the procedure of Example 26(e), methyl (±)-7-[[[2-(3-Indolyl)ethyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate was saponified to give the title compound as a colorless solid. MS (ES) m/e 421.0 (M+H)+. Anal. Calcd for C23H24N4O4 • 1.3 H20: C, 20 62.24; H, 6.04; N, 12.24. Found: C, 62.31; H, 5.61; N, 12.04.
Example 55 Preparation of (Sy7-nT2-(4-phenvlimidazolvi)methvnaminolcarbonvn-4-methvl-3-oxo-2.3.4.5-tetrahvdro-1H-1.4-benzodiazepine-2-acetic acid 25 a) Methyl (S)-7-[[[2-(4-phenylimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5 -tetrahydro-1H-1,4-benzodiazepine-2-acetate Following the procedure of Example 23(a) except substituting 2-(aminomethyl)-4-phenyl imidazole (Aust. J. Chem., 1971,24,2389) for 2-(aminomethyl)imidazole, the title compound was prepared: MS (ES) m/e 448 (M+H)+. b) (S)-7-[[[2-(4-Phenylimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid Following the procedure of Example 23(b) methyl (S)-7-[[[2-(4-phenylimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-35 1,4-benzodiazepine-2-acetate was saponified to give the title compound: MS (ES) 139 WO 96/00730 PCT/US95/08306 m/e 434 (M+H)+. Anal. Calcd for C23H23N5O4 • 0.5 CF3CO2H • 0.5 HCl • 1.75 H20: C, 47.01; H, 4.80; N 11.42. Found: C, 47.14; H, 4.17; N, 11.51.
Examples 56-75 Following the general procedures of Examples 1-55, the following compounds were prepared: 56. (+/-)-2,3,4,5-Tetrahydro-7-[[[benzimidazol-2-yl)methyl]methylamino]carbonyl]-4-(3,3-dimethylbutyl)-3-oxo-1H-1,4-benzodiazepine-2-acetic acid; 10 57. (-)-7-[[[6-Trifluoromethylbenzimidazoyl-2-ylmethyl]aminomethyl]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-benzodiazepine-2-acetic acid; 58. (-)-7-[[[4,7-Dimethoxybenzimidazoyl-2-ylmethyl]aminomethyl]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-benzodiazepine-2-acetic acid; 59. (+/-)-2,3,4,5-Tetrahydro-7-[[[(benzimidazol-2-yl)methylamino]carbonyl]-4-15 (3,3-dimethylbutyl)-3-oxo-1H-1,4-benzodiazepine-2-acetic acid; 60. (-)-7-[[[7-Methylbenzimidazol-2-ylmethyl]methyIamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-l,4-benzodiazepine-2-acetic acid; 61. (2S)-[[[N-aminobutyl-N-(benzimidazlo-2-yl)methyl]amino]carbonyl]-3-oxo-4-methyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acidbis(trifluoroacetate)salt; 62. (2S)-[[[N-cyanomethyl-N-(benzimidazlo-2-yl)methyl]amino]carbonyl]-3-oxo-4-methy 1-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid dihydrochloride salt; 63. (S)-2,3,4,5-Tetrahydro-7-[[[(benzimidazol-2-yl)]methyl]amino]carbonyl]-4-25 (4-phthalimidobutyl)-3-oxo-l,4-benzodiazepine-2-acetic acid; 64. (-)-7-[[[Imidazo[4,5B]-4,6-dimethylpyridyl-2-ylmethyl]aminomethyl]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-benzodiazepine-2-acetic acid trifluoroacetate salt; 65. (+/-)-7-[[(2-Benzimidazol-2-ylmethyl)-N-methylamino]carbonyl]-2,3,4,5-30 tetrahydro-3-oxo-4-[2-(3',4'-methylenedioxyphenyl)ethyl]-1H-1,4-benzodiazepine-2- acetic acid; 66. (+/-)-2,3,4,5-Tetrahydro-7-[[[(Benzimidazol-2-yl)methyl]amino]carbonyl]-4-(2-methoxyethyl)-3-oxo-1H-1,4-benzodiazepine-2-acetic acid; 67. (S)-7-[[2-[ 1 -Methylbenzimidazolyl]benzimidazolylmethylamino]carbonyl]-35 2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l,4-benzodiazepine-2-acetic acid; 140 PCTYUS95/08306 68. (S)-7-[[[N-Cyclohexyl-N-(benzimidazol-2-yl)methyl]amino]carbonyl]-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; 69. (S)-7-[[[2-Bis-(Benzimidazolylmethyl)aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-lH-l ,4-benzodiazepine-2-acetic acid; 70 (+/-)-2,3,4,5-Tetrahydro-7-[[[imidazo[4,5-B]pyrid-2- yl]methyl]methylamino]carbonyl]-4-(3,3-dimethylbutyl)-3-oxo-1H-1,4-benzodiazepine-2-acetic acid; 71. (+/-)-7-[[(2-Benzimidazol-2-ylmethyl)-N-methylamino]carbonyl-2,3,4,5-tetrahydro-3-oxo-4-(2',2',2'-trifluoroethyl)-lH-l,4-benzodaizepine-2-acetic acid; 10 72. (+/-)-7-[[(2-Benzimidazolyl)acetyl]amino]-5-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; 73. (+/-)-7-[[(2-Benzimidazol-2-ylmethyl)amino]carbonyl]-2,3,4,5-tetrahydro-3-oxo-4-(2',2',2'-trifluoroethyl)-lH-l,4-benzodiazepine-2-acetic acid; 74. (-)-7-[[[5,6-Difluorobenzimidazoyl-2-yImethyl]aminomethyl]carbonylj-15 2,3,4,5-tetrahydro-4-methyl-3-oxo-l,4-benzodiazepine-2-acetic acid; and 75. (+/-)-7-[[Bis-(Benzimidazol-2-ylmethyl)amino]carbonyl]-2,3,4,5-tetrahydro-4-phenylethyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acidtris(trifluoroacetate)salt.
Example 76 Preparation of 4-r2-fTri-ffBenzimidazoI-2-vl')methvllbenzimidazol-2-vnmethvllmethvlaminolacetvllphenoxvacetic acid a) 4-[2-(BOC-methylamino)acetyl]phenol A solution of di-tert-butyl dicarbonate (5.96 g, 27.3 mmol) in 1,4-dioxane (25 mL) was added dropwise at 0°C to a mixture of 4-[2-25 (methylamino)acetyl]phenol hydrochloride (5.0 g, 24.8 mmol), 1,4-dioxane (30 mL), H2O (25 mL) and 1.0 N NaOH (25 mL, 25 mmol). After 24 h, the reaction was warmed to RT and stirred for 1.5 hr. More 1.0 N NaOH (25 mL, 25 mmol) was added, and the reaction was stirred for an additional 0.5 h at RT, then was evaporated on the rotavap. The residue was diluted with EtOAc (80 mL), and the 30 mixture was acidified to pH 2 using 1.0 M NaHS04. The resulting mixture was extracted with EtOAc, and the combined organic layers were washed with H2O and dried (Na2S04). Filtration and concentration gave the title compound (6.49 g, 99%): *H NMR (250 MHz, CDCI3) 5 6.70-8.05 (m, 4 H), 4.53 (s, 2H), 2.98 (s, 3H), 1.50 (s, 9H). 141 b) Benzyl 4-[2-(BOC-methylamino)acetyl]phenoxyacetate A mixture of 4-[2-(BOC-methylamino)acetyl]phenol (5.04 g, 19.0 mmol) and K2CO3 (2.63 g, 19.0 mmol) in acetone (100 mL) was stirred at reflux under argon for lh. The mixture was cooled to RT and benzyl bromoacetate (5.23 g, 22.8 5 mmol) was added. The reaction was heated at reflux for 18 h, then was cooled and filtered. The filter cake was washed with acetone, and the filtrate was concentrated on the rotavap. The residue was dissolved in CH2CI2 (300 mL) and washed sequentially with H2O (50 mL) and brine (50 mL). Drying (Na2S04), concentration, and flash chromatography ( silica gel, 1:3 EtOAc/hexanes) yielded the 10 title compound (7.28 g, 93%): *H NMR (250 MHz, CDCI3) 8 6.85-7.95 (m, 9 H), 5.23 (s, 2H), 4.71 (s, 2H), 4.55 (d, 2H), 2.95 (d, 3H), 1.45 (d, 9H). c) Benzyl 4-[2-(methylamino)acetyl]phenoxyacetate hydrochloride A mixture of benzyl 4-[2-(BOC-methylamino)acetyl]phenoxyacetate (7.26 g, 15 17.57 mmol) and 4 M HCl in 1,4-dioxane (150 mL) was stirred for 1 h at RT.
Evaporation on the rotavap and trituration with Et20 afforded the title compound as a white powder (5.93 g, 97%): *H NMR (250 MHz, CD3OD) 8 7.05-8.00 (m, 9 H), 5.23 (s, 2H), 4.88 (s, 2H), 4.65 (s, 2H), 2.80 (s, 3H). d) Benzyl 4-[2-[[[l-[(benzimidazol-2-yl)methyl]benzimidazol-2-yl]methyl]methylamino]acetyl]phenoxyacetate Et3N (0.28 g, 2.78 mmol) was added slowly to a mixture of benzyl 4-[2-(methylamino)acetyl]phenoxyacetate hydrochloride (0.39 g, 1.11 mmol), 2-(chloromethyl)benzimidazole (0.24 g, 1.45 mmol), CH3CN (20 mL), and CH2CI2 (5 25 mL) at RT under argon. After 5 h, the reaction mixture was concentrated on the rotavap. The residue was dissolved in CH2CI2 and washed sequentially with 5% NaHC03 and brine. Drying (MgS04), concentration, and flash chromatography ( silica gel, step gradient, 7-15% MeOH/CH2Cl2) yielded the title compound as an off-white powder (0.08 g, 12%): MS (ES) mit 574.2 [M + H]+. e) 4-[2-[[[l -[(Benzimidazol-2-yl)methy]]benzimidazol-2-yl]methyl]methylamino]acetyl] phenoxyacetic acid A mixture of benzyl 4-[2-[[[l-[(benzimidazol-2-yl)methyl]benzimidazol-2-yl]methyl]methylamino]acetyl]phenoxyacetate (0.08 g, 0.18 mmol) and 5% Pd/C 35 (0.11 g) in MeOH (15 m L) was shaken.on a Parr apparatus under H2 (41 psi) for 1 h. The mixture was filtered through a bed of Celite®, and the filter pad was washed 142 PCTAJS95/08306 with glacial AcOH and MeOH. The filtrate was concentrated to give the crude product (0.07 g). Preparative HPLC (Hamilton PRP-1® column, step gradient, 10-30% CH3CN/H2O-0.1% TFA) afforded the title compound: MS (ES) m/e 484.2 [M + H]+ Anal. Calcd for C27H25N5O4 • 3 C2HF3O2: C, 48.01; H, 3.42 N, 8.48 .
Found: C, 48.40; H, 3.72; N, 8.77.
Example 77 (±)-4-ff2-f(BenzimidazoI-2-vl')methvllmethvlamino1-l-hvdroxvethvl1-1.2-phenvlenedioxvdiacetic acid 10 a) N-Cbz-Adrenalone Adrenalone hydrochloride (28.6 g, 0.121 mole) was added to 2.0 N NaOH (200 mL, 0.2 mol) which was first cooled to 5°C in an ice bath. 2.0 N NaOH (60 mL, 0.06 mole) in one addition funnel and a solution of benzyl chloroformate (17.3 mL, 0.121 mol) in toluene(18 mL) in another addition funnel were added at rates 15 such that the reaction temperature remained between 5- 10°C and that addition of both solutions was completed simultaneously. The resulting brown solution was stirred at 5°C for 75 min, then was diluted with H2O (230 mL) and acidified with 1.0 N HCl (536 mL). A gummy precipitate formed initially, but solidified on trituration with a glass rod followed by stirring for 30 min. The pale green solid was filtered, 20 stirred briefly with H2O, filtered, stirred briefly with EtOH, and filtered. The resulting solid was ground in a mortar with more EtOH, then was filtered and dried in vacuum to afford the title compound (28.6 g, 75%): mp 183-186°C. b) Dimethyl 4-[2-(Cbz-methylamino)acetyl]-1,2-phenylenedioxydiacetate 25 A mixture of N-Cbz-adrenalone (23.6 g, 74.8 mmole), acetone (340 mL), and anhydrous K2CO3 (21.0 g, 152 mmole) was heated at reflux under argon. After 70 min, the beige suspension was cooled to RT, and methyl bromoacetate (17.9 mL, 189 mmole) was added. The resulting suspension was stirred at RT under argon for 16 hr, then was heated to 50°C. After 6 h, the mixture was cooled to RT and 30 filtered, and the filtrate was concentrated to dryness. The residue was dissolved in CH2CI2 and washed sequentially with H2O and 5% K2CO3. Drying (Na2S04) and concentration gave the title compound as an oil which solidified on standing (26.35 g, 82%): mp 56 - 59°C. 143 c) Dimethyl 4-[2-(methylamino)-1 -hydroxyethyl]-1,2-phenylenedioxydiacetate Following the procedure of Example 76(e), except substituting dimethyl 4-[2-(Cbz-methylamino)acetyl]-1,2-phenylenedioxydiacetate (2.1 g, 4.57 mmol) for benzyl 4-[2-[[[ 1 -[(benzimidazol-2-yl)methyl]benzimidazol-2-5 yl]methyl]methylamino]acetyl] phenoxyacetate and using EtOAc (50 mL) and MeOH (20 mL) as solvents, the title compound (1.34 g, 90 %) was prepared: MS (ES) m/e 328.0 [M + H]+. d) Dimethyl (±)-4-[[2-[(benzimidazol-2-yl)methyl]methylamino]-l-hydroxyethyl]-10 1,2-phenylenedioxydiacetate Following the procedure of Example 76(d), except substituting dimethyl 4-[2-(methylamino)-l-hydroxyethyl]-1,2-phenylenedioxydiacetate (1.37 g, 4.20 mmol) for benzyl 4-[2-(methylamino)acetyl]phenoxyacetate hydrochloride, the title compound was prepared (0.25g, 13 %): MS (ES) m/e 458.2 [M + H]+. e) (±)-4-[[2-[(Benzimidazol-2-yl)methyl]methylamino]-1 -hydroxyethyl]-1,2-phenylenedioxydiacetic acid A mixture of dimethyl (±)-4-[[2-[(benzimidazol-2-yl)methyl]methylamino]-1-hydroxyethyl]-1,2-phenylenedioxydiacetate (0.23 g, 0.5 mmol), THF (10 mL), 20 H2O (10 mL), and 1.0 N Li OH (2.0 mL, 2.0 mmol) was stirred at RT for 26 h. The reaction mixture was concentrated on the rotavap, and the aqueous residue was acidified with 1.0 N AcOH (2 mL) with cooling in an ice bath. The resulting mixture was lyophilized to give the crude product (0.32 g). Preparative HPLC (Hamilton PRP-1® column, 10% CH3CN/H20-0.1% TFA) afforded the title 25 compound: MS (ES) m/e 430.2 [M + H]+. Anal. Calcd for C21H23N3O7 • 7/2 C2HF3O2: C, 39.73; H, 3.39 N, 4.97 Found: C, 39.47; H, 3.38; N, 4.86.
Example 78 4-r2-rr(Benzimidazol-2-vl)methvllmethvlamino1acetvll-1.2-phenvlenedioxvdiacetic 30 acid a) l-BOC-2-methylbenzimidazole A mixture of 2-methylbenzimidazole (1.5 g, 11.35 mmole), Et3N (1.66 mL, 11.92 mmole), DMAP (0.20 g, 1.6 mmole), and (BOQ2O (2.60 g, 11.92 mmole) in anhydrous CH2CI2 (15 mL) was stirred at RT for 24 hr, then was concentrated. The 35 residue was taken up in H2O, stirred, and filtered to afford the title compound as a colorless solid (2.63 g, 100%): mp 71-72°C. 144 FCT/US95/08306 b) 1 -BOC-2-(bromomethyl)benzimidazole NBS (8.43 g, 47.4 mmol) and AD3N (2.1 g, 12.8 mmol) were added to a solution of l-BOC-2-methylbenzimidazole (10.0 g, 43.1 mmol) in CCI4 (120 mL) at 5 reflux. After 21 h, the reaction was cooled and filtered. The filtrate was concentrated, and the resulting brown oil was chromatographed (silica gel, 15% EtOAc/hexanes) to afford the title compound: 'H NMR (400 MHz, CDCI3) 6 7.94 -8.01 (m, 1 H), 7.70-7.75 (m, 1 H), 7.31 - 7.44 (m, 2 H), 4.96 (s, 2 H), 1.75 (s, 9 H). c) 4-[2-(BOC-methylamino)acetyl]-l,2-dihydroxybenzene Following the procedure of Example 76(a), except substituting adrenalone hydrochloride (5.0 g, 23.0 mmol) for 4-[2-(methylamino)acetyl]phenol hydrochloride, the title compound (1.2 g, 19%) was prepared following flash chromatography (silica gel, 1:1 EtOAc/hexanes): MS (ES) m/e 282.2 [M+H]+. d) Dimethyl 4-[2-(BOC-methylamino)acetyl]-1,2-phenylenedioxydiacetate Following the procedure of Example 76(b), except substituting 4-[2-(BOC-methylamino)acetyl]-l,2-dihydroxybenzene (0.9 g, 3.2 mmol) for 4-[2-(BOC-methylamino)acetyl]phenol and methyl bromoacetaie (1.23 g, 8.0 mmol) for benzyl 20 bromoacetate, the title compound (1.11 g, 81%) was prepared: MS (ES) m/e 426.2 [M+H]+. e) Dimethyl 4~[2-(methylamino)acetyl]-1,2-phenylenedioxydiacetate hydrochloride Following the procedure of Example 76(c), except substituting dimethyl 4-25 [2-(BOC-methylamino)acetyl]-1,2-phenylenedioxydiacetate (1.11 g, 2.6 mmol) for benzyl 4-[2-(BOC-methyIamino)acetyl]phenoxyacetate, the title compound was prepared (1.1 g, quantitative): MS (ES) m/e 326.0 [M+H]+. f) Dimethyl 4-[2-[[( 1 -BOC-benzimidazol-2-yl)methyl]methylamino]acetyl]-1,2-30 phenylenedioxydiacetate Following the procedure of Example 76(d), except substituting dimethyl 4-[2-(methylamino)acetylJ- 1,2-phenylenedioxydiacetate hydrochloride (0.24 g, 0.66 mmol) for benzyl 4-[2-(methylamino)acetyl]phenoxyacetate hydrochloride, 1-BOC-2-(bromomethyl)benzimidazole (0.31 g, 0.99 mmol) for 2-35 (chloromethyl)benzimidazole, and using THF (5 mL) and CH2CI2 (5 mL) as 145 solvents, the title compound was prepared (0.14 g, 38%): MS (ES) m/e 556.2 [M+H]+ g) Dimethyl 4-[2-[[(benzimidazol-2-yl)methyl]methylamino]acetyl]-1,2-5 phenylenedioxydiacetate bis(trifluoroacetate) A mixture of dimethyl 4-[2-[[(l-BOC-benzimidazoI-2-yl)methyl]methylamino]acetyl]-1,2-phenylenedioxydiacetate (0.13 g, 0.23 mmol) in TFA 4 mL) and CH2.CI2 (12 mL) was stirred at RT under argon for 20 min.
Removal of the solvents on the rotavap gave the title compound (0.18 g, 10 quantitative): MS (ES) m/e 456.2 [M + H]+. h) 4-[2-[[(Benzimidazol-2-yl)methyl]methylamino]acetyl]-1,2-phenylenedioxydiacetic acid Following the procedure of Example 77(e), except substituting dimethyl 4-15 [2-[[(benzimidazol-2-yl)methyl]methylamino]acetyl]-1,2-phenylenedioxydiacetate bis(trifluoroacetate) (0.16 g, 0.23 mmol) for dimethyl (±)-4-[[2-[(benzimidazol-2-yl )methyl] methylamino]-1 -hydroxyethyl] -1,2-phenylenedioxydiacetate, the title compound was prepared (0.08 g, 80%): MS (ES) m/e 428.2 [M + H]+. Anal. Calcd for C21H21N3O7 • 11/5 C2HF3O2 • 9/5 H2O: C, 42.93; H, 3.80 N, 5.91. Found: 20 C, 42.62; H, 3.52; N, 6.30.
Example 79 Preparation of 3-n4-nT(Benzimidazol-2-vl)methvlamino1carbonvllphenvIlamino1 propionic Acid 25 a) ethyl 3-[4-(carboxy)phenylamino]propionate A solution of 4-aminobenzoic acid (6.85 g, 0.05 mol) and ethyl acrylate (15 g, 0.15 mol) in acetic acid (40 mL) was heated to 100°C for 15 h. The solid which formed was filtered, washed with hexane and dried to give of the title compound (7.5 g, 63%). b) ethyl 3-[[4-[[[(benzimidazol-2-yl)methy]amino]carbonyl]phenyl]amino]propionic acid The compound of Example 79(a)(0.3 g, 1.26 mmol) in thionyl chloride (10 mL) was heated to reflux for 10 min, cooled, concentrated in vacuo, and residual 35 thionyl chloride was removed by addition of methylene chloride followed by concentration in vacuo. The residual oil was dissolved in methylene chloride and 146 treated with 2-(aminomethyl)benzimidazole dihydrochloride hydrate (0.33 g, 1.5 mmol) and diisopropylethylamine (0.56 g, 4.3 mmol). The resulting mixture was stirred overnight, washed with water and the organic phase was dried (sodium sulfate) and concentrated in vacuo. The resulting pale yellow solid was 5 chromatographed (silica gel, methanol-dichloromethane 3:97) and fractions containing the product were pooled and concentrated in vacuo to give the title compound. MS(ES) m/e 367 [M+H]+. c) 3-[[4-[[[(benzimidazol-2-yl)methy]amino]carbonyl]phenyl]amino]propionic acid 10 A solution of the compound of Example 79(b)(0.4 g, 1.1 mmol) in methanol (20 mL), water (2 mL) and 0.95N aqueous sodium hydroxide (2.5 mL) was stirred and heated to 50°C for 2 h. The mixture was treated with trifluoroacetic acid (1 mL), concentrated in vacuo, and the residue was triturated with dichloromethane (4 x 100 mL). The resulting white solid was recrystallized from 20% 15 acetonitrile/water-0.1 % trifluoroacetic acid to give the title compound. MS(ES) m/e 339 [M+H]+.
Example 80 Preparation of 4-14-1"l-f2-MethvlbenzimidazovPpiperidinvm-piperidineacetic acid 20 sodium salt a) Methyl 4-[4-[l-(t-butyloxycarbonyl)piperidinyl]]piperidineacetate A mixture of t-butyl l-(4,4'-bipiperidine)carboxylate (3.1 g, 10 mmol), prepared as described by Bondinell, et al. (WO 93/00095), methyl bromoacetate (1.7 g, 11 mmol), and triethylamine (2.3 g, 22 mmol) in DMF (15 mL) was heated ar 85 °C for 25 4 h. The reaction mixture was diluted with EtOAc (50 mL), partitioned between NaHC03 (5% soution, 100 mL) and extracted with EtOAc (2x50 mL). The combined organic extracts were washed with H2O, saturated NaCl soution, dried over MgS04, and evaporated to give the titled compound (3.37 g, 99%). MS (ES) m/e 341.2 [m+H]+ . b) Methyl 4-[4-(l-piperidinyl)]piperidineacetate 147 A mixture of Example 1(a) (3.37 g, 10 mmol) and 4M HCl in dioxane (20 mL) in CH2CI2 (25 mL) was stirred at RT for 18 h. The resulting white suspension was filtered to give the titled compounds as the dihydrocjloride (3.1 g, 99%). c) Methyl 4-[4-[-l-(2-Methylbenzimidazoyl)piperidinyl]]-piperidineacetate To a stirred solution of Example 1(b) (2 g, 6.4 mmol) and triethylamine (3.6 mL, 25.6 mmol) in CH2CI2 (50 mL) was added in portions a suspension of 2-chloromethylbenzimidazole (1.1 g, 6.6 mmol) in CH2CI2 (25 mL) at RT. After stirring for 4 h, the reaction mixture was diluted with CH2CI2 (50 mL), partitioned 10 between NaHC03 (5% soution, 100 mL) and extracted with CH2CI2 (2x50 mL). The combined organic extractswere washed with H2O, a saturated NaCl soution, dried over MgSC>4, and evaporated. The titled compound was purified by flash chromatograpy (SiCty 6% MeOH/CH2Cl2) to yield the titled compound (0.36 g, 16%). *H NMR (400MHz, CDCI3) 8 1.07 (m, 2H), 1.35 (m, 4H), 1.65 (t, J= 9.1, 15 4H), 2.09 (q, J= 10.9,4H), 2.93 (m, 4H), 3.20 (s, 2H), 3.71 (s, 3H), 3.79 (s, 2H), 7.22 (m, 2H), 7.56 (bs, 2H). MS (ES) m/e 471.2 [m+H]+ d) 4-[4-[l-(2-Methylbenzimidazoyl)piperidinyl]]-piperidineacetic acid sodium salt To a stirred solution of Example 1(c) (0.45 g, 1.2 mmol) in MeOH (15 mL) was 20 added IN NaOH solution (8.5 mL, 8.5 mmol) at RT. After 18 h, the white suspension was filtered to white solid (0.2 g, mp > 250 °C, 43%,) as the titled compound. MS (ES) m/e 357.2 [m+H]+. JH NMR (400MHz, CD3OD) 8 1.10 (bm, 2H), 1.34 (bm, 4H), 1.73 (bm, 4H), 2.11 (bm, 4H), 3.05 (m, 6H)„ 3.77 (s, 2H), 7.21 (bm, 2H), 7.52 (bm, 2H).
Anal. Calcd for C20 H27 N4 02Na. 0.375 H2O: C, 62.36; H, 7.26, N, 14.54 Found: C, 62.38; H, 7.20: N, 14.32.
Example 81 la) Benzyl 4-bromobutyrate: To a stirred, cooled (0°C) mixture of benzyl alcohol (1.0 g, 5.392 mmol) and pyridine (0.47 g, 5.9312 mmol) in anhydrous methylene chloride (10 mL) was added 148 4-bromobutyryl chloride (0.58 g, 5.9312 mmol). After stirring in 1 h at room temperature, the mixture was concentrated, taken up in H2O, extracted with EtOAc, washed with brine, dried over MgSO^ filtered and concentrated to give a colorless oil (1.38 g, 100%). NMR (CDCI3, 300 MHz): 6 2.24 (m, 2H), 2.59 (t, 1=5.1 Hz, 5 2H), 3.48 (t, J=5.7 Hz, 2H), 5.14 (s, 2H), 7.38 (m, 5H). lb) (S)-Benzyl 4-(N-t-Boc-tyrosine methyl ester)butyrate: A mixture of Example la (1.57 g, 6.1177 mmol), N-t-Boc-tyrosine methyl ester (1.80 g, 6.1177 mmol), and CSCO3 in dried DMF (10 mL) was stirred at RT in 20 h. 10 The mixture was concentrated, taken up in H2O, extracted with EtOAc. The organic extracts were washed by brine, dried over MgSO^ filtered and concentrated to give 2.30 g brown oil of the tide compound (79%). *H NMR (300 MHz, CDCI3) 6 1.47 (s, 9H), 2.15 (m, 2H), 2.59 (t, J= 5.7 Hz, 2H), 3.03 (m, 2H), 3.70 (s, 3H), 3.97 (t, J=5.7 Hz, 2H), 4.55 (m, IH), 4.97 (d, 5.8 Hz, IH), 5.12 (s, 2H), 6.78 (d, J= 8.3 Hz, 15 2H), 7.05 (d,J=8.3 Hz, 2H), 7.41 (m,5H). lc) (S)-Benzyl 4-(tyrosine methyl ester)butyrate: To a stirred solution of Examplelb (2.30 g, 4.8778 mmol) in dried CH2CI2 (10 mL) was added 12 mL of TFA. After stirring at RT in 3 h, the mixture was concentrated, 20 taken up in H2O, neutralized by 2.5N NaOH, extracted with CH2C12, dried over MgS04, filtered, and concentrated to give a brown oil (1.60 g, 88%). IH NMR (300 MHz, CDC13) 5 2.15 (m, 2H), 2.55 (t, J=5.7 Hz, 2H), 2.95 (dd, J=13.8 Hz, 7.3 Hz, IH), 3.13 (dd, J=13.8 Hz, 7.3 Hz, IH), 3.70 (s, 3H), 3.97 (t, J=5.7 Hz, IH), 4.95 (d, J=7.3 Hz, IH), 5.15 (s, 2H), 6.80 (d, J=8.3 Hz, 2H), 7.10 (d, J=8.3 Hz, 2H), 7.35 (m, 25 5H).
Id) (S)-Benzyl 4-[(N-butylsulfonyl) tyrosine methyl ester]butyrate: To a stirred mixture of Example lc (1.60 g, 4.3079 mmol) and pyridine (0.41 g, 5.1695 mmol) in dried CH2CI2 (15 mL) was added n-butylsulfonyl chloride (0.81 g, 30 5.1695 mmol). After stirring at RT in 2 h, the mixture was concentrated, taken up in H2O, extracted with EtOAc. The organic extracts were washed by 2N HCl, saturated NaHC03, brine, dried over MgSO^ filtered, and concentrated to give a brown oil (2.01 g, 95%). IH NMR (300 MHz, CDC13) 60.89 (t, J=7.3 Hz, 3H), 1.37 (m, 2H), 1.65 (m, 2H), 2.20 (m, 2H), 2.60 (t, J=5.7 Hz, 2H), 2.72 (t, J=7.3 Hz, 2H), 2.95 (dd, J=13.8 Hz, 7.3 Hz, IH), 3.10 (dd, J=13.8 Hz, 7.3 Hz, IH), 3.77 (s, 3H), 3.93 (t, 5 J=5.7 Hz, 2H), 4.30 (m, IH), 4.70 (d, J=7.3 Hz, IH), 5.12 (s, 2H), 6.80 (d, J=8.3 Hz, 2H), 7.03 (d, J=8.3 Hz, 2H), 7.35 (m, 5H). le) (S)-4-[(N-butylsulfonyl)tyrosine methyl ester]butyric acid: A solution of Example Id (0.781 g, 1.589 mmol) in MeOH (10 mL) was 10 hydrogenated at 50 PSI in 10% Pd/C (0.50 g) in 3 h. The catalyst was filtered through celite. The filtrate was concentrated to give a white solid (0.59 g, 93%). IH NMR (300 MHz, CDC13) 5 0.89 (t, J=7.3 Hz, 3H), 1.35 (m, 2H), 1.65 (m, 2H), 2.10 (m, 2H), 2.55 (t, J=5.7 Hz, 2H), 2.75 (t, J=7.3 Hz, 2H), 2.95 (dd, J=13.8 Hz, 7.3 Hz, IH), 3.05 (dd, J=13.8 Hz, 7.3 Hz, IH), 3.48 (s, 3H), 3.97 (t, J=5.7 Hz, 2H), 4.30 (m, 15 IH), 4.90 (d, J=7.3 Hz, IH), 6.90 (d, J=8.3 Hz, 2H), 7.10 (d, J=8.3 Hz, 2H).
If) (S)-N-butylsulfonyl-4-(3-(benzimidazol-2-yl)propyl)tyrosine methyl ester: To a stirred, cooled (O^C) mixture of Example le (0.595 g, 1.4823 mmol) and Et3N (0.16 g, 1.5565 mmol) in dried THF (7 mL) was added isobutylchloroformate (0.212 20 g, 1.5565 mmol). After stirring at O^C in 1 h, o-phenylenediamine (0.16 g, 14823 mmol) and 1 mL of HO Ac was added. The reaction mixture was heated at reflux overnight. The mixture was cooled, diluted with EtOAc, washed by H2O, saturated NaHC03, brine, dried overMgS04, concentrated and purified by flash column chromatograph (5% MeOH/CH2Cl2) to.give a white foam (0.487 g, 69%). *H NMR 25 (300 MHz, CDCI3) 5 0.89 (t, J=7.3 Hz, 3H), 1.35 (m, 2H), 1.65 (m, 2H), 2.30 (m, 2H), 2.80 (t, J=5.7 Hz, 2H), 2.95 (dd, J=13.8 Hz, 7.3 Hz, IH), 3.10 (m, 3H), 3.0 (s, 3H), 3.98 (t, J=5.7 Hz, 2H), 4.35 (m, IH), 4.90 (d, 7.3 Hz, IH), 6.77 (d, j=8.3 Hz, 2H), 7.03 (d, J=8.3 Hz, 2H), 7.26 (m, 2H), 7.58 (m, 2H). lg) (S)-N-Butylsulfonyl-p-[3-(2-benzimidazoyl)propyl]tyrosine: 150 WO 96/00730 PCT/US95/08306 To a stirred solution of Example If (0,487 g, 1.0285 mmol) in MeOH (5 mL) was added IJOH.H2O (0.09 g, 2.0571 mmol) in 24 h. The mixture was concentrated, diluted in H2O, neutralized with 2.0N HCl. The off white solid was filtered, triturated in hot EtOH to give the title compound as a white solid (0.377 g, 80%, 5 Mp: >230 °C). *H NMR (300 MHz, DMSO-d6) 8 0.75 (t, 7.3 Hz, 3H), 1.15 (m, 2H), 1.30 (m, 2H), 2.20 (m, 2H), 2.52 (m, 2H), 2.75 (dd, J=13.8 Hz, 7.3 Hz, IH), 2.97 (dd, J= 13.8Hz, 7.3 Hz, IH), 3.00 (t, J=5.7 Hz, 2H), 3.90 (m, IH), 4.10 (t, J=5.7 Hz, 2H), 6.85 (d, 8.3 Hz, 2H), 7.10 (m, 2H), 7.20 (d, J=8.3 Hz, 2H), 7.50 (m, 2H), 7.61 (d, J=7.3 Hz, IH). IR (cm*1, KBr) 3300-3400, 3244, 3000-3100,2800-300, 10 1634, 1612, 1512,1466,1384, 1245, 1148, li 10. MS (ESI, M+H) 460.2. Anal.
Calc. for C23H29N305S: C, 60.11; H, 6.36; N, 9.14; Found: C.60.01; H, 6.34; N, 9.01.
Example 82 Preparation of 4-f2-fIT 1 -r(Benzimidazol-2-vl)methvl1benzimidazol-2-vllmethvllmethvlaminolacetvllphenoxvacetic acid a) 4-[2-(BOC-methylamino)acetyl]phenol A solution of di-tert-butyl dicarbonate (5.96 g, 27.3 mmol) in 1,4-dioxane (25 mL) was added dropwise at 0°C to a mixture of 4-[2-20 (methylamino)acetyl]phenol hydrochloride (5.0 g, 24.8 mmol), 1,4-dioxane (30 mL), H2O (25 mL) and 1.0 N NaOH (25 mL, 25 mmol). After 24 hr, the reaction was warmed to RT and stirred for 1.5 hr. More 1.0 N NaOH (25 mL, 25 mmol) was added, and the reaction was stirred for an additional 0.5 h at RT, then was evaporated on the rotavap. The residue was diluted with EtOAc (80 mL), and the 25 mixture was acidified to pH 2 using 1.0 M NaHS04. The resulting mixture was extracted with EtOAc (2 x 50 mL), and the combined organic layers were washed with H2O (30 mL) and dried (Na2S04). Filtration and concentration gave the title compound (6.49 g, 99%): *H NMR (250 MHz, CDCI3) 8 6.70-8.05 (m, 4 H), 4.53 (s, 2H), 2.98 (s, 3H), 1.50 (s,9H). 151 WO 96/00730 PCT/US95/08306 b) Benzyl 4-[2-(BOC-methylamino)acetyl]phenoxyacetate A mixture of4-[2-(BOC-methylamino)acetyl]phenol (5.04 g, 19.0 mmol) and K2CO3 (2.63 g, 19.0 mmol) in acetone (100 mL) was stirred at reflux under argon for lh. The mixture was cooled to RT and benzyl bromoacetate (5.23 g, 22.8 5 mmol) was added. The reaction was heated at reflux for 18 h, then was cooled and filtered. The filter cake was washed with acetone, and the filtrate was concentrated on the rotavap. The residue was dissolved in CH2CI2 (300 mL) and washed sequentially with H2O (50 mL) and brine (50 mL). Drying (Na2S04), concentration, and silica gel flash chromatography (1:3 EtOAc/hexanes) yielded the 10 title compound (7.28 g, 93%): !h NMR (250 MHz, CDCI3) 8 6.85-7.95 (m, 9 H), 5.23 (s, 2H), 4.71 (s, 2H), 4.55 (d, 2H), 2.95 (d, 3H), 1.45 (d, 9H). c) Benzyl 4-[2-(methylamino)acetyl]phenoxyacetate hydrochloride A mixture of benzyl 4-[2-(BOC-methylamino)acetyl]phenoxyacetate (7.26 g, 15 17.57 mmol) and 4 M HCl in 1,4-dioxane (150 mL) was stirred for 1 h at RT. Evaporation on the rotavap and trituration with Et20 afforded the title compound (5.93 g, 97%) as a white powder: *H NMR (250 MHz, CD3OD) 8 7.05-8.00 (m, 9 H), 5.23 (s, 2H), 4.88 (s, 2H), 4.65 (s, 2H), 2.80 (s, 3H). d) Benzyl 4-[2-[[[I-[(benzimidazol-2-yl)methyl]benzimidazol-2-yl]methyl]methylamino]acetyl]phenoxyacetate Et3N (0.28 g, 2.78 mmol) was added slowly to a mixture of benzyl 4-[2-(methylamino)acetyl]phenoxyacetate hydrochloride (0.39 g, 1.11 mmol), 2-(chloromethyl)benzimidazole (0.24 g, 1.45 mmol), CH3CN (20 mL), and CH2CI2 (5 25 mL) at FT under argon. After 5 h, the reaction mixture was concentrated on the rotavap. The residue was dissolved in CH2CI2 (100 mL) and washed sequentially with 5% NaHC03 (2 x 20 mL) and brine (20 mL). Drying (MgSQ4), concentration, and silica gel flash chromatography (step gradient, 7-15% MeOH/CH2Cl2) yielded the title compound (0.08 g, 12%) as an off-white powder: MS (ES) m/e 574.2 [M + 30 H]+. 152 WO 96/00730 PCT/US95/08306 e) 4-[2-[[[l-[(Benzimidazol-2-yl)methyl]benzimidazol-2-yl]methyl]methylamino]acetyl] phenoxyacetic acid A mixture of benzyl 4-[2-[[[l-[(benzimidazol-2-yl)methyl]benzimidazol-2-yl]methyl]methylamino]acetyl]phenoxyacetate (0.08 g, 0.18 mmol) and 5% Pd/C 5 (0.11 g) in MeOH (15 m L) was shaken on a Parr apparatus under H2 (41 psi) for 1 h. The mixture was filtered through a bed of celite®, and the filter pad was washed with glacial AcOH and MeOH. The filtrate was concentrated to give the crude product (0.07 g). Preparative HPLC (Hamilton PRP-1® column, step gradient, 10 -30% CH3CN/H2O containing 0.1% TFA) afforded the title compound: MS (ES) 10 m/e 484.2 [M + H]+ Anal. Calcd for C27H25N5O4 • 3 C2HF3O2: C, 48.01; H, 3.42 N, 8.48 . Found: C, 48.40; H, 3.72; N, 8.77.
Example 83 (±)-4-rr2-[YBenzimidazol-2-vl1methvnmethvlamino1-l-hvdroxvethvn-1.2-15 phenvlenedioxvdiacetic acid a) N-Cbz-Adrenalone Adrenalone hydrochloride (28.6 g, 0.121 mole) was added to 2.0 N NaOH (200 mL, 0.2 mole) which was first cooled to 5°C in an ice bath. 2.0 N NaOH (60 mL, 0.06 mole) in one addition funnel and a solution of benzyl chloroformate (17.3 20 mL, 0.121 mole) in toluene (18 mL) in another addition funnel were added at rates such that the reaction temperature remained between 5 - 10°C and that addition of both solutions was completed simultaneously. The resulting brown solution was stirred at 5°C for 75 min, then was diluted with H2O (230 mL) and acidified with 1.0 N HCl (536 mL). A gummy precipitate formed initially, but solidified on 25 trituration with a glass rod followed by stirring for 30 min. The pale green solid was filtered, stirred briefly with H2O (180 mL), filtered, stirred briefly with EtOH (135 mL), and filtered. The resulting solid was ground in a mortar with more EtOH (135 mL), then was filtered and dried in vacuum to afford the title compound (28.6 g, 75%): mp 183- 186°C. 153 b) Dimethyl 4-[2-(Cbz-methylamino)acetyl]-1,2-phenylenedioxydiacetate A mixture of N-Cbz-adrenalone (23.6 g, 74.8 mmole), acetone (340 mL), and anhydrous K2CO3 (21.0 g, 152 mmole) was heated at reflux under argon. After 70 min, the beige suspension was cooled to RT, and methyl bromoacetate (17.9 mL, 5 189 mmole) was added. The resulting suspension was stirred at RT under argon for 16 hr, then was heated to 50°C. After 6 hr, the mixture was cooled to RT and filtered, and the filtrate was concentrated to dryness. The residue was dissolved in CH2CI2 (800 mL) and washed sequentially with H2O (160 mL) and 5% K2CO3 (2 x 100 mL). Drying (Na2S04) and concentration gave the title compound (26.35 g, 10 82%) as an oil which solidified on standing: mp56-59°C. c) Dimethyl 4-[2-(methylamino)-l-hydroxyethyl]-1,2-phenylenedioxydiacetate Following the procedure of Example 82(e), except substituting dimethyl 4-[2-(Cbz-methylamino)acetyl]-1,2-phenylenedioxydiacetate (2.1 g, 4.57 mmol) for 15 benzyl 4-[2-[[[l-[(benzimidazol-2-yl)methyl]benzimidazol-2- yl]methyl]methylamino]acetyl]-phenoxyacetate and using EtOAc (50 mL) and MeOH (20 mL) as solvents, the title compound (1.34 g, 90 %) was prepared: MS (ES) m/e 328.0 [M + H]+ d) Dimethyl (±)-4-[[2-[(benzimidazol-2-yl)methyl]methylamino]-l-hydroxyethyl]-1,2-phenylenedioxydiacetate Following the procedure of Example 82(d), except substituting dimethyl 4-[2-(methylamino)-l-hydroxyethyl]-1,2-phenylenedioxydiacetate (1.37 g, 4.20 mmol) for benzyl 4-[2-(methylamino)acetyl]phenoxyacetate hydrochloride, the title 25 compound (0.25g, 13 %) was prepared: MS (ES) m/e 458.2 [M + H]+. e) (±)-4-[[2-[(Benzimidazol-2-yl)methyl]methylamino]-1 -hydroxyethyl]-1,2-phenylenedioxydiacetic acid A mixture of dimethyl (±)-4-[[2-[(benzimidazol-2-yl)methyl]methylamino]-30 1-hydroxyethyl]-1,2-phenylenedioxydiacetate (0.23 g, 0.5 mmol), THF (10 mL), H2O (10 mL), and 1.0 N LiOH (2.0 mL, 2.0 mmol) was stirred at RT for 26 h. The 154 reaction mixture was concentrated on the rotavap, and the aqueous residue was acidified with 1.0 N AcOH (2 mL) with cooling in an ice bath. The resulting mixture was lyophilized to give the crude product (0.32 g). Preparative HPLC (Hamilton PRP-1® column, 10% CH3CN/H2O containing 0.1% TFA) afforded the 5 title compound: MS (ES) m/e 430.2 [M + H]+. Anal. Calcd for C21H23N3O7 • 7/2 C2HF3O2: C, 39.73; H, 3.39 N, 4.97 Found: C, 39.47; H, 3.38; N, 4.86.
Example 84 4-r2-rf(Benzimidazol-2-vl)methvllmethvlamino1acetvll-1.2-phenvlenedioxvdiacetic 0 acid a) 1 -B OC-2-methylbenzimidazole A mixture of 2-methylbenzimidazole (1.5 g, 11.35 mmole), Et3N (1.66 mL, 11.92 mmole), DMAP (0.20 g, 1.6 mmole), and (b0c)20 (2.60 g, 11.92 mmole) in anhydrous CH2CI2 (15 mL) was stirred at RT for 24 hr, then was concentrated. The 5 residue was taken up in H2O, stirred, and filtered to afford the title compound (2.63 g, 100%) as a colorless solid: mp 71 - 72CC. b) 1 -BOC-2-(bromomethyl)benzimidazole NBS (8.43 g, 47.4 mmole) and AIBN (2.1 g, 12.8 mmole) were added to a 0 solution of l-BOC-2-methylbenzimidazole (10.0 g, 43.1 mmole) in CCI4 (120 mL) at reflux. After 21 hr, the reaction was cooled and filtered. The filtrate was concentrated, and the resulting brown oil was chromatographed on silica gel (15% EtOAc/hexanes) to afford the title product: ^H NMR (400 MHz, CDCI3) 6 7.94 -8.01 (m, 1 H), 7.70 - 7.75 (m, 1 H), 7.31 - 7.44 (m, 2 H), 4.96 (s, 2 H), 1.75 (s, 9 H). c) 4-[2-(B OC-methylamino)acetyl]-1,2-dihydroxybenzene Following the procedure of Example 82(a), except substituting adrenalone hydrochloride (5.0 g, 23.0 mmol) for 4-[2-(methylamino)acetyl]phenol hydrochloride, the title compound (1.2 g, 19%) was prepared following silica gel 0 flash chromatography (1:1 EtOAc/hexanes): MS (ES) m/e 282.2 [M + H]+. 155 d) Dimethyl 4-[2-(BOC-methylamino)acetyl]-1,2-phenylenedioxydiacetate Following the procedure of Example 82(b), except substituting 4-[2-(BOC-methylamino)acetyl]-l,2-dihydroxybenzene (0.9 g, 3.2 mmol) for 4-[2-(BOC-methylamino)acetyl]phenol and methyl bromoacetate (1.23 g, 8.0 mmol) for benzyl bromoacetate, the title compound (1.11 g, 81%) was prepared: MS (ES) m/e 426.2 [M + H]+ e) Dimethyl 4-[2-(methylamino)acetyl]-1,2-phenylenedioxydiacetate hydrochloride Following the procedure of Example 82(c), except substituting dimethyl 4-[2-(BOC-methylamino)acetyl]-1,2-phenylenedioxydiacetate (1.11 g, 2.6 mmol) for benzyl 4-[2-(BOC-methylamino)acetyl]phenoxyacetate, the title compound(l.l g, quantitative) was prepared: MS (ES) m/e 326.0 [M + H]+. f) Dimethyl 4-[2-[[( l-BOC-benzimidazol-2-yl)methyl]methylamino]acetyl]-1,2-phenylenedioxydiacetate Following the procedure of Example 82(d), except substituting dimethyl 4-[2-(methylamino)acetyl]- 1,2-phenylenedioxydiacetate hydrochloride (0.24 g, 0.66 mmol) for benzyl 4-[2-(methylamino)acetyl]phenoxyacetate hydrochloride, 1-BOC-2-(bromomethyl)benzimidazole (0.31 g,0.99 mmol) for 2-(chloromethyl)benzimidazole, and using THF (5 mL) and CH2CI2 (5 mL) as solvents, the title compound (0.14 g, 38%) was prepared: MS (ES) m/e 556.2 [M + H]+. g) Dimethyl 4-[2-[[(benzimidazol-2-yl)methyl]methylamino]acetyl]-1,2-phenylenedioxydiacetate bis(trifluoroacetate) A mixture of dimethyl 4-[2-[[(l-BOC-benzimidazol-2-yl)methyl]methylamino]-acetyl]-l,2-phenylenedioxydiacetate (0.13 g, 0.23 mmol) in TFA 4 mL) and CH2CI2 (12 mL) was stirred at RT under argon for 20 min.
Removal of the solvents on the rotavap gave the title compound (0.18 g, quantitative): MS (ES) m/e 456.2 [M + H]+. 156 h) 4-[2-[[(Benzimidazol-2-yl)methyl]methylamino]acetyl]-1,2-phenylenedioxydiacetic acid Following the procedure of Example 82(e), except substituting dimethyl 4-[2-[[(benzimidazol-2-yl)methyl]methylamino]acetyl]-1,2-phenylenedioxydiacetate bis(trifluoroacetate) (0.16 g, 0.23 mmol) for dimethyl (±)-4-[[2-[(benzimidazol-2-yl)methyl]methylamino]-1 -hydroxyethyl]-1,2-phenylenedioxydiacetate, the title compound (0.08 g, 80%) was prepared: MS (ES) m/e 428.2 [M + H]+. Anal. Calcd for C21H21N3O7 • 11/5 C2HF3O2 • 9/5 H2O: C, 42.93; H, 3.80 N, 5.91. Found: C, 42.62; H, 3.52; N, 6.30.
Example 85 Preparation of 3-IT4-rrr(Bfnzimidazol-2-vDmethv1amino1carbonvnphenvnamino1 propionic Acid a) ethyl 3-[4-(carboxy)phenylamino]propionate A solution of 4-aminobenzoic acid (6.85 g, 0.05 mol) and ethyl acrylate (15 g, 0.15 mol) in acetic acid (40 mL) was heated to 100°C for 15 h. The solid which formed was filtered, washed with hexane and dried to give the title compound (7.5 g, 63%). b) ethyl 3-[[4-[[[(benzimidazol-2-yl)methy]amino]carbonyl]phenyl]amino]propionic acid The compound of Example 85(a)(0.3 g, 1.26 mmol) in thionyl chloride (10 mL) was heated to reflux for 10 min, cooled, concentrated in vacuo, and residual thionyl chloride was removed by addition of methylene chloride followed by concentration in vacuo. The residual oil was dissolved in methylene chloride and treated with 2-(aminomethyl)benzimidazole dihydrochloride hydrate (0.33 g, 1.5 mmol) and diisopropylethylamine (0.56 g, 4.3 mmol). The resulting mixture was stirred overnight, washed with water and the organic phase was dried (sodium sulfate) and concentrated in vacuo. The resulting pale yellow solid was chromatographed (silica gel, methanol-dichloromethane 3:97) and fractions 157 PCTAJS95/08306 containing the product were pooled and concentrated in vacuo to give the title compound. MS(ES) m/e 367 [M+H]+. c) 3-[[4-[[[(benzimidazol-2-yl)methy]amino]carbonyI]phenyl]amino]propionic acid C20 mL), water (2 mL) and 0.95N aqueous sodium hydroxide (2.5 mL) was stirred and heated to 50°C for 2 h. The mixture was treated with trifluoroacetic acid (1 mL), concentrated in vacuo, and the residue was triturated with dichloromethane (4 x 100 mL). The resulting white solid was recrystallized from 20% 10 acetonitrile/water-0.1 % trifluoroacetic acid to give the title compound. MS(ES) m/e 339 [M+H]+.
Example 86-92 Following the general procedures of Examples 1-55, the following compounds 15 are parpared: A solution of the compound of Example 85(b)(0.4 g, 1.1 mmol) in methanol n h n n /""A \_y cojh I "N h N h n N\^C02H C02H 158 Example The above description fully discloses how to make and use the present invention. However, the present invention is not limited to the particular 15 embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprises the state of the art and are incorporated herein by reference as though fully set forth. 159

Claims (39)

WO 96/00730 PCT/US95/08306 Example 93 Parenteral Dosage Unit Composition A preparation which contains 20 mg of the compound of Example 1 as a sterile dry powder is prepared as follows: 20 mg of the compound is dissolved in 15 5 mL of distilled water. The solution is filtered under sterile conditions into a 25 mL multi-dose ampoule and lyophilized. The powder is reconstituted by addition of 20 mL of 5% dextrose in water (D5W) for intravenous or intramuscular injection. The dosage is thereby determined by the injection volume. Subsequent dilution may be made by addition of a metered volume of this dosage unit to another volume of D5W 10 for injection, or a metered dose may be added to another mechanism for dispensing the drug, as in a bottle or bag for IV drip infusion or other injection-infusion system. Example 94 Oral Dosage Unit Composition 15 A capsule for oral administration is prepared by mixing and milling 50 mg of the compound of Example 1 with 75 mg of lactose and 5 mg of magnesium stearate. The resulting powder is screened and filled into a hard gelatin capsule. Example 95 20 Oral Dosage Unit Composition A tablet for oral administration is prepared by mixing and granulating 20 mg of sucrose, 150 mg of calcium sulfate dihydrate and 50 mg of the compound of Example 1 with a 10% gelatin solution. The wet granules are screened, dried, mixed with 10 mg starch, 5 mg talc and 3 mg stearic acid; and compressed into a tablet. 25 The foregoing is illustrative of the making and using of this invention. This invention, however, is not limited to the precise embodiments described herein, but encompasses all modifications within the scope of the claims which follow. 160 P50256-1 What is claimed is: 290008
1. A compound according to formula (I) or (II) or (IV): W A V\ (i) R | w A or (II) N I N W A R (IV) wherein: W is CHRga-U- CHRSb-V- or or N—(CH)q >< _J . 9 A is a fibrinogen receptor antagonist template; U and V are absent or CO, CRg2, C(=CRg2), S(0)k, O, NRg, CRgORg, CRg(ORk)CRg2, CRg2CRg(ORk), C(0)CRg2, CRg2C(0), CONR', NR'CO, OC(O), C(0)0, C(S)0, OC(S), C(S)NRg, NRgC(S), S(0)2NRg, NR8S(0)2 N=N, NRgNRg, NRgCRg2, NRgCRg2, CRg20, OCRg2, C=C or CRg=CRg; G is NRe; Rg is H, C[_6alkyl, Het-C0_6alkyl, C3_7cycloalkyl-Co.6alkyl or Ar- Cg^alkyl; Rk is Rg, -C(0)Rg, or -C(0)0Rf; R1 is is H, Cj_6alkyl, Het-Co^alkyl, C3_7cycloalkyl-Co_6alkyl, Ar- C0_6alkyl, or C^galkyl substituted by one to three groups chosen from halogen, CN, NRg2, ORg, SRg, C02R§, and CON(Rg)2; Rf is H, Chalky 1 or Ar-Ci.galkyi; 161 "MitLUtUTUAL PRUPERTY OFFICE OF N.Z. 2 9 JUN 1998 .RECEIVED P50256-1 ?Q n n 0 Re is H, Cj.galkyl, Ar-Cj.galkyl, Het-Cj.galkyl, C3.7cycloalkyl-C1_6alkyl, or (CH2)kC02Rg; k is 0,1 or 2; q is 1 or 2; 5 a is 0,1 or 2; b is 0,1 or 2; Rb and Rc are independently selected from H, C^alkyl, Ar-Co.galkyl, Het- C0.6alkyl, or C3-6cycloalkyl-Co-6alkyl, halogen, CF3, ORf, S(0)kRf, CORf, N02, N(Rf)2, CO(NRf)2, CH2N(Rf)2, or Rb and Rc are joined together to 10 form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF3, C1.4alkyl, ORf, S(0)kRf, CORf, C02Rf OH, N02,. N(Rf)2, CO(NRf)2, and CH2N(Rf)2; 0r methylenedioxy; or a phannaceutically acceptable salt thereof, 15 with the proviso that: (i) when A is 1,2,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-1H-1,4-benzodiazepine-2-acetic acid, then W is not -(CH2)2-3NHCO- attached at the 1-position of an imidazole ring; and (ii) when A is 1,2,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)- IH-1,4- 20 benzodiazepine-2-acetic acid, then W is not -(CH2)2 NHCO- attached at the 4(5)-position of an imidazole ring.
2. A compound according to claim 1 wherein the fibrinogen receptor antagonist template A is 25 wherein: A1 to A5 form an accessible substituted seven-membered ring, which may be saturated or unsaturated, optionally containing up to two heteroatoms chosen from the group of O, S and N wherein S and N may be optionally oxidized; 30 D1 to D4 form an accessible substituted six membered ring, optionally containing up to two nitrogen atoms; flNltLLtUTUAL PROPfflfTomFFl ' OF NZ 162 I 2 9 JUN 1998 .RECEIVED P50256-1 290008 30 R is at least one substituent chosen from the group of R7, or Q-C^alkyl, Q-C2-4alkenyl, Q-C2-4alkynyl, optionally substituted by one or more of =0, R11 or R7; R* is H, Q-Cj.galkyl, Q-C^goxoalkyl, Q-C2-6alkenyl, Q-C3.4oxoalkenyl, Q-C3_40X0alkynyl, Q-C2-4alkynyl, C3-6cycloalkyl, Ar or Het, optionally substituted by one or more of R11; Q is H, C3_6cycloalkyl, Het or Ar; R7 is -COR8, -COCR'2R9, -C(S)R8, -S(0)m0R', -S(0)mNR'R", -PO(OR'), -PO(OR')2, -B(OR')2, -N02 and Tet; R8 is -OR', -NR'R", -NR'S02R\ -NR'OR', -0CR'2C(0)0R', -0CR'20C(0)-R', -0CR'2C(0)NR'2, CF3 or AA1; R9 is -OR', -CN, -S(0)rR', S(0)mNR'2, -C(0)R' C(0)NR'2 or -C02R'; R11 is H, halo, -OR12, -CN, -NR'R12, -N02, -CF3, CF3S(0)r-, -C02R', -CONR'2, Q-Co^alkyl-, Q-Cj.goxoalkyl-, Q-C2-6alkenyI-, Q-C2-6alkynyl-, Q-C0. 6alkyloxy-, Q-Co_6alkylamino- or Q-Co„6alkyl-S(0)r-; R12 is R', -C(0)R', -C(0)NR'2, -C(0)0Rl5, -S(0)mR' or S(0)mNR'2; R15 is H, Ci.galkyl or Ar-Co-4alkyl; R' is H, Cj.galkyl, C3.7cycloalkyl-Co-4alkyl or Ar-Co-4alkyl; R" is R\ -C(0)R' or -C(0)0Rl5; AA1 is an amino acid attached through its amino group and having its carboxyl group optionally protected; m is 1 or 2; and r is 0 to 2; phannaceutically acceptable salts thereof, with the proviso that: (i) when A is l,2,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-lH-l,4-benzodiazepine-2-acetic acid, then W is not -(CH2)2-3NHCO- attached at the 1-position of an imidazole ring; and (ii) when A is l,2,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-lH-l,4-benzodiazepine-2-acetic acid, then W is not -(CH2)2 NHCO- attached at the 4(5)-position of an imidazole ring.
3. A compound according to claim 2 wherein: Al is CRlRl', CR1, NR1, N, O or S(0)x; A2 is CR2R2', CR2, NR2; A3 is CR3R3', CR3, NR3, N, O or S(0)x; A4 is CR4R4', CR4, NR4, or N; A5 is CR5R5', CR5, NR5, N, O or S(0)x; 163 P50256-1 DJ-D4 are CH orN; R1 and R1' are R* or R, or together are =0; 5 R2 and R2' are R*, R or =0 R3 and R3' are R*, R or =0 R4 and R4' are R*, R or =0 R5 and R5 are R*, R or =0 x is 0, 1 or 2; and R and R* are as defined in claim 2. 10
4. A compound according to claim 2 wherein: A1 is CRiR1', CR1, NR1, N, O or S; A2 is CR2R2', NR2 or CR2; A3 is CR3R3'; A4 is CR4R4', CR4, NR4, or N; A5 is CR5R5', CR5, NR5, N, or O; D1 and D4 are CH; one of D2 or D3 is CH and the other is CH or N; one of R2 or R4 are R_ and the other is H,* R3,R3' and R5,R5' are =0 or R*,H; R1 and R1' are R* or R; and R2' and R4' are
5. A compound according to claim 2 wherein: A1 is CHR1, CR1, NR", N or S; A2 is CR2 or CR2R2'; A3 is CR3R3'; A4 is CR4R4' or NR4; A5 is CR5R5' and D1- D4 are CH in which R1 is R* or R; R2 and R2' are R*, 20 R or together are =0; R3 and R3' are R*, R or together are =0; R4 and R4' are R*, R or together are =0; R5 and R5' are R*, R or together are =0; and R, R* and R" are as defined in claim 2.
6. A compound according to claim 2 wherein: 25 A1 is CR1, A2 is CR2, A3 is C=0, A4 is NR4 and A5 are CHR5 in which R1 is R* or R; R2 is R* or R; R4 is R* or R; R5 is R* or R; and R and R* are as defined in claim 2.
7. A compound according to claim 2 wherein: 30 A1 is NR1, A2 is CHCR2, A3 is CR3R3', A4 is NR4, and A5 are C=0 in which R1 is R* or R; R2 is R*, R; R3 and R3' are R*, R or together are =0; R4 is R* or R; and R and R* are as defined in claim 2.
8. A compound according to claim 2 wherein: 35 A1 and A4 are C=0, A2 is NR2, A3 is CHR3' and A5 is NR5 in which R2 is R* or R; R3' is R* or R; R5 is R* or R or =0; and R and R* are as defined in claim 2. 15 H. 164 f C JL'L •- J P50256-1 0
9. A compound according to claim 2 wherein: A1 is NR1, A2 is CHR2, A3 is C=0, A4 is NR' and A5 is CHR5 in which R1 is R* or R; R2 is R* or R; R5 is R* or R; R, R* and R' are as defined in claim 2. 5 10. A compound according to claim 1 wherein A is: r5 / 5 R. rs p5' ,r4 r1 ri"
10 in which: Rj and Rp are R* or R, or together are =0; R2 and R2> are R*, R or together are =0 R3 and R3' are R*, R or together are =0 R4 and R4- are R*, R or together are =0 15 R5 and R5> are R*, R or together are =0; and R and R* are as defined in claim 2. R1 R
11. A compound according to claim 1 wherein A is: 20 in which: 165 2 9 JUN 1998 -£££BM/£D 10 P50256-1 r* H A i! D • P- . ^ U ' ^ Rj is R or R; R2 and R2- are R*, R or together are =0; R4 is R* or R; R5 and R51 are R*, R or together are =0; and R and R* are as defined in claim 2.
12. A compound according to claim 11 wherein: Rx is H or C^alkyl; R2, R2- are H,-CH2C02H; R4 is R* or R; and RfRs1 are H,H in which R and R* are as defined in claim 2.
13. A compound according to claim 2 which is: (2S)-7-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5 -tetrahydro- lH-l,4-benzodiazepine-2-acetic acid; 7-[[[2-(4-aza-5-methylbenzimidazolyl)mefchyl]methylaminoJcarbonyl]-4-methyl-3-15 oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; (±)-7-[[[2-(4-Azabenzimidazolyl)methyl]methylamino]carbonyl]-4-(2- methoxyethyl)-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; (±)-7-[[[2-(benzimidazolyl)methyl]methylamino]carbonyl]-4-(2-methoxyethyl)-3-20 oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; 7-[[[2-(4-azabenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; (2S)-7-[[[N-butyl-N-benzimidazol-2-yl)methyl]amino]carbonyl]-3-oxo-4-methyl-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; 25 7-[[[(2-benzimidazolyl)methyl]methylamino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; 7-[[[N-(2-benzimidazolyl)methyl-N-(2-phenylethyl)]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; (±)-7-[[[2-(benzimidazoIyl)methyl]amino]carbonyl-4-[2-(3,4-30 methylenedioxyphenyl)ethyl]-3-oxo-2,3,4,5-tetrahydro- IH-1,4- benzodiazepine-2-acetic acid; and (±)-7-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-IH-1,4-benzodiazepine-2-acetic acid. (±)-7-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-35 tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; (±)-7 - [ [ [(2-benzimidazolyl)methyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; 166 P50256-1 290008 ™ (±)-4-isopropyl-7-[[[(2-benzimidazolyI)methyl]amino]carbonyl]-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; (±)-7- [[ [N- [2-(5(6)-chlorobenzimidazolyl)methyl]-N-methyl]amino] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- 1H-1,4-benzodiazepine-2-acetic acid; 5 (2S)-7-[[[(2-Benzimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetic acid; (2R)-7-[[[(2-Benzimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetic acid; (±) -7-[ [[(2-benzimidazolyl)methyl] amino]carbony 1] -9-chloro-4-methy 1-3 -oxo-10 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; (±)-8-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-2-methyl-3-oxo-2,3,4,5-tetrahydro-1 H-2-benzazepine-4-acetic acid; (±)-8-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyl]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetic acid; 15 (±)-7-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro- 1H-1,4-benzodiazepine-2-acetic acid; (±)-7-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]methyl]-l,4-dimethyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; (±)-7-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-20 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; (±)-7-[[[2-(2-benzimidazolyl)ethyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetic acid; (±)-7-[[(2-benzimidazolyl)amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-1,4-benzodiazepine-2-acetic acid; 25 (2S)-7-[[[N-(2-benzimidazolyl)methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; (±)-4-Methyl-7-[[[N-(2-(l-methyl)benzimidazolyl)methyl-N-methyl]amino] carbonyl]-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; (±)-7-[[[(2-(5(6)-methoxy)benzimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-30 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; (±)-7-[[[N-[2-(4-azabenzimidazolyl)]methyl-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; (±)-7-[[[N-[2-(5(6)-Azabenzimidazolyl)]methyl-N-methyl]amino] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; 35 (±)-7-[[[(2-imidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-IH-1,4-benzodiazepine-2-acetate; 167 2 9 JUN 1998 P50256-1 290008 (±)-7-[[[2-(benzimidazolyl)methyl]methylamino]carbonyl]-4-(2-methoxyethyl)-3-oxo-2,3,4,5-tetrahydro-IH-1,4-benzodiazepine-2-acetic acid; (±)-7-[[[2-(4-Azabenzimidazolyl)methyl]methylamino]carbonyl]-4-(2- methoxyethyl)-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic 5 acid; (±)-7-[[[(2-imidazolyl)methyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro-IH-l,4-benzodiazepine-2-acetic acid; (±)-7-[[[(2-benzimidazolyl)methyl]amino]methyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetic acid; 10 (±)-7-[[[(2-benzimidazolyl)methyl]amino]carbonyl]-l,4-dimethyl-3-oxo-2,3,4,5-tetrahydro-IH-l,4-benzodiazepine-2-acetic acid; (±)-7-[[[(2-benzimidazolyl)methyl]methylamino]carbonyl]-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; (2S)-7-[[[N-butyl-N-benziinidazol-2-yl)methyl]amino]carboriyl]-3-oxo-4-methyl-15 2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetic acid; 7-[[[N-(2-benzimidazolyl)methyl-N-(2-phenylethyl)]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-IH-1,4-benzodiazepine-2-acetic acid; 7-[[[N-(2-benzimidazolyl)methyl-N-carboxymethyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; 20 7-[[[N-(2-benzimidazolyl)methyl-N-cyclohexyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetic acid; (±)-7-[[[2-(5-nitrobenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetic acid; (±)-7-[[[2-(5-aminobenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-25 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; 7-[[[2-(5,6-methylendioxybenzimidazolyl)methyl]methylamino] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; 7-[[[2-(4,6-diazabenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetic acid; 30 7-[[[2-(4-azabenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; [ 1 -[2R-(2-benzimidazoly l)pyrrolidiny l]carbonyl] -4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2S-acetic acid; [l-[2S-(2-benzimidazolyl)pyrrolidinyl]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-35 lH-l,4-benzodiazepine-2S-acetic acid; (±)-7-[[[2-(4-azabenzimidazolyl)methyl]methylamino]carbonyl]-4-isopropyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; 168 P50256-1 290008 7-[[[2-(4-aza-5-methylbenzimidazolyl)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; 7 - [[ [2-(5,6-dimethoxybenzimidazolyl)methyl] methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; 5 (±)-8-[[2-(2-benzimidazolyl)acetyl]amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetic acid; (±)-8-[[[(2-benzimidazolyi)methyl]methylamino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- lH-2-benzazepine-4-acetic acid; 7-[[[(2-benzimidazolyl)methyl]methylamino]carbonyl]-3-oxo-4-(2-phenylethyl)-10 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; (±)-7-[[[2-(benzimidazolyl)methyl]amino]carbonyl-4-[2-(3,4- methylenedioxyphenyl)ethyl]-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetic acid; (±)-7-[[[(4(5)-imidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-15 tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; (±)-[[[4-(2-phenylimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; 7-[[[2-(4-phenylimidazolyl)methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetic acid; 20 (+/-)-2,3,4,5-Tetrahydro-7-[[[benzimidazol-2-yl)methyl]methylamino]carbonyl]-4-(3,3-dimethylbutyl)-3-oxo- IH-1,4-benzodiazepine-2-acetic acid; (-)-7-[[[6-Trifluoromethylbenzimidazoyl-2-ylmethyl]aminomethyl]carbonyl]-2,3,4,5-tetrahydro-4-methyl-j-oxo-benzodiazepine-2-acetic acid; (-)-7-[[[4,7-Dimethoxybenzimidazoyl-2-ylmethyl]aminomethyl]carbonyl]-2,3,4,5-25 tetrahydro-4-methyl-3-oxo-benzodiazepine-2-acetic acid; (+/-)-2,3,4,5-Tetrahydro-7-[[[(benzimidazol-2-yl)methylamino]carbonyl]-4-(3,3-dimethylbutyl)-3-oxo- IH-1,4-benzodiazepine-2-acetic acid; (-)-7-[[[7-Methylbenzimidazol-2-ylmethyl]methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-l,4-benzodiazepine-2-acef.ic acid; 30 (2S)-[[[N-aminobutyl-N-(benzimidazlo-2-yl)methyl]amino]c<iibonyl]-3-oxo-4-methyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acidbis(trifluoroacetate)salt; (2S)-[[[N-cyanomethyl-N-(benzimidazlo-2-yl)methyl]amino]carbonyl]-3-oxo-4-methyl-2,3,4,5-tetrahydro-IH-1,4-benzodiazepine-2-acetic acid 35 dihydrochloride salt; 2,3,4,5-Tetrahydro-7-[[[(benzimidazol-2-yl)]methyl]amino]carbonyl]-4-(4- phthalimidobutyl)-3-oxo-1,4-benzodiazepine-2-acetic grF^trrfifriu.iL |ij„. 169 I of ^ 2 9 JUN 1998 HECEIVf n P50256-1 290008 (-)-7-[[[Imidazo[4,5B]-4,6-dimethylpyridyl-2-ylmethyl]aminomethyl]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-benzodiazepine-2-acetic acid trifluoroacetate salt; (+/-)-7-[[(2-Benzimidazol-2-ylmethyl)-N-methylamino]carbonyl]-2,3,4,5-tetrahydro-3-oxo-4-[2-(3',4'-methylenedioxyphenyl)ethyl]-lH-l,4-benzodiazepine-2-acetic acid; (+/-)-2,3,4,5-Tetrahydro-7-[[[(Benzimidazol-2-yl)methyl]amino]carbonyl]-4-(2-methoxyethyl)-3-oxo- IH-1,4-benzodiazepine-2-acetic acid; 7-[[2-[l-Methylbenzimidazolyl]benzimidazolylmethylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid; 7-[[[N-Cyclohexyl-N-(benzimidazol-2-yl)methyl]amino]carbonyl]-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetic acid; 7-[[[2-Bis-(Benzimidazolylmethyl)aminocarbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo- 1H-l,4-benzodiazepine-2-acetic acid; (+/-)-2,3,4,5-Tetrahydro-7-[[[imidazo[415-B]pyrid-2- yl]methyl]methylamino]carbonyl]-4-(3,3-dimethylbutyl)-3-oxo-lH-l,4-benzodiazepine-2-acetic acid; (+/-)-7-[[(2-Benzirnidazol-2-ylmethyl)-N-methylamino]carbonyl-2,3,4,5-tetrahydro-3-oxo-4-(2',2,,2,-trifluoroethyl)-lH-l,4-benzodiazepine-2-acetic acid; (+/-)-7-[[(2-Benzimidazolyl)acetyl]amino]-5-oxo-4-(2-phenylethyl)-2,3,4,5-tetrahydro- IH-1,4-benzodiazepine-2-acetic acid; (+/-)-7-[[(2-Benziniidazol-2-ylmethyl)amino]carbonyl]-2,3,4,5-tetrahydro-3-oxo-4-(2',2,,2'-trifluoroethyl)-lH-l,4-benzodiazepine-2-acetic acid; (-)-7-[[[5,6-Difluorobeazimidazoyl-2-ylmethyl]aminomethyl]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-l,4-benzodiazepine-2-acetic acid; and (+/-)-7-[[Bis-(Benzimidazol-2-ylmethyl)amino]carbonyl]-2,3,4,5-tetrahydro-4-phenylethyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acidtris(trifluoroacetate)salt.
14. A compound according to claim 1 wherein the fibrinogen receptor antagonist template A is Y 2' 170 P50256-1 290008 wherein: R6 is aryl, Cj.joalkyl, C3_6cycloalkyl, C4.i0aralkyl, Ci_i0alkoxyalkyl, Cj.ioalkaryl, Ci.io^kylthioalkyl, Ci.ioalkoxythioalkyl, C].j0alkylamino, C4.|0aralkylainino, Ci_10alkanoylamino, C4_ioaralkanoylamino, C^igalkanoyl, C4_1oaralkanoyl, or C]_10carboxyalkyl; Y is H, Ci_4alkyl, C^alkoxy, C^alkoxycarbonyl, F, CI, Br, I, CF3, ORf, S(0)kRf, CORf, N02, N(Rf)2, CO(NRf)2, CH2N(Rf)2, methylenedioxy, CN, C02Rf, 0C(0)Rf, or NHC(0)Rf; Rf is H, C^galkyl or Ar-C^galkyl; and k is 0,1 or 2.
15. A compound according to claim 14 wherein R^ is aryl, Cj.ioalkyl, C3.6cycloalkyl, or C4_ iQaralkyl.
16. A compound according to claim 15 which is (S)-(2-butylsulfonyl-amino)-3-[4-(3-benzimidazo-2-yl)propyloxy)]phenylpropionic acid or a phannaceutically acceptable salt thereof.
17. A compound according to claim 1 wherein the fibrinogen receptor antagonist template A is M1 is CH orN; M2 is CH or N, with the proviso that when M1 is CH, M2 is N; G' is N or N®R"; Rf is H, Cj.galkyl or Ar-C^galkyl; and Rg is H, Cj.galkyl, Het-Cg^alky], C3_7cycloalkyl-Co_6alkyl or Ar- Cg^alkyl.
18. A compound according to claim 17 wherein G' is N and M1 is N.
19. A compound according to claim 1 wherein the fibrinogen receptor antagonist template A is wherein: CH2C02R' OH 171 P50256-1 290008 wherein: M1 is CH or N; and M2 is CH or N, with the proviso that when M1 is CH, M2 is N; and Rf is H, Cj.galkyl or Ar-C^galkyl.
20. A compound according to claim 1 wherein the fibrinogen receptor antagonist template A is M1 is CH orN; Y is H, Ci_4alkyl, C^alkoxy, C j _4alkoxy carbonyl, F, CI, Br, I, CF3, ORf, S(0)kRf, CORf, N02, N(Rf)2, CO(NRf)2, CH2N(Rf)2, methylenedioxy, CN, C02Rf, 0C(0)Rf, or NHC(0)Rf; is CH2 or C=0; Rh is (CH2)qC02Rf; Rf is H, Cj.galkyl or Ar-Ci.galkyi; k is 0, 1 or 2; and q is 1 or 2.
21. A compound according to claim 1 wherein the fibrinogen receptor antagonist template A is Y is H, Ci_4alkyl, Ci_4alkoxy, Cj.4alkoxycarbonyl, F, CI, Br, I, CF3, ORf, S(0)kRf, CORf, N02, N(Rf)2, CO(NRf)2, CH2N(Rf)2, methylenedioxy, CN, C02Rf, 0C(0)Rf, or NHC(0)Rf; Rh is (CH2)qC02Rf; Re is H, Cj.galkyl, Ar-C2.6alkyl, Het-Cj.galkyl, C3.7cycloalkyl-C].6alkyl, or (CH2)kC02Rg; Rf is H, Ci_6alkyl or Ar-Cj.galkyl; k is 0,1 or 2; and Y wherein: R wherein: 172 P50256-1 q is 1 or 2. 290008
22. A compound according to claim 1 wherein the fibrinogen receptor antagonist template A is 5 B wherein: Y is H, C^alkyl, Cj.4alkoxy, C^alkoxycarbonyl, F, CI, Br, I, CF3, ORf, S(0)kRf, CORf, N02, N(Rf)2, CO(NRf)2, CH2N(Rf)2, methylenedioxy, CN, C02Rf, 0C(0)Rf,0rNHC(0)Rf; 10 Rh is (CH2)nC02Rf; and 15 B is H3a , N f , or Rf is H, Ci.galkyl or Ar-C^galkyl; k is 0,1 or 2; and n is 0 or 3.
23. A compound according to claim 1 wherein the fibrinogen receptor antagonist template A is L-C02R9 20 wherein: L* is -C(0)NR8-(CH2)-, -C(0)-(CH2)q-, NRg-(CH2)q-, -0-(CH2)q-, or S(0)k-(CH2)q-; Rg is H, C ^<5alkyl, Het-C0_6alkyl, C3_7cycloalkyl-Co_5alkyl or Ar-C0.galkyl; k is 0, 1 or 2; and 25 q is 1 or 2. 173 ^^TUAJF^f^ToFFicE] 2 9 JUN 1998 JSECEjVED P50256-1 290008
24. A compound according to claim 1 wherein the fibrinogen receptor antagonist template A is / \ -N N—CH,—CCLR9 wherein: Rg is H, Cj.galkyl, Het-Co^alkyl, C3_7cycloalkyl-C0_6alkyl or Ar-Co^alkyl.
25. A compound according to claim 1 wherein the fibrinogen receptor antagonist template A is -CCLR9 10 wherein: Y is H, C^alkyl, Cj^alkoxy, C^alkoxycarbonyl, F, CI, Br, I, CF3, ORf, S(0)kRf, CORf, N02, N(Rf)2, CO(NRf)2, CH2N(Rf)2, methylenedioxy, CN, C02Rf, OC(0)Rf,orNHC(0)Rf; Rg is H, Cj.galkyl, Het-Cg^alkyl, C3_7cycloalkyl-Co_6alkyl or Ar-Cg^alkyl; 15 Rf is H, C^alkyl or Ar-Cj.galkyl; and k is 0,1 or 2. 20
26. A compound according to claim 1 wherein the fibrinogen receptor antagonist template A is ^ (CH2)qC02R9 25 wherein: Rg is H, Cj.galkyl, Het-Co^alkyl, C3_7cycloalkyl-Co_6alkyl or Ar-Co^alkyl; and q is 1 or 2.
27. A compound according to claim 1 which is: P50256-1 290008 R' wherein : Rx, Ry and Rz are independently Cj.galkyl, methoxy, nitro, trifluoromethyl, fluoro, chloro, or amino; or Rx and Ry are adjacent to one another and are joined to form a 5 methylenedioxy group; and W, A and G are as defined in claim 1.
28. A compound according to claim 1 which is: 10 Rx and Ry are independently Chalky], methoxy, nitro, trifluoromethyl, fluoro, chloro, or amino; or Rx and Ry are adjacent to one another and are joined to form a methylenedioxy group; and W, A and G are as defined in claim 1.
29. A pharmaceutical composition which comprises a phannaceutically acceptable 15 carrier and a compound according to any one of claims 1-28.
30. The use of a compound according to any one of claims 1-28 in the manufacture of a medicament. 20
31. The use of a compound according to formula (I) or (II) or (IV): wherein; (I) or (II) or 175 -MlUA i ' C • " - P50256-1 290008 R9—Tf N A r Re (IV) wherein: W is CHRga-U- CHRSb-V- or V A is a fibrinogen receptor antagonist template; U and V are absent or CO, CRg2, C(=CRg2), S(0)k, O, NRg, CRgORg, CRg(ORk)CRg2, CRg2CRg(ORk), C(0)CRg2, CRg2C(0), CONR', NR'CO, OC(O), C(0)0, C(S)0, OC(S), C(S)NRg, NRgC(S), S(0)2NRg, NRSS(0)2 N=N, NRgNRg, NRgCRg2, NRgCRg2, CRg20, OCRg2, C=C or CRg=CRg; G 's NRe; Rg ii H, Cj.6alkyl, Het-Co^alkyl, C3.7cycloalkyl-Co.6alkyl or Ar- Cg-galkyl; Rk is Rg, -C(0)Rg, or -C(0)0Rf; R' is is H, C^galkyl, Het-Co^alkyl, C3_7cycloalkyl-Q).6alkyl, Ar- Co^alkyl, or C^alkyl substituted by one to three groups chosed from halogen, CN, NRg2, ORg, SRg, C02Rg, and CON(Rg)2; Rf is H, Ci.galkyl or Ar-Cj.galkyl; Re is H, Cj.galkyl, Ar-Ci.galkyi, Het-Ci.galkyl, C3_7cycloalkyl-Cj.galkyl, or (CH2)kC02Rg; k is 0, 1 or 2; q is 1 or 2; a is 0,1 or 2; b is 0, 1 or 2; Rb and Rc are independently selected from H, Cj.galkyl, Ar-Cg^alkyl, Het- Co.galkyl, or C3_6cycloalkyl-Co_6alkyl, halogen, CF3, ORf, S(0)kRf, CORf, N02, N(Rf)2> CO(NRf)2, CH2N(Rf)2, or Rb and Rc are joined together to OF N.2. 176 : 9 "'i'N 1998 P50256-1 290008 heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF3, C1.4alkyl, ORf, S(0)kRf, CORf, C02Rf OH, N02, N(Rf)2, CO(NRf)2, and CH2N(Rf)2; or methylenedioxy'. or a phannaceutically acceptable salt thereof, in the manufacture of a medicament
32. The use according to claim 31 wherein the compound inhibits the vitronectin receptor at a concentration of less than 50 micromolar. 10
33. The use according to claim 31 wherein the compound inhibits the vitronectin receptor with a Ki at the vitronectin receptor that is ten-fold greater than the Ki for said compound at the fibrinogen receptor.
34. The use according to claim 31 wherein the compound inhibits the vitronectin 15 receptor with a Ki at the vitronectin receptor that is thirty-fold greater than the Ki for said compound at the fibrinogen receptor.
35. The use according to claim 31 wherein the compound inhibits the vitronectin receptor with a Ki at the vitronectin receptor that is a hundred-fold greater than the 20 Ki for said compound at the fibrinogen receptor.
36. The use of a compound according to formula (I) or (II) or (IV) as defined in claim 31 in the manufacture of a medicament for the treatment of diseases in which bone resorption is a factor. 25
37. The use of a compound according to formula (I) or (II) or (IV) as defined in claim 31 in the manufacture of a medicament for the treatment of osteoporosis, inflammation, restenosis, or atherosclerosis. 30
38. A compound according to formula (XXX): 5 for the inhibition of the vitronectin receptor in a mammal in need thereof. (XXX) 177 P50256-1 290008 wherein Pr1 is a nitrogen protecting group, Rf is H, Cj.galkyl or ArCj^alkyl, a1 is 1-3, and Rx, Ry and Rz are independently H, halogen, SRf, ORf, CF3, N(Rf)2, N02 and Ci.galkyl.
39. A process for preparing a compound of the formula (II): wherein A, W, G, Rb and Rc are as defined in claim 1, which process comprises reacting a compound of the formula (XII) with a compound of the formula (XX): wherein: Rb, Rc, G and A are as defined in formula (II), with any reactive functional groups protected; and L1 and L2 are groups which react to form a covalent bond in the moiety W; and thereafter removing any protecting groups, and optionally forming a phannaceutically acceptable salt. (II) LJ-A (XX) (xn) END OF CLAIMS 178
NZ290008A 1994-06-29 1995-06-29 Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle NZ290008A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26769594A 1994-06-29 1994-06-29
US42893395A 1995-04-25 1995-04-25
PCT/US1995/008306 WO1996000730A1 (en) 1994-06-29 1995-06-29 Vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
NZ290008A true NZ290008A (en) 1998-08-26

Family

ID=26952569

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ290008A NZ290008A (en) 1994-06-29 1995-06-29 Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
NZ329656A NZ329656A (en) 1994-06-29 1998-01-28 Oxazole and thiazoles derivatives containing a fibrinogen receptor antagonist template
NZ329822A NZ329822A (en) 1994-06-29 1998-02-23 Pyrrole derivatives bound to a fibrinogen receptor antagonist template

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ329656A NZ329656A (en) 1994-06-29 1998-01-28 Oxazole and thiazoles derivatives containing a fibrinogen receptor antagonist template
NZ329822A NZ329822A (en) 1994-06-29 1998-02-23 Pyrrole derivatives bound to a fibrinogen receptor antagonist template

Country Status (13)

Country Link
EP (1) EP0767792A4 (en)
JP (1) JPH10504808A (en)
CN (1) CN1156995A (en)
AU (1) AU702661B2 (en)
BR (1) BR9508178A (en)
CA (1) CA2193966A1 (en)
CZ (1) CZ382496A3 (en)
HU (1) HUT76344A (en)
MX (1) MX9700041A (en)
NO (1) NO965608L (en)
NZ (3) NZ290008A (en)
PL (1) PL318199A1 (en)
WO (1) WO1996000730A1 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2230209A1 (en) 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
DE59706273D1 (en) 1996-03-20 2002-03-21 Hoechst Ag Bone resorption inhibitors and vitronectin receptor antagonists
DE19629817A1 (en) * 1996-07-24 1998-01-29 Hoechst Ag New imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
DE19629816A1 (en) * 1996-07-24 1998-01-29 Hoechst Ag New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
UA60311C2 (en) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Vitronectin receptor antagonists
JP2001501951A (en) * 1996-10-07 2001-02-13 スミスクライン・ビーチャム・コーポレイション How to stimulate bone formation
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
DE19653645A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
DE19653646A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Substituted purine derivatives, processes for their preparation, agents containing them and their use
DE19653647A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
JP2001511452A (en) * 1997-08-04 2001-08-14 スミスクライン・ビーチャム・コーポレイション Integrin receptor antagonist
US6313119B1 (en) 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
EP1054871A2 (en) 1998-04-01 2000-11-29 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
US6228985B1 (en) 1998-05-21 2001-05-08 Schering Corporation Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents
DE69921124T2 (en) * 1998-06-12 2005-11-10 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Imidazole derivatives and their use as a somatostatin receptor
TR200100363T2 (en) * 1998-08-07 2001-06-21 Smithkline Beecham Corporation Vitronectin receptor antagonists.
DE19842415A1 (en) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmaceutical preparation for treating e.g. tumors, thrombosis or inflammation, contains cyclic pentapeptide integrin inhibitor and chemotherapeutic agent and/or angiogenesis inhibitor
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
CN1161340C (en) * 1998-11-30 2004-08-11 先灵公司 Benzimidazole compounds that are vitronectin receptor antagonists
US6204282B1 (en) 1998-11-30 2001-03-20 Schering Corporation Benzimidazole compounds that are vitronectin receptor antagonists
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6358949B1 (en) 1999-04-02 2002-03-19 Neurogen Corporation Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
MXPA01009949A (en) * 1999-04-02 2003-07-14 Neurogen Corp ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS.
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
AU4055300A (en) * 1999-04-02 2000-10-23 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of Bradykinin B2 receptors
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
CZ20013593A3 (en) 1999-04-06 2002-03-13 Sankyo Company, Limited Alpha-substituted derivatives of carboxylic acids
CO5180550A1 (en) 1999-04-19 2002-07-30 Smithkline Beecham Corp FAB I INHIBITORS
CO5370679A1 (en) 1999-06-01 2004-02-27 Smithkline Beecham Corp FAB INHIBITORS 1
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
NZ517706A (en) 1999-10-08 2004-01-30 Affinium Pharm Inc Fab I inhibitors
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US6509366B2 (en) 2000-01-18 2003-01-21 Neurogen Corporation Substituted imidazoles as selective modulators of Bradykinin B2 receptors
FR2806082B1 (en) * 2000-03-07 2002-05-17 Adir NOVEL BICYCLIC ANTAGONIST VITRONECTIN RECEPTOR COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2001090186A1 (en) 2000-05-26 2001-11-29 Glaxo Group Limited Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
ES2282275T3 (en) 2000-08-01 2007-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) IMIDAZOLIL DERIVATIVES
WO2002018377A1 (en) * 2000-08-29 2002-03-07 Pharmacia Corporation Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
FR2822463B1 (en) 2001-03-21 2004-07-30 Lipha BICYCLIC GUANIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
ES2320984T3 (en) 2001-04-06 2009-06-01 Affinium Pharmaceuticals, Inc. FAB INHIBITORS I.
RU2316337C2 (en) 2001-04-24 2008-02-10 Мерк Патент Гмбх Combined therapy by using antiangiogenic agents and tnf-alpha
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
FR2829765A1 (en) * 2001-09-14 2003-03-21 Lipha Use of new and known benzimidazolyl alkoxyaryl alkanoic acid derivatives for treating pathologies associated with insulin resistance or hyperglycemia
KR101159061B1 (en) 2001-10-22 2012-06-22 더 스크립스 리서치 인스티튜트 Antibody targeting compounds
FR2847254B1 (en) 2002-11-19 2005-01-28 Aventis Pharma Sa NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, PROCESS FOR PREPARING THEM, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS REFLECTING THEM
PE20040804A1 (en) * 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma CARBOXAMID DERIVATIVES AS INHIBITORS OF THE Xa FACTOR
FR2870541B1 (en) 2004-05-18 2006-07-14 Proskelia Sas ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
ES2521679T3 (en) 2006-01-18 2014-11-13 Merck Patent Gmbh Specific therapy using integrin ligands for cancer treatment
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
MX2009007597A (en) 2007-01-18 2009-07-22 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer.
EP2125802A4 (en) 2007-02-16 2014-08-20 Debiopharm Int Sa Salts, prodrugs and polymorphs of fab i inhibitors
JP5359879B2 (en) * 2007-11-16 2013-12-04 宇部興産株式会社 Benzazepinone compounds
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
JP5572996B2 (en) * 2009-05-15 2014-08-20 宇部興産株式会社 Medicine containing benzazepinone compound as active ingredient
EA201101651A1 (en) 2009-05-25 2012-08-30 Мерк Патент Гмбх CONTINUOUS INTRODUCTION OF INTEGRINE LIGANDS FOR CANCER TREATMENT
ES2571334T3 (en) 2010-06-24 2016-05-24 Gilead Sciences Inc Pyrazolo [1,5-a] pyrimidines and -triazines as antiviral agents
JP6122868B2 (en) 2011-12-22 2017-04-26 ギリアード サイエンシーズ， インコーポレイテッド Pyrazolo [1,5-A] pyrimidine as an antiviral agent
CN104583211A (en) 2012-04-17 2015-04-29 吉里德科学公司 Compounds and methods for antiviral treatment
SI2861608T1 (en) 2012-06-19 2019-08-30 Debiopharm International Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
CN106572997A (en) 2014-05-30 2017-04-19 辉瑞公司 Carbonitrile derivatives as selective androgen receptor modulators
CA3014541A1 (en) 2016-02-26 2017-08-31 Debiopharm International S.A. Medicament for treatment of diabetic foot infections
CN108707116B (en) * 2018-07-05 2021-11-30 华侨大学 2-alkyl substituted benzimidazole derivative and preparation method thereof
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR71915B (en) * 1979-11-27 1983-08-16 Pfizer
US4556660A (en) * 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
GB8316645D0 (en) * 1983-06-18 1983-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
FR2643903A1 (en) * 1989-03-03 1990-09-07 Union Pharma Scient Appl NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
RU1836357C (en) * 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Benzimidazole derivatives, their isomers, mixtures of isomers, hydrates or their physiologically bearable salts possessing properties antagonistic to angiotenzine
NZ243326A (en) * 1991-06-28 1995-10-26 Smithkline Beecham Corp Benzodiazepine, benzazepine; benzothiazepine and benzoxazepine derivatives; pharmaceutical compositions
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
WO1994014776A2 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
AU6087194A (en) * 1993-01-15 1994-08-15 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors
US5300668A (en) * 1993-03-10 1994-04-05 Pfizer Inc. Certain esters of 1-(4-X-methylphenyl)cyclopent-3-ene-1-carboxylic acid, wherein X is a trialkylsilyloxy, bromo or hydroxy group, as intermediates

Also Published As

Publication number Publication date
NO965608L (en) 1997-02-27
JPH10504808A (en) 1998-05-12
BR9508178A (en) 1997-11-18
NZ329656A (en) 2000-01-28
PL318199A1 (en) 1997-05-26
HUT76344A (en) 1997-08-28
EP0767792A1 (en) 1997-04-16
NO965608D0 (en) 1996-12-27
CA2193966A1 (en) 1996-01-11
HU9603525D0 (en) 1997-02-28
AU702661B2 (en) 1999-02-25
MX9700041A (en) 1997-04-30
WO1996000730A1 (en) 1996-01-11
CZ382496A3 (en) 1997-12-17
AU3001095A (en) 1996-01-25
NZ329822A (en) 2000-02-28
CN1156995A (en) 1997-08-13
EP0767792A4 (en) 2002-11-20

Similar Documents

Publication Publication Date Title
AU702661B2 (en) Vitronectin receptor antagonists
WO1997024119A1 (en) Vitronectin receptor antagonists
US5977101A (en) Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US6159964A (en) Vitronectin receptor antagonists
US6239138B1 (en) Vitronectin receptor antagonist
WO1997024122A1 (en) Vitronectin receptor antagonists
WO1996000574A1 (en) Vitronectin receptor antagonists
NZ259802A (en) Bicyclic derivatives and pharmaceutical compositions
WO1996026190A1 (en) Integrin receptor antagonists
EP1007051A1 (en) Integrin receptor antagonists
WO1997001540A1 (en) Integrin receptor antagonists
CZ299076B6 (en) Vitronectin derivatives
EP0946180A1 (en) Method for stimulating bone formation
RU2126401C1 (en) Benzimidazole derivatives, tautomers or salts thereof and drug having antagonistic angiotensine ii effect
JP2001514253A (en) Integrin receptor antagonist
US6008213A (en) Integrin receptor antagonists
US20010034445A1 (en) Vitronectin receptor antagonists
US20020032187A1 (en) Method for stimulating bone formation
US6458784B1 (en) Vitronectin receptor antagonists
PL191595B1 (en) Antagonistic integrin receptors